id	sid	tid	token	lemma	pos
aiua-10838	1	1	stesura	stesura	PROPN
aiua-10838	1	2	seveso	seveso	PROPN
aiua-10838	1	3	archivio	archivio	PROPN
aiua-10838	1	4	italiano	italiano	X
aiua-10838	1	5	di	di	X
aiua-10838	1	6	urologia	urologia	PROPN
aiua-10838	1	7	e	e	PROPN
aiua-10838	1	8	andrologia	andrologia	PROPN
aiua-10838	1	9	2022	2022	NUM
aiua-10838	1	10	;	;	PUNCT
aiua-10838	1	11	94	94	NUM
aiua-10838	1	12	,	,	PUNCT
aiua-10838	1	13	4476	4476	NUM
aiua-10838	1	14	review	review	VERB
aiua-10838	1	15	no	no	DET
aiua-10838	1	16	conflict	conflict	NOUN
aiua-10838	1	17	of	of	ADP
aiua-10838	1	18	interest	interest	NOUN
aiua-10838	1	19	declared	declare	VERB
aiua-10838	1	20	.	.	PUNCT
aiua-10838	2	1	was	be	AUX
aiua-10838	2	2	considered	consider	VERB
aiua-10838	2	3	the	the	DET
aiua-10838	2	4	standard	standard	NOUN
aiua-10838	2	5	of	of	ADP
aiua-10838	2	6	treatment	treatment	NOUN
aiua-10838	2	7	justified	justify	VERB
aiua-10838	2	8	by	by	ADP
aiua-10838	2	9	two	two	NUM
aiua-10838	2	10	randomized	randomized	ADJ
aiua-10838	2	11	phase	phase	NOUN
aiua-10838	2	12	3	3	NUM
aiua-10838	2	13	trials	trial	NOUN
aiua-10838	2	14	(	(	PUNCT
aiua-10838	2	15	swog	swog	NOUN
aiua-10838	2	16	8949	8949	NUM
aiua-10838	2	17	,	,	PUNCT
aiua-10838	2	18	eortc30947	eortc30947	PROPN
aiua-10838	2	19	)	)	PUNCT
aiua-10838	2	20	(	(	PUNCT
aiua-10838	2	21	1	1	NUM
aiua-10838	2	22	,	,	PUNCT
aiua-10838	2	23	2	2	NUM
aiua-10838	2	24	)	)	PUNCT
aiua-10838	2	25	.	.	PUNCT
aiua-10838	3	1	both	both	DET
aiua-10838	3	2	trials	trial	NOUN
aiua-10838	3	3	showed	show	VERB
aiua-10838	3	4	an	an	DET
aiua-10838	3	5	overall	overall	ADJ
aiua-10838	3	6	survival	survival	NOUN
aiua-10838	3	7	(	(	PUNCT
aiua-10838	3	8	os	os	NOUN
aiua-10838	3	9	)	)	PUNCT
aiua-10838	3	10	benefit	benefit	NOUN
aiua-10838	3	11	of	of	ADP
aiua-10838	3	12	cn	cn	PROPN
aiua-10838	3	13	followed	follow	VERB
aiua-10838	3	14	by	by	ADP
aiua-10838	3	15	interferon	interferon	ADJ
aiua-10838	3	16	-	-	PUNCT
aiua-10838	3	17	alpha	alpha	NOUN
aiua-10838	3	18	(	(	PUNCT
aiua-10838	3	19	ifn	ifn	PROPN
aiua-10838	3	20	-	-	PUNCT
aiua-10838	3	21	a	a	NOUN
aiua-10838	3	22	)	)	PUNCT
aiua-10838	3	23	2b	2b	NOUN
aiua-10838	3	24	versus	versus	ADP
aiua-10838	3	25	interferon	interferon	NOUN
aiua-10838	3	26	alone	alone	ADV
aiua-10838	3	27	(	(	PUNCT
aiua-10838	3	28	1	1	NUM
aiua-10838	3	29	-	-	SYM
aiua-10838	3	30	3	3	NUM
aiua-10838	3	31	)	)	PUNCT
aiua-10838	3	32	.	.	PUNCT
aiua-10838	4	1	since	since	SCONJ
aiua-10838	4	2	2005	2005	NUM
aiua-10838	4	3	,	,	PUNCT
aiua-10838	4	4	systemic	systemic	ADJ
aiua-10838	4	5	therapies	therapy	NOUN
aiua-10838	4	6	(	(	PUNCT
aiua-10838	4	7	st	st	NOUN
aiua-10838	4	8	)	)	PUNCT
aiua-10838	4	9	,	,	PUNCT
aiua-10838	4	10	such	such	ADJ
aiua-10838	4	11	as	as	ADP
aiua-10838	4	12	vascular	vascular	ADJ
aiua-10838	4	13	endothelial	endothelial	ADJ
aiua-10838	4	14	growth	growth	NOUN
aiua-10838	4	15	factor	factor	NOUN
aiua-10838	4	16	receptors	receptor	NOUN
aiua-10838	4	17	(	(	PUNCT
aiua-10838	4	18	vegfr)-tyrosine	vegfr)-tyrosine	VERB
aiua-10838	4	19	kinase	kinase	VERB
aiua-10838	4	20	inhibitors	inhibitor	NOUN
aiua-10838	4	21	(	(	PUNCT
aiua-10838	4	22	tki	tki	NOUN
aiua-10838	4	23	)	)	PUNCT
aiua-10838	4	24	and	and	CCONJ
aiua-10838	4	25	mammalian	mammalian	ADJ
aiua-10838	4	26	target	target	NOUN
aiua-10838	4	27	of	of	ADP
aiua-10838	4	28	rapamycin	rapamycin	NOUN
aiua-10838	4	29	(	(	PUNCT
aiua-10838	4	30	mtor	mtor	NOUN
aiua-10838	4	31	)	)	PUNCT
aiua-10838	4	32	inhibitors	inhibitor	NOUN
aiua-10838	4	33	,	,	PUNCT
aiua-10838	4	34	replaced	replace	VERB
aiua-10838	4	35	cytokines	cytokine	NOUN
aiua-10838	4	36	as	as	SCONJ
aiua-10838	4	37	they	they	PRON
aiua-10838	4	38	have	have	AUX
aiua-10838	4	39	been	be	AUX
aiua-10838	4	40	proven	prove	VERB
aiua-10838	4	41	superior	superior	ADJ
aiua-10838	4	42	to	to	ADP
aiua-10838	4	43	cytokines	cytokine	NOUN
aiua-10838	4	44	(	(	PUNCT
aiua-10838	4	45	4	4	NUM
aiua-10838	4	46	,	,	PUNCT
aiua-10838	4	47	5	5	NUM
aiua-10838	4	48	)	)	PUNCT
aiua-10838	4	49	.	.	PUNCT
aiua-10838	5	1	cn	cn	PROPN
aiua-10838	5	2	was	be	AUX
aiua-10838	5	3	evaluated	evaluate	VERB
aiua-10838	5	4	,	,	PUNCT
aiua-10838	5	5	regarding	regard	VERB
aiua-10838	5	6	possible	possible	ADJ
aiua-10838	5	7	advantages	advantage	NOUN
aiua-10838	5	8	on	on	ADP
aiua-10838	5	9	os	os	NOUN
aiua-10838	5	10	in	in	ADP
aiua-10838	5	11	mrcc	mrcc	NOUN
aiua-10838	5	12	patients	patient	NOUN
aiua-10838	5	13	treated	treat	VERB
aiua-10838	5	14	with	with	ADP
aiua-10838	5	15	st	st	PROPN
aiua-10838	5	16	,	,	PUNCT
aiua-10838	5	17	through	through	ADP
aiua-10838	5	18	multiple	multiple	ADJ
aiua-10838	5	19	retrospective	retrospective	ADJ
aiua-10838	5	20	studies	study	NOUN
aiua-10838	5	21	.	.	PUNCT
aiua-10838	6	1	the	the	DET
aiua-10838	6	2	carmena	carmena	PROPN
aiua-10838	6	3	trial	trial	NOUN
aiua-10838	6	4	(	(	PUNCT
aiua-10838	6	5	6	6	NUM
aiua-10838	6	6	)	)	PUNCT
aiua-10838	6	7	and	and	CCONJ
aiua-10838	6	8	the	the	DET
aiua-10838	6	9	surtime	surtime	NOUN
aiua-10838	6	10	trial	trial	NOUN
aiua-10838	6	11	(	(	PUNCT
aiua-10838	6	12	7	7	NUM
aiua-10838	6	13	)	)	PUNCT
aiua-10838	6	14	,	,	PUNCT
aiua-10838	6	15	are	be	AUX
aiua-10838	6	16	the	the	DET
aiua-10838	6	17	only	only	ADJ
aiua-10838	6	18	randomized	randomize	VERB
aiua-10838	6	19	controlled	control	VERB
aiua-10838	6	20	trials	trial	NOUN
aiua-10838	6	21	(	(	PUNCT
aiua-10838	6	22	rct	rct	PROPN
aiua-10838	6	23	)	)	PUNCT
aiua-10838	6	24	investigating	investigate	VERB
aiua-10838	6	25	the	the	DET
aiua-10838	6	26	role	role	NOUN
aiua-10838	6	27	of	of	ADP
aiua-10838	6	28	cn	cn	PROPN
aiua-10838	6	29	in	in	ADP
aiua-10838	6	30	the	the	DET
aiua-10838	6	31	st	st	PROPN
aiua-10838	6	32	era	era	PROPN
aiua-10838	6	33	.	.	PUNCT
aiua-10838	7	1	these	these	DET
aiua-10838	7	2	two	two	NUM
aiua-10838	7	3	studies	study	NOUN
aiua-10838	7	4	reduced	reduce	VERB
aiua-10838	7	5	the	the	DET
aiua-10838	7	6	enthusiasm	enthusiasm	NOUN
aiua-10838	7	7	on	on	ADP
aiua-10838	7	8	upfront	upfront	ADJ
aiua-10838	7	9	cn	cn	PROPN
aiua-10838	7	10	and	and	CCONJ
aiua-10838	7	11	opened	open	VERB
aiua-10838	7	12	a	a	DET
aiua-10838	7	13	discussion	discussion	NOUN
aiua-10838	7	14	about	about	ADP
aiua-10838	7	15	which	which	PRON
aiua-10838	7	16	patients	patient	NOUN
aiua-10838	7	17	treated	treat	VERB
aiua-10838	7	18	with	with	ADP
aiua-10838	7	19	st	st	PROPN
aiua-10838	7	20	could	could	AUX
aiua-10838	7	21	benefit	benefit	VERB
aiua-10838	7	22	more	more	ADJ
aiua-10838	7	23	by	by	ADP
aiua-10838	7	24	cn	cn	PROPN
aiua-10838	7	25	.	.	PUNCT
aiua-10838	8	1	furthermore	furthermore	ADV
aiua-10838	8	2	,	,	PUNCT
aiua-10838	8	3	new	new	ADJ
aiua-10838	8	4	therapeutic	therapeutic	ADJ
aiua-10838	8	5	agents	agent	NOUN
aiua-10838	8	6	such	such	ADJ
aiua-10838	8	7	as	as	ADP
aiua-10838	8	8	immune	immune	ADJ
aiua-10838	8	9	check	check	NOUN
aiua-10838	8	10	point	point	NOUN
aiua-10838	8	11	inhibitors	inhibitor	NOUN
aiua-10838	8	12	(	(	PUNCT
aiua-10838	8	13	ici	ici	PROPN
aiua-10838	8	14	)	)	PUNCT
aiua-10838	8	15	,	,	PUNCT
aiua-10838	8	16	presented	present	VERB
aiua-10838	8	17	as	as	ADP
aiua-10838	8	18	superior	superior	ADJ
aiua-10838	8	19	to	to	ADP
aiua-10838	8	20	tki	tki	NOUN
aiua-10838	8	21	in	in	ADP
aiua-10838	8	22	recent	recent	ADJ
aiua-10838	8	23	studies	study	NOUN
aiua-10838	8	24	(	(	PUNCT
aiua-10838	8	25	8	8	NUM
aiua-10838	8	26	-	-	SYM
aiua-10838	8	27	10	10	NUM
aiua-10838	8	28	)	)	PUNCT
aiua-10838	8	29	.	.	PUNCT
aiua-10838	9	1	these	these	DET
aiua-10838	9	2	controversial	controversial	ADJ
aiua-10838	9	3	observations	observation	NOUN
aiua-10838	9	4	prompted	prompt	VERB
aiua-10838	9	5	us	we	PRON
aiua-10838	9	6	to	to	PART
aiua-10838	9	7	conduct	conduct	VERB
aiua-10838	9	8	a	a	DET
aiua-10838	9	9	systematic	systematic	ADJ
aiua-10838	9	10	review	review	NOUN
aiua-10838	9	11	in	in	ADP
aiua-10838	9	12	order	order	NOUN
aiua-10838	9	13	to	to	PART
aiua-10838	9	14	examine	examine	VERB
aiua-10838	9	15	the	the	DET
aiua-10838	9	16	role	role	NOUN
aiua-10838	9	17	of	of	ADP
aiua-10838	9	18	cn	cn	PROPN
aiua-10838	9	19	for	for	ADP
aiua-10838	9	20	synchronous	synchronous	ADJ
aiua-10838	9	21	mrcc	mrcc	NOUN
aiua-10838	9	22	patients	patient	NOUN
aiua-10838	9	23	in	in	ADP
aiua-10838	9	24	the	the	DET
aiua-10838	9	25	st	st	PROPN
aiua-10838	9	26	era	era	NOUN
aiua-10838	9	27	and	and	CCONJ
aiua-10838	9	28	beyond	beyond	ADP
aiua-10838	9	29	regarding	regard	VERB
aiua-10838	9	30	the	the	DET
aiua-10838	9	31	overall	overall	ADJ
aiua-10838	9	32	survival	survival	NOUN
aiua-10838	9	33	(	(	PUNCT
aiua-10838	9	34	os	os	NOUN
aiua-10838	9	35	)	)	PUNCT
aiua-10838	9	36	,	,	PUNCT
aiua-10838	9	37	the	the	DET
aiua-10838	9	38	optimal	optimal	ADJ
aiua-10838	9	39	sequence	sequence	NOUN
aiua-10838	9	40	between	between	ADP
aiua-10838	9	41	st	st	PROPN
aiua-10838	9	42	and	and	CCONJ
aiua-10838	9	43	cn	cn	PROPN
aiua-10838	9	44	and	and	CCONJ
aiua-10838	9	45	prognostic	prognostic	ADJ
aiua-10838	9	46	factors	factor	NOUN
aiua-10838	9	47	.	.	PUNCT
aiua-10838	10	1	methods	method	NOUN
aiua-10838	10	2	the	the	DET
aiua-10838	10	3	systematic	systematic	ADJ
aiua-10838	10	4	review	review	NOUN
aiua-10838	10	5	was	be	AUX
aiua-10838	10	6	conducted	conduct	VERB
aiua-10838	10	7	in	in	ADP
aiua-10838	10	8	accordance	accordance	NOUN
aiua-10838	10	9	with	with	ADP
aiua-10838	10	10	the	the	DET
aiua-10838	10	11	prisma	prisma	NOUN
aiua-10838	10	12	guidelines	guideline	NOUN
aiua-10838	10	13	(	(	PUNCT
aiua-10838	10	14	preferred	preferred	ADJ
aiua-10838	10	15	reporting	reporting	NOUN
aiua-10838	10	16	items	item	NOUN
aiua-10838	10	17	for	for	ADP
aiua-10838	10	18	systematic	systematic	ADJ
aiua-10838	10	19	reviews	review	NOUN
aiua-10838	10	20	and	and	CCONJ
aiua-10838	10	21	meta	meta	ADJ
aiua-10838	10	22	-	-	PUNCT
aiua-10838	10	23	analysis	analysis	NOUN
aiua-10838	10	24	)	)	PUNCT
aiua-10838	10	25	(	(	PUNCT
aiua-10838	10	26	11	11	NUM
aiua-10838	10	27	)	)	PUNCT
aiua-10838	10	28	.	.	PUNCT
aiua-10838	11	1	bibliographic	bibliographic	ADJ
aiua-10838	11	2	search	search	NOUN
aiua-10838	11	3	was	be	AUX
aiua-10838	11	4	performed	perform	VERB
aiua-10838	11	5	in	in	ADP
aiua-10838	11	6	medline	medline	NOUN
aiua-10838	11	7	(	(	PUNCT
aiua-10838	11	8	pubmed	pubmed	PROPN
aiua-10838	11	9	)	)	PUNCT
aiua-10838	11	10	,	,	PUNCT
aiua-10838	11	11	clinicaltrials.gov	clinicaltrials.gov	X
aiua-10838	11	12	,	,	PUNCT
aiua-10838	11	13	and	and	CCONJ
aiua-10838	11	14	cochrane	cochrane	PROPN
aiua-10838	11	15	library	library	PROPN
aiua-10838	11	16	-	-	PUNCT
aiua-10838	11	17	cochrane	cochrane	PROPN
aiua-10838	11	18	central	central	ADJ
aiua-10838	11	19	register	register	NOUN
aiua-10838	11	20	of	of	ADP
aiua-10838	11	21	controlled	control	VERB
aiua-10838	11	22	trials	trial	NOUN
aiua-10838	11	23	(	(	PUNCT
aiua-10838	11	24	central	central	ADJ
aiua-10838	11	25	)	)	PUNCT
aiua-10838	11	26	.	.	PUNCT
aiua-10838	12	1	studies	study	NOUN
aiua-10838	12	2	included	include	VERB
aiua-10838	12	3	were	be	AUX
aiua-10838	12	4	those	those	PRON
aiua-10838	12	5	indexed	index	VERB
aiua-10838	12	6	from	from	ADP
aiua-10838	12	7	2005	2005	NUM
aiua-10838	12	8	in	in	ADP
aiua-10838	12	9	an	an	DET
aiua-10838	12	10	attempt	attempt	NOUN
aiua-10838	12	11	to	to	PART
aiua-10838	12	12	limit	limit	VERB
aiua-10838	12	13	those	those	PRON
aiua-10838	12	14	conducted	conduct	VERB
aiua-10838	12	15	in	in	ADP
aiua-10838	12	16	the	the	DET
aiua-10838	12	17	cytokine	cytokine	ADJ
aiua-10838	12	18	era	era	NOUN
aiua-10838	12	19	.	.	PUNCT
aiua-10838	13	1	the	the	DET
aiua-10838	13	2	last	last	ADJ
aiua-10838	13	3	search	search	NOUN
aiua-10838	13	4	date	date	NOUN
aiua-10838	13	5	was	be	AUX
aiua-10838	13	6	march	march	PROPN
aiua-10838	13	7	14	14	NUM
aiua-10838	13	8	,	,	PUNCT
aiua-10838	13	9	2022	2022	NUM
aiua-10838	13	10	.	.	PUNCT
aiua-10838	14	1	the	the	DET
aiua-10838	14	2	following	follow	VERB
aiua-10838	14	3	medical	medical	ADJ
aiua-10838	14	4	subject	subject	NOUN
aiua-10838	14	5	heading	head	VERB
aiua-10838	14	6	terms	term	NOUN
aiua-10838	14	7	were	be	AUX
aiua-10838	14	8	used	use	VERB
aiua-10838	14	9	in	in	ADP
aiua-10838	14	10	combination	combination	NOUN
aiua-10838	14	11	with	with	ADP
aiua-10838	14	12	boolean	boolean	ADJ
aiua-10838	14	13	operators	operator	NOUN
aiua-10838	14	14	(	(	PUNCT
aiua-10838	14	15	and	and	CCONJ
aiua-10838	14	16	,	,	PUNCT
aiua-10838	14	17	or	or	CCONJ
aiua-10838	14	18	,	,	PUNCT
aiua-10838	14	19	not	not	PART
aiua-10838	14	20	):	):	PUNCT
aiua-10838	14	21	(	(	PUNCT
aiua-10838	14	22	“	"	PUNCT
aiua-10838	14	23	cytoreductive	cytoreductive	ADJ
aiua-10838	14	24	nephrectomy	nephrectomy	NOUN
aiua-10838	14	25	”	"	PUNCT
aiua-10838	14	26	)	)	PUNCT
aiua-10838	14	27	and	and	CCONJ
aiua-10838	14	28	(	(	PUNCT
aiua-10838	14	29	"	"	PUNCT
aiua-10838	14	30	targeted	targeted	ADJ
aiua-10838	14	31	therapy	therapy	NOUN
aiua-10838	14	32	"	"	PUNCT
aiua-10838	14	33	or	or	CCONJ
aiua-10838	14	34	"	"	PUNCT
aiua-10838	14	35	systemic	systemic	ADJ
aiua-10838	14	36	therapy	therapy	NOUN
aiua-10838	14	37	"	"	PUNCT
aiua-10838	14	38	or	or	CCONJ
aiua-10838	14	39	“	"	PUNCT
aiua-10838	14	40	immune	immune	ADJ
aiua-10838	14	41	oncology	oncology	NOUN
aiua-10838	14	42	[	[	X
aiua-10838	14	43	io	io	X
aiua-10838	14	44	]	]	X
aiua-10838	14	45	”	"	PUNCT
aiua-10838	14	46	or	or	CCONJ
aiua-10838	14	47	immunotherapy	immunotherapy	NOUN
aiua-10838	14	48	or	or	CCONJ
aiua-10838	14	49	"	"	PUNCT
aiua-10838	14	50	immune	immune	ADJ
aiua-10838	14	51	checkpoint	checkpoint	NOUN
aiua-10838	14	52	inhibitor	inhibitor	NOUN
aiua-10838	14	53	*	*	PUNCT
aiua-10838	14	54	"	"	PUNCT
aiua-10838	14	55	or	or	CCONJ
aiua-10838	14	56	“	"	PUNCT
aiua-10838	14	57	immunooncology	immunooncology	NOUN
aiua-10838	14	58	”	"	PUNCT
aiua-10838	14	59	)	)	PUNCT
aiua-10838	14	60	not	not	PART
aiua-10838	14	61	(	(	PUNCT
aiua-10838	14	62	review[publication	review[publication	NOUN
aiua-10838	14	63	type	type	NOUN
aiua-10838	14	64	]	]	PUNCT
aiua-10838	14	65	)	)	PUNCT
aiua-10838	14	66	not	not	PART
aiua-10838	14	67	(	(	PUNCT
aiua-10838	14	68	meta	meta	ADJ
aiua-10838	14	69	-	-	PUNCT
aiua-10838	14	70	analysis[publication	analysis[publication	NOUN
aiua-10838	14	71	type	type	NOUN
aiua-10838	14	72	]	]	PUNCT
aiua-10838	14	73	)	)	PUNCT
aiua-10838	14	74	not	not	PART
aiua-10838	14	75	(	(	PUNCT
aiua-10838	14	76	systematic	systematic	ADJ
aiua-10838	14	77	review[publication	review[publication	NOUN
aiua-10838	14	78	type	type	NOUN
aiua-10838	14	79	]	]	PUNCT
aiua-10838	14	80	)	)	PUNCT
aiua-10838	14	81	.	.	PUNCT
aiua-10838	15	1	two	two	NUM
aiua-10838	15	2	independent	independent	ADJ
aiua-10838	15	3	reviewers	reviewer	NOUN
aiua-10838	15	4	(	(	PUNCT
aiua-10838	15	5	k.s	k.s	PROPN
aiua-10838	15	6	,	,	PUNCT
aiua-10838	15	7	t.l	t.l	PROPN
aiua-10838	15	8	)	)	PUNCT
aiua-10838	15	9	screened	screen	VERB
aiua-10838	15	10	all	all	DET
aiua-10838	15	11	articles	article	NOUN
aiua-10838	15	12	retrieved	retrieve	VERB
aiua-10838	15	13	by	by	ADP
aiua-10838	15	14	the	the	DET
aiua-10838	15	15	initial	initial	ADJ
aiua-10838	15	16	search	search	NOUN
aiua-10838	15	17	.	.	PUNCT
aiua-10838	16	1	all	all	DET
aiua-10838	16	2	disagreements	disagreement	NOUN
aiua-10838	16	3	were	be	AUX
aiua-10838	16	4	objective	objective	ADJ
aiua-10838	16	5	:	:	PUNCT
aiua-10838	16	6	to	to	PART
aiua-10838	16	7	assess	assess	VERB
aiua-10838	16	8	the	the	DET
aiua-10838	16	9	role	role	NOUN
aiua-10838	16	10	of	of	ADP
aiua-10838	16	11	cytoreductive	cytoreductive	ADJ
aiua-10838	16	12	nephrectomy	nephrectomy	NOUN
aiua-10838	16	13	for	for	ADP
aiua-10838	16	14	synchronous	synchronous	ADJ
aiua-10838	16	15	metastatic	metastatic	ADJ
aiua-10838	16	16	renal	renal	ADJ
aiua-10838	16	17	cell	cell	NOUN
aiua-10838	16	18	carcinoma	carcinoma	NOUN
aiua-10838	16	19	patients	patient	NOUN
aiua-10838	16	20	in	in	ADP
aiua-10838	16	21	the	the	DET
aiua-10838	16	22	systemic	systemic	ADJ
aiua-10838	16	23	therapy	therapy	NOUN
aiua-10838	16	24	era	era	NOUN
aiua-10838	16	25	and	and	CCONJ
aiua-10838	16	26	beyond	beyond	ADP
aiua-10838	16	27	regarding	regard	VERB
aiua-10838	16	28	the	the	DET
aiua-10838	16	29	overall	overall	ADJ
aiua-10838	16	30	survival	survival	NOUN
aiua-10838	16	31	,	,	PUNCT
aiua-10838	16	32	the	the	DET
aiua-10838	16	33	optimal	optimal	ADJ
aiua-10838	16	34	sequence	sequence	NOUN
aiua-10838	16	35	between	between	ADP
aiua-10838	16	36	systemic	systemic	ADJ
aiua-10838	16	37	therapy	therapy	NOUN
aiua-10838	16	38	and	and	CCONJ
aiua-10838	16	39	cytoreductive	cytoreductive	ADJ
aiua-10838	16	40	nephrectomy	nephrectomy	ADJ
aiua-10838	16	41	and	and	CCONJ
aiua-10838	16	42	prognostic	prognostic	ADJ
aiua-10838	16	43	factors	factor	NOUN
aiua-10838	16	44	.	.	PUNCT
aiua-10838	17	1	methods	method	NOUN
aiua-10838	17	2	:	:	PUNCT
aiua-10838	17	3	the	the	DET
aiua-10838	17	4	systematic	systematic	ADJ
aiua-10838	17	5	review	review	NOUN
aiua-10838	17	6	was	be	AUX
aiua-10838	17	7	conducted	conduct	VERB
aiua-10838	17	8	in	in	ADP
aiua-10838	17	9	accordance	accordance	NOUN
aiua-10838	17	10	with	with	ADP
aiua-10838	17	11	the	the	DET
aiua-10838	17	12	prisma	prisma	PROPN
aiua-10838	17	13	guidelines	guideline	NOUN
aiua-10838	17	14	.	.	PUNCT
aiua-10838	18	1	bibliographic	bibliographic	ADJ
aiua-10838	18	2	search	search	NOUN
aiua-10838	18	3	was	be	AUX
aiua-10838	18	4	performed	perform	VERB
aiua-10838	18	5	in	in	ADP
aiua-10838	18	6	medline	medline	NOUN
aiua-10838	18	7	(	(	PUNCT
aiua-10838	18	8	pubmed	pubmed	PROPN
aiua-10838	18	9	)	)	PUNCT
aiua-10838	18	10	,	,	PUNCT
aiua-10838	18	11	clinicaltrials.gov	clinicaltrials.gov	X
aiua-10838	18	12	,	,	PUNCT
aiua-10838	18	13	and	and	CCONJ
aiua-10838	18	14	cochrane	cochrane	PROPN
aiua-10838	18	15	library	library	PROPN
aiua-10838	18	16	-	-	PUNCT
aiua-10838	18	17	cochrane	cochrane	PROPN
aiua-10838	18	18	central	central	ADJ
aiua-10838	18	19	register	register	NOUN
aiua-10838	18	20	of	of	ADP
aiua-10838	18	21	controlled	control	VERB
aiua-10838	18	22	trials	trial	NOUN
aiua-10838	18	23	(	(	PUNCT
aiua-10838	18	24	central	central	ADJ
aiua-10838	18	25	)	)	PUNCT
aiua-10838	18	26	.	.	PUNCT
aiua-10838	19	1	studies	study	NOUN
aiua-10838	19	2	included	include	VERB
aiua-10838	19	3	were	be	AUX
aiua-10838	19	4	those	those	PRON
aiua-10838	19	5	indexed	index	VERB
aiua-10838	19	6	from	from	ADP
aiua-10838	19	7	2005	2005	NUM
aiua-10838	19	8	in	in	ADP
aiua-10838	19	9	an	an	DET
aiua-10838	19	10	attempt	attempt	NOUN
aiua-10838	19	11	to	to	PART
aiua-10838	19	12	limit	limit	VERB
aiua-10838	19	13	those	those	PRON
aiua-10838	19	14	conducted	conduct	VERB
aiua-10838	19	15	in	in	ADP
aiua-10838	19	16	the	the	DET
aiua-10838	19	17	cytokine	cytokine	ADJ
aiua-10838	19	18	era	era	NOUN
aiua-10838	19	19	.	.	PUNCT
aiua-10838	20	1	risk	risk	NOUN
aiua-10838	20	2	of	of	ADP
aiua-10838	20	3	bias	bias	NOUN
aiua-10838	20	4	assessment	assessment	NOUN
aiua-10838	20	5	was	be	AUX
aiua-10838	20	6	performed	perform	VERB
aiua-10838	20	7	by	by	ADP
aiua-10838	20	8	two	two	NUM
aiua-10838	20	9	authors	author	NOUN
aiua-10838	20	10	(	(	PUNCT
aiua-10838	20	11	k.s	k.s	NOUN
aiua-10838	20	12	and	and	CCONJ
aiua-10838	20	13	t.l	t.l	NOUN
aiua-10838	20	14	)	)	PUNCT
aiua-10838	20	15	using	use	VERB
aiua-10838	20	16	the	the	DET
aiua-10838	20	17	cochrane	cochrane	NOUN
aiua-10838	20	18	collaborative	collaborative	ADJ
aiua-10838	20	19	risk	risk	NOUN
aiua-10838	20	20	of	of	ADP
aiua-10838	20	21	bias	bias	NOUN
aiua-10838	20	22	tool	tool	NOUN
aiua-10838	20	23	for	for	ADP
aiua-10838	20	24	randomized	randomized	ADJ
aiua-10838	20	25	trials	trial	NOUN
aiua-10838	20	26	,	,	PUNCT
aiua-10838	20	27	the	the	DET
aiua-10838	20	28	cochrane	cochrane	NOUN
aiua-10838	20	29	risk	risk	NOUN
aiua-10838	20	30	of	of	ADP
aiua-10838	20	31	bias	bias	NOUN
aiua-10838	20	32	in	in	ADP
aiua-10838	20	33	non	non	ADJ
aiua-10838	20	34	-	-	ADJ
aiua-10838	20	35	randomized	randomized	ADJ
aiua-10838	20	36	studies	study	NOUN
aiua-10838	20	37	of	of	ADP
aiua-10838	20	38	interventions	intervention	NOUN
aiua-10838	20	39	(	(	PUNCT
aiua-10838	20	40	robins	robin	NOUN
aiua-10838	20	41	-	-	PUNCT
aiua-10838	20	42	i	i	NOUN
aiua-10838	20	43	)	)	PUNCT
aiua-10838	20	44	tool	tool	NOUN
aiua-10838	20	45	for	for	ADP
aiua-10838	20	46	nonrandomized	nonrandomize	VERB
aiua-10838	20	47	studies	study	NOUN
aiua-10838	20	48	.	.	PUNCT
aiua-10838	21	1	results	result	NOUN
aiua-10838	21	2	:	:	PUNCT
aiua-10838	21	3	cytoreductive	cytoreductive	ADJ
aiua-10838	21	4	nephrectomy	nephrectomy	NOUN
aiua-10838	21	5	was	be	AUX
aiua-10838	21	6	associated	associate	VERB
aiua-10838	21	7	with	with	ADP
aiua-10838	21	8	improved	improve	VERB
aiua-10838	21	9	overall	overall	ADJ
aiua-10838	21	10	survival	survival	NOUN
aiua-10838	21	11	in	in	ADP
aiua-10838	21	12	all	all	PRON
aiua-10838	21	13	but	but	SCONJ
aiua-10838	21	14	one	one	NUM
aiua-10838	21	15	of	of	ADP
aiua-10838	21	16	the	the	DET
aiua-10838	21	17	observational	observational	ADJ
aiua-10838	21	18	studies	study	NOUN
aiua-10838	21	19	.	.	PUNCT
aiua-10838	22	1	while	while	SCONJ
aiua-10838	22	2	in	in	ADP
aiua-10838	22	3	all	all	PRON
aiua-10838	22	4	of	of	ADP
aiua-10838	22	5	these	these	DET
aiua-10838	22	6	studies	study	NOUN
aiua-10838	22	7	the	the	DET
aiua-10838	22	8	unvariable	unvariable	ADJ
aiua-10838	22	9	analysis	analysis	NOUN
aiua-10838	22	10	showed	show	VERB
aiua-10838	22	11	improved	improve	VERB
aiua-10838	22	12	overall	overall	ADJ
aiua-10838	22	13	survival	survival	NOUN
aiua-10838	22	14	in	in	ADP
aiua-10838	22	15	favor	favor	NOUN
aiua-10838	22	16	of	of	ADP
aiua-10838	22	17	the	the	DET
aiua-10838	22	18	cytoreductive	cytoreductive	ADJ
aiua-10838	22	19	nephrectomy	nephrectomy	ADJ
aiua-10838	22	20	group	group	NOUN
aiua-10838	22	21	in	in	ADP
aiua-10838	22	22	some	some	DET
aiua-10838	22	23	studies	study	NOUN
aiua-10838	22	24	the	the	DET
aiua-10838	22	25	subgroup	subgroup	NOUN
aiua-10838	22	26	analysis	analysis	NOUN
aiua-10838	22	27	showed	show	VERB
aiua-10838	22	28	no	no	DET
aiua-10838	22	29	benefit	benefit	NOUN
aiua-10838	22	30	.	.	PUNCT
aiua-10838	23	1	regarding	regard	VERB
aiua-10838	23	2	the	the	DET
aiua-10838	23	3	optimal	optimal	ADJ
aiua-10838	23	4	sequence	sequence	NOUN
aiua-10838	23	5	,	,	PUNCT
aiua-10838	23	6	deferred	defer	VERB
aiua-10838	23	7	cytoreductive	cytoreductive	ADJ
aiua-10838	23	8	nephrectomy	nephrectomy	NOUN
aiua-10838	23	9	demonstrated	demonstrate	VERB
aiua-10838	23	10	better	well	ADJ
aiua-10838	23	11	results	result	NOUN
aiua-10838	23	12	in	in	ADP
aiua-10838	23	13	more	more	ADJ
aiua-10838	23	14	studies	study	NOUN
aiua-10838	23	15	than	than	ADP
aiua-10838	23	16	upfront	upfront	ADJ
aiua-10838	23	17	cytoreductive	cytoreductive	ADJ
aiua-10838	23	18	nephrectomy	nephrectomy	NOUN
aiua-10838	23	19	but	but	CCONJ
aiua-10838	23	20	a	a	DET
aiua-10838	23	21	advantage	advantage	NOUN
aiua-10838	23	22	was	be	AUX
aiua-10838	23	23	not	not	PART
aiua-10838	23	24	clearly	clearly	ADV
aiua-10838	23	25	certain	certain	ADJ
aiua-10838	23	26	.	.	PUNCT
aiua-10838	24	1	in	in	ADP
aiua-10838	24	2	the	the	DET
aiua-10838	24	3	analysis	analysis	NOUN
aiua-10838	24	4	of	of	ADP
aiua-10838	24	5	possible	possible	ADJ
aiua-10838	24	6	prognostic	prognostic	ADJ
aiua-10838	24	7	factors	factor	NOUN
aiua-10838	24	8	for	for	ADP
aiua-10838	24	9	overall	overall	ADJ
aiua-10838	24	10	survival	survival	NOUN
aiua-10838	24	11	with	with	ADP
aiua-10838	24	12	cytoreductive	cytoreductive	ADJ
aiua-10838	24	13	nephrectomy	nephrectomy	NOUN
aiua-10838	24	14	,	,	PUNCT
aiua-10838	24	15	most	most	ADV
aiua-10838	24	16	common	common	ADJ
aiua-10838	24	17	prognostic	prognostic	ADJ
aiua-10838	24	18	factors	factor	NOUN
aiua-10838	24	19	found	find	VERB
aiua-10838	24	20	were	be	AUX
aiua-10838	24	21	age	age	NOUN
aiua-10838	24	22	(	(	PUNCT
aiua-10838	24	23	in	in	ADP
aiua-10838	24	24	8	8	NUM
aiua-10838	24	25	studies	study	NOUN
aiua-10838	24	26	)	)	PUNCT
aiua-10838	24	27	,	,	PUNCT
aiua-10838	24	28	tumor	tumor	NOUN
aiua-10838	24	29	histology	histology	NOUN
aiua-10838	24	30	(	(	PUNCT
aiua-10838	24	31	in	in	ADP
aiua-10838	24	32	7	7	NUM
aiua-10838	24	33	studies	study	NOUN
aiua-10838	24	34	)	)	PUNCT
aiua-10838	24	35	,	,	PUNCT
aiua-10838	24	36	number	number	NOUN
aiua-10838	24	37	of	of	ADP
aiua-10838	24	38	metastasis	metastasis	NOUN
aiua-10838	24	39	(	(	PUNCT
aiua-10838	24	40	in	in	ADP
aiua-10838	24	41	6	6	NUM
aiua-10838	24	42	studies	study	NOUN
aiua-10838	24	43	)	)	PUNCT
aiua-10838	24	44	,	,	PUNCT
aiua-10838	24	45	and	and	CCONJ
aiua-10838	24	46	t	t	NOUN
aiua-10838	24	47	stage	stage	NOUN
aiua-10838	24	48	.	.	PUNCT
aiua-10838	25	1	conclusions	conclusion	NOUN
aiua-10838	25	2	:	:	PUNCT
aiua-10838	25	3	cytoreductive	cytoreductive	ADJ
aiua-10838	25	4	nephrectomy	nephrectomy	NOUN
aiua-10838	25	5	can	can	AUX
aiua-10838	25	6	still	still	ADV
aiua-10838	25	7	play	play	VERB
aiua-10838	25	8	an	an	DET
aiua-10838	25	9	important	important	ADJ
aiua-10838	25	10	role	role	NOUN
aiua-10838	25	11	in	in	ADP
aiua-10838	25	12	wisely	wisely	ADV
aiua-10838	25	13	selected	select	VERB
aiua-10838	25	14	patients	patient	NOUN
aiua-10838	25	15	,	,	PUNCT
aiua-10838	25	16	although	although	SCONJ
aiua-10838	25	17	the	the	DET
aiua-10838	25	18	role	role	NOUN
aiua-10838	25	19	of	of	ADP
aiua-10838	25	20	cytoreductive	cytoreductive	ADJ
aiua-10838	25	21	nephrectomy	nephrectomy	NOUN
aiua-10838	25	22	in	in	ADP
aiua-10838	25	23	the	the	DET
aiua-10838	25	24	new	new	ADJ
aiua-10838	25	25	immunotherapy	immunotherapy	NOUN
aiua-10838	25	26	era	era	NOUN
aiua-10838	25	27	needs	need	VERB
aiua-10838	25	28	to	to	PART
aiua-10838	25	29	be	be	AUX
aiua-10838	25	30	defined	define	VERB
aiua-10838	25	31	.	.	PUNCT
aiua-10838	26	1	key	key	ADJ
aiua-10838	26	2	words	word	NOUN
aiua-10838	26	3	:	:	PUNCT
aiua-10838	26	4	cytoreductive	cytoreductive	ADJ
aiua-10838	26	5	nephrectomy	nephrectomy	NOUN
aiua-10838	26	6	;	;	PUNCT
aiua-10838	26	7	metastatic	metastatic	ADJ
aiua-10838	26	8	renal	renal	ADJ
aiua-10838	26	9	cell	cell	NOUN
aiua-10838	26	10	carcinoma	carcinoma	NOUN
aiua-10838	26	11	;	;	PUNCT
aiua-10838	26	12	systemic	systemic	ADJ
aiua-10838	26	13	therapy	therapy	NOUN
aiua-10838	26	14	;	;	PUNCT
aiua-10838	26	15	immune	immune	ADJ
aiua-10838	26	16	check	check	NOUN
aiua-10838	26	17	point	point	NOUN
aiua-10838	26	18	inhibitors	inhibitor	NOUN
aiua-10838	26	19	.	.	PUNCT
aiua-10838	26	20	submitted	submit	VERB
aiua-10838	26	21	4	4	NUM
aiua-10838	26	22	september	september	PROPN
aiua-10838	26	23	2022	2022	NUM
aiua-10838	26	24	;	;	PUNCT
aiua-10838	26	25	accepted	accept	VERB
aiua-10838	26	26	2	2	NUM
aiua-10838	26	27	october	october	PROPN
aiua-10838	26	28	2022	2022	NUM
aiua-10838	26	29	introduction	introduction	NOUN
aiua-10838	26	30	during	during	ADP
aiua-10838	26	31	the	the	DET
aiua-10838	26	32	last	last	ADJ
aiua-10838	26	33	two	two	NUM
aiua-10838	26	34	decades	decade	NOUN
aiua-10838	26	35	,	,	PUNCT
aiua-10838	26	36	the	the	DET
aiua-10838	26	37	role	role	NOUN
aiua-10838	26	38	of	of	ADP
aiua-10838	26	39	cytoreductive	cytoreductive	ADJ
aiua-10838	26	40	nephrectomy	nephrectomy	NOUN
aiua-10838	26	41	(	(	PUNCT
aiua-10838	26	42	cn	cn	INTJ
aiua-10838	26	43	)	)	PUNCT
aiua-10838	26	44	in	in	ADP
aiua-10838	26	45	the	the	DET
aiua-10838	26	46	treatment	treatment	NOUN
aiua-10838	26	47	of	of	ADP
aiua-10838	26	48	synchronous	synchronous	ADJ
aiua-10838	26	49	metastatic	metastatic	ADJ
aiua-10838	26	50	renal	renal	ADJ
aiua-10838	26	51	cell	cell	NOUN
aiua-10838	26	52	carcinoma	carcinoma	NOUN
aiua-10838	26	53	(	(	PUNCT
aiua-10838	26	54	mrcc	mrcc	NOUN
aiua-10838	26	55	)	)	PUNCT
aiua-10838	26	56	has	have	AUX
aiua-10838	26	57	been	be	AUX
aiua-10838	26	58	reevaluated	reevaluate	VERB
aiua-10838	26	59	many	many	ADJ
aiua-10838	26	60	times	time	NOUN
aiua-10838	26	61	according	accord	VERB
aiua-10838	26	62	to	to	ADP
aiua-10838	26	63	the	the	DET
aiua-10838	26	64	newly	newly	ADV
aiua-10838	26	65	discovered	discover	VERB
aiua-10838	26	66	different	different	ADJ
aiua-10838	26	67	oncological	oncological	ADJ
aiua-10838	26	68	therapies	therapy	NOUN
aiua-10838	26	69	.	.	PUNCT
aiua-10838	27	1	in	in	ADP
aiua-10838	27	2	the	the	DET
aiua-10838	27	3	cytokine	cytokine	ADJ
aiua-10838	27	4	era	era	NOUN
aiua-10838	27	5	,	,	PUNCT
aiua-10838	27	6	due	due	ADP
aiua-10838	27	7	to	to	ADP
aiua-10838	27	8	lack	lack	NOUN
aiua-10838	27	9	of	of	ADP
aiua-10838	27	10	significant	significant	ADJ
aiua-10838	27	11	effectiveness	effectiveness	NOUN
aiua-10838	27	12	of	of	ADP
aiua-10838	27	13	medical	medical	ADJ
aiua-10838	27	14	therapies	therapy	NOUN
aiua-10838	27	15	,	,	PUNCT
aiua-10838	27	16	cn	cn	X
aiua-10838	27	17	cytoreductive	cytoreductive	ADJ
aiua-10838	27	18	nephrectomy	nephrectomy	ADV
aiua-10838	27	19	for	for	ADP
aiua-10838	27	20	synchronous	synchronous	ADJ
aiua-10838	27	21	metastatic	metastatic	ADJ
aiua-10838	27	22	renal	renal	ADJ
aiua-10838	27	23	cell	cell	NOUN
aiua-10838	27	24	carcinoma	carcinoma	NOUN
aiua-10838	27	25	.	.	PUNCT
aiua-10838	28	1	is	be	AUX
aiua-10838	28	2	there	there	PRON
aiua-10838	28	3	enough	enough	ADJ
aiua-10838	28	4	evidence	evidence	NOUN
aiua-10838	28	5	?	?	PUNCT
aiua-10838	29	1	stamatios	stamatio	NOUN
aiua-10838	29	2	katsimperis	katsimperis	NOUN
aiua-10838	29	3	,	,	PUNCT
aiua-10838	29	4	lazaros	lazaro	VERB
aiua-10838	29	5	tzelves	tzelve	NOUN
aiua-10838	29	6	,	,	PUNCT
aiua-10838	29	7	themistoklis	themistoklis	PROPN
aiua-10838	29	8	bellos	bello	NOUN
aiua-10838	29	9	,	,	PUNCT
aiua-10838	29	10	konstantinos	konstantinos	PROPN
aiua-10838	29	11	pikramenos	pikramenos	PROPN
aiua-10838	29	12	,	,	PUNCT
aiua-10838	29	13	ioannis	ioannis	PROPN
aiua-10838	29	14	manolitsis	manolitsis	PROPN
aiua-10838	29	15	,	,	PUNCT
aiua-10838	29	16	ioannis	ioannis	PROPN
aiua-10838	29	17	tsikopoulos	tsikopoulos	PROPN
aiua-10838	29	18	,	,	PUNCT
aiua-10838	29	19	iraklis	iraklis	PROPN
aiua-10838	29	20	mitsogiannis	mitsogiannis	PROPN
aiua-10838	29	21	department	department	PROPN
aiua-10838	29	22	of	of	ADP
aiua-10838	29	23	urology	urology	NOUN
aiua-10838	29	24	,	,	PUNCT
aiua-10838	29	25	athens	athens	PROPN
aiua-10838	29	26	,	,	PUNCT
aiua-10838	29	27	greece	greece	PROPN
aiua-10838	29	28	.	.	PUNCT
aiua-10838	30	1	doi	doi	PROPN
aiua-10838	30	2	:	:	PUNCT
aiua-10838	30	3	10.4081	10.4081	NUM
aiua-10838	30	4	/	/	SYM
aiua-10838	30	5	aiua.2022.4.476	aiua.2022.4.476	NOUN
aiua-10838	30	6	summary	summary	NOUN
aiua-10838	30	7	477archivio	477archivio	PROPN
aiua-10838	30	8	italiano	italiano	NOUN
aiua-10838	30	9	di	di	X
aiua-10838	30	10	urologia	urologia	PROPN
aiua-10838	30	11	e	e	PROPN
aiua-10838	30	12	andrologia	andrologia	PROPN
aiua-10838	30	13	2022	2022	NUM
aiua-10838	30	14	;	;	PUNCT
aiua-10838	30	15	94	94	NUM
aiua-10838	30	16	,	,	PUNCT
aiua-10838	30	17	4	4	NUM
aiua-10838	30	18	nephrectomy	nephrectomy	NOUN
aiua-10838	30	19	for	for	ADP
aiua-10838	30	20	metastatic	metastatic	ADJ
aiua-10838	30	21	renal	renal	ADJ
aiua-10838	30	22	cell	cell	NOUN
aiua-10838	30	23	carcinoma	carcinoma	NOUN
aiua-10838	30	24	resolved	resolve	VERB
aiua-10838	30	25	with	with	ADP
aiua-10838	30	26	discussion	discussion	NOUN
aiua-10838	30	27	,	,	PUNCT
aiua-10838	30	28	and	and	CCONJ
aiua-10838	30	29	final	final	ADJ
aiua-10838	30	30	decision	decision	NOUN
aiua-10838	30	31	was	be	AUX
aiua-10838	30	32	reached	reach	VERB
aiua-10838	30	33	by	by	ADP
aiua-10838	30	34	consensus	consensus	NOUN
aiua-10838	30	35	with	with	ADP
aiua-10838	30	36	a	a	DET
aiua-10838	30	37	third	third	ADJ
aiua-10838	30	38	reviewer	reviewer	NOUN
aiua-10838	30	39	(	(	PUNCT
aiua-10838	30	40	m.i	m.i	PROPN
aiua-10838	30	41	.	.	PROPN
aiua-10838	30	42	)	)	PUNCT
aiua-10838	30	43	.	.	PUNCT
aiua-10838	31	1	reference	reference	NOUN
aiua-10838	31	2	lists	list	NOUN
aiua-10838	31	3	were	be	AUX
aiua-10838	31	4	systematically	systematically	ADV
aiua-10838	31	5	searched	search	VERB
aiua-10838	31	6	for	for	ADP
aiua-10838	31	7	relevant	relevant	ADJ
aiua-10838	31	8	articles	article	NOUN
aiua-10838	31	9	in	in	ADP
aiua-10838	31	10	a	a	DET
aiua-10838	31	11	snowball	snowball	ADJ
aiua-10838	31	12	procedure	procedure	NOUN
aiua-10838	31	13	.	.	PUNCT
aiua-10838	32	1	an	an	DET
aiua-10838	32	2	ethical	ethical	ADJ
aiua-10838	32	3	approval	approval	NOUN
aiua-10838	32	4	is	be	AUX
aiua-10838	32	5	not	not	PART
aiua-10838	32	6	required	require	VERB
aiua-10838	32	7	because	because	SCONJ
aiua-10838	32	8	this	this	DET
aiua-10838	32	9	study	study	NOUN
aiua-10838	32	10	is	be	AUX
aiua-10838	32	11	a	a	DET
aiua-10838	32	12	review	review	NOUN
aiua-10838	32	13	of	of	ADP
aiua-10838	32	14	the	the	DET
aiua-10838	32	15	existing	exist	VERB
aiua-10838	32	16	international	international	ADJ
aiua-10838	32	17	literature	literature	NOUN
aiua-10838	32	18	.	.	PUNCT
aiua-10838	33	1	study	study	NOUN
aiua-10838	33	2	criteria	criterion	NOUN
aiua-10838	33	3	clinical	clinical	ADJ
aiua-10838	33	4	trials	trial	NOUN
aiua-10838	33	5	,	,	PUNCT
aiua-10838	33	6	cohort	cohort	NOUN
aiua-10838	33	7	studies	study	NOUN
aiua-10838	33	8	,	,	PUNCT
aiua-10838	33	9	and	and	CCONJ
aiua-10838	33	10	case	case	NOUN
aiua-10838	33	11	-	-	PUNCT
aiua-10838	33	12	control	control	NOUN
aiua-10838	33	13	studies	study	NOUN
aiua-10838	33	14	were	be	AUX
aiua-10838	33	15	considered	consider	VERB
aiua-10838	33	16	for	for	ADP
aiua-10838	33	17	inclusion	inclusion	NOUN
aiua-10838	33	18	(	(	PUNCT
aiua-10838	33	19	figure	figure	NOUN
aiua-10838	33	20	1	1	NUM
aiua-10838	33	21	)	)	PUNCT
aiua-10838	33	22	.	.	PUNCT
aiua-10838	34	1	excluded	exclude	VERB
aiua-10838	34	2	studies	study	NOUN
aiua-10838	34	3	met	meet	VERB
aiua-10838	34	4	≥	≥	NOUN
aiua-10838	34	5	1	1	NUM
aiua-10838	34	6	of	of	ADP
aiua-10838	34	7	the	the	DET
aiua-10838	34	8	following	follow	VERB
aiua-10838	34	9	criteria	criterion	NOUN
aiua-10838	34	10	:	:	PUNCT
aiua-10838	34	11	(	(	PUNCT
aiua-10838	34	12	1	1	X
aiua-10838	34	13	)	)	PUNCT
aiua-10838	34	14	irrelevant	irrelevant	ADJ
aiua-10838	34	15	to	to	ADP
aiua-10838	34	16	the	the	DET
aiua-10838	34	17	subject	subject	ADJ
aiua-10838	34	18	studies	study	NOUN
aiua-10838	34	19	,	,	PUNCT
aiua-10838	34	20	(	(	PUNCT
aiua-10838	34	21	2	2	X
aiua-10838	34	22	)	)	PUNCT
aiua-10838	34	23	studies	study	NOUN
aiua-10838	34	24	published	publish	VERB
aiua-10838	34	25	in	in	ADP
aiua-10838	34	26	a	a	DET
aiua-10838	34	27	nonenglish	nonenglish	ADJ
aiua-10838	34	28	language	language	NOUN
aiua-10838	34	29	,	,	PUNCT
aiua-10838	34	30	(	(	PUNCT
aiua-10838	34	31	3	3	X
aiua-10838	34	32	)	)	PUNCT
aiua-10838	34	33	case	case	NOUN
aiua-10838	34	34	reports	report	NOUN
aiua-10838	34	35	,	,	PUNCT
aiua-10838	34	36	case	case	NOUN
aiua-10838	34	37	series	series	NOUN
aiua-10838	34	38	including	include	VERB
aiua-10838	34	39	less	less	ADJ
aiua-10838	34	40	than	than	ADP
aiua-10838	34	41	10	10	NUM
aiua-10838	34	42	patients	patient	NOUN
aiua-10838	34	43	,	,	PUNCT
aiua-10838	34	44	systematic	systematic	ADJ
aiua-10838	34	45	reviews	review	NOUN
aiua-10838	34	46	and	and	CCONJ
aiua-10838	34	47	meta	meta	NOUN
aiua-10838	34	48	-	-	PUNCT
aiua-10838	34	49	analyses	analysis	NOUN
aiua-10838	34	50	,	,	PUNCT
aiua-10838	34	51	and	and	CCONJ
aiua-10838	34	52	(	(	PUNCT
aiua-10838	34	53	4	4	X
aiua-10838	34	54	)	)	PUNCT
aiua-10838	34	55	editorials	editorial	NOUN
aiua-10838	34	56	,	,	PUNCT
aiua-10838	34	57	perspectives	perspective	NOUN
aiua-10838	34	58	,	,	PUNCT
aiua-10838	34	59	and	and	CCONJ
aiua-10838	34	60	letters	letter	NOUN
aiua-10838	34	61	to	to	ADP
aiua-10838	34	62	the	the	DET
aiua-10838	34	63	editors	editor	NOUN
aiua-10838	34	64	,	,	PUNCT
aiua-10838	34	65	(	(	PUNCT
aiua-10838	34	66	5	5	X
aiua-10838	34	67	)	)	PUNCT
aiua-10838	34	68	studies	study	NOUN
aiua-10838	34	69	including	include	VERB
aiua-10838	34	70	only	only	ADJ
aiua-10838	34	71	drugs	drug	NOUN
aiua-10838	34	72	from	from	ADP
aiua-10838	34	73	cytokine	cytokine	ADJ
aiua-10838	34	74	era	era	NOUN
aiua-10838	34	75	(	(	PUNCT
aiua-10838	34	76	studies	study	NOUN
aiua-10838	34	77	excluded	exclude	VERB
aiua-10838	34	78	are	be	AUX
aiua-10838	34	79	summarized	summarize	VERB
aiua-10838	34	80	in	in	ADP
aiua-10838	34	81	supplementary	supplementary	ADJ
aiua-10838	34	82	table	table	NOUN
aiua-10838	34	83	1	1	NUM
aiua-10838	34	84	)	)	PUNCT
aiua-10838	34	85	.	.	PUNCT
aiua-10838	35	1	types	type	NOUN
aiua-10838	35	2	of	of	ADP
aiua-10838	35	3	participants	participant	NOUN
aiua-10838	35	4	and	and	CCONJ
aiua-10838	35	5	exposure	exposure	NOUN
aiua-10838	35	6	patients	patient	NOUN
aiua-10838	35	7	diagnosed	diagnose	VERB
aiua-10838	35	8	with	with	ADP
aiua-10838	35	9	synchronous	synchronous	ADJ
aiua-10838	35	10	mrcc	mrcc	NOUN
aiua-10838	35	11	,	,	PUNCT
aiua-10838	35	12	who	who	PRON
aiua-10838	35	13	underwent	undergo	VERB
aiua-10838	35	14	cn	cn	PROPN
aiua-10838	35	15	.	.	PUNCT
aiua-10838	35	16	studies	study	NOUN
aiua-10838	35	17	with	with	ADP
aiua-10838	35	18	patients	patient	NOUN
aiua-10838	35	19	undergoing	undergo	VERB
aiua-10838	35	20	partial	partial	ADJ
aiua-10838	35	21	nephrectomy	nephrectomy	NOUN
aiua-10838	35	22	,	,	PUNCT
aiua-10838	35	23	ablative	ablative	ADJ
aiua-10838	35	24	procedures	procedure	NOUN
aiua-10838	35	25	or	or	CCONJ
aiua-10838	35	26	nephrectomy	nephrectomy	NOUN
aiua-10838	35	27	for	for	ADP
aiua-10838	35	28	palliative	palliative	ADJ
aiua-10838	35	29	reasons	reason	NOUN
aiua-10838	35	30	were	be	AUX
aiua-10838	35	31	not	not	PART
aiua-10838	35	32	included	include	VERB
aiua-10838	35	33	.	.	PUNCT
aiua-10838	36	1	primary	primary	ADJ
aiua-10838	36	2	research	research	NOUN
aiua-10838	36	3	question	question	NOUN
aiua-10838	36	4	was	be	AUX
aiua-10838	36	5	the	the	DET
aiua-10838	36	6	effect	effect	NOUN
aiua-10838	36	7	of	of	ADP
aiua-10838	36	8	cn	cn	PROPN
aiua-10838	36	9	in	in	ADP
aiua-10838	36	10	the	the	DET
aiua-10838	36	11	os	os	NOUN
aiua-10838	36	12	.	.	PUNCT
aiua-10838	37	1	secondary	secondary	ADJ
aiua-10838	37	2	questions	question	NOUN
aiua-10838	37	3	were	be	AUX
aiua-10838	37	4	the	the	DET
aiua-10838	37	5	optimal	optimal	ADJ
aiua-10838	37	6	sequence	sequence	NOUN
aiua-10838	37	7	between	between	ADP
aiua-10838	37	8	systemic	systemic	ADJ
aiua-10838	37	9	therapies	therapy	NOUN
aiua-10838	37	10	and	and	CCONJ
aiua-10838	37	11	cn	cn	NOUN
aiua-10838	37	12	,	,	PUNCT
aiua-10838	37	13	and	and	CCONJ
aiua-10838	37	14	possible	possible	ADJ
aiua-10838	37	15	prognostic	prognostic	ADJ
aiua-10838	37	16	factors	factor	NOUN
aiua-10838	37	17	.	.	PUNCT
aiua-10838	38	1	risk	risk	NOUN
aiua-10838	38	2	of	of	ADP
aiua-10838	38	3	bias	bias	NOUN
aiua-10838	38	4	assessment	assessment	NOUN
aiua-10838	38	5	risk	risk	NOUN
aiua-10838	38	6	of	of	ADP
aiua-10838	38	7	bias	bias	NOUN
aiua-10838	38	8	assessment	assessment	NOUN
aiua-10838	38	9	was	be	AUX
aiua-10838	38	10	performed	perform	VERB
aiua-10838	38	11	by	by	ADP
aiua-10838	38	12	two	two	NUM
aiua-10838	38	13	authors	author	NOUN
aiua-10838	38	14	(	(	PUNCT
aiua-10838	38	15	k.s	k.s	NOUN
aiua-10838	38	16	and	and	CCONJ
aiua-10838	38	17	t.l	t.l	NOUN
aiua-10838	38	18	)	)	PUNCT
aiua-10838	38	19	using	use	VERB
aiua-10838	38	20	the	the	DET
aiua-10838	38	21	cochrane	cochrane	NOUN
aiua-10838	38	22	collaborative	collaborative	ADJ
aiua-10838	38	23	risk	risk	NOUN
aiua-10838	38	24	of	of	ADP
aiua-10838	38	25	bias	bias	NOUN
aiua-10838	38	26	tool	tool	NOUN
aiua-10838	38	27	for	for	ADP
aiua-10838	38	28	randomized	randomized	ADJ
aiua-10838	38	29	trials	trial	NOUN
aiua-10838	38	30	(	(	PUNCT
aiua-10838	38	31	12	12	NUM
aiua-10838	38	32	)	)	PUNCT
aiua-10838	38	33	,	,	PUNCT
aiua-10838	38	34	the	the	DET
aiua-10838	38	35	cochrane	cochrane	NOUN
aiua-10838	38	36	risk	risk	NOUN
aiua-10838	38	37	of	of	ADP
aiua-10838	38	38	bias	bias	NOUN
aiua-10838	38	39	in	in	ADP
aiua-10838	38	40	non	non	ADJ
aiua-10838	38	41	-	-	ADJ
aiua-10838	38	42	randomized	randomized	ADJ
aiua-10838	38	43	studies	study	NOUN
aiua-10838	38	44	of	of	ADP
aiua-10838	38	45	interventions	intervention	NOUN
aiua-10838	38	46	(	(	PUNCT
aiua-10838	38	47	robins	robin	NOUN
aiua-10838	38	48	-	-	PUNCT
aiua-10838	38	49	i	i	NOUN
aiua-10838	38	50	)	)	PUNCT
aiua-10838	38	51	tool	tool	NOUN
aiua-10838	38	52	for	for	ADP
aiua-10838	38	53	nonrandomized	nonrandomize	VERB
aiua-10838	38	54	studies	study	NOUN
aiua-10838	38	55	(	(	PUNCT
aiua-10838	38	56	13	13	NUM
aiua-10838	38	57	)	)	PUNCT
aiua-10838	38	58	(	(	PUNCT
aiua-10838	38	59	table	table	NOUN
aiua-10838	38	60	1	1	NUM
aiua-10838	38	61	)	)	PUNCT
aiua-10838	38	62	.	.	PUNCT
aiua-10838	39	1	most	most	ADJ
aiua-10838	39	2	common	common	ADJ
aiua-10838	39	3	reasons	reason	NOUN
aiua-10838	39	4	for	for	SCONJ
aiua-10838	39	5	the	the	DET
aiua-10838	39	6	studies	study	NOUN
aiua-10838	39	7	evaluating	evaluate	VERB
aiua-10838	39	8	the	the	DET
aiua-10838	39	9	relationship	relationship	NOUN
aiua-10838	39	10	between	between	ADP
aiua-10838	39	11	cn	cn	PROPN
aiua-10838	39	12	and	and	CCONJ
aiua-10838	39	13	os	os	NOUN
aiua-10838	39	14	to	to	PART
aiua-10838	39	15	be	be	AUX
aiua-10838	39	16	classified	classify	VERB
aiua-10838	39	17	as	as	ADP
aiua-10838	39	18	having	have	VERB
aiua-10838	39	19	moderate	moderate	ADJ
aiua-10838	39	20	or	or	CCONJ
aiua-10838	39	21	serious	serious	ADJ
aiua-10838	39	22	risk	risk	NOUN
aiua-10838	39	23	of	of	ADP
aiua-10838	39	24	bias	bias	NOUN
aiua-10838	39	25	were	be	AUX
aiua-10838	39	26	the	the	DET
aiua-10838	39	27	unmeasured	unmeasured	ADJ
aiua-10838	39	28	differences	difference	NOUN
aiua-10838	39	29	between	between	ADP
aiua-10838	39	30	cn	cn	PROPN
aiua-10838	39	31	and	and	CCONJ
aiua-10838	39	32	control	control	NOUN
aiua-10838	39	33	groups	group	NOUN
aiua-10838	39	34	and	and	CCONJ
aiua-10838	39	35	the	the	DET
aiua-10838	39	36	inadequate	inadequate	ADJ
aiua-10838	39	37	adjustment	adjustment	NOUN
aiua-10838	39	38	for	for	ADP
aiua-10838	39	39	confounding	confound	VERB
aiua-10838	39	40	factors	factor	NOUN
aiua-10838	39	41	.	.	PUNCT
aiua-10838	40	1	the	the	DET
aiua-10838	40	2	inability	inability	NOUN
aiua-10838	40	3	to	to	PART
aiua-10838	40	4	adjust	adjust	VERB
aiua-10838	40	5	for	for	ADP
aiua-10838	40	6	differences	difference	NOUN
aiua-10838	40	7	between	between	ADP
aiua-10838	40	8	groups	group	NOUN
aiua-10838	40	9	was	be	AUX
aiua-10838	40	10	also	also	ADV
aiua-10838	40	11	found	find	VERB
aiua-10838	40	12	in	in	ADP
aiua-10838	40	13	the	the	DET
aiua-10838	40	14	studies	study	NOUN
aiua-10838	40	15	assessing	assess	VERB
aiua-10838	40	16	the	the	DET
aiua-10838	40	17	prognostic	prognostic	ADJ
aiua-10838	40	18	factors	factor	NOUN
aiua-10838	40	19	and	and	CCONJ
aiua-10838	40	20	the	the	DET
aiua-10838	40	21	role	role	NOUN
aiua-10838	40	22	of	of	ADP
aiua-10838	40	23	sequence	sequence	NOUN
aiua-10838	40	24	between	between	ADP
aiua-10838	40	25	st	st	PROPN
aiua-10838	40	26	and	and	CCONJ
aiua-10838	40	27	cn	cn	PROPN
aiua-10838	40	28	.	.	PUNCT
aiua-10838	41	1	moreover	moreover	ADV
aiua-10838	41	2	,	,	PUNCT
aiua-10838	41	3	the	the	DET
aiua-10838	41	4	studies	study	NOUN
aiua-10838	41	5	assessing	assess	VERB
aiua-10838	41	6	the	the	DET
aiua-10838	41	7	sequence	sequence	NOUN
aiua-10838	41	8	between	between	ADP
aiua-10838	41	9	st	st	PROPN
aiua-10838	41	10	and	and	CCONJ
aiua-10838	41	11	cn	cn	PROPN
aiua-10838	41	12	also	also	ADV
aiua-10838	41	13	demonstrated	demonstrate	VERB
aiua-10838	41	14	selection	selection	NOUN
aiua-10838	41	15	bias	bias	NOUN
aiua-10838	41	16	.	.	PUNCT
aiua-10838	42	1	results	result	VERB
aiua-10838	42	2	cytoreductive	cytoreductive	ADJ
aiua-10838	42	3	nephrectomy	nephrectomy	ADV
aiua-10838	42	4	and	and	CCONJ
aiua-10838	42	5	overall	overall	ADJ
aiua-10838	42	6	survivor	survivor	NOUN
aiua-10838	42	7	thirty	thirty	NUM
aiua-10838	42	8	studies	study	NOUN
aiua-10838	42	9	were	be	AUX
aiua-10838	42	10	included	include	VERB
aiua-10838	42	11	in	in	ADP
aiua-10838	42	12	the	the	DET
aiua-10838	42	13	analysis	analysis	NOUN
aiua-10838	42	14	of	of	ADP
aiua-10838	42	15	the	the	DET
aiua-10838	42	16	relafigure	relafigure	NOUN
aiua-10838	42	17	1	1	NUM
aiua-10838	42	18	.	.	PUNCT
aiua-10838	43	1	prisma	prisma	PROPN
aiua-10838	43	2	2020	2020	NUM
aiua-10838	43	3	flow	flow	NOUN
aiua-10838	43	4	diagram	diagram	NOUN
aiua-10838	43	5	for	for	ADP
aiua-10838	43	6	new	new	ADJ
aiua-10838	43	7	systematic	systematic	ADJ
aiua-10838	43	8	reviews	review	NOUN
aiua-10838	43	9	which	which	PRON
aiua-10838	43	10	included	include	VERB
aiua-10838	43	11	searches	search	NOUN
aiua-10838	43	12	of	of	ADP
aiua-10838	43	13	databases	database	NOUN
aiua-10838	43	14	and	and	CCONJ
aiua-10838	43	15	registers	register	NOUN
aiua-10838	43	16	only	only	ADV
aiua-10838	43	17	.	.	PUNCT
aiua-10838	44	1	archivio	archivio	NOUN
aiua-10838	44	2	italiano	italiano	NOUN
aiua-10838	44	3	di	di	X
aiua-10838	44	4	urologia	urologia	PROPN
aiua-10838	44	5	e	e	PROPN
aiua-10838	44	6	andrologia	andrologia	PROPN
aiua-10838	44	7	2022	2022	NUM
aiua-10838	44	8	;	;	PUNCT
aiua-10838	44	9	94	94	NUM
aiua-10838	44	10	,	,	PUNCT
aiua-10838	44	11	4	4	NUM
aiua-10838	44	12	s.	s.	PROPN
aiua-10838	44	13	katsimperis	katsimperis	PROPN
aiua-10838	44	14	,	,	PUNCT
aiua-10838	44	15	l.	l.	PROPN
aiua-10838	44	16	tzelves	tzelves	PROPN
aiua-10838	44	17	,	,	PUNCT
aiua-10838	44	18	t.	t.	PROPN
aiua-10838	44	19	bellos	bellos	PROPN
aiua-10838	44	20	,	,	PUNCT
aiua-10838	44	21	k.	k.	PROPN
aiua-10838	44	22	pikramenos	pikramenos	PROPN
aiua-10838	44	23	,	,	PUNCT
aiua-10838	44	24	i.	i.	PROPN
aiua-10838	44	25	manolitsis	manolitsis	PROPN
aiua-10838	44	26	,	,	PUNCT
aiua-10838	44	27	i.	i.	PROPN
aiua-10838	44	28	tsikopoulos	tsikopoulos	PROPN
aiua-10838	44	29	,	,	PUNCT
aiua-10838	44	30	i.	i.	PROPN
aiua-10838	44	31	mitsogiannis	mitsogiannis	PROPN
aiua-10838	44	32	478	478	NUM
aiua-10838	44	33	tionship	tionship	NOUN
aiua-10838	44	34	between	between	ADP
aiua-10838	44	35	cn	cn	PROPN
aiua-10838	44	36	and	and	CCONJ
aiua-10838	44	37	os	os	PROPN
aiua-10838	44	38	(	(	PUNCT
aiua-10838	44	39	14	14	NUM
aiua-10838	44	40	-	-	SYM
aiua-10838	44	41	42	42	NUM
aiua-10838	44	42	,	,	PUNCT
aiua-10838	44	43	65	65	NUM
aiua-10838	44	44	)	)	PUNCT
aiua-10838	44	45	(	(	PUNCT
aiua-10838	44	46	table	table	NOUN
aiua-10838	44	47	2	2	NUM
aiua-10838	44	48	)	)	PUNCT
aiua-10838	44	49	.	.	PUNCT
aiua-10838	45	1	all	all	PRON
aiua-10838	45	2	of	of	ADP
aiua-10838	45	3	the	the	DET
aiua-10838	45	4	studies	study	NOUN
aiua-10838	45	5	except	except	SCONJ
aiua-10838	45	6	for	for	ADP
aiua-10838	45	7	one	one	NUM
aiua-10838	45	8	(	(	PUNCT
aiua-10838	45	9	41	41	NUM
aiua-10838	45	10	)	)	PUNCT
aiua-10838	45	11	,	,	PUNCT
aiua-10838	45	12	which	which	PRON
aiua-10838	45	13	was	be	AUX
aiua-10838	45	14	a	a	DET
aiua-10838	45	15	prospective	prospective	ADJ
aiua-10838	45	16	randomized	randomized	ADJ
aiua-10838	45	17	trial	trial	NOUN
aiua-10838	45	18	,	,	PUNCT
aiua-10838	45	19	were	be	AUX
aiua-10838	45	20	retrospective	retrospective	ADJ
aiua-10838	45	21	cohort	cohort	NOUN
aiua-10838	45	22	studies	study	NOUN
aiua-10838	45	23	.	.	PUNCT
aiua-10838	46	1	ten	ten	NUM
aiua-10838	46	2	of	of	ADP
aiua-10838	46	3	them	they	PRON
aiua-10838	46	4	were	be	AUX
aiua-10838	46	5	from	from	ADP
aiua-10838	46	6	the	the	DET
aiua-10838	46	7	surveillance	surveillance	NOUN
aiua-10838	46	8	,	,	PUNCT
aiua-10838	46	9	epidemiology	epidemiology	NOUN
aiua-10838	46	10	,	,	PUNCT
aiua-10838	46	11	and	and	CCONJ
aiua-10838	46	12	end	end	VERB
aiua-10838	46	13	results	result	NOUN
aiua-10838	46	14	(	(	PUNCT
aiua-10838	46	15	seer	seer	NOUN
aiua-10838	46	16	)	)	PUNCT
aiua-10838	46	17	database	database	NOUN
aiua-10838	46	18	,	,	PUNCT
aiua-10838	46	19	4	4	NUM
aiua-10838	46	20	from	from	ADP
aiua-10838	46	21	international	international	ADJ
aiua-10838	46	22	metastatic	metastatic	ADJ
aiua-10838	46	23	rcc	rcc	PROPN
aiua-10838	46	24	database	database	PROPN
aiua-10838	46	25	consortium	consortium	PROPN
aiua-10838	46	26	(	(	PUNCT
aiua-10838	46	27	imdc	imdc	PROPN
aiua-10838	46	28	)	)	PUNCT
aiua-10838	46	29	,	,	PUNCT
aiua-10838	46	30	two	two	NUM
aiua-10838	46	31	from	from	ADP
aiua-10838	46	32	national	national	ADJ
aiua-10838	46	33	cancer	cancer	NOUN
aiua-10838	46	34	database	database	NOUN
aiua-10838	46	35	(	(	PUNCT
aiua-10838	46	36	ncdb	ncdb	NOUN
aiua-10838	46	37	)	)	PUNCT
aiua-10838	46	38	and	and	CCONJ
aiua-10838	46	39	the	the	DET
aiua-10838	46	40	rest	rest	NOUN
aiua-10838	46	41	were	be	AUX
aiua-10838	46	42	single	single	ADJ
aiua-10838	46	43	or	or	CCONJ
aiua-10838	46	44	multi	multi	ADJ
aiua-10838	46	45	-	-	ADJ
aiua-10838	46	46	center	center	ADJ
aiua-10838	46	47	studies	study	NOUN
aiua-10838	46	48	.	.	PUNCT
aiua-10838	47	1	most	most	ADJ
aiua-10838	47	2	common	common	ADJ
aiua-10838	47	3	systemic	systemic	ADJ
aiua-10838	47	4	agent	agent	NOUN
aiua-10838	47	5	used	use	VERB
aiua-10838	47	6	was	be	AUX
aiua-10838	47	7	sunitinib	sunitinib	NOUN
aiua-10838	47	8	(	(	PUNCT
aiua-10838	47	9	table	table	NOUN
aiua-10838	47	10	1	1	NUM
aiua-10838	47	11	)	)	PUNCT
aiua-10838	47	12	,	,	PUNCT
aiua-10838	47	13	while	while	SCONJ
aiua-10838	47	14	there	there	PRON
aiua-10838	47	15	were	be	VERB
aiua-10838	47	16	three	three	NUM
aiua-10838	47	17	studies	study	NOUN
aiua-10838	47	18	(	(	PUNCT
aiua-10838	47	19	2	2	NUM
aiua-10838	47	20	,	,	PUNCT
aiua-10838	47	21	40	40	NUM
aiua-10838	47	22	,	,	PUNCT
aiua-10838	47	23	42	42	NUM
aiua-10838	47	24	)	)	PUNCT
aiua-10838	47	25	comparing	compare	VERB
aiua-10838	47	26	cn	cn	PROPN
aiua-10838	47	27	with	with	ADP
aiua-10838	47	28	the	the	DET
aiua-10838	47	29	use	use	NOUN
aiua-10838	47	30	of	of	ADP
aiua-10838	47	31	icis	icis	PROPN
aiua-10838	47	32	.	.	PUNCT
aiua-10838	48	1	these	these	DET
aiua-10838	48	2	studies	study	NOUN
aiua-10838	48	3	are	be	AUX
aiua-10838	48	4	of	of	ADP
aiua-10838	48	5	great	great	ADJ
aiua-10838	48	6	importance	importance	NOUN
aiua-10838	48	7	,	,	PUNCT
aiua-10838	48	8	as	as	SCONJ
aiua-10838	48	9	they	they	PRON
aiua-10838	48	10	are	be	AUX
aiua-10838	48	11	the	the	DET
aiua-10838	48	12	first	first	ADJ
aiua-10838	48	13	retrospective	retrospective	ADJ
aiua-10838	48	14	studies	study	NOUN
aiua-10838	48	15	on	on	ADP
aiua-10838	48	16	the	the	DET
aiua-10838	48	17	role	role	NOUN
aiua-10838	48	18	of	of	ADP
aiua-10838	48	19	cn	cn	PROPN
aiua-10838	48	20	in	in	ADP
aiua-10838	48	21	the	the	DET
aiua-10838	48	22	immunotherapy	immunotherapy	NOUN
aiua-10838	48	23	era	era	NOUN
aiua-10838	48	24	and	and	CCONJ
aiua-10838	48	25	demonstrated	demonstrate	VERB
aiua-10838	48	26	an	an	DET
aiua-10838	48	27	os	os	ADJ
aiua-10838	48	28	benefit	benefit	NOUN
aiua-10838	48	29	in	in	ADP
aiua-10838	48	30	patients	patient	NOUN
aiua-10838	48	31	treated	treat	VERB
aiua-10838	48	32	with	with	ADP
aiua-10838	48	33	ici	ici	PROPN
aiua-10838	48	34	plus	plus	CCONJ
aiua-10838	48	35	cn	cn	PROPN
aiua-10838	48	36	compared	compare	VERB
aiua-10838	48	37	to	to	ADP
aiua-10838	48	38	ici	ici	PROPN
aiua-10838	48	39	alone	alone	ADV
aiua-10838	48	40	(	(	PUNCT
aiua-10838	48	41	hr	hr	NOUN
aiua-10838	48	42	0.23	0.23	NUM
aiua-10838	48	43	-	-	SYM
aiua-10838	48	44	0.39	0.39	NUM
aiua-10838	48	45	,	,	PUNCT
aiua-10838	48	46	table	table	NOUN
aiua-10838	48	47	1	1	NUM
aiua-10838	48	48	.	.	PUNCT
aiua-10838	48	49	risk	risk	NOUN
aiua-10838	48	50	of	of	ADP
aiua-10838	48	51	bias	bias	NOUN
aiua-10838	48	52	assessment	assessment	NOUN
aiua-10838	48	53	for	for	ADP
aiua-10838	48	54	non	non	ADJ
aiua-10838	48	55	-	-	ADJ
aiua-10838	48	56	randomized	randomized	ADJ
aiua-10838	48	57	studies	study	NOUN
aiua-10838	48	58	.	.	PUNCT
aiua-10838	49	1	first	first	ADJ
aiua-10838	49	2	author	author	NOUN
aiua-10838	49	3	confounding	confound	VERB
aiua-10838	49	4	participant	participant	ADJ
aiua-10838	49	5	intervention	intervention	NOUN
aiua-10838	49	6	deviation	deviation	NOUN
aiua-10838	49	7	from	from	ADP
aiua-10838	49	8	missing	miss	VERB
aiua-10838	49	9	outcome	outcome	NOUN
aiua-10838	49	10	selected	select	VERB
aiua-10838	49	11	overall	overall	ADV
aiua-10838	49	12	(	(	PUNCT
aiua-10838	49	13	year	year	NOUN
aiua-10838	49	14	)	)	PUNCT
aiua-10838	49	15	selection	selection	NOUN
aiua-10838	49	16	classification	classification	NOUN
aiua-10838	49	17	inteended	inteende	VERB
aiua-10838	49	18	treatment	treatment	NOUN
aiua-10838	49	19	data	datum	NOUN
aiua-10838	49	20	measurement	measurement	NOUN
aiua-10838	49	21	reporrting	reporrte	VERB
aiua-10838	49	22	bias	bias	NOUN
aiua-10838	49	23	day	day	NOUN
aiua-10838	49	24	(	(	PUNCT
aiua-10838	49	25	2016	2016	NUM
aiua-10838	49	26	)	)	PUNCT
aiua-10838	49	27	moderate	moderate	ADJ
aiua-10838	49	28	moderate	moderate	ADJ
aiua-10838	49	29	low	low	ADJ
aiua-10838	49	30	low	low	ADJ
aiua-10838	49	31	moderate	moderate	ADJ
aiua-10838	49	32	low	low	ADJ
aiua-10838	49	33	low	low	ADJ
aiua-10838	49	34	moderate	moderate	ADJ
aiua-10838	49	35	de	de	X
aiua-10838	49	36	groot	groot	X
aiua-10838	49	37	(	(	PUNCT
aiua-10838	49	38	2016	2016	NUM
aiua-10838	49	39	)	)	PUNCT
aiua-10838	49	40	moderate	moderate	ADJ
aiua-10838	49	41	serious	serious	ADJ
aiua-10838	49	42	low	low	ADJ
aiua-10838	49	43	low	low	ADJ
aiua-10838	49	44	moderate	moderate	ADJ
aiua-10838	49	45	low	low	ADJ
aiua-10838	49	46	low	low	ADJ
aiua-10838	49	47	serious	serious	ADJ
aiua-10838	49	48	hanna	hanna	NOUN
aiua-10838	49	49	(	(	PUNCT
aiua-10838	49	50	2016	2016	NUM
aiua-10838	49	51	)	)	PUNCT
aiua-10838	49	52	moderate	moderate	ADJ
aiua-10838	49	53	serious	serious	ADJ
aiua-10838	49	54	low	low	ADJ
aiua-10838	49	55	low	low	ADJ
aiua-10838	49	56	moderate	moderate	ADJ
aiua-10838	49	57	low	low	ADJ
aiua-10838	49	58	low	low	ADJ
aiua-10838	49	59	serious	serious	ADJ
aiua-10838	49	60	heng	heng	PROPN
aiua-10838	49	61	(	(	PUNCT
aiua-10838	49	62	2014	2014	NUM
aiua-10838	49	63	)	)	PUNCT
aiua-10838	49	64	moderate	moderate	ADJ
aiua-10838	49	65	serious	serious	ADJ
aiua-10838	49	66	low	low	ADJ
aiua-10838	49	67	low	low	ADJ
aiua-10838	49	68	low	low	ADJ
aiua-10838	49	69	low	low	ADJ
aiua-10838	49	70	low	low	ADJ
aiua-10838	49	71	serious	serious	ADJ
aiua-10838	49	72	klatte	klatte	NOUN
aiua-10838	49	73	(	(	PUNCT
aiua-10838	49	74	2018	2018	NUM
aiua-10838	49	75	)	)	PUNCT
aiua-10838	49	76	moderate	moderate	ADJ
aiua-10838	49	77	serious	serious	ADJ
aiua-10838	49	78	low	low	ADJ
aiua-10838	49	79	low	low	ADJ
aiua-10838	49	80	low	low	ADJ
aiua-10838	49	81	low	low	ADJ
aiua-10838	49	82	low	low	ADJ
aiua-10838	49	83	serious	serious	ADJ
aiua-10838	49	84	patel	patel	NOUN
aiua-10838	49	85	(	(	PUNCT
aiua-10838	49	86	2017	2017	NUM
aiua-10838	49	87	)	)	PUNCT
aiua-10838	49	88	serious	serious	ADJ
aiua-10838	49	89	moderate	moderate	ADJ
aiua-10838	49	90	low	low	ADJ
aiua-10838	49	91	low	low	ADJ
aiua-10838	49	92	moderate	moderate	ADJ
aiua-10838	49	93	moderate	moderate	ADJ
aiua-10838	49	94	low	low	ADJ
aiua-10838	49	95	serious	serious	ADJ
aiua-10838	49	96	tatsugami	tatsugami	NOUN
aiua-10838	49	97	(	(	PUNCT
aiua-10838	49	98	2015	2015	NUM
aiua-10838	49	99	)	)	PUNCT
aiua-10838	49	100	moderate	moderate	ADJ
aiua-10838	49	101	moderate	moderate	ADJ
aiua-10838	49	102	low	low	ADJ
aiua-10838	49	103	low	low	ADJ
aiua-10838	49	104	moderate	moderate	ADJ
aiua-10838	49	105	low	low	ADJ
aiua-10838	49	106	low	low	ADJ
aiua-10838	49	107	moderate	moderate	ADJ
aiua-10838	49	108	you	you	PRON
aiua-10838	49	109	(	(	PUNCT
aiua-10838	49	110	2011	2011	NUM
aiua-10838	49	111	)	)	PUNCT
aiua-10838	49	112	moderate	moderate	ADJ
aiua-10838	49	113	moderate	moderate	ADJ
aiua-10838	49	114	low	low	ADJ
aiua-10838	49	115	low	low	ADJ
aiua-10838	49	116	low	low	ADJ
aiua-10838	49	117	low	low	ADJ
aiua-10838	49	118	low	low	ADJ
aiua-10838	49	119	moderate	moderate	ADJ
aiua-10838	49	120	abern	abern	NOUN
aiua-10838	49	121	(	(	PUNCT
aiua-10838	49	122	2014	2014	NUM
aiua-10838	49	123	)	)	PUNCT
aiua-10838	49	124	serious	serious	ADJ
aiua-10838	49	125	moderate	moderate	ADJ
aiua-10838	49	126	low	low	ADJ
aiua-10838	49	127	low	low	ADJ
aiua-10838	49	128	low	low	ADJ
aiua-10838	49	129	low	low	ADJ
aiua-10838	49	130	low	low	ADJ
aiua-10838	49	131	serious	serious	ADJ
aiua-10838	49	132	conti	conti	X
aiua-10838	49	133	(	(	PUNCT
aiua-10838	49	134	2014	2014	NUM
aiua-10838	49	135	)	)	PUNCT
aiua-10838	49	136	serious	serious	ADJ
aiua-10838	49	137	moderate	moderate	ADJ
aiua-10838	49	138	low	low	ADJ
aiua-10838	49	139	low	low	ADJ
aiua-10838	49	140	low	low	ADJ
aiua-10838	49	141	low	low	ADJ
aiua-10838	49	142	low	low	ADJ
aiua-10838	49	143	serious	serious	ADJ
aiua-10838	49	144	marchioni	marchioni	NOUN
aiua-10838	49	145	(	(	PUNCT
aiua-10838	49	146	2019	2019	NUM
aiua-10838	49	147	)	)	PUNCT
aiua-10838	49	148	serious	serious	ADJ
aiua-10838	49	149	moderate	moderate	ADJ
aiua-10838	49	150	low	low	ADJ
aiua-10838	49	151	low	low	ADJ
aiua-10838	49	152	low	low	ADJ
aiua-10838	49	153	low	low	ADJ
aiua-10838	49	154	low	low	ADJ
aiua-10838	49	155	serious	serious	ADJ
aiua-10838	49	156	patel	patel	NOUN
aiua-10838	49	157	(	(	PUNCT
aiua-10838	49	158	2017	2017	NUM
aiua-10838	49	159	)	)	PUNCT
aiua-10838	49	160	serious	serious	ADJ
aiua-10838	49	161	moderate	moderate	ADJ
aiua-10838	49	162	low	low	ADJ
aiua-10838	49	163	low	low	ADJ
aiua-10838	49	164	moderate	moderate	ADJ
aiua-10838	49	165	moderate	moderate	ADJ
aiua-10838	49	166	low	low	ADJ
aiua-10838	49	167	serious	serious	ADJ
aiua-10838	49	168	aizer	aizer	NOUN
aiua-10838	49	169	(	(	PUNCT
aiua-10838	49	170	2014	2014	NUM
aiua-10838	49	171	)	)	PUNCT
aiua-10838	49	172	serious	serious	ADJ
aiua-10838	49	173	moderate	moderate	ADJ
aiua-10838	49	174	low	low	ADJ
aiua-10838	49	175	low	low	ADJ
aiua-10838	49	176	low	low	ADJ
aiua-10838	49	177	moderate	moderate	ADJ
aiua-10838	49	178	low	low	ADJ
aiua-10838	49	179	serious	serious	ADJ
aiua-10838	49	180	song	song	NOUN
aiua-10838	49	181	(	(	PUNCT
aiua-10838	49	182	2016	2016	NUM
aiua-10838	49	183	)	)	PUNCT
aiua-10838	49	184	serious	serious	ADJ
aiua-10838	49	185	serious	serious	ADJ
aiua-10838	49	186	low	low	ADJ
aiua-10838	49	187	low	low	ADJ
aiua-10838	49	188	low	low	ADJ
aiua-10838	49	189	low	low	ADJ
aiua-10838	49	190	low	low	ADJ
aiua-10838	49	191	serious	serious	ADJ
aiua-10838	49	192	abel	abel	NOUN
aiua-10838	49	193	(	(	PUNCT
aiua-10838	49	194	2017	2017	NUM
aiua-10838	49	195	)	)	PUNCT
aiua-10838	49	196	moderate	moderate	ADJ
aiua-10838	49	197	moderate	moderate	ADJ
aiua-10838	49	198	low	low	ADJ
aiua-10838	49	199	low	low	ADJ
aiua-10838	49	200	moderate	moderate	ADJ
aiua-10838	49	201	low	low	ADJ
aiua-10838	49	202	low	low	ADJ
aiua-10838	49	203	moderate	moderate	ADJ
aiua-10838	49	204	corcoran	corcoran	NOUN
aiua-10838	49	205	(	(	PUNCT
aiua-10838	49	206	2014	2014	NUM
aiua-10838	49	207	)	)	PUNCT
aiua-10838	49	208	moderate	moderate	ADJ
aiua-10838	49	209	moderate	moderate	ADJ
aiua-10838	49	210	low	low	ADJ
aiua-10838	49	211	low	low	ADJ
aiua-10838	49	212	low	low	ADJ
aiua-10838	49	213	low	low	ADJ
aiua-10838	49	214	low	low	ADJ
aiua-10838	49	215	moderate	moderate	ADJ
aiua-10838	49	216	culp	culp	PROPN
aiua-10838	49	217	(	(	PUNCT
aiua-10838	49	218	2010	2010	NUM
aiua-10838	49	219	)	)	PUNCT
aiua-10838	49	220	moderate	moderate	ADJ
aiua-10838	49	221	moderate	moderate	ADJ
aiua-10838	49	222	low	low	ADJ
aiua-10838	49	223	low	low	ADJ
aiua-10838	49	224	low	low	ADJ
aiua-10838	49	225	low	low	ADJ
aiua-10838	49	226	low	low	ADJ
aiua-10838	49	227	moderate	moderate	ADJ
aiua-10838	49	228	culp	culp	PROPN
aiua-10838	49	229	(	(	PUNCT
aiua-10838	49	230	2014	2014	NUM
aiua-10838	49	231	)	)	PUNCT
aiua-10838	49	232	moderate	moderate	ADJ
aiua-10838	49	233	moderate	moderate	ADJ
aiua-10838	49	234	low	low	ADJ
aiua-10838	49	235	low	low	ADJ
aiua-10838	49	236	low	low	ADJ
aiua-10838	49	237	low	low	ADJ
aiua-10838	49	238	low	low	ADJ
aiua-10838	49	239	moderate	moderate	ADJ
aiua-10838	49	240	kalogirou	kalogirou	NOUN
aiua-10838	49	241	(	(	PUNCT
aiua-10838	49	242	2017	2017	NUM
aiua-10838	49	243	)	)	PUNCT
aiua-10838	49	244	serious	serious	ADJ
aiua-10838	49	245	moderate	moderate	ADJ
aiua-10838	49	246	low	low	ADJ
aiua-10838	49	247	low	low	ADJ
aiua-10838	49	248	low	low	ADJ
aiua-10838	49	249	low	low	ADJ
aiua-10838	49	250	low	low	ADJ
aiua-10838	49	251	serious	serious	ADJ
aiua-10838	49	252	sakai	sakai	NOUN
aiua-10838	49	253	(	(	PUNCT
aiua-10838	49	254	2014	2014	NUM
aiua-10838	49	255	)	)	PUNCT
aiua-10838	49	256	moderate	moderate	ADJ
aiua-10838	49	257	moderate	moderate	ADJ
aiua-10838	49	258	low	low	ADJ
aiua-10838	49	259	low	low	ADJ
aiua-10838	49	260	low	low	ADJ
aiua-10838	49	261	low	low	ADJ
aiua-10838	49	262	low	low	ADJ
aiua-10838	49	263	moderate	moderate	ADJ
aiua-10838	49	264	sharma	sharma	PROPN
aiua-10838	49	265	(	(	PUNCT
aiua-10838	49	266	2015	2015	NUM
aiua-10838	49	267	)	)	PUNCT
aiua-10838	49	268	moderate	moderate	ADJ
aiua-10838	49	269	moderate	moderate	ADJ
aiua-10838	49	270	low	low	ADJ
aiua-10838	49	271	low	low	ADJ
aiua-10838	49	272	moderate	moderate	ADJ
aiua-10838	49	273	low	low	ADJ
aiua-10838	49	274	low	low	ADJ
aiua-10838	49	275	moderate	moderate	ADJ
aiua-10838	49	276	you	you	PRON
aiua-10838	49	277	(	(	PUNCT
aiua-10838	49	278	2015	2015	NUM
aiua-10838	49	279	)	)	PUNCT
aiua-10838	49	280	serious	serious	ADJ
aiua-10838	49	281	moderate	moderate	ADJ
aiua-10838	49	282	low	low	ADJ
aiua-10838	49	283	low	low	ADJ
aiua-10838	49	284	low	low	ADJ
aiua-10838	49	285	low	low	ADJ
aiua-10838	49	286	low	low	ADJ
aiua-10838	49	287	serious	serious	PROPN
aiua-10838	49	288	macleod	macleod	PROPN
aiua-10838	49	289	(	(	PUNCT
aiua-10838	49	290	2017	2017	NUM
aiua-10838	49	291	)	)	PUNCT
aiua-10838	49	292	moderate	moderate	ADJ
aiua-10838	49	293	moderate	moderate	ADJ
aiua-10838	49	294	low	low	ADJ
aiua-10838	49	295	low	low	ADJ
aiua-10838	49	296	moderate	moderate	ADJ
aiua-10838	49	297	low	low	ADJ
aiua-10838	49	298	low	low	ADJ
aiua-10838	49	299	moderate	moderate	ADJ
aiua-10838	49	300	stroup	stroup	NOUN
aiua-10838	49	301	(	(	PUNCT
aiua-10838	49	302	2013	2013	NUM
aiua-10838	49	303	)	)	PUNCT
aiua-10838	49	304	serious	serious	ADJ
aiua-10838	49	305	moderate	moderate	ADJ
aiua-10838	49	306	low	low	ADJ
aiua-10838	49	307	low	low	ADJ
aiua-10838	49	308	low	low	ADJ
aiua-10838	49	309	low	low	ADJ
aiua-10838	49	310	low	low	ADJ
aiua-10838	49	311	serious	serious	ADJ
aiua-10838	49	312	wood	wood	NOUN
aiua-10838	49	313	(	(	PUNCT
aiua-10838	49	314	2009	2009	NUM
aiua-10838	49	315	)	)	PUNCT
aiua-10838	49	316	serious	serious	ADJ
aiua-10838	49	317	moderate	moderate	ADJ
aiua-10838	49	318	low	low	ADJ
aiua-10838	49	319	low	low	ADJ
aiua-10838	49	320	low	low	ADJ
aiua-10838	49	321	low	low	ADJ
aiua-10838	49	322	low	low	ADJ
aiua-10838	49	323	serious	serious	ADJ
aiua-10838	49	324	luzaggo	luzaggo	NOUN
aiua-10838	49	325	(	(	PUNCT
aiua-10838	49	326	2021	2021	NUM
aiua-10838	49	327	)	)	PUNCT
aiua-10838	49	328	moderate	moderate	ADJ
aiua-10838	49	329	moderate	moderate	ADJ
aiua-10838	49	330	low	low	ADJ
aiua-10838	49	331	low	low	ADJ
aiua-10838	49	332	low	low	ADJ
aiua-10838	49	333	low	low	ADJ
aiua-10838	49	334	low	low	ADJ
aiua-10838	49	335	moderate	moderate	ADJ
aiua-10838	49	336	singla	singla	PROPN
aiua-10838	49	337	(	(	PUNCT
aiua-10838	49	338	2020	2020	NUM
aiua-10838	49	339	)	)	PUNCT
aiua-10838	49	340	moderate	moderate	ADJ
aiua-10838	49	341	moderate	moderate	ADJ
aiua-10838	49	342	low	low	ADJ
aiua-10838	49	343	low	low	ADJ
aiua-10838	49	344	low	low	ADJ
aiua-10838	49	345	low	low	ADJ
aiua-10838	49	346	low	low	ADJ
aiua-10838	49	347	moderate	moderate	ADJ
aiua-10838	49	348	palumbo	palumbo	NOUN
aiua-10838	49	349	(	(	PUNCT
aiua-10838	49	350	2020	2020	NUM
aiua-10838	49	351	)	)	PUNCT
aiua-10838	49	352	moderate	moderate	ADJ
aiua-10838	49	353	moderate	moderate	ADJ
aiua-10838	49	354	low	low	ADJ
aiua-10838	49	355	low	low	ADJ
aiua-10838	49	356	low	low	ADJ
aiua-10838	49	357	low	low	ADJ
aiua-10838	49	358	low	low	ADJ
aiua-10838	49	359	moderate	moderate	ADJ
aiua-10838	49	360	choi	choi	NOUN
aiua-10838	49	361	(	(	PUNCT
aiua-10838	49	362	2018	2018	NUM
aiua-10838	49	363	)	)	PUNCT
aiua-10838	49	364	moderate	moderate	ADJ
aiua-10838	49	365	serious	serious	ADJ
aiua-10838	49	366	low	low	ADJ
aiua-10838	49	367	low	low	ADJ
aiua-10838	49	368	low	low	ADJ
aiua-10838	49	369	low	low	ADJ
aiua-10838	49	370	low	low	ADJ
aiua-10838	49	371	serious	serious	ADJ
aiua-10838	49	372	janish	janish	NOUN
aiua-10838	49	373	(	(	PUNCT
aiua-10838	49	374	2020	2020	NUM
aiua-10838	49	375	)	)	PUNCT
aiua-10838	49	376	moderate	moderate	ADJ
aiua-10838	49	377	serious	serious	ADJ
aiua-10838	49	378	low	low	ADJ
aiua-10838	49	379	low	low	ADJ
aiua-10838	49	380	moderate	moderate	ADJ
aiua-10838	49	381	low	low	ADJ
aiua-10838	49	382	moderate	moderate	ADJ
aiua-10838	49	383	serious	serious	ADJ
aiua-10838	49	384	alnimer	alnimer	NOUN
aiua-10838	49	385	(	(	PUNCT
aiua-10838	49	386	2021	2021	NUM
aiua-10838	49	387	)	)	PUNCT
aiua-10838	49	388	moderate	moderate	ADJ
aiua-10838	49	389	moderate	moderate	ADJ
aiua-10838	49	390	low	low	ADJ
aiua-10838	49	391	low	low	ADJ
aiua-10838	49	392	low	low	ADJ
aiua-10838	49	393	low	low	ADJ
aiua-10838	49	394	low	low	ADJ
aiua-10838	49	395	moderate	moderate	ADJ
aiua-10838	49	396	vaishampayan	vaishampayan	NOUN
aiua-10838	49	397	(	(	PUNCT
aiua-10838	49	398	2019	2019	NUM
aiua-10838	49	399	)	)	PUNCT
aiua-10838	49	400	serious	serious	ADJ
aiua-10838	49	401	moderate	moderate	ADJ
aiua-10838	49	402	low	low	ADJ
aiua-10838	49	403	low	low	ADJ
aiua-10838	49	404	low	low	ADJ
aiua-10838	49	405	low	low	ADJ
aiua-10838	49	406	low	low	ADJ
aiua-10838	49	407	serious	serious	ADJ
aiua-10838	49	408	graham	graham	PROPN
aiua-10838	49	409	(	(	PUNCT
aiua-10838	49	410	2019	2019	NUM
aiua-10838	49	411	)	)	PUNCT
aiua-10838	49	412	moderate	moderate	ADJ
aiua-10838	49	413	serious	serious	ADJ
aiua-10838	49	414	low	low	ADJ
aiua-10838	49	415	low	low	ADJ
aiua-10838	49	416	low	low	ADJ
aiua-10838	49	417	moderate	moderate	ADJ
aiua-10838	49	418	low	low	ADJ
aiua-10838	49	419	serious	serious	ADJ
aiua-10838	49	420	you	you	PRON
aiua-10838	49	421	(	(	PUNCT
aiua-10838	49	422	2014	2014	NUM
aiua-10838	49	423	)	)	PUNCT
aiua-10838	49	424	moderate	moderate	ADJ
aiua-10838	49	425	moderate	moderate	ADJ
aiua-10838	49	426	low	low	ADJ
aiua-10838	49	427	low	low	ADJ
aiua-10838	49	428	low	low	ADJ
aiua-10838	49	429	low	low	ADJ
aiua-10838	49	430	low	low	ADJ
aiua-10838	49	431	moderate	moderate	ADJ
aiua-10838	49	432	zhao	zhao	NOUN
aiua-10838	49	433	(	(	PUNCT
aiua-10838	49	434	2019	2019	NUM
aiua-10838	49	435	)	)	PUNCT
aiua-10838	49	436	serious	serious	ADJ
aiua-10838	49	437	moderate	moderate	ADJ
aiua-10838	49	438	low	low	ADJ
aiua-10838	49	439	low	low	ADJ
aiua-10838	49	440	low	low	ADJ
aiua-10838	49	441	low	low	ADJ
aiua-10838	49	442	low	low	ADJ
aiua-10838	49	443	serious	serious	ADJ
aiua-10838	49	444	poprach	poprach	NOUN
aiua-10838	49	445	(	(	PUNCT
aiua-10838	49	446	2020	2020	NUM
aiua-10838	49	447	)	)	PUNCT
aiua-10838	49	448	moderate	moderate	ADJ
aiua-10838	49	449	moderate	moderate	ADJ
aiua-10838	49	450	low	low	ADJ
aiua-10838	49	451	low	low	ADJ
aiua-10838	49	452	low	low	ADJ
aiua-10838	49	453	low	low	ADJ
aiua-10838	49	454	low	low	ADJ
aiua-10838	49	455	moderate	moderate	ADJ
aiua-10838	49	456	bakouny	bakouny	NOUN
aiua-10838	49	457	(	(	PUNCT
aiua-10838	49	458	2020	2020	NUM
aiua-10838	49	459	)	)	PUNCT
aiua-10838	49	460	serious	serious	ADJ
aiua-10838	49	461	moderate	moderate	ADJ
aiua-10838	49	462	low	low	ADJ
aiua-10838	49	463	low	low	ADJ
aiua-10838	49	464	low	low	ADJ
aiua-10838	49	465	low	low	ADJ
aiua-10838	49	466	low	low	ADJ
aiua-10838	49	467	serious	serious	ADJ
aiua-10838	49	468	dragomir	dragomir	NOUN
aiua-10838	49	469	(	(	PUNCT
aiua-10838	49	470	2021	2021	NUM
aiua-10838	49	471	)	)	PUNCT
aiua-10838	49	472	serious	serious	ADJ
aiua-10838	49	473	moderate	moderate	ADJ
aiua-10838	49	474	low	low	ADJ
aiua-10838	49	475	low	low	ADJ
aiua-10838	49	476	low	low	ADJ
aiua-10838	49	477	moderate	moderate	ADJ
aiua-10838	49	478	low	low	ADJ
aiua-10838	49	479	serious	serious	ADJ
aiua-10838	49	480	ljungberg	ljungberg	PROPN
aiua-10838	49	481	(	(	PUNCT
aiua-10838	49	482	2020	2020	NUM
aiua-10838	49	483	)	)	PUNCT
aiua-10838	49	484	serious	serious	ADJ
aiua-10838	49	485	serious	serious	ADJ
aiua-10838	49	486	low	low	ADJ
aiua-10838	49	487	low	low	ADJ
aiua-10838	49	488	low	low	ADJ
aiua-10838	49	489	low	low	ADJ
aiua-10838	49	490	low	low	ADJ
aiua-10838	49	491	serious	serious	ADJ
aiua-10838	49	492	mcintosh	mcintosh	PROPN
aiua-10838	49	493	(	(	PUNCT
aiua-10838	49	494	2020	2020	NUM
aiua-10838	49	495	)	)	PUNCT
aiua-10838	49	496	moderate	moderate	ADJ
aiua-10838	49	497	moderate	moderate	ADJ
aiua-10838	49	498	low	low	ADJ
aiua-10838	49	499	low	low	ADJ
aiua-10838	49	500	low	low	ADJ
aiua-10838	49	501	low	low	ADJ
aiua-10838	49	502	low	low	ADJ
aiua-10838	49	503	moderate	moderate	ADJ
aiua-10838	49	504	rosiello	rosiello	NOUN
aiua-10838	49	505	(	(	PUNCT
aiua-10838	49	506	2019	2019	NUM
aiua-10838	49	507	)	)	PUNCT
aiua-10838	49	508	serious	serious	ADJ
aiua-10838	49	509	serious	serious	ADJ
aiua-10838	49	510	low	low	ADJ
aiua-10838	49	511	low	low	ADJ
aiua-10838	49	512	low	low	ADJ
aiua-10838	49	513	low	low	ADJ
aiua-10838	49	514	low	low	ADJ
aiua-10838	49	515	serious	serious	ADJ
aiua-10838	49	516	teishima	teishima	NOUN
aiua-10838	49	517	(	(	PUNCT
aiua-10838	49	518	2018	2018	NUM
aiua-10838	49	519	)	)	PUNCT
aiua-10838	49	520	serious	serious	ADJ
aiua-10838	49	521	moderate	moderate	ADJ
aiua-10838	49	522	low	low	ADJ
aiua-10838	49	523	low	low	ADJ
aiua-10838	49	524	low	low	ADJ
aiua-10838	49	525	low	low	ADJ
aiua-10838	49	526	low	low	ADJ
aiua-10838	49	527	serious	serious	ADJ
aiua-10838	49	528	adashek	adashek	PROPN
aiua-10838	49	529	(	(	PUNCT
aiua-10838	49	530	2021	2021	NUM
aiua-10838	49	531	)	)	PUNCT
aiua-10838	49	532	moderate	moderate	ADJ
aiua-10838	49	533	moderate	moderate	ADJ
aiua-10838	49	534	low	low	ADJ
aiua-10838	49	535	low	low	ADJ
aiua-10838	49	536	low	low	ADJ
aiua-10838	49	537	low	low	ADJ
aiua-10838	49	538	low	low	ADJ
aiua-10838	49	539	moderate	moderate	ADJ
aiua-10838	49	540	bhindi	bhindi	NOUN
aiua-10838	49	541	(	(	PUNCT
aiua-10838	49	542	2020	2020	NUM
aiua-10838	49	543	)	)	PUNCT
aiua-10838	49	544	moderate	moderate	ADJ
aiua-10838	49	545	moderate	moderate	ADJ
aiua-10838	49	546	low	low	ADJ
aiua-10838	49	547	low	low	ADJ
aiua-10838	49	548	low	low	ADJ
aiua-10838	49	549	low	low	ADJ
aiua-10838	49	550	low	low	ADJ
aiua-10838	49	551	moderate	moderate	ADJ
aiua-10838	49	552	de	de	X
aiua-10838	49	553	bruijn	bruijn	NOUN
aiua-10838	49	554	(	(	PUNCT
aiua-10838	49	555	2020	2020	NUM
aiua-10838	49	556	)	)	PUNCT
aiua-10838	49	557	serious	serious	ADJ
aiua-10838	49	558	serious	serious	ADJ
aiua-10838	49	559	low	low	ADJ
aiua-10838	49	560	low	low	ADJ
aiua-10838	49	561	low	low	ADJ
aiua-10838	49	562	low	low	ADJ
aiua-10838	49	563	low	low	ADJ
aiua-10838	49	564	serious	serious	ADJ
aiua-10838	49	565	uprety	uprety	NOUN
aiua-10838	49	566	(	(	PUNCT
aiua-10838	49	567	2018	2018	NUM
aiua-10838	49	568	)	)	PUNCT
aiua-10838	49	569	moderate	moderate	ADJ
aiua-10838	49	570	moderate	moderate	ADJ
aiua-10838	49	571	low	low	ADJ
aiua-10838	49	572	low	low	ADJ
aiua-10838	49	573	low	low	ADJ
aiua-10838	49	574	low	low	ADJ
aiua-10838	49	575	low	low	ADJ
aiua-10838	49	576	moderate	moderate	ADJ
aiua-10838	49	577	study	study	NOUN
aiua-10838	49	578	random	random	ADJ
aiua-10838	49	579	allocation	allocation	NOUN
aiua-10838	49	580	blinding	blinding	NOUN
aiua-10838	49	581	of	of	ADP
aiua-10838	49	582	participants	participant	NOUN
aiua-10838	49	583	blinded	blind	VERB
aiua-10838	49	584	outcome	outcome	VERB
aiua-10838	49	585	incomplete	incomplete	ADJ
aiua-10838	49	586	selective	selective	ADJ
aiua-10838	49	587	other	other	ADJ
aiua-10838	49	588	overall	overall	ADJ
aiua-10838	49	589	sequence	sequence	NOUN
aiua-10838	49	590	generation	generation	NOUN
aiua-10838	49	591	concealment	concealment	NOUN
aiua-10838	49	592	and	and	CCONJ
aiua-10838	49	593	personnel	personnel	NOUN
aiua-10838	49	594	assessment	assessment	NOUN
aiua-10838	49	595	outcome	outcome	NOUN
aiua-10838	49	596	data	datum	NOUN
aiua-10838	49	597	reporting	reporting	NOUN
aiua-10838	49	598	bias	bias	NOUN
aiua-10838	49	599	risk	risk	NOUN
aiua-10838	49	600	of	of	ADP
aiua-10838	49	601	bias	bias	NOUN
aiua-10838	49	602	bex	bex	PROPN
aiua-10838	49	603	(	(	PUNCT
aiua-10838	49	604	2017	2017	NUM
aiua-10838	49	605	)	)	PUNCT
aiua-10838	49	606	low	low	ADJ
aiua-10838	49	607	low	low	ADJ
aiua-10838	49	608	low	low	ADJ
aiua-10838	49	609	low	low	ADJ
aiua-10838	49	610	low	low	ADJ
aiua-10838	49	611	low	low	ADJ
aiua-10838	49	612	moderate	moderate	ADJ
aiua-10838	49	613	moderate	moderate	ADJ
aiua-10838	49	614	mejean	mejean	ADJ
aiua-10838	49	615	(	(	PUNCT
aiua-10838	49	616	2018	2018	NUM
aiua-10838	49	617	)	)	PUNCT
aiua-10838	49	618	low	low	ADJ
aiua-10838	49	619	low	low	ADJ
aiua-10838	49	620	low	low	ADJ
aiua-10838	49	621	low	low	ADJ
aiua-10838	49	622	low	low	ADJ
aiua-10838	49	623	low	low	ADJ
aiua-10838	49	624	moderate	moderate	ADJ
aiua-10838	49	625	moderate	moderate	ADJ
aiua-10838	49	626	risk	risk	NOUN
aiua-10838	49	627	of	of	ADP
aiua-10838	49	628	bias	bias	NOUN
aiua-10838	49	629	assessment	assessment	NOUN
aiua-10838	49	630	for	for	ADP
aiua-10838	49	631	randomized	randomized	ADJ
aiua-10838	49	632	studies	study	NOUN
aiua-10838	49	633	.	.	PUNCT
aiua-10838	50	1	479archivio	479archivio	PROPN
aiua-10838	50	2	italiano	italiano	NOUN
aiua-10838	50	3	di	di	X
aiua-10838	50	4	urologia	urologia	PROPN
aiua-10838	50	5	e	e	PROPN
aiua-10838	50	6	andrologia	andrologia	PROPN
aiua-10838	50	7	2022	2022	NUM
aiua-10838	50	8	;	;	PUNCT
aiua-10838	50	9	94	94	NUM
aiua-10838	50	10	,	,	PUNCT
aiua-10838	50	11	4	4	NUM
aiua-10838	50	12	nephrectomy	nephrectomy	NOUN
aiua-10838	50	13	for	for	ADP
aiua-10838	50	14	metastatic	metastatic	ADJ
aiua-10838	50	15	renal	renal	ADJ
aiua-10838	50	16	cell	cell	NOUN
aiua-10838	50	17	carcinoma	carcinoma	NOUN
aiua-10838	50	18	table	table	NOUN
aiua-10838	50	19	2	2	NUM
aiua-10838	50	20	.	.	PUNCT
aiua-10838	51	1	studies	study	NOUN
aiua-10838	51	2	evaluating	evaluate	VERB
aiua-10838	51	3	the	the	DET
aiua-10838	51	4	association	association	NOUN
aiua-10838	51	5	between	between	ADP
aiua-10838	51	6	cn	cn	PROPN
aiua-10838	51	7	and	and	CCONJ
aiua-10838	51	8	os	os	PROPN
aiua-10838	51	9	.	.	PUNCT
aiua-10838	52	1	study	study	NOUN
aiua-10838	52	2	number	number	NOUN
aiua-10838	52	3	systemic	systemic	ADJ
aiua-10838	52	4	agents	agent	NOUN
aiua-10838	52	5	cn	cn	ADJ
aiua-10838	52	6	-	-	ADJ
aiua-10838	52	7	systemic	systemic	ADJ
aiua-10838	52	8	therapy	therapy	NOUN
aiua-10838	52	9	median	median	NOUN
aiua-10838	52	10	os	os	PROPN
aiua-10838	53	1	(	(	PUNCT
aiua-10838	53	2	cn	cn	PROPN
aiua-10838	53	3	vs	vs	ADP
aiua-10838	53	4	no	no	DET
aiua-10838	53	5	cn	cn	PROPN
aiua-10838	53	6	)	)	PUNCT
aiua-10838	53	7	supplementary	supplementary	ADJ
aiua-10838	53	8	info	info	NOUN
aiua-10838	53	9	of	of	ADP
aiua-10838	53	10	patients	patient	NOUN
aiua-10838	53	11	used	use	VERB
aiua-10838	53	12	sequence	sequence	NOUN
aiua-10838	53	13	os	os	PROPN
aiua-10838	53	14	hr	hr	NOUN
aiua-10838	53	15	(	(	PUNCT
aiua-10838	53	16	95	95	NUM
aiua-10838	53	17	%	%	NOUN
aiua-10838	53	18	ci	ci	NOUN
aiua-10838	53	19	)	)	PUNCT
aiua-10838	53	20	for	for	ADP
aiua-10838	53	21	the	the	DET
aiua-10838	53	22	study	study	PROPN
aiua-10838	53	23	conti	conti	PROPN
aiua-10838	53	24	(	(	PUNCT
aiua-10838	53	25	2014	2014	NUM
aiua-10838	53	26	)	)	PUNCT
aiua-10838	53	27	(	(	PUNCT
aiua-10838	53	28	14	14	NUM
aiua-10838	53	29	)	)	PUNCT
aiua-10838	53	30	,	,	PUNCT
aiua-10838	53	31	retrospective	retrospective	ADJ
aiua-10838	53	32	cohort	cohort	NOUN
aiua-10838	53	33	,	,	PUNCT
aiua-10838	53	34	n	n	CCONJ
aiua-10838	53	35	(	(	PUNCT
aiua-10838	53	36	total	total	NOUN
aiua-10838	53	37	)	)	PUNCT
aiua-10838	53	38	=	=	SYM
aiua-10838	53	39	20104	20104	NUM
aiua-10838	53	40	nr	nr	INTJ
aiua-10838	53	41	nr	nr	PROPN
aiua-10838	53	42	15	15	NUM
aiua-10838	53	43	vs	vs	ADP
aiua-10838	53	44	4	4	NUM
aiua-10838	53	45	,	,	PUNCT
aiua-10838	53	46	hr	hr	NOUN
aiua-10838	53	47	0.41	0.41	NUM
aiua-10838	53	48	non	non	ADJ
aiua-10838	53	49	–	–	PROPN
aiua-10838	53	50	clear	clear	ADJ
aiua-10838	53	51	cell	cell	NOUN
aiua-10838	53	52	renal	renal	ADJ
aiua-10838	53	53	cell	cell	NOUN
aiua-10838	53	54	carcinoma	carcinoma	NOUN
aiua-10838	53	55	studied	study	VERB
aiua-10838	53	56	usa	usa	PROPN
aiua-10838	53	57	(	(	PUNCT
aiua-10838	53	58	seer	seer	PROPN
aiua-10838	53	59	)	)	PUNCT
aiua-10838	53	60	1993	1993	NUM
aiua-10838	53	61	-	-	SYM
aiua-10838	53	62	2010	2010	NUM
aiua-10838	53	63	n	n	CCONJ
aiua-10838	53	64	(	(	PUNCT
aiua-10838	53	65	cn	cn	PROPN
aiua-10838	53	66	)	)	PUNCT
aiua-10838	53	67	=	=	SYM
aiua-10838	53	68	6915	6915	NUM
aiua-10838	53	69	(	(	PUNCT
aiua-10838	53	70	95	95	NUM
aiua-10838	53	71	%	%	NOUN
aiua-10838	53	72	ci	ci	NOUN
aiua-10838	53	73	0.37–0.55	0.37–0.55	NUM
aiua-10838	53	74	)	)	PUNCT
aiua-10838	54	1	n	n	CCONJ
aiua-10838	54	2	(	(	PUNCT
aiua-10838	54	3	no	no	DET
aiua-10838	54	4	cn	cn	NOUN
aiua-10838	54	5	)	)	PUNCT
aiua-10838	54	6	=	=	SYM
aiua-10838	54	7	13819	13819	NUM
aiua-10838	54	8	aizer	aizer	NOUN
aiua-10838	54	9	(	(	PUNCT
aiua-10838	54	10	2014	2014	NUM
aiua-10838	54	11	)	)	PUNCT
aiua-10838	54	12	(	(	PUNCT
aiua-10838	54	13	15	15	NUM
aiua-10838	54	14	)	)	PUNCT
aiua-10838	54	15	,	,	PUNCT
aiua-10838	54	16	retrospective	retrospective	ADJ
aiua-10838	54	17	cohort	cohort	NOUN
aiua-10838	54	18	,	,	PUNCT
aiua-10838	54	19	n	n	CCONJ
aiua-10838	54	20	(	(	PUNCT
aiua-10838	54	21	total	total	NOUN
aiua-10838	54	22	)	)	PUNCT
aiua-10838	54	23	=	=	SYM
aiua-10838	55	1	591	591	NUM
aiua-10838	55	2	nr	nr	NOUN
aiua-10838	55	3	nr	nr	PROPN
aiua-10838	55	4	14	14	NUM
aiua-10838	55	5	vs	vs	ADP
aiua-10838	55	6	6	6	NUM
aiua-10838	55	7	,	,	PUNCT
aiua-10838	55	8	hr	hr	NOUN
aiua-10838	55	9	0.45	0.45	NUM
aiua-10838	55	10	cytokines	cytokine	NOUN
aiua-10838	55	11	+	+	CCONJ
aiua-10838	55	12	st	st	PROPN
aiua-10838	55	13	usa	usa	PROPN
aiua-10838	55	14	(	(	PUNCT
aiua-10838	55	15	seer	seer	PROPN
aiua-10838	55	16	)	)	PUNCT
aiua-10838	55	17	2000	2000	NUM
aiua-10838	55	18	-	-	SYM
aiua-10838	55	19	2009	2009	NUM
aiua-10838	55	20	n	n	CCONJ
aiua-10838	55	21	(	(	PUNCT
aiua-10838	55	22	cn	cn	PROPN
aiua-10838	55	23	)	)	PUNCT
aiua-10838	55	24	=	=	SYM
aiua-10838	55	25	384	384	NUM
aiua-10838	55	26	(	(	PUNCT
aiua-10838	55	27	95	95	NUM
aiua-10838	55	28	%	%	NOUN
aiua-10838	55	29	ci	ci	NOUN
aiua-10838	55	30	0.39–0.43	0.39–0.43	PROPN
aiua-10838	55	31	)	)	PUNCT
aiua-10838	55	32	n	n	CCONJ
aiua-10838	55	33	(	(	PUNCT
aiua-10838	55	34	no	no	DET
aiua-10838	55	35	cn	cn	NOUN
aiua-10838	55	36	)	)	PUNCT
aiua-10838	55	37	=	=	SYM
aiua-10838	55	38	207	207	NUM
aiua-10838	55	39	abern	abern	NOUN
aiua-10838	55	40	(	(	PUNCT
aiua-10838	55	41	2014	2014	NUM
aiua-10838	55	42	)	)	PUNCT
aiua-10838	55	43	(	(	PUNCT
aiua-10838	55	44	16	16	NUM
aiua-10838	55	45	)	)	PUNCT
aiua-10838	55	46	,	,	PUNCT
aiua-10838	55	47	retrospective	retrospective	ADJ
aiua-10838	55	48	cohort	cohort	NOUN
aiua-10838	55	49	,	,	PUNCT
aiua-10838	55	50	n	n	CCONJ
aiua-10838	55	51	(	(	PUNCT
aiua-10838	55	52	total	total	ADJ
aiua-10838	55	53	)	)	PUNCT
aiua-10838	55	54	=	=	SYM
aiua-10838	55	55	7143	7143	NUM
aiua-10838	55	56	nr	nr	NOUN
aiua-10838	55	57	nr	nr	PROPN
aiua-10838	55	58	hr	hr	NOUN
aiua-10838	55	59	0.33	0.33	NUM
aiua-10838	55	60	median	median	NOUN
aiua-10838	55	61	os	os	NOUN
aiua-10838	55	62	in	in	ADP
aiua-10838	55	63	months	month	NOUN
aiua-10838	55	64	:	:	PUNCT
aiua-10838	56	1	nr	nr	PROPN
aiua-10838	56	2	usa	usa	PROPN
aiua-10838	56	3	(	(	PUNCT
aiua-10838	56	4	seer	seer	PROPN
aiua-10838	56	5	)	)	PUNCT
aiua-10838	56	6	2005	2005	NUM
aiua-10838	56	7	-	-	SYM
aiua-10838	56	8	2009	2009	NUM
aiua-10838	56	9	n	n	CCONJ
aiua-10838	56	10	(	(	PUNCT
aiua-10838	56	11	cn	cn	PROPN
aiua-10838	56	12	)	)	PUNCT
aiua-10838	56	13	=	=	SYM
aiua-10838	56	14	2629	2629	NUM
aiua-10838	56	15	(	(	PUNCT
aiua-10838	56	16	95	95	NUM
aiua-10838	56	17	%	%	NOUN
aiua-10838	56	18	ci	ci	NOUN
aiua-10838	56	19	0.31–0.36	0.31–0.36	NUM
aiua-10838	56	20	)	)	PUNCT
aiua-10838	57	1	n	n	CCONJ
aiua-10838	57	2	(	(	PUNCT
aiua-10838	57	3	no	no	DET
aiua-10838	57	4	cn	cn	NOUN
aiua-10838	57	5	)	)	PUNCT
aiua-10838	57	6	=	=	SYM
aiua-10838	57	7	4514	4514	NUM
aiua-10838	57	8	vaishampayan	vaishampayan	VERB
aiua-10838	57	9	(	(	PUNCT
aiua-10838	57	10	2019	2019	NUM
aiua-10838	57	11	)	)	PUNCT
aiua-10838	57	12	(	(	PUNCT
aiua-10838	57	13	17	17	NUM
aiua-10838	57	14	)	)	PUNCT
aiua-10838	57	15	,	,	PUNCT
aiua-10838	57	16	retrospective	retrospective	ADJ
aiua-10838	57	17	cohort	cohort	NOUN
aiua-10838	57	18	,	,	PUNCT
aiua-10838	57	19	n	n	CCONJ
aiua-10838	57	20	(	(	PUNCT
aiua-10838	57	21	total	total	NOUN
aiua-10838	57	22	)	)	PUNCT
aiua-10838	57	23	=	=	SYM
aiua-10838	58	1	18422	18422	NUM
aiua-10838	58	2	nr	nr	INTJ
aiua-10838	58	3	nr	nr	PROPN
aiua-10838	58	4	18	18	NUM
aiua-10838	58	5	vs	vs	ADP
aiua-10838	58	6	3	3	NUM
aiua-10838	58	7	,	,	PUNCT
aiua-10838	58	8	hr	hr	NOUN
aiua-10838	58	9	0.39	0.39	NUM
aiua-10838	58	10	usa	usa	PROPN
aiua-10838	58	11	(	(	PUNCT
aiua-10838	58	12	seer	seer	PROPN
aiua-10838	58	13	)	)	PUNCT
aiua-10838	58	14	2010	2010	NUM
aiua-10838	58	15	-	-	SYM
aiua-10838	58	16	2016	2016	NUM
aiua-10838	58	17	n	n	CCONJ
aiua-10838	58	18	(	(	PUNCT
aiua-10838	58	19	cn)=	cn)=	ADP
aiua-10838	58	20	7660	7660	NUM
aiua-10838	58	21	(	(	PUNCT
aiua-10838	58	22	95	95	NUM
aiua-10838	58	23	%	%	NOUN
aiua-10838	58	24	ci	ci	PROPN
aiua-10838	58	25	0.30–0.33	0.30–0.33	PROPN
aiua-10838	58	26	)	)	PUNCT
aiua-10838	58	27	n	n	CCONJ
aiua-10838	58	28	(	(	PUNCT
aiua-10838	58	29	no	no	DET
aiua-10838	58	30	cn	cn	NOUN
aiua-10838	58	31	)	)	PUNCT
aiua-10838	58	32	=	=	NOUN
aiua-10838	58	33	10762	10762	NUM
aiua-10838	58	34	zhao	zhao	NOUN
aiua-10838	58	35	(	(	PUNCT
aiua-10838	58	36	2019	2019	NUM
aiua-10838	58	37	)	)	PUNCT
aiua-10838	58	38	(	(	PUNCT
aiua-10838	58	39	18	18	NUM
aiua-10838	58	40	)	)	PUNCT
aiua-10838	58	41	,	,	PUNCT
aiua-10838	58	42	retrospective	retrospective	ADJ
aiua-10838	58	43	cohort	cohort	NOUN
aiua-10838	58	44	,	,	PUNCT
aiua-10838	58	45	n	n	CCONJ
aiua-10838	58	46	(	(	PUNCT
aiua-10838	58	47	total	total	ADJ
aiua-10838	58	48	)	)	PUNCT
aiua-10838	58	49	=	=	SYM
aiua-10838	58	50	1113	1113	NUM
aiua-10838	58	51	nr	nr	INTJ
aiua-10838	58	52	nr	nr	PROPN
aiua-10838	58	53	26	26	NUM
aiua-10838	58	54	vs	vs	ADP
aiua-10838	58	55	9	9	NUM
aiua-10838	58	56	,	,	PUNCT
aiua-10838	58	57	hr	hr	NOUN
aiua-10838	58	58	0.40	0.40	NUM
aiua-10838	58	59	usa	usa	PROPN
aiua-10838	58	60	(	(	PUNCT
aiua-10838	58	61	seer	seer	PROPN
aiua-10838	58	62	)	)	PUNCT
aiua-10838	58	63	2010	2010	NUM
aiua-10838	58	64	-	-	SYM
aiua-10838	58	65	2014	2014	NUM
aiua-10838	58	66	n	n	CCONJ
aiua-10838	58	67	(	(	PUNCT
aiua-10838	58	68	cn	cn	PROPN
aiua-10838	58	69	)	)	PUNCT
aiua-10838	58	70	=	=	SYM
aiua-10838	58	71	618	618	NUM
aiua-10838	58	72	(	(	PUNCT
aiua-10838	58	73	95	95	NUM
aiua-10838	58	74	%	%	NOUN
aiua-10838	58	75	ci	ci	NOUN
aiua-10838	58	76	0.35–0.47	0.35–0.47	NOUN
aiua-10838	58	77	)	)	PUNCT
aiua-10838	58	78	n	n	CCONJ
aiua-10838	58	79	(	(	PUNCT
aiua-10838	58	80	no	no	DET
aiua-10838	58	81	cn	cn	NOUN
aiua-10838	58	82	)	)	PUNCT
aiua-10838	58	83	=	=	SYM
aiua-10838	58	84	415	415	NUM
aiua-10838	58	85	marchioni	marchioni	NOUN
aiua-10838	58	86	(	(	PUNCT
aiua-10838	58	87	2019	2019	NUM
aiua-10838	58	88	)	)	PUNCT
aiua-10838	58	89	(	(	PUNCT
aiua-10838	58	90	19	19	NUM
aiua-10838	58	91	)	)	PUNCT
aiua-10838	58	92	,	,	PUNCT
aiua-10838	58	93	retrospective	retrospective	ADJ
aiua-10838	58	94	cohort	cohort	NOUN
aiua-10838	58	95	,	,	PUNCT
aiua-10838	58	96	n	n	CCONJ
aiua-10838	58	97	(	(	PUNCT
aiua-10838	58	98	total	total	NOUN
aiua-10838	58	99	)	)	PUNCT
aiua-10838	58	100	=	=	SYM
aiua-10838	58	101	851	851	NUM
aiua-10838	58	102	nr	nr	PROPN
aiua-10838	58	103	nr	nr	PROPN
aiua-10838	58	104	hr	hr	NOUN
aiua-10838	58	105	0.38	0.38	NUM
aiua-10838	58	106	median	median	NOUN
aiua-10838	58	107	os	os	NOUN
aiua-10838	58	108	in	in	ADP
aiua-10838	58	109	months	month	NOUN
aiua-10838	58	110	:	:	PUNCT
aiua-10838	58	111	nr	nr	PROPN
aiua-10838	58	112	usa	usa	PROPN
aiua-10838	58	113	(	(	PUNCT
aiua-10838	58	114	seer	seer	PROPN
aiua-10838	58	115	)	)	PUNCT
aiua-10838	58	116	2001	2001	NUM
aiua-10838	58	117	-	-	SYM
aiua-10838	58	118	2014	2014	NUM
aiua-10838	58	119	n	n	CCONJ
aiua-10838	58	120	(	(	PUNCT
aiua-10838	58	121	cn	cn	PROPN
aiua-10838	58	122	)	)	PUNCT
aiua-10838	58	123	=	=	SYM
aiua-10838	58	124	575	575	NUM
aiua-10838	58	125	(	(	PUNCT
aiua-10838	58	126	95	95	NUM
aiua-10838	58	127	%	%	NOUN
aiua-10838	58	128	ci	ci	NOUN
aiua-10838	58	129	0.30–0.47	0.30–0.47	NUM
aiua-10838	58	130	)	)	PUNCT
aiua-10838	58	131	non	non	ADJ
aiua-10838	58	132	-	-	ADJ
aiua-10838	58	133	clear	clear	ADJ
aiua-10838	58	134	cell	cell	NOUN
aiua-10838	58	135	renal	renal	ADJ
aiua-10838	58	136	cell	cell	NOUN
aiua-10838	58	137	carcinoma	carcinoma	NOUN
aiua-10838	58	138	studied	study	VERB
aiua-10838	58	139	n	n	PROPN
aiua-10838	58	140	(	(	PUNCT
aiua-10838	58	141	no	no	DET
aiua-10838	58	142	cn	cn	NOUN
aiua-10838	58	143	)	)	PUNCT
aiua-10838	58	144	=	=	SYM
aiua-10838	58	145	276	276	NUM
aiua-10838	58	146	palumbo	palumbo	NOUN
aiua-10838	58	147	(	(	PUNCT
aiua-10838	58	148	2020	2020	NUM
aiua-10838	58	149	)	)	PUNCT
aiua-10838	58	150	(	(	PUNCT
aiua-10838	58	151	20	20	NUM
aiua-10838	58	152	)	)	PUNCT
aiua-10838	58	153	,	,	PUNCT
aiua-10838	58	154	retrospective	retrospective	ADJ
aiua-10838	58	155	cohort	cohort	NOUN
aiua-10838	58	156	,	,	PUNCT
aiua-10838	58	157	n	n	CCONJ
aiua-10838	58	158	(	(	PUNCT
aiua-10838	58	159	total	total	NOUN
aiua-10838	58	160	)	)	PUNCT
aiua-10838	58	161	=	=	SYM
aiua-10838	58	162	2241	2241	NUM
aiua-10838	58	163	nr	nr	PROPN
aiua-10838	58	164	nr	nr	PROPN
aiua-10838	58	165	28	28	NUM
aiua-10838	58	166	vs	vs	ADP
aiua-10838	58	167	12	12	NUM
aiua-10838	58	168	,	,	PUNCT
aiua-10838	58	169	hr	hr	NOUN
aiua-10838	58	170	0.49	0.49	NUM
aiua-10838	58	171	usa	usa	PROPN
aiua-10838	58	172	(	(	PUNCT
aiua-10838	58	173	seer	seer	PROPN
aiua-10838	58	174	)	)	PUNCT
aiua-10838	58	175	2010	2010	NUM
aiua-10838	58	176	-	-	SYM
aiua-10838	58	177	2015	2015	NUM
aiua-10838	58	178	n	n	CCONJ
aiua-10838	58	179	(	(	PUNCT
aiua-10838	58	180	cn	cn	PROPN
aiua-10838	58	181	)	)	PUNCT
aiua-10838	58	182	=	=	NOUN
aiua-10838	58	183	1168	1168	NUM
aiua-10838	58	184	(	(	PUNCT
aiua-10838	58	185	95	95	NUM
aiua-10838	58	186	%	%	NOUN
aiua-10838	58	187	ci	ci	NOUN
aiua-10838	58	188	0.41–0.58	0.41–0.58	NUM
aiua-10838	58	189	)	)	PUNCT
aiua-10838	58	190	n	n	CCONJ
aiua-10838	58	191	(	(	PUNCT
aiua-10838	58	192	no	no	DET
aiua-10838	58	193	cn	cn	NOUN
aiua-10838	58	194	)	)	PUNCT
aiua-10838	58	195	=	=	SYM
aiua-10838	58	196	1073	1073	NUM
aiua-10838	58	197	luzzago	luzzago	NOUN
aiua-10838	58	198	(	(	PUNCT
aiua-10838	58	199	2021	2021	NUM
aiua-10838	58	200	)	)	PUNCT
aiua-10838	58	201	(	(	PUNCT
aiua-10838	58	202	21	21	NUM
aiua-10838	58	203	)	)	PUNCT
aiua-10838	58	204	,	,	PUNCT
aiua-10838	58	205	retrospective	retrospective	ADJ
aiua-10838	58	206	cohort	cohort	NOUN
aiua-10838	58	207	,	,	PUNCT
aiua-10838	58	208	n	n	CCONJ
aiua-10838	58	209	(	(	PUNCT
aiua-10838	58	210	total	total	ADJ
aiua-10838	58	211	)	)	PUNCT
aiua-10838	58	212	=	=	SYM
aiua-10838	58	213	1573	1573	NUM
aiua-10838	58	214	nr	nr	INTJ
aiua-10838	58	215	cn	cn	PROPN
aiua-10838	58	216	before	before	ADP
aiua-10838	58	217	st	st	PROPN
aiua-10838	58	218	no	no	DET
aiua-10838	58	219	treatment	treatment	NOUN
aiua-10838	58	220	=	=	SYM
aiua-10838	58	221	3	3	NUM
aiua-10838	58	222	usa	usa	PROPN
aiua-10838	58	223	(	(	PUNCT
aiua-10838	58	224	seer	seer	PROPN
aiua-10838	58	225	)	)	PUNCT
aiua-10838	58	226	2006	2006	NUM
aiua-10838	58	227	-	-	SYM
aiua-10838	58	228	2015	2015	NUM
aiua-10838	58	229	n	n	CCONJ
aiua-10838	58	230	(	(	PUNCT
aiua-10838	58	231	no	no	DET
aiua-10838	58	232	-	-	PUNCT
aiua-10838	58	233	treatment	treatment	NOUN
aiua-10838	58	234	)	)	PUNCT
aiua-10838	58	235	=	=	SYM
aiua-10838	58	236	350	350	NUM
aiua-10838	58	237	st	st	NOUN
aiua-10838	58	238	alone	alone	ADV
aiua-10838	58	239	=	=	SYM
aiua-10838	58	240	7	7	NUM
aiua-10838	58	241	n	n	PROPN
aiua-10838	58	242	(	(	PUNCT
aiua-10838	58	243	st	st	PROPN
aiua-10838	58	244	alone	alone	ADV
aiua-10838	58	245	)	)	PUNCT
aiua-10838	58	246	=	=	SYM
aiua-10838	59	1	387	387	NUM
aiua-10838	59	2	cn	cn	NOUN
aiua-10838	59	3	=	=	NOUN
aiua-10838	59	4	9	9	NUM
aiua-10838	59	5	n	n	CCONJ
aiua-10838	59	6	(	(	PUNCT
aiua-10838	59	7	cn	cn	PROPN
aiua-10838	59	8	)	)	PUNCT
aiua-10838	59	9	=	=	SYM
aiua-10838	59	10	396	396	NUM
aiua-10838	59	11	cn+st	cn+st	NOUN
aiua-10838	59	12	=	=	SYM
aiua-10838	59	13	13	13	NUM
aiua-10838	59	14	n	n	NOUN
aiua-10838	59	15	(	(	PUNCT
aiua-10838	59	16	cn+st	cn+st	NOUN
aiua-10838	59	17	)	)	PUNCT
aiua-10838	59	18	=	=	SYM
aiua-10838	59	19	440	440	NUM
aiua-10838	59	20	hr	hr	NOUN
aiua-10838	59	21	=	=	PROPN
aiua-10838	59	22	nr	nr	PROPN
aiua-10838	59	23	non	non	ADJ
aiua-10838	59	24	–	–	PUNCT
aiua-10838	59	25	clear	clear	ADJ
aiua-10838	59	26	cell	cell	NOUN
aiua-10838	59	27	renal	renal	ADJ
aiua-10838	59	28	cell	cell	NOUN
aiua-10838	59	29	carcinoma	carcinoma	NOUN
aiua-10838	59	30	studied	study	VERB
aiua-10838	59	31	alnimer	alnimer	NOUN
aiua-10838	59	32	(	(	PUNCT
aiua-10838	59	33	2021	2021	NUM
aiua-10838	59	34	)	)	PUNCT
aiua-10838	59	35	(	(	PUNCT
aiua-10838	59	36	22	22	NUM
aiua-10838	59	37	)	)	PUNCT
aiua-10838	59	38	,	,	PUNCT
aiua-10838	59	39	retrospective	retrospective	ADJ
aiua-10838	59	40	cohort	cohort	NOUN
aiua-10838	59	41	,	,	PUNCT
aiua-10838	59	42	n	n	CCONJ
aiua-10838	59	43	(	(	PUNCT
aiua-10838	59	44	total	total	NOUN
aiua-10838	59	45	)	)	PUNCT
aiua-10838	59	46	=	=	SYM
aiua-10838	59	47	5483	5483	NUM
aiua-10838	59	48	nr	nr	NOUN
aiua-10838	59	49	nr	nr	PROPN
aiua-10838	59	50	24	24	NUM
aiua-10838	59	51	vs	vs	ADP
aiua-10838	59	52	6	6	NUM
aiua-10838	59	53	,	,	PUNCT
aiua-10838	59	54	hr	hr	NOUN
aiua-10838	59	55	0.33	0.33	NUM
aiua-10838	59	56	usa	usa	PROPN
aiua-10838	59	57	(	(	PUNCT
aiua-10838	59	58	seer	seer	PROPN
aiua-10838	59	59	)	)	PUNCT
aiua-10838	59	60	2010	2010	NUM
aiua-10838	59	61	-	-	SYM
aiua-10838	59	62	2016	2016	NUM
aiua-10838	59	63	n	n	CCONJ
aiua-10838	59	64	(	(	PUNCT
aiua-10838	59	65	cn	cn	PROPN
aiua-10838	59	66	)	)	PUNCT
aiua-10838	59	67	=	=	SYM
aiua-10838	59	68	2991	2991	NUM
aiua-10838	59	69	(	(	PUNCT
aiua-10838	59	70	95	95	NUM
aiua-10838	59	71	%	%	NOUN
aiua-10838	59	72	ci	ci	NOUN
aiua-10838	59	73	0.28–0.40	0.28–0.40	NUM
aiua-10838	59	74	)	)	PUNCT
aiua-10838	60	1	n	n	CCONJ
aiua-10838	60	2	(	(	PUNCT
aiua-10838	60	3	no	no	DET
aiua-10838	60	4	cn	cn	NOUN
aiua-10838	60	5	)	)	PUNCT
aiua-10838	60	6	=	=	SYM
aiua-10838	60	7	2483	2483	NUM
aiua-10838	60	8	hanna	hanna	NOUN
aiua-10838	60	9	(	(	PUNCT
aiua-10838	60	10	2016	2016	NUM
aiua-10838	60	11	)	)	PUNCT
aiua-10838	60	12	(	(	PUNCT
aiua-10838	60	13	23	23	NUM
aiua-10838	60	14	)	)	PUNCT
aiua-10838	60	15	,	,	PUNCT
aiua-10838	60	16	retrospective	retrospective	ADJ
aiua-10838	60	17	cohort	cohort	NOUN
aiua-10838	60	18	,	,	PUNCT
aiua-10838	60	19	n	n	CCONJ
aiua-10838	60	20	(	(	PUNCT
aiua-10838	60	21	total	total	NOUN
aiua-10838	60	22	)	)	PUNCT
aiua-10838	60	23	=	=	SYM
aiua-10838	60	24	15390	15390	NUM
aiua-10838	60	25	nr	nr	NOUN
aiua-10838	60	26	cn	cn	X
aiua-10838	60	27	before	before	ADP
aiua-10838	60	28	or	or	CCONJ
aiua-10838	60	29	after	after	ADP
aiua-10838	60	30	st	st	PROPN
aiua-10838	60	31	17.1	17.1	NUM
aiua-10838	60	32	vs	vs	ADP
aiua-10838	60	33	7.7	7.7	NUM
aiua-10838	60	34	,	,	PUNCT
aiua-10838	60	35	hr	hr	NOUN
aiua-10838	60	36	0.49	0.49	NUM
aiua-10838	60	37	usa	usa	PROPN
aiua-10838	60	38	(	(	PUNCT
aiua-10838	60	39	ncdb	ncdb	PROPN
aiua-10838	60	40	)	)	PUNCT
aiua-10838	60	41	2006	2006	NUM
aiua-10838	60	42	-	-	SYM
aiua-10838	60	43	2013	2013	NUM
aiua-10838	60	44	n	n	CCONJ
aiua-10838	60	45	(	(	PUNCT
aiua-10838	60	46	cn	cn	PROPN
aiua-10838	60	47	)	)	PUNCT
aiua-10838	60	48	=	=	SYM
aiua-10838	60	49	5374	5374	NUM
aiua-10838	60	50	(	(	PUNCT
aiua-10838	60	51	95	95	NUM
aiua-10838	60	52	%	%	NOUN
aiua-10838	60	53	ci	ci	NOUN
aiua-10838	60	54	0.46–0.52	0.46–0.52	NUM
aiua-10838	60	55	)	)	PUNCT
aiua-10838	60	56	n	n	CCONJ
aiua-10838	60	57	(	(	PUNCT
aiua-10838	60	58	no	no	DET
aiua-10838	60	59	cn	cn	NOUN
aiua-10838	60	60	)	)	PUNCT
aiua-10838	60	61	=	=	SYM
aiua-10838	60	62	10016	10016	NUM
aiua-10838	60	63	singla	singla	NOUN
aiua-10838	60	64	(	(	PUNCT
aiua-10838	60	65	2020	2020	NUM
aiua-10838	60	66	)	)	PUNCT
aiua-10838	60	67	(	(	PUNCT
aiua-10838	60	68	24	24	NUM
aiua-10838	60	69	)	)	PUNCT
aiua-10838	60	70	,	,	PUNCT
aiua-10838	60	71	retrospective	retrospective	ADJ
aiua-10838	60	72	cohort	cohort	NOUN
aiua-10838	60	73	,	,	PUNCT
aiua-10838	60	74	n	n	CCONJ
aiua-10838	60	75	(	(	PUNCT
aiua-10838	60	76	total	total	NOUN
aiua-10838	60	77	)	)	PUNCT
aiua-10838	60	78	=	=	SYM
aiua-10838	61	1	391	391	NUM
aiua-10838	61	2	upfront	upfront	NOUN
aiua-10838	61	3	cn	cn	PROPN
aiua-10838	61	4	=	=	SYM
aiua-10838	61	5	197	197	NUM
aiua-10838	61	6	,	,	PUNCT
aiua-10838	61	7	no	no	DET
aiua-10838	61	8	cn	cn	NOUN
aiua-10838	61	9	=	=	NOUN
aiua-10838	61	10	11.6	11.6	NUM
aiua-10838	61	11	median	median	NOUN
aiua-10838	61	12	os	os	NOUN
aiua-10838	61	13	was	be	AUX
aiua-10838	61	14	not	not	PART
aiua-10838	61	15	reached	reach	VERB
aiua-10838	61	16	in	in	ADP
aiua-10838	61	17	the	the	DET
aiua-10838	61	18	cn	cn	PROPN
aiua-10838	61	19	group	group	NOUN
aiua-10838	61	20	.	.	PUNCT
aiua-10838	62	1	usa	usa	PROPN
aiua-10838	62	2	(	(	PUNCT
aiua-10838	62	3	ncdb	ncdb	PROPN
aiua-10838	62	4	)	)	PUNCT
aiua-10838	62	5	2015	2015	NUM
aiua-10838	62	6	-	-	SYM
aiua-10838	62	7	2016	2016	NUM
aiua-10838	62	8	n	n	CCONJ
aiua-10838	62	9	(	(	PUNCT
aiua-10838	62	10	cn	cn	PROPN
aiua-10838	62	11	)	)	PUNCT
aiua-10838	62	12	=	=	SYM
aiua-10838	62	13	221	221	NUM
aiua-10838	62	14	st	st	NOUN
aiua-10838	62	15	before	before	ADP
aiua-10838	62	16	cn	cn	PROPN
aiua-10838	62	17	=	=	PROPN
aiua-10838	62	18	24	24	NUM
aiua-10838	62	19	hr	hr	NOUN
aiua-10838	62	20	0.23	0.23	NUM
aiua-10838	62	21	(	(	PUNCT
aiua-10838	62	22	95	95	NUM
aiua-10838	62	23	%	%	NOUN
aiua-10838	62	24	ci	ci	PROPN
aiua-10838	62	25	0.15–0.37	0.15–0.37	PROPN
aiua-10838	62	26	)	)	PUNCT
aiua-10838	62	27	patients	patient	NOUN
aiua-10838	62	28	were	be	AUX
aiua-10838	62	29	treated	treat	VERB
aiua-10838	62	30	with	with	ADP
aiua-10838	62	31	immune	immune	ADJ
aiua-10838	62	32	n	n	NOUN
aiua-10838	62	33	(	(	PUNCT
aiua-10838	62	34	no	no	DET
aiua-10838	62	35	cn	cn	NOUN
aiua-10838	62	36	)	)	PUNCT
aiua-10838	62	37	=	=	SYM
aiua-10838	62	38	170	170	NUM
aiua-10838	62	39	checkpoint	checkpoint	NOUN
aiua-10838	62	40	inhibitors	inhibitor	NOUN
aiua-10838	62	41	choi	choi	NOUN
aiua-10838	62	42	(	(	PUNCT
aiua-10838	62	43	2018	2018	NUM
aiua-10838	62	44	)	)	PUNCT
aiua-10838	62	45	(	(	PUNCT
aiua-10838	62	46	25	25	NUM
aiua-10838	62	47	)	)	PUNCT
aiua-10838	62	48	,	,	PUNCT
aiua-10838	62	49	retrospective	retrospective	ADJ
aiua-10838	62	50	cohort	cohort	NOUN
aiua-10838	62	51	,	,	PUNCT
aiua-10838	62	52	n	n	CCONJ
aiua-10838	62	53	(	(	PUNCT
aiua-10838	62	54	total	total	NOUN
aiua-10838	62	55	)	)	PUNCT
aiua-10838	62	56	=	=	SYM
aiua-10838	62	57	294	294	NUM
aiua-10838	62	58	sunitinib	sunitinib	NOUN
aiua-10838	62	59	(	(	PUNCT
aiua-10838	62	60	52.4	52.4	NUM
aiua-10838	62	61	%	%	NOUN
aiua-10838	62	62	)	)	PUNCT
aiua-10838	62	63	st	st	PROPN
aiua-10838	62	64	before	before	ADP
aiua-10838	62	65	cn	cn	PROPN
aiua-10838	62	66	29	29	NUM
aiua-10838	62	67	vs	vs	ADP
aiua-10838	62	68	11	11	NUM
aiua-10838	62	69	,	,	PUNCT
aiua-10838	62	70	hr	hr	NOUN
aiua-10838	62	71	0.40	0.40	NUM
aiua-10838	62	72	korea	korea	PROPN
aiua-10838	62	73	(	(	PUNCT
aiua-10838	62	74	single	single	ADJ
aiua-10838	62	75	center	center	NOUN
aiua-10838	62	76	)	)	PUNCT
aiua-10838	62	77	2005	2005	NUM
aiua-10838	62	78	-	-	SYM
aiua-10838	62	79	2015	2015	NUM
aiua-10838	62	80	n	n	CCONJ
aiua-10838	62	81	(	(	PUNCT
aiua-10838	62	82	cn	cn	PROPN
aiua-10838	62	83	)	)	PUNCT
aiua-10838	62	84	=	=	SYM
aiua-10838	62	85	109	109	NUM
aiua-10838	62	86	pazopanib	pazopanib	NOUN
aiua-10838	62	87	(	(	PUNCT
aiua-10838	62	88	26.2	26.2	NUM
aiua-10838	62	89	%	%	NOUN
aiua-10838	62	90	)	)	PUNCT
aiua-10838	62	91	(	(	PUNCT
aiua-10838	62	92	95	95	NUM
aiua-10838	62	93	%	%	NOUN
aiua-10838	62	94	ci	ci	NOUN
aiua-10838	62	95	0.28–0.58	0.28–0.58	NUM
aiua-10838	62	96	)	)	PUNCT
aiua-10838	62	97	n	n	CCONJ
aiua-10838	62	98	(	(	PUNCT
aiua-10838	62	99	no	no	DET
aiua-10838	62	100	cn	cn	NOUN
aiua-10838	62	101	)	)	PUNCT
aiua-10838	62	102	=	=	SYM
aiua-10838	62	103	105	105	NUM
aiua-10838	62	104	sorafenib	sorafenib	NOUN
aiua-10838	62	105	(	(	PUNCT
aiua-10838	62	106	10.9	10.9	NUM
aiua-10838	62	107	%	%	NOUN
aiua-10838	62	108	)	)	PUNCT
aiua-10838	62	109	temsirolimus	temsirolimus	NOUN
aiua-10838	62	110	(	(	PUNCT
aiua-10838	62	111	4.4	4.4	NUM
aiua-10838	62	112	%	%	NOUN
aiua-10838	62	113	)	)	PUNCT
aiua-10838	62	114	janish	janish	PROPN
aiua-10838	62	115	(	(	PUNCT
aiua-10838	62	116	2020	2020	NUM
aiua-10838	62	117	)	)	PUNCT
aiua-10838	62	118	(	(	PUNCT
aiua-10838	62	119	26	26	NUM
aiua-10838	62	120	)	)	PUNCT
aiua-10838	62	121	,	,	PUNCT
aiua-10838	62	122	retrospective	retrospective	ADJ
aiua-10838	62	123	cohort	cohort	NOUN
aiua-10838	62	124	,	,	PUNCT
aiua-10838	62	125	n	n	CCONJ
aiua-10838	62	126	(	(	PUNCT
aiua-10838	62	127	total	total	NOUN
aiua-10838	62	128	)	)	PUNCT
aiua-10838	62	129	=	=	SYM
aiua-10838	62	130	262	262	NUM
aiua-10838	62	131	sunitinib	sunitinib	NOUN
aiua-10838	62	132	(	(	PUNCT
aiua-10838	62	133	66	66	NUM
aiua-10838	62	134	%	%	NOUN
aiua-10838	62	135	)	)	PUNCT
aiua-10838	62	136	cn	cn	PROPN
aiua-10838	62	137	before	before	ADP
aiua-10838	62	138	st	st	PROPN
aiua-10838	62	139	27	27	NUM
aiua-10838	62	140	months	month	NOUN
aiua-10838	62	141	for	for	ADP
aiua-10838	62	142	the	the	DET
aiua-10838	62	143	cn	cn	PROPN
aiua-10838	62	144	group	group	NOUN
aiua-10838	62	145	no	no	DET
aiua-10838	62	146	difference	difference	NOUN
aiua-10838	62	147	in	in	ADP
aiua-10838	62	148	os	os	NOUN
aiua-10838	62	149	between	between	ADP
aiua-10838	62	150	the	the	DET
aiua-10838	62	151	two	two	NUM
aiua-10838	62	152	groups	group	NOUN
aiua-10838	62	153	germany	germany	PROPN
aiua-10838	62	154	(	(	PUNCT
aiua-10838	62	155	single	single	ADJ
aiua-10838	62	156	center	center	NOUN
aiua-10838	62	157	)	)	PUNCT
aiua-10838	62	158	2000	2000	NUM
aiua-10838	62	159	-	-	SYM
aiua-10838	62	160	2016	2016	NUM
aiua-10838	62	161	n	n	CCONJ
aiua-10838	62	162	(	(	PUNCT
aiua-10838	62	163	cn	cn	PROPN
aiua-10838	62	164	)	)	PUNCT
aiua-10838	62	165	=	=	SYM
aiua-10838	62	166	104	104	NUM
aiua-10838	62	167	sorafenib	sorafenib	NOUN
aiua-10838	62	168	(	(	PUNCT
aiua-10838	62	169	20	20	NUM
aiua-10838	62	170	%	%	NOUN
aiua-10838	62	171	)	)	PUNCT
aiua-10838	62	172	p	p	X
aiua-10838	62	173	>	>	X
aiua-10838	62	174	0.05	0.05	NUM
aiua-10838	62	175	n	n	NOUN
aiua-10838	62	176	(	(	PUNCT
aiua-10838	62	177	no	no	DET
aiua-10838	62	178	cn	cn	NOUN
aiua-10838	62	179	)	)	PUNCT
aiua-10838	62	180	=	=	SYM
aiua-10838	62	181	158	158	NUM
aiua-10838	62	182	pazopanib	pazopanib	NOUN
aiua-10838	62	183	(	(	PUNCT
aiua-10838	62	184	10	10	NUM
aiua-10838	62	185	%	%	NOUN
aiua-10838	62	186	)	)	PUNCT
aiua-10838	62	187	you	you	PRON
aiua-10838	62	188	(	(	PUNCT
aiua-10838	62	189	2011	2011	NUM
aiua-10838	62	190	)	)	PUNCT
aiua-10838	62	191	(	(	PUNCT
aiua-10838	62	192	27	27	NUM
aiua-10838	62	193	)	)	PUNCT
aiua-10838	62	194	,	,	PUNCT
aiua-10838	62	195	retrospective	retrospective	ADJ
aiua-10838	62	196	cohort	cohort	NOUN
aiua-10838	62	197	,	,	PUNCT
aiua-10838	62	198	n	n	CCONJ
aiua-10838	62	199	(	(	PUNCT
aiua-10838	62	200	total	total	NOUN
aiua-10838	62	201	)	)	PUNCT
aiua-10838	62	202	=	=	SYM
aiua-10838	62	203	78	78	NUM
aiua-10838	62	204	sunitinib	sunitinib	NOUN
aiua-10838	62	205	(	(	PUNCT
aiua-10838	62	206	81	81	NUM
aiua-10838	62	207	%	%	NOUN
aiua-10838	62	208	)	)	PUNCT
aiua-10838	62	209	cn	cn	PROPN
aiua-10838	62	210	before	before	ADP
aiua-10838	62	211	st	st	PROPN
aiua-10838	62	212	21.6	21.6	NUM
aiua-10838	62	213	vs	vs	ADP
aiua-10838	62	214	13.9	13.9	NUM
aiua-10838	62	215	,	,	PUNCT
aiua-10838	62	216	hr	hr	PROPN
aiua-10838	62	217	0.53	0.53	NUM
aiua-10838	62	218	korea	korea	PROPN
aiua-10838	62	219	(	(	PUNCT
aiua-10838	62	220	single	single	ADJ
aiua-10838	62	221	center	center	NOUN
aiua-10838	62	222	)	)	PUNCT
aiua-10838	62	223	2006	2006	NUM
aiua-10838	62	224	-	-	SYM
aiua-10838	62	225	2009	2009	NUM
aiua-10838	62	226	n	n	CCONJ
aiua-10838	62	227	(	(	PUNCT
aiua-10838	62	228	cn	cn	PROPN
aiua-10838	62	229	)	)	PUNCT
aiua-10838	62	230	=	=	SYM
aiua-10838	62	231	45	45	NUM
aiua-10838	62	232	sorafenib	sorafenib	NOUN
aiua-10838	62	233	(	(	PUNCT
aiua-10838	62	234	19	19	NUM
aiua-10838	62	235	%	%	NOUN
aiua-10838	62	236	)	)	PUNCT
aiua-10838	62	237	(	(	PUNCT
aiua-10838	62	238	95	95	NUM
aiua-10838	62	239	%	%	NOUN
aiua-10838	62	240	ci	ci	PROPN
aiua-10838	62	241	0.24–1.15	0.24–1.15	PROPN
aiua-10838	62	242	)	)	PUNCT
aiua-10838	62	243	n	n	CCONJ
aiua-10838	62	244	(	(	PUNCT
aiua-10838	62	245	no	no	DET
aiua-10838	62	246	cn	cn	NOUN
aiua-10838	62	247	)	)	PUNCT
aiua-10838	62	248	=	=	PROPN
aiua-10838	62	249	33	33	NUM
aiua-10838	62	250	graham	graham	PROPN
aiua-10838	62	251	(	(	PUNCT
aiua-10838	62	252	2019	2019	NUM
aiua-10838	62	253	)	)	PUNCT
aiua-10838	62	254	(	(	PUNCT
aiua-10838	62	255	28	28	NUM
aiua-10838	62	256	)	)	PUNCT
aiua-10838	62	257	,	,	PUNCT
aiua-10838	62	258	retrospective	retrospective	ADJ
aiua-10838	62	259	cohort	cohort	NOUN
aiua-10838	62	260	,	,	PUNCT
aiua-10838	62	261	n	n	CCONJ
aiua-10838	62	262	(	(	PUNCT
aiua-10838	62	263	total	total	NOUN
aiua-10838	62	264	)	)	PUNCT
aiua-10838	62	265	=	=	SYM
aiua-10838	62	266	353	353	NUM
aiua-10838	62	267	sunitinib	sunitinib	NOUN
aiua-10838	62	268	(	(	PUNCT
aiua-10838	62	269	54	54	NUM
aiua-10838	62	270	%	%	NOUN
aiua-10838	62	271	)	)	PUNCT
aiua-10838	62	272	cn	cn	PROPN
aiua-10838	62	273	before	before	ADP
aiua-10838	62	274	st	st	PROPN
aiua-10838	62	275	16.3	16.3	NUM
aiua-10838	62	276	vs	vs	ADP
aiua-10838	62	277	8.6	8.6	NUM
aiua-10838	62	278	,	,	PUNCT
aiua-10838	62	279	hr	hr	NOUN
aiua-10838	62	280	0.62	0.62	NUM
aiua-10838	62	281	metastatic	metastatic	ADJ
aiua-10838	62	282	papillary	papillary	ADJ
aiua-10838	62	283	renal	renal	ADJ
aiua-10838	62	284	cell	cell	NOUN
aiua-10838	62	285	international	international	ADJ
aiua-10838	62	286	(	(	PUNCT
aiua-10838	62	287	imdc	imdc	PROPN
aiua-10838	62	288	)	)	PUNCT
aiua-10838	62	289	2005	2005	NUM
aiua-10838	62	290	-	-	SYM
aiua-10838	62	291	2017	2017	NUM
aiua-10838	62	292	n	n	CCONJ
aiua-10838	62	293	(	(	PUNCT
aiua-10838	62	294	cn	cn	PROPN
aiua-10838	62	295	)	)	PUNCT
aiua-10838	62	296	=	=	SYM
aiua-10838	62	297	244	244	NUM
aiua-10838	62	298	temsirolimus	temsirolimus	NOUN
aiua-10838	62	299	(	(	PUNCT
aiua-10838	62	300	23	23	NUM
aiua-10838	62	301	%	%	NOUN
aiua-10838	62	302	)	)	PUNCT
aiua-10838	62	303	(	(	PUNCT
aiua-10838	62	304	95	95	NUM
aiua-10838	62	305	%	%	NOUN
aiua-10838	62	306	ci	ci	NOUN
aiua-10838	62	307	0.45–0.85	0.45–0.85	PROPN
aiua-10838	62	308	)	)	PUNCT
aiua-10838	62	309	carcinoma	carcinoma	NOUN
aiua-10838	62	310	studied	study	VERB
aiua-10838	62	311	n	n	PROPN
aiua-10838	62	312	(	(	PUNCT
aiua-10838	62	313	no	no	DET
aiua-10838	62	314	cn	cn	NOUN
aiua-10838	62	315	)	)	PUNCT
aiua-10838	62	316	=	=	SYM
aiua-10838	62	317	109	109	NUM
aiua-10838	62	318	pazopanib	pazopanib	NOUN
aiua-10838	62	319	(	(	PUNCT
aiua-10838	62	320	11	11	NUM
aiua-10838	62	321	%	%	NOUN
aiua-10838	62	322	)	)	PUNCT
aiua-10838	62	323	sorafenib	sorafenib	NOUN
aiua-10838	62	324	(	(	PUNCT
aiua-10838	62	325	2.8	2.8	NUM
aiua-10838	62	326	%	%	NOUN
aiua-10838	62	327	)	)	PUNCT
aiua-10838	62	328	klatte	klatte	NOUN
aiua-10838	62	329	(	(	PUNCT
aiua-10838	62	330	2017	2017	NUM
aiua-10838	62	331	)	)	PUNCT
aiua-10838	62	332	(	(	PUNCT
aiua-10838	62	333	29	29	NUM
aiua-10838	62	334	)	)	PUNCT
aiua-10838	62	335	,	,	PUNCT
aiua-10838	62	336	retrospective	retrospective	ADJ
aiua-10838	62	337	cohort	cohort	NOUN
aiua-10838	62	338	,	,	PUNCT
aiua-10838	62	339	n	n	CCONJ
aiua-10838	62	340	(	(	PUNCT
aiua-10838	62	341	total	total	NOUN
aiua-10838	62	342	)	)	PUNCT
aiua-10838	62	343	=	=	SYM
aiua-10838	62	344	261	261	NUM
aiua-10838	62	345	sunitinib	sunitinib	NOUN
aiua-10838	62	346	(	(	PUNCT
aiua-10838	62	347	60.5	60.5	NUM
aiua-10838	62	348	%	%	NOUN
aiua-10838	62	349	)	)	PUNCT
aiua-10838	62	350	cn	cn	PROPN
aiua-10838	62	351	before	before	SCONJ
aiua-10838	62	352	st	st	PROPN
aiua-10838	62	353	unadjusted	unadjuste	VERB
aiua-10838	62	354	:	:	PUNCT
aiua-10838	62	355	uk	uk	PROPN
aiua-10838	62	356	(	(	PUNCT
aiua-10838	62	357	single	single	ADJ
aiua-10838	62	358	center	center	NOUN
aiua-10838	62	359	)	)	PUNCT
aiua-10838	62	360	,	,	PUNCT
aiua-10838	62	361	2006	2006	NUM
aiua-10838	62	362	-	-	SYM
aiua-10838	62	363	2017	2017	NUM
aiua-10838	62	364	n	n	CCONJ
aiua-10838	62	365	(	(	PUNCT
aiua-10838	62	366	cn	cn	PROPN
aiua-10838	62	367	)	)	PUNCT
aiua-10838	62	368	=	=	NOUN
aiua-10838	62	369	97	97	NUM
aiua-10838	62	370	pazopanib	pazopanib	NOUN
aiua-10838	62	371	(	(	PUNCT
aiua-10838	62	372	28.4	28.4	NUM
aiua-10838	62	373	%	%	NOUN
aiua-10838	62	374	)	)	PUNCT
aiua-10838	62	375	25.6	25.6	NUM
aiua-10838	62	376	vs	vs	ADP
aiua-10838	62	377	12.4	12.4	NUM
aiua-10838	62	378	,	,	PUNCT
aiua-10838	62	379	hr	hr	NOUN
aiua-10838	62	380	0.46	0.46	NUM
aiua-10838	62	381	n	n	PROPN
aiua-10838	62	382	(	(	PUNCT
aiua-10838	62	383	no	no	DET
aiua-10838	62	384	cn	cn	NOUN
aiua-10838	62	385	)	)	PUNCT
aiua-10838	62	386	=	=	SYM
aiua-10838	62	387	164	164	NUM
aiua-10838	62	388	cabozantinib	cabozantinib	NOUN
aiua-10838	62	389	or	or	CCONJ
aiua-10838	62	390	(	(	PUNCT
aiua-10838	62	391	95	95	NUM
aiua-10838	62	392	%	%	NOUN
aiua-10838	62	393	ci	ci	NOUN
aiua-10838	62	394	0.34–0.62	0.34–0.62	NOUN
aiua-10838	62	395	)	)	PUNCT
aiua-10838	62	396	nivolumab	nivolumab	NOUN
aiua-10838	62	397	(	(	PUNCT
aiua-10838	62	398	8.4	8.4	NUM
aiua-10838	62	399	%	%	NOUN
aiua-10838	62	400	)	)	PUNCT
aiua-10838	62	401	iptw	iptw	NOUN
aiua-10838	62	402	-	-	PUNCT
aiua-10838	62	403	adjusted	adjust	VERB
aiua-10838	62	404	:	:	PUNCT
aiua-10838	62	405	20.9	20.9	NUM
aiua-10838	62	406	vs	vs	ADP
aiua-10838	62	407	12.6	12.6	NUM
aiua-10838	62	408	,	,	PUNCT
aiua-10838	62	409	other	other	ADJ
aiua-10838	62	410	(	(	PUNCT
aiua-10838	62	411	34.5	34.5	NUM
aiua-10838	62	412	%	%	NOUN
aiua-10838	62	413	)	)	PUNCT
aiua-10838	62	414	hr	hr	NOUN
aiua-10838	62	415	0.63	0.63	NUM
aiua-10838	62	416	(	(	PUNCT
aiua-10838	62	417	95	95	NUM
aiua-10838	62	418	%	%	NOUN
aiua-10838	62	419	ci	ci	NOUN
aiua-10838	62	420	0.46–0.84	0.46–0.84	NOUN
aiua-10838	62	421	)	)	PUNCT
aiua-10838	62	422	you	you	PRON
aiua-10838	62	423	(	(	PUNCT
aiua-10838	62	424	2014	2014	NUM
aiua-10838	62	425	)	)	PUNCT
aiua-10838	62	426	(	(	PUNCT
aiua-10838	62	427	30	30	NUM
aiua-10838	62	428	)	)	PUNCT
aiua-10838	62	429	,	,	PUNCT
aiua-10838	62	430	retrospective	retrospective	ADJ
aiua-10838	62	431	cohort	cohort	NOUN
aiua-10838	62	432	,	,	PUNCT
aiua-10838	62	433	n	n	CCONJ
aiua-10838	62	434	(	(	PUNCT
aiua-10838	62	435	total	total	NOUN
aiua-10838	62	436	)	)	PUNCT
aiua-10838	62	437	=	=	SYM
aiua-10838	62	438	171	171	NUM
aiua-10838	62	439	sunitinib	sunitinib	NOUN
aiua-10838	62	440	(	(	PUNCT
aiua-10838	62	441	70	70	NUM
aiua-10838	62	442	%	%	NOUN
aiua-10838	62	443	)	)	PUNCT
aiua-10838	62	444	,	,	PUNCT
aiua-10838	62	445	cn	cn	PROPN
aiua-10838	62	446	before	before	ADP
aiua-10838	62	447	st	st	PROPN
aiua-10838	62	448	19.9	19.9	NUM
aiua-10838	62	449	vs	vs	ADP
aiua-10838	62	450	11.7	11.7	NUM
aiua-10838	62	451	korea	korea	PROPN
aiua-10838	62	452	(	(	PUNCT
aiua-10838	62	453	single	single	ADJ
aiua-10838	62	454	center	center	NOUN
aiua-10838	62	455	)	)	PUNCT
aiua-10838	62	456	2006	2006	NUM
aiua-10838	62	457	-	-	SYM
aiua-10838	62	458	2012	2012	NUM
aiua-10838	62	459	n	n	CCONJ
aiua-10838	62	460	(	(	PUNCT
aiua-10838	62	461	cn	cn	PROPN
aiua-10838	62	462	)	)	PUNCT
aiua-10838	62	463	=	=	SYM
aiua-10838	62	464	96	96	NUM
aiua-10838	62	465	sorafenib(19	sorafenib(19	NOUN
aiua-10838	62	466	%	%	NOUN
aiua-10838	62	467	)	)	PUNCT
aiua-10838	62	468	,	,	PUNCT
aiua-10838	62	469	hr	hr	NOUN
aiua-10838	62	470	:	:	PUNCT
aiua-10838	62	471	nr	nr	PROPN
aiua-10838	62	472	n	n	INTJ
aiua-10838	62	473	(	(	PUNCT
aiua-10838	62	474	no	no	DET
aiua-10838	62	475	cn	cn	NOUN
aiua-10838	62	476	)	)	PUNCT
aiua-10838	62	477	=	=	SYM
aiua-10838	62	478	75	75	NUM
aiua-10838	62	479	pazopanib	pazopanib	NOUN
aiua-10838	62	480	(	(	PUNCT
aiua-10838	62	481	4	4	NUM
aiua-10838	62	482	%	%	NOUN
aiua-10838	62	483	)	)	PUNCT
aiua-10838	62	484	,	,	PUNCT
aiua-10838	62	485	temsirolimus	temsirolimus	NOUN
aiua-10838	62	486	(	(	PUNCT
aiua-10838	62	487	7	7	NUM
aiua-10838	62	488	%	%	NOUN
aiua-10838	62	489	)	)	PUNCT
aiua-10838	62	490	tatsugami	tatsugami	NOUN
aiua-10838	62	491	(	(	PUNCT
aiua-10838	62	492	2015	2015	NUM
aiua-10838	62	493	)	)	PUNCT
aiua-10838	62	494	(	(	PUNCT
aiua-10838	62	495	31	31	NUM
aiua-10838	62	496	)	)	PUNCT
aiua-10838	62	497	,	,	PUNCT
aiua-10838	62	498	retrospective	retrospective	ADJ
aiua-10838	62	499	cohort	cohort	NOUN
aiua-10838	62	500	,	,	PUNCT
aiua-10838	62	501	n	n	CCONJ
aiua-10838	62	502	(	(	PUNCT
aiua-10838	62	503	total	total	NOUN
aiua-10838	62	504	)	)	PUNCT
aiua-10838	62	505	=	=	PUNCT
aiua-10838	62	506	330	330	NUM
aiua-10838	62	507	nr	nr	PROPN
aiua-10838	62	508	nr	nr	PROPN
aiua-10838	62	509	27.4	27.4	NUM
aiua-10838	62	510	vs	vs	ADP
aiua-10838	62	511	10.3	10.3	NUM
aiua-10838	62	512	,	,	PUNCT
aiua-10838	62	513	hr	hr	NOUN
aiua-10838	62	514	0.40	0.40	NUM
aiua-10838	62	515	mixed	mixed	ADJ
aiua-10838	62	516	population	population	NOUN
aiua-10838	62	517	of	of	ADP
aiua-10838	62	518	approximately	approximately	ADV
aiua-10838	62	519	half	half	ADJ
aiua-10838	62	520	japan	japan	PROPN
aiua-10838	62	521	(	(	PUNCT
aiua-10838	62	522	multicenter	multicenter	NOUN
aiua-10838	62	523	)	)	PUNCT
aiua-10838	62	524	2001	2001	NUM
aiua-10838	62	525	-	-	SYM
aiua-10838	62	526	2015	2015	NUM
aiua-10838	62	527	n	n	CCONJ
aiua-10838	62	528	(	(	PUNCT
aiua-10838	62	529	cn	cn	PROPN
aiua-10838	62	530	)	)	PUNCT
aiua-10838	62	531	=	=	NOUN
aiua-10838	62	532	254	254	NUM
aiua-10838	62	533	(	(	PUNCT
aiua-10838	62	534	95	95	NUM
aiua-10838	62	535	%	%	NOUN
aiua-10838	62	536	ci	ci	NOUN
aiua-10838	62	537	0.29–0.57	0.29–0.57	PROPN
aiua-10838	62	538	)	)	PUNCT
aiua-10838	62	539	patients	patient	NOUN
aiua-10838	62	540	receiving	receive	VERB
aiua-10838	62	541	cytokines	cytokine	NOUN
aiua-10838	62	542	and	and	CCONJ
aiua-10838	62	543	half	half	DET
aiua-10838	62	544	n	n	NOUN
aiua-10838	62	545	(	(	PUNCT
aiua-10838	62	546	no	no	DET
aiua-10838	62	547	cn	cn	NOUN
aiua-10838	62	548	)	)	PUNCT
aiua-10838	62	549	=	=	SYM
aiua-10838	62	550	76	76	NUM
aiua-10838	62	551	subgroup	subgroup	NOUN
aiua-10838	62	552	analysis	analysis	NOUN
aiua-10838	62	553	for	for	ADP
aiua-10838	62	554	patients	patient	NOUN
aiua-10838	62	555	receiving	receive	VERB
aiua-10838	62	556	systemic	systemic	ADJ
aiua-10838	62	557	therapy	therapy	NOUN
aiua-10838	62	558	receiving	receive	VERB
aiua-10838	62	559	only	only	ADV
aiua-10838	62	560	st	st	PROPN
aiua-10838	62	561	:	:	PUNCT
aiua-10838	62	562	30.9	30.9	NUM
aiua-10838	62	563	vs	vs	ADP
aiua-10838	62	564	15.5	15.5	NUM
aiua-10838	62	565	,	,	PUNCT
aiua-10838	62	566	hr	hr	NOUN
aiua-10838	62	567	0.48	0.48	NUM
aiua-10838	62	568	(	(	PUNCT
aiua-10838	62	569	95	95	NUM
aiua-10838	62	570	%	%	NOUN
aiua-10838	62	571	ci	ci	NOUN
aiua-10838	62	572	0.28–0.90	0.28–0.90	PROPN
aiua-10838	62	573	)	)	PUNCT
aiua-10838	62	574	archivio	archivio	NOUN
aiua-10838	62	575	italiano	italiano	X
aiua-10838	62	576	di	di	X
aiua-10838	62	577	urologia	urologia	PROPN
aiua-10838	62	578	e	e	PROPN
aiua-10838	62	579	andrologia	andrologia	PROPN
aiua-10838	62	580	2022	2022	NUM
aiua-10838	62	581	;	;	PUNCT
aiua-10838	62	582	94	94	NUM
aiua-10838	62	583	,	,	PUNCT
aiua-10838	62	584	4	4	NUM
aiua-10838	62	585	s.	s.	PROPN
aiua-10838	62	586	katsimperis	katsimperis	PROPN
aiua-10838	62	587	,	,	PUNCT
aiua-10838	62	588	l.	l.	PROPN
aiua-10838	62	589	tzelves	tzelves	PROPN
aiua-10838	62	590	,	,	PUNCT
aiua-10838	62	591	t.	t.	PROPN
aiua-10838	62	592	bellos	bellos	PROPN
aiua-10838	62	593	,	,	PUNCT
aiua-10838	62	594	k.	k.	PROPN
aiua-10838	62	595	pikramenos	pikramenos	PROPN
aiua-10838	62	596	,	,	PUNCT
aiua-10838	62	597	i.	i.	PROPN
aiua-10838	62	598	manolitsis	manolitsis	PROPN
aiua-10838	62	599	,	,	PUNCT
aiua-10838	62	600	i.	i.	PROPN
aiua-10838	62	601	tsikopoulos	tsikopoulos	PROPN
aiua-10838	62	602	,	,	PUNCT
aiua-10838	62	603	i.	i.	NOUN
aiua-10838	62	604	mitsogiannis	mitsogiannis	PROPN
aiua-10838	62	605	480	480	NUM
aiua-10838	62	606	with	with	ADP
aiua-10838	62	607	95	95	NUM
aiua-10838	62	608	%	%	NOUN
aiua-10838	62	609	ci	ci	NOUN
aiua-10838	62	610	0.15	0.15	NUM
aiua-10838	62	611	-	-	SYM
aiua-10838	62	612	0.37	0.37	NUM
aiua-10838	62	613	and	and	CCONJ
aiua-10838	62	614	0.19	0.19	NUM
aiua-10838	62	615	-	-	NUM
aiua-10838	62	616	0.83	0.83	NUM
aiua-10838	62	617	)	)	PUNCT
aiua-10838	62	618	.	.	PUNCT
aiua-10838	63	1	regarding	regard	VERB
aiua-10838	63	2	the	the	DET
aiua-10838	63	3	sequence	sequence	NOUN
aiua-10838	63	4	of	of	ADP
aiua-10838	63	5	cn	cn	PROPN
aiua-10838	63	6	and	and	CCONJ
aiua-10838	63	7	st	st	PROPN
aiua-10838	63	8	,	,	PUNCT
aiua-10838	63	9	cn	cn	PROPN
aiua-10838	63	10	was	be	AUX
aiua-10838	63	11	administered	administer	VERB
aiua-10838	63	12	before	before	ADP
aiua-10838	63	13	st	st	PROPN
aiua-10838	63	14	in	in	ADP
aiua-10838	63	15	12	12	NUM
aiua-10838	63	16	studies	study	NOUN
aiua-10838	63	17	(	(	PUNCT
aiua-10838	63	18	21	21	NUM
aiua-10838	63	19	,	,	PUNCT
aiua-10838	63	20	26	26	NUM
aiua-10838	63	21	-	-	SYM
aiua-10838	63	22	30	30	NUM
aiua-10838	63	23	,	,	PUNCT
aiua-10838	63	24	32	32	NUM
aiua-10838	63	25	,	,	PUNCT
aiua-10838	63	26	33	33	NUM
aiua-10838	63	27	,	,	PUNCT
aiua-10838	63	28	35	35	NUM
aiua-10838	63	29	-	-	SYM
aiua-10838	63	30	37	37	NUM
aiua-10838	63	31	)	)	PUNCT
aiua-10838	63	32	,	,	PUNCT
aiua-10838	63	33	before	before	ADP
aiua-10838	63	34	or	or	CCONJ
aiua-10838	63	35	after	after	ADP
aiua-10838	63	36	in	in	ADP
aiua-10838	63	37	5	5	NUM
aiua-10838	63	38	(	(	PUNCT
aiua-10838	63	39	23	23	NUM
aiua-10838	63	40	,	,	PUNCT
aiua-10838	63	41	38	38	NUM
aiua-10838	63	42	,	,	PUNCT
aiua-10838	63	43	40	40	NUM
aiua-10838	63	44	-	-	SYM
aiua-10838	63	45	42	42	NUM
aiua-10838	63	46	)	)	PUNCT
aiua-10838	63	47	,	,	PUNCT
aiua-10838	63	48	after	after	ADP
aiua-10838	63	49	in	in	ADP
aiua-10838	63	50	one	one	NUM
aiua-10838	63	51	study	study	NOUN
aiua-10838	63	52	(	(	PUNCT
aiua-10838	63	53	25	25	NUM
aiua-10838	63	54	)	)	PUNCT
aiua-10838	63	55	while	while	SCONJ
aiua-10838	63	56	sequence	sequence	NOUN
aiua-10838	63	57	was	be	AUX
aiua-10838	63	58	not	not	PART
aiua-10838	63	59	specified	specify	VERB
aiua-10838	63	60	in	in	ADP
aiua-10838	63	61	the	the	DET
aiua-10838	63	62	rest	rest	NOUN
aiua-10838	63	63	.	.	PUNCT
aiua-10838	64	1	cn	cn	PROPN
aiua-10838	64	2	was	be	AUX
aiua-10838	64	3	associated	associate	VERB
aiua-10838	64	4	with	with	ADP
aiua-10838	64	5	improved	improve	VERB
aiua-10838	64	6	os	os	NOUN
aiua-10838	64	7	in	in	ADP
aiua-10838	64	8	all	all	PRON
aiua-10838	64	9	but	but	SCONJ
aiua-10838	64	10	one	one	NUM
aiua-10838	64	11	of	of	ADP
aiua-10838	64	12	the	the	DET
aiua-10838	64	13	observational	observational	ADJ
aiua-10838	64	14	studies	study	NOUN
aiua-10838	64	15	(	(	PUNCT
aiua-10838	64	16	26	26	NUM
aiua-10838	64	17	)	)	PUNCT
aiua-10838	64	18	,	,	PUNCT
aiua-10838	64	19	with	with	ADP
aiua-10838	64	20	hrs	hrs	NOUN
aiua-10838	64	21	ranging	range	VERB
aiua-10838	64	22	from	from	ADP
aiua-10838	64	23	0.23	0.23	NUM
aiua-10838	64	24	to	to	ADP
aiua-10838	64	25	1.90	1.90	NUM
aiua-10838	64	26	(	(	PUNCT
aiua-10838	64	27	table	table	NOUN
aiua-10838	64	28	1	1	NUM
aiua-10838	64	29	)	)	PUNCT
aiua-10838	64	30	.	.	PUNCT
aiua-10838	65	1	in	in	ADP
aiua-10838	65	2	all	all	PRON
aiua-10838	65	3	of	of	ADP
aiua-10838	65	4	these	these	DET
aiua-10838	65	5	studies	study	NOUN
aiua-10838	65	6	(	(	PUNCT
aiua-10838	65	7	14	14	NUM
aiua-10838	65	8	-	-	SYM
aiua-10838	65	9	25	25	NUM
aiua-10838	65	10	,	,	PUNCT
aiua-10838	65	11	27	27	NUM
aiua-10838	65	12	-	-	SYM
aiua-10838	65	13	42	42	NUM
aiua-10838	65	14	)	)	PUNCT
aiua-10838	65	15	the	the	DET
aiua-10838	65	16	univariable	univariable	ADJ
aiua-10838	65	17	analysis	analysis	NOUN
aiua-10838	65	18	showed	showed	AUX
aiua-10838	65	19	improved	improve	VERB
aiua-10838	65	20	os	os	NOUN
aiua-10838	65	21	in	in	ADP
aiua-10838	65	22	favor	favor	NOUN
aiua-10838	65	23	of	of	ADP
aiua-10838	65	24	the	the	DET
aiua-10838	65	25	cn	cn	PROPN
aiua-10838	65	26	group	group	NOUN
aiua-10838	65	27	although	although	SCONJ
aiua-10838	65	28	in	in	ADP
aiua-10838	65	29	some	some	DET
aiua-10838	65	30	studies	study	NOUN
aiua-10838	65	31	subgroup	subgroup	ADJ
aiua-10838	65	32	analysis	analysis	NOUN
aiua-10838	65	33	day	day	NOUN
aiua-10838	65	34	(	(	PUNCT
aiua-10838	65	35	2016	2016	NUM
aiua-10838	65	36	)	)	PUNCT
aiua-10838	65	37	(	(	PUNCT
aiua-10838	65	38	32	32	NUM
aiua-10838	65	39	)	)	PUNCT
aiua-10838	65	40	,	,	PUNCT
aiua-10838	65	41	retrospective	retrospective	ADJ
aiua-10838	65	42	cohort	cohort	NOUN
aiua-10838	65	43	,	,	PUNCT
aiua-10838	65	44	n	n	CCONJ
aiua-10838	65	45	(	(	PUNCT
aiua-10838	65	46	total	total	NOUN
aiua-10838	65	47	)	)	PUNCT
aiua-10838	65	48	=	=	SYM
aiua-10838	66	1	91	91	NUM
aiua-10838	66	2	sunitinib	sunitinib	NOUN
aiua-10838	66	3	(	(	PUNCT
aiua-10838	66	4	74	74	NUM
aiua-10838	66	5	%	%	NOUN
aiua-10838	66	6	)	)	PUNCT
aiua-10838	66	7	cn	cn	PROPN
aiua-10838	66	8	before	before	ADP
aiua-10838	66	9	st	st	PROPN
aiua-10838	66	10	23	23	NUM
aiua-10838	66	11	vs	vs	ADP
aiua-10838	66	12	10.9	10.9	NUM
aiua-10838	66	13	,	,	PUNCT
aiua-10838	66	14	hr	hr	NOUN
aiua-10838	66	15	0.33	0.33	NUM
aiua-10838	66	16	australia	australia	NOUN
aiua-10838	66	17	(	(	PUNCT
aiua-10838	66	18	multicenter	multicenter	NOUN
aiua-10838	66	19	)	)	PUNCT
aiua-10838	66	20	2006	2006	NUM
aiua-10838	66	21	-	-	SYM
aiua-10838	66	22	2012	2012	NUM
aiua-10838	66	23	n	n	CCONJ
aiua-10838	66	24	(	(	PUNCT
aiua-10838	66	25	cn	cn	PROPN
aiua-10838	66	26	)	)	PUNCT
aiua-10838	66	27	=	=	SYM
aiua-10838	66	28	46	46	NUM
aiua-10838	66	29	pazopanib	pazopanib	NOUN
aiua-10838	66	30	(	(	PUNCT
aiua-10838	66	31	4	4	NUM
aiua-10838	66	32	%	%	NOUN
aiua-10838	66	33	)	)	PUNCT
aiua-10838	66	34	(	(	PUNCT
aiua-10838	66	35	95	95	NUM
aiua-10838	66	36	%	%	NOUN
aiua-10838	66	37	ci	ci	NOUN
aiua-10838	66	38	0.20–0.55	0.20–0.55	NOUN
aiua-10838	66	39	)	)	PUNCT
aiua-10838	66	40	n	n	CCONJ
aiua-10838	66	41	(	(	PUNCT
aiua-10838	66	42	no	no	DET
aiua-10838	66	43	cn	cn	NOUN
aiua-10838	66	44	)	)	PUNCT
aiua-10838	66	45	=	=	SYM
aiua-10838	66	46	45	45	NUM
aiua-10838	66	47	everolimus	everolimus	NOUN
aiua-10838	66	48	(	(	PUNCT
aiua-10838	66	49	4	4	NUM
aiua-10838	66	50	%	%	NOUN
aiua-10838	66	51	)	)	PUNCT
aiua-10838	66	52	bevacizumab	bevacizumab	NOUN
aiua-10838	66	53	(	(	PUNCT
aiua-10838	66	54	2	2	NUM
aiua-10838	66	55	%	%	NOUN
aiua-10838	66	56	)	)	PUNCT
aiua-10838	66	57	interferon	interferon	NOUN
aiua-10838	66	58	(	(	PUNCT
aiua-10838	66	59	2	2	NUM
aiua-10838	66	60	%	%	NOUN
aiua-10838	66	61	)	)	PUNCT
aiua-10838	66	62	temsirolimus	temsirolimus	NOUN
aiua-10838	66	63	(	(	PUNCT
aiua-10838	66	64	1	1	NUM
aiua-10838	66	65	%	%	NOUN
aiua-10838	66	66	)	)	PUNCT
aiua-10838	66	67	choueiri	choueiri	NOUN
aiua-10838	66	68	(	(	PUNCT
aiua-10838	66	69	2011	2011	NUM
aiua-10838	66	70	)	)	PUNCT
aiua-10838	66	71	(	(	PUNCT
aiua-10838	66	72	33	33	NUM
aiua-10838	66	73	)	)	PUNCT
aiua-10838	66	74	,	,	PUNCT
aiua-10838	66	75	retrospective	retrospective	ADJ
aiua-10838	66	76	cohort	cohort	NOUN
aiua-10838	66	77	,	,	PUNCT
aiua-10838	66	78	n	n	CCONJ
aiua-10838	66	79	(	(	PUNCT
aiua-10838	66	80	total	total	NOUN
aiua-10838	66	81	)	)	PUNCT
aiua-10838	66	82	=	=	SYM
aiua-10838	66	83	314	314	NUM
aiua-10838	66	84	sunitinib	sunitinib	NOUN
aiua-10838	66	85	(	(	PUNCT
aiua-10838	66	86	63	63	NUM
aiua-10838	66	87	%	%	NOUN
aiua-10838	66	88	)	)	PUNCT
aiua-10838	66	89	cn	cn	PROPN
aiua-10838	66	90	before	before	ADP
aiua-10838	66	91	st	st	PROPN
aiua-10838	66	92	19.8	19.8	NUM
aiua-10838	66	93	vs	vs	ADP
aiua-10838	66	94	9.4	9.4	NUM
aiua-10838	66	95	,	,	PUNCT
aiua-10838	66	96	hr	hr	NOUN
aiua-10838	66	97	0.68	0.68	NUM
aiua-10838	66	98	canada	canada	PROPN
aiua-10838	66	99	and	and	CCONJ
aiua-10838	66	100	usa	usa	PROPN
aiua-10838	66	101	(	(	PUNCT
aiua-10838	66	102	multicenter	multicenter	NOUN
aiua-10838	66	103	)	)	PUNCT
aiua-10838	66	104	2004	2004	NUM
aiua-10838	66	105	-	-	SYM
aiua-10838	66	106	2008	2008	NUM
aiua-10838	66	107	n	n	CCONJ
aiua-10838	66	108	(	(	PUNCT
aiua-10838	66	109	cn	cn	PROPN
aiua-10838	66	110	)	)	PUNCT
aiua-10838	66	111	=	=	SYM
aiua-10838	66	112	201	201	NUM
aiua-10838	66	113	sorafenib	sorafenib	NOUN
aiua-10838	66	114	(	(	PUNCT
aiua-10838	66	115	30	30	NUM
aiua-10838	66	116	%	%	NOUN
aiua-10838	66	117	)	)	PUNCT
aiua-10838	66	118	(	(	PUNCT
aiua-10838	66	119	95	95	NUM
aiua-10838	66	120	%	%	NOUN
aiua-10838	66	121	ci	ci	NOUN
aiua-10838	66	122	0.46–0.99	0.46–0.99	NUM
aiua-10838	66	123	)	)	PUNCT
aiua-10838	66	124	n	n	CCONJ
aiua-10838	66	125	(	(	PUNCT
aiua-10838	66	126	no	no	DET
aiua-10838	66	127	cn	cn	NOUN
aiua-10838	66	128	)	)	PUNCT
aiua-10838	66	129	=	=	SYM
aiua-10838	66	130	113	113	NUM
aiua-10838	66	131	bevacizumab	bevacizumab	NOUN
aiua-10838	66	132	(	(	PUNCT
aiua-10838	66	133	7	7	NUM
aiua-10838	66	134	%	%	NOUN
aiua-10838	66	135	)	)	PUNCT
aiua-10838	66	136	heng	heng	PROPN
aiua-10838	66	137	(	(	PUNCT
aiua-10838	66	138	2014	2014	NUM
aiua-10838	66	139	)	)	PUNCT
aiua-10838	66	140	(	(	PUNCT
aiua-10838	66	141	34	34	NUM
aiua-10838	66	142	)	)	PUNCT
aiua-10838	66	143	,	,	PUNCT
aiua-10838	66	144	retrospective	retrospective	ADJ
aiua-10838	66	145	cohort	cohort	NOUN
aiua-10838	66	146	,	,	PUNCT
aiua-10838	66	147	n	n	CCONJ
aiua-10838	66	148	(	(	PUNCT
aiua-10838	66	149	total	total	NOUN
aiua-10838	66	150	)	)	PUNCT
aiua-10838	66	151	=	=	SYM
aiua-10838	66	152	1658	1658	NUM
aiua-10838	66	153	cn	cn	NOUN
aiua-10838	66	154	;	;	PUNCT
aiua-10838	66	155	no	no	DET
aiua-10838	66	156	cn	cn	PROPN
aiua-10838	66	157	nr	nr	PROPN
aiua-10838	66	158	20.6	20.6	NUM
aiua-10838	66	159	vs	vs	ADP
aiua-10838	66	160	9.6	9.6	NUM
aiua-10838	66	161	,	,	PUNCT
aiua-10838	66	162	hr	hr	NOUN
aiua-10838	66	163	0.60	0.60	NUM
aiua-10838	66	164	international	international	ADJ
aiua-10838	66	165	(	(	PUNCT
aiua-10838	66	166	imdc	imdc	PROPN
aiua-10838	66	167	)	)	PUNCT
aiua-10838	66	168	,	,	PUNCT
aiua-10838	66	169	years	year	NOUN
aiua-10838	66	170	not	not	PART
aiua-10838	66	171	specified	specify	VERB
aiua-10838	66	172	n	n	PROPN
aiua-10838	66	173	(	(	PUNCT
aiua-10838	66	174	cn	cn	PROPN
aiua-10838	66	175	)	)	PUNCT
aiua-10838	66	176	=	=	SYM
aiua-10838	66	177	982	982	NUM
aiua-10838	66	178	sunitinib	sunitinib	NOUN
aiua-10838	66	179	(	(	PUNCT
aiua-10838	66	180	67	67	NUM
aiua-10838	66	181	%	%	NOUN
aiua-10838	66	182	;	;	PUNCT
aiua-10838	66	183	79	79	NUM
aiua-10838	66	184	%	%	NOUN
aiua-10838	66	185	)	)	PUNCT
aiua-10838	66	186	(	(	PUNCT
aiua-10838	66	187	95	95	NUM
aiua-10838	66	188	%	%	NOUN
aiua-10838	66	189	ci	ci	NOUN
aiua-10838	66	190	0.52–0.69	0.52–0.69	NOUN
aiua-10838	66	191	)	)	PUNCT
aiua-10838	66	192	n	n	CCONJ
aiua-10838	66	193	(	(	PUNCT
aiua-10838	66	194	no	no	DET
aiua-10838	66	195	cn	cn	NOUN
aiua-10838	66	196	)	)	PUNCT
aiua-10838	66	197	=	=	SYM
aiua-10838	66	198	676	676	NUM
aiua-10838	66	199	sorafenib	sorafenib	NOUN
aiua-10838	66	200	(	(	PUNCT
aiua-10838	66	201	20	20	NUM
aiua-10838	66	202	%	%	NOUN
aiua-10838	66	203	;	;	PUNCT
aiua-10838	66	204	8.6	8.6	NUM
aiua-10838	66	205	%	%	NOUN
aiua-10838	66	206	)	)	PUNCT
aiua-10838	66	207	axitinib	axitinib	NOUN
aiua-10838	66	208	(	(	PUNCT
aiua-10838	66	209	0.4	0.4	NUM
aiua-10838	66	210	%	%	NOUN
aiua-10838	66	211	;	;	PUNCT
aiua-10838	66	212	0.4	0.4	NUM
aiua-10838	66	213	%	%	NOUN
aiua-10838	66	214	)	)	PUNCT
aiua-10838	66	215	bevacizumab	bevacizumab	NOUN
aiua-10838	66	216	(	(	PUNCT
aiua-10838	66	217	4	4	NUM
aiua-10838	66	218	%	%	NOUN
aiua-10838	66	219	;	;	PUNCT
aiua-10838	66	220	1.5	1.5	NUM
aiua-10838	66	221	%	%	NOUN
aiua-10838	66	222	)	)	PUNCT
aiua-10838	66	223	temsirolimus	temsirolimus	NOUN
aiua-10838	66	224	(	(	PUNCT
aiua-10838	66	225	3.6	3.6	NUM
aiua-10838	66	226	%	%	NOUN
aiua-10838	66	227	;	;	PUNCT
aiua-10838	66	228	6.4	6.4	NUM
aiua-10838	66	229	%	%	NOUN
aiua-10838	66	230	)	)	PUNCT
aiua-10838	66	231	pazopanib	pazopanib	NOUN
aiua-10838	66	232	(	(	PUNCT
aiua-10838	66	233	2.8	2.8	NUM
aiua-10838	66	234	%	%	NOUN
aiua-10838	66	235	;	;	PUNCT
aiua-10838	66	236	2.8	2.8	NUM
aiua-10838	66	237	%	%	NOUN
aiua-10838	66	238	)	)	PUNCT
aiua-10838	66	239	everolimus	everolimus	NOUN
aiua-10838	66	240	(	(	PUNCT
aiua-10838	66	241	1	1	NUM
aiua-10838	66	242	%	%	NOUN
aiua-10838	66	243	;	;	PUNCT
aiua-10838	66	244	1	1	NUM
aiua-10838	66	245	%	%	NOUN
aiua-10838	66	246	)	)	PUNCT
aiua-10838	66	247	other	other	ADJ
aiua-10838	66	248	(	(	PUNCT
aiua-10838	66	249	0.7	0.7	NUM
aiua-10838	66	250	%	%	NOUN
aiua-10838	66	251	;	;	PUNCT
aiua-10838	66	252	0.3	0.3	NUM
aiua-10838	66	253	%	%	NOUN
aiua-10838	66	254	)	)	PUNCT
aiua-10838	66	255	de	de	X
aiua-10838	66	256	groot	groot	X
aiua-10838	66	257	(	(	PUNCT
aiua-10838	66	258	2016	2016	NUM
aiua-10838	66	259	)	)	PUNCT
aiua-10838	66	260	(	(	PUNCT
aiua-10838	66	261	35	35	NUM
aiua-10838	66	262	)	)	PUNCT
aiua-10838	66	263	,	,	PUNCT
aiua-10838	66	264	retrospective	retrospective	ADJ
aiua-10838	66	265	population	population	NOUN
aiua-10838	66	266	n	n	CCONJ
aiua-10838	66	267	(	(	PUNCT
aiua-10838	66	268	total	total	NOUN
aiua-10838	66	269	)	)	PUNCT
aiua-10838	66	270	=	=	SYM
aiua-10838	66	271	146	146	NUM
aiua-10838	66	272	sunitinib	sunitinib	NOUN
aiua-10838	66	273	cn	cn	PROPN
aiua-10838	66	274	before	before	ADP
aiua-10838	66	275	st	st	PROPN
aiua-10838	66	276	17.9	17.9	NUM
aiua-10838	66	277	vs	vs	ADP
aiua-10838	66	278	8.8	8.8	NUM
aiua-10838	66	279	,	,	PUNCT
aiua-10838	66	280	hr	hr	NOUN
aiua-10838	66	281	0.61	0.61	NUM
aiua-10838	66	282	based	base	VERB
aiua-10838	66	283	matched	match	VERB
aiua-10838	66	284	cohort	cohort	NOUN
aiua-10838	66	285	,	,	PUNCT
aiua-10838	66	286	the	the	DET
aiua-10838	66	287	netherlands	netherlands	PROPN
aiua-10838	66	288	2008	2008	NUM
aiua-10838	66	289	-	-	SYM
aiua-10838	66	290	2010	2010	NUM
aiua-10838	66	291	n	n	CCONJ
aiua-10838	66	292	(	(	PUNCT
aiua-10838	66	293	cn	cn	PROPN
aiua-10838	66	294	)	)	PUNCT
aiua-10838	66	295	=	=	SYM
aiua-10838	66	296	73	73	NUM
aiua-10838	66	297	(	(	PUNCT
aiua-10838	66	298	95	95	NUM
aiua-10838	66	299	%	%	NOUN
aiua-10838	66	300	ci	ci	NOUN
aiua-10838	66	301	0.41–0.92	0.41–0.92	PROPN
aiua-10838	66	302	)	)	PUNCT
aiua-10838	66	303	n	n	CCONJ
aiua-10838	66	304	(	(	PUNCT
aiua-10838	66	305	no	no	DET
aiua-10838	66	306	cn	cn	NOUN
aiua-10838	66	307	)	)	PUNCT
aiua-10838	66	308	=	=	SYM
aiua-10838	66	309	73	73	NUM
aiua-10838	66	310	poprach	poprach	NOUN
aiua-10838	66	311	(	(	PUNCT
aiua-10838	66	312	2020	2020	NUM
aiua-10838	66	313	)	)	PUNCT
aiua-10838	66	314	(	(	PUNCT
aiua-10838	66	315	36	36	NUM
aiua-10838	66	316	)	)	PUNCT
aiua-10838	66	317	,	,	PUNCT
aiua-10838	66	318	retrospective	retrospective	ADJ
aiua-10838	66	319	cohort	cohort	NOUN
aiua-10838	66	320	,	,	PUNCT
aiua-10838	66	321	n	n	CCONJ
aiua-10838	66	322	(	(	PUNCT
aiua-10838	66	323	total	total	NOUN
aiua-10838	66	324	)	)	PUNCT
aiua-10838	66	325	=	=	SYM
aiua-10838	66	326	730	730	NUM
aiua-10838	66	327	sunitinib	sunitinib	NOUN
aiua-10838	66	328	(	(	PUNCT
aiua-10838	66	329	78.8	78.8	NUM
aiua-10838	66	330	%	%	NOUN
aiua-10838	66	331	)	)	PUNCT
aiua-10838	66	332	cn	cn	PROPN
aiua-10838	66	333	before	before	ADP
aiua-10838	66	334	st	st	PROPN
aiua-10838	66	335	27.2	27.2	NUM
aiua-10838	66	336	vs	vs	ADP
aiua-10838	66	337	14.2	14.2	NUM
aiua-10838	66	338	,	,	PUNCT
aiua-10838	66	339	hr	hr	NOUN
aiua-10838	66	340	0.55	0.55	NUM
aiua-10838	66	341	czech	czech	PROPN
aiua-10838	66	342	republic	republic	NOUN
aiua-10838	66	343	(	(	PUNCT
aiua-10838	66	344	national	national	ADJ
aiua-10838	66	345	registry	registry	NOUN
aiua-10838	66	346	)	)	PUNCT
aiua-10838	66	347	2007	2007	NUM
aiua-10838	66	348	-	-	SYM
aiua-10838	66	349	2018	2018	NUM
aiua-10838	66	350	n	n	CCONJ
aiua-10838	66	351	(	(	PUNCT
aiua-10838	66	352	cn	cn	PROPN
aiua-10838	66	353	)	)	PUNCT
aiua-10838	66	354	=	=	SYM
aiua-10838	66	355	458	458	NUM
aiua-10838	66	356	pazopanib	pazopanib	NOUN
aiua-10838	66	357	(	(	PUNCT
aiua-10838	66	358	21.2	21.2	NUM
aiua-10838	66	359	%	%	NOUN
aiua-10838	66	360	)	)	PUNCT
aiua-10838	66	361	(	(	PUNCT
aiua-10838	66	362	95	95	NUM
aiua-10838	66	363	%	%	NOUN
aiua-10838	66	364	ci	ci	NOUN
aiua-10838	66	365	0.45–0.68	0.45–0.68	PROPN
aiua-10838	66	366	)	)	PUNCT
aiua-10838	66	367	n	n	CCONJ
aiua-10838	66	368	(	(	PUNCT
aiua-10838	66	369	no	no	DET
aiua-10838	66	370	cn	cn	NOUN
aiua-10838	66	371	)	)	PUNCT
aiua-10838	66	372	=	=	SYM
aiua-10838	66	373	272	272	NUM
aiua-10838	66	374	song	song	NOUN
aiua-10838	66	375	(	(	PUNCT
aiua-10838	66	376	2016	2016	NUM
aiua-10838	66	377	)	)	PUNCT
aiua-10838	66	378	(	(	PUNCT
aiua-10838	66	379	37	37	NUM
aiua-10838	66	380	)	)	PUNCT
aiua-10838	66	381	,	,	PUNCT
aiua-10838	66	382	retrospective	retrospective	ADJ
aiua-10838	66	383	cohort	cohort	NOUN
aiua-10838	66	384	,	,	PUNCT
aiua-10838	66	385	n	n	CCONJ
aiua-10838	66	386	(	(	PUNCT
aiua-10838	66	387	total	total	NOUN
aiua-10838	66	388	)	)	PUNCT
aiua-10838	66	389	=	=	SYM
aiua-10838	66	390	74	74	NUM
aiua-10838	66	391	sunitinib	sunitinib	NOUN
aiua-10838	66	392	(	(	PUNCT
aiua-10838	66	393	44.6	44.6	NUM
aiua-10838	66	394	%	%	NOUN
aiua-10838	66	395	)	)	PUNCT
aiua-10838	66	396	cn	cn	PROPN
aiua-10838	66	397	before	before	ADP
aiua-10838	66	398	st	st	PROPN
aiua-10838	66	399	32.2	32.2	NUM
aiua-10838	66	400	vs	vs	ADP
aiua-10838	66	401	23	23	NUM
aiua-10838	66	402	china	china	PROPN
aiua-10838	66	403	(	(	PUNCT
aiua-10838	66	404	single	single	ADJ
aiua-10838	66	405	center	center	NOUN
aiua-10838	66	406	)	)	PUNCT
aiua-10838	66	407	2006	2006	NUM
aiua-10838	66	408	-	-	SYM
aiua-10838	66	409	2014	2014	NUM
aiua-10838	66	410	n	n	CCONJ
aiua-10838	66	411	(	(	PUNCT
aiua-10838	66	412	cn	cn	PROPN
aiua-10838	66	413	)	)	PUNCT
aiua-10838	66	414	=	=	SYM
aiua-10838	66	415	51	51	NUM
aiua-10838	66	416	sorafenib	sorafenib	NOUN
aiua-10838	66	417	(	(	PUNCT
aiua-10838	66	418	29.7	29.7	NUM
aiua-10838	66	419	%	%	NOUN
aiua-10838	66	420	)	)	PUNCT
aiua-10838	66	421	hr	hr	NOUN
aiua-10838	66	422	:	:	PUNCT
aiua-10838	66	423	nr	nr	PROPN
aiua-10838	66	424	n	n	INTJ
aiua-10838	66	425	(	(	PUNCT
aiua-10838	66	426	no	no	DET
aiua-10838	66	427	cn	cn	NOUN
aiua-10838	66	428	)	)	PUNCT
aiua-10838	66	429	=	=	SYM
aiua-10838	66	430	23	23	NUM
aiua-10838	66	431	famitinib	famitinib	NOUN
aiua-10838	66	432	(	(	PUNCT
aiua-10838	66	433	18.9	18.9	NUM
aiua-10838	66	434	%	%	NOUN
aiua-10838	66	435	)	)	PUNCT
aiua-10838	66	436	pazopanib	pazopanib	NOUN
aiua-10838	66	437	(	(	PUNCT
aiua-10838	66	438	6.7	6.7	NUM
aiua-10838	66	439	%	%	NOUN
aiua-10838	66	440	)	)	PUNCT
aiua-10838	66	441	bhindi	bhindi	NOUN
aiua-10838	66	442	(	(	PUNCT
aiua-10838	66	443	2020	2020	NUM
aiua-10838	66	444	)	)	PUNCT
aiua-10838	66	445	(	(	PUNCT
aiua-10838	66	446	38	38	NUM
aiua-10838	66	447	)	)	PUNCT
aiua-10838	66	448	,	,	PUNCT
aiua-10838	66	449	retrospective	retrospective	ADJ
aiua-10838	66	450	cohort	cohort	NOUN
aiua-10838	66	451	,	,	PUNCT
aiua-10838	66	452	n	n	CCONJ
aiua-10838	66	453	(	(	PUNCT
aiua-10838	66	454	total	total	NOUN
aiua-10838	66	455	)	)	PUNCT
aiua-10838	66	456	=	=	SYM
aiua-10838	66	457	1541	1541	NUM
aiua-10838	66	458	sunitinib	sunitinib	NOUN
aiua-10838	66	459	cn	cn	VERB
aiua-10838	66	460	before	before	ADP
aiua-10838	66	461	or	or	CCONJ
aiua-10838	66	462	after	after	SCONJ
aiua-10838	66	463	st	st	PROPN
aiua-10838	66	464	cn+sunitinib	cn+sunitinib	PROPN
aiua-10838	66	465	vs	vs	ADP
aiua-10838	66	466	sunitinib	sunitinib	NOUN
aiua-10838	66	467	comparative	comparative	VERB
aiua-10838	66	468	analyses	analysis	NOUN
aiua-10838	66	469	of	of	ADP
aiua-10838	66	470	upfront	upfront	ADJ
aiua-10838	66	471	cn+	cn+	PROPN
aiua-10838	66	472	sunitinib	sunitinib	PROPN
aiua-10838	66	473	imdc	imdc	VERB
aiua-10838	66	474	2006	2006	NUM
aiua-10838	66	475	-	-	SYM
aiua-10838	66	476	2018	2018	NUM
aiua-10838	66	477	n	n	PROPN
aiua-10838	66	478	(	(	PUNCT
aiua-10838	66	479	cn+sunitinib	cn+sunitinib	PROPN
aiua-10838	66	480	)	)	PUNCT
aiua-10838	66	481	=	=	SYM
aiua-10838	67	1	805	805	NUM
aiua-10838	67	2	vs	vs	ADP
aiua-10838	67	3	sunitinib+dcn	sunitinib+dcn	NOUN
aiua-10838	67	4	19	19	NUM
aiua-10838	67	5	vs	vs	ADP
aiua-10838	67	6	10	10	NUM
aiua-10838	67	7	vs	vs	ADP
aiua-10838	67	8	46	46	NUM
aiua-10838	67	9	vs	vs	ADP
aiua-10838	67	10	sunitinib+	sunitinib+	X
aiua-10838	67	11	dcn	dcn	PROPN
aiua-10838	67	12	vs	vs	ADP
aiua-10838	67	13	sunitinib	sunitinib	PROPN
aiua-10838	67	14	n	n	CCONJ
aiua-10838	67	15	(	(	PUNCT
aiua-10838	67	16	no	no	DET
aiua-10838	67	17	cn	cn	NOUN
aiua-10838	67	18	)	)	PUNCT
aiua-10838	67	19	=	=	SYM
aiua-10838	67	20	651	651	NUM
aiua-10838	67	21	upfront	upfront	ADJ
aiua-10838	67	22	cn+sunitinib	cn+sunitinib	NOUN
aiua-10838	67	23	vs	vs	ADP
aiua-10838	67	24	sunitinib	sunitinib	NOUN
aiua-10838	67	25	n	n	PROPN
aiua-10838	67	26	(	(	PUNCT
aiua-10838	67	27	sunitinib+dcn	sunitinib+dcn	NOUN
aiua-10838	67	28	)	)	PUNCT
aiua-10838	67	29	=	=	SYM
aiua-10838	67	30	85	85	NUM
aiua-10838	67	31	hr	hr	NOUN
aiua-10838	67	32	0.89	0.89	NUM
aiua-10838	67	33	(	(	PUNCT
aiua-10838	67	34	95	95	NUM
aiua-10838	67	35	%	%	NOUN
aiua-10838	67	36	ci	ci	NOUN
aiua-10838	67	37	0.71–1.1	0.71–1.1	NOUN
aiua-10838	67	38	)	)	PUNCT
aiua-10838	67	39	sunitinib+dcn	sunitinib+dcn	NOUN
aiua-10838	67	40	vs	vs	ADP
aiua-10838	67	41	sunitinib	sunitinib	NOUN
aiua-10838	67	42	hr	hr	NOUN
aiua-10838	67	43	0.89	0.89	NUM
aiua-10838	67	44	(	(	PUNCT
aiua-10838	67	45	95	95	NUM
aiua-10838	67	46	%	%	NOUN
aiua-10838	67	47	ci	ci	NOUN
aiua-10838	67	48	0.71–1.1	0.71–1.1	NOUN
aiua-10838	67	49	)	)	PUNCT
aiua-10838	67	50	sunitinib+dcn	sunitinib+dcn	NOUN
aiua-10838	67	51	vs	vs	ADP
aiua-10838	67	52	upfront	upfront	ADJ
aiua-10838	67	53	cn	cn	PUNCT
aiua-10838	68	1	+	+	NOUN
aiua-10838	68	2	sunitinib	sunitinib	NOUN
aiua-10838	68	3	hr	hr	NOUN
aiua-10838	68	4	0.52	0.52	NUM
aiua-10838	68	5	(	(	PUNCT
aiua-10838	68	6	95	95	NUM
aiua-10838	68	7	%	%	NOUN
aiua-10838	68	8	ci	ci	NOUN
aiua-10838	68	9	0.39–0.70	0.39–0.70	NUM
aiua-10838	68	10	)	)	PUNCT
aiua-10838	68	11	patel	patel	NOUN
aiua-10838	68	12	(	(	PUNCT
aiua-10838	68	13	2017	2017	NUM
aiua-10838	68	14	)	)	PUNCT
aiua-10838	68	15	(	(	PUNCT
aiua-10838	68	16	39	39	NUM
aiua-10838	68	17	)	)	PUNCT
aiua-10838	68	18	,	,	PUNCT
aiua-10838	68	19	retrospective	retrospective	ADJ
aiua-10838	68	20	cohort	cohort	NOUN
aiua-10838	68	21	,	,	PUNCT
aiua-10838	68	22	n	n	CCONJ
aiua-10838	68	23	(	(	PUNCT
aiua-10838	68	24	total	total	ADJ
aiua-10838	68	25	)	)	PUNCT
aiua-10838	68	26	=	=	SYM
aiua-10838	68	27	1062	1062	NUM
aiua-10838	68	28	nr	nr	INTJ
aiua-10838	68	29	nr	nr	PROPN
aiua-10838	68	30	hr	hr	VERB
aiua-10838	68	31	1.90	1.90	NUM
aiua-10838	68	32	(	(	PUNCT
aiua-10838	68	33	95	95	NUM
aiua-10838	68	34	%	%	NOUN
aiua-10838	68	35	ci	ci	NOUN
aiua-10838	68	36	1.61–2.25	1.61–2.25	NUM
aiua-10838	68	37	)	)	PUNCT
aiua-10838	68	38	os	os	NOUN
aiua-10838	68	39	in	in	ADP
aiua-10838	68	40	months	month	NOUN
aiua-10838	68	41	nr	nr	PROPN
aiua-10838	68	42	australia	australia	PROPN
aiua-10838	68	43	2001	2001	NUM
aiua-10838	68	44	-	-	SYM
aiua-10838	68	45	2009	2009	NUM
aiua-10838	68	46	n	n	CCONJ
aiua-10838	68	47	(	(	PUNCT
aiua-10838	68	48	cn	cn	PROPN
aiua-10838	68	49	)	)	PUNCT
aiua-10838	68	50	=	=	SYM
aiua-10838	68	51	289	289	NUM
aiua-10838	68	52	includes	include	VERB
aiua-10838	68	53	cytokine	cytokine	ADJ
aiua-10838	68	54	era	era	NOUN
aiua-10838	68	55	n	n	CCONJ
aiua-10838	68	56	(	(	PUNCT
aiua-10838	68	57	no	no	DET
aiua-10838	68	58	cn	cn	NOUN
aiua-10838	68	59	)	)	PUNCT
aiua-10838	68	60	=	=	SYM
aiua-10838	68	61	773	773	NUM
aiua-10838	68	62	dragomir	dragomir	NOUN
aiua-10838	68	63	(	(	PUNCT
aiua-10838	68	64	2021	2021	NUM
aiua-10838	68	65	)	)	PUNCT
aiua-10838	68	66	(	(	PUNCT
aiua-10838	68	67	40	40	NUM
aiua-10838	68	68	)	)	PUNCT
aiua-10838	68	69	,	,	PUNCT
aiua-10838	68	70	retrospective	retrospective	ADJ
aiua-10838	68	71	cohort	cohort	NOUN
aiua-10838	68	72	,	,	PUNCT
aiua-10838	68	73	n	n	CCONJ
aiua-10838	68	74	(	(	PUNCT
aiua-10838	68	75	total	total	ADJ
aiua-10838	68	76	)	)	PUNCT
aiua-10838	68	77	=	=	SYM
aiua-10838	68	78	788	788	NUM
aiua-10838	68	79	sunitinib	sunitinib	NOUN
aiua-10838	68	80	(	(	PUNCT
aiua-10838	68	81	51.1	51.1	NUM
aiua-10838	68	82	%	%	NOUN
aiua-10838	68	83	)	)	PUNCT
aiua-10838	68	84	cn	cn	PROPN
aiua-10838	68	85	before	before	ADP
aiua-10838	68	86	cn+st	cn+st	PROPN
aiua-10838	68	87	vs	vs	ADP
aiua-10838	68	88	st	st	PROPN
aiua-10838	68	89	36	36	NUM
aiua-10838	68	90	vs	vs	ADP
aiua-10838	68	91	18	18	NUM
aiua-10838	68	92	,	,	PUNCT
aiua-10838	68	93	hr	hr	NOUN
aiua-10838	68	94	0.65	0.65	NUM
aiua-10838	68	95	one	one	NUM
aiua-10838	68	96	of	of	ADP
aiua-10838	68	97	few	few	ADJ
aiua-10838	68	98	studies	study	NOUN
aiua-10838	68	99	including	include	VERB
aiua-10838	68	100	patients	patient	NOUN
aiua-10838	68	101	treated	treat	VERB
aiua-10838	68	102	canada	canada	PROPN
aiua-10838	68	103	(	(	PUNCT
aiua-10838	68	104	multicenter	multicenter	NOUN
aiua-10838	68	105	)	)	PUNCT
aiua-10838	68	106	2011	2011	NUM
aiua-10838	68	107	-	-	SYM
aiua-10838	68	108	2020	2020	NUM
aiua-10838	68	109	n	n	CCONJ
aiua-10838	68	110	(	(	PUNCT
aiua-10838	68	111	cn	cn	PROPN
aiua-10838	68	112	)	)	PUNCT
aiua-10838	68	113	=	=	SYM
aiua-10838	68	114	80	80	NUM
aiua-10838	68	115	pazopanib	pazopanib	NOUN
aiua-10838	68	116	(	(	PUNCT
aiua-10838	68	117	16.8	16.8	NUM
aiua-10838	68	118	%	%	NOUN
aiua-10838	68	119	)	)	PUNCT
aiua-10838	68	120	or	or	CCONJ
aiua-10838	68	121	after	after	ADP
aiua-10838	68	122	st	st	PROPN
aiua-10838	68	123	(	(	PUNCT
aiua-10838	68	124	95	95	NUM
aiua-10838	68	125	%	%	NOUN
aiua-10838	68	126	ci	ci	NOUN
aiua-10838	68	127	0.52–0.82	0.52–0.82	NUM
aiua-10838	68	128	)	)	PUNCT
aiua-10838	68	129	with	with	ADP
aiua-10838	68	130	ici	ici	PROPN
aiua-10838	68	131	n	n	PROPN
aiua-10838	68	132	(	(	PUNCT
aiua-10838	68	133	cn+st	cn+st	NOUN
aiua-10838	68	134	)	)	PUNCT
aiua-10838	68	135	=	=	SYM
aiua-10838	68	136	383	383	NUM
aiua-10838	68	137	ipilimumab/	ipilimumab/	NUM
aiua-10838	68	138	st+cn	st+cn	NOUN
aiua-10838	68	139	vs	vs	ADP
aiua-10838	68	140	st	st	PROPN
aiua-10838	68	141	48	48	NUM
aiua-10838	68	142	vs	vs	ADP
aiua-10838	68	143	18	18	NUM
aiua-10838	68	144	,	,	PUNCT
aiua-10838	68	145	hr	hr	NOUN
aiua-10838	68	146	0.41	0.41	NUM
aiua-10838	68	147	n	n	CCONJ
aiua-10838	68	148	(	(	PUNCT
aiua-10838	68	149	st+cn	st+cn	NOUN
aiua-10838	68	150	)	)	PUNCT
aiua-10838	68	151	=	=	SYM
aiua-10838	68	152	73	73	NUM
aiua-10838	68	153	nivolumab	nivolumab	NOUN
aiua-10838	68	154	(	(	PUNCT
aiua-10838	68	155	13.8	13.8	NUM
aiua-10838	68	156	%	%	NOUN
aiua-10838	68	157	)	)	PUNCT
aiua-10838	68	158	(	(	PUNCT
aiua-10838	68	159	95	95	NUM
aiua-10838	68	160	%	%	NOUN
aiua-10838	68	161	ci	ci	NOUN
aiua-10838	68	162	0.28–0.60	0.28–0.60	PROPN
aiua-10838	68	163	)	)	PUNCT
aiua-10838	68	164	n	n	CCONJ
aiua-10838	68	165	(	(	PUNCT
aiua-10838	68	166	st	st	PROPN
aiua-10838	68	167	only	only	ADV
aiua-10838	68	168	)	)	PUNCT
aiua-10838	68	169	=	=	SYM
aiua-10838	69	1	282	282	NUM
aiua-10838	69	2	other	other	ADJ
aiua-10838	69	3	(	(	PUNCT
aiua-10838	69	4	18.9	18.9	NUM
aiua-10838	69	5	%	%	NOUN
aiua-10838	69	6	)	)	PUNCT
aiua-10838	69	7	cn	cn	PROPN
aiua-10838	69	8	(	(	PUNCT
aiua-10838	69	9	only	only	ADV
aiua-10838	69	10	)	)	PUNCT
aiua-10838	69	11	vs	vs	ADP
aiua-10838	69	12	st	st	PROPN
aiua-10838	69	13	(	(	PUNCT
aiua-10838	69	14	only	only	ADV
aiua-10838	69	15	)	)	PUNCT
aiua-10838	69	16	24	24	NUM
aiua-10838	69	17	vs	vs	ADP
aiua-10838	69	18	18	18	NUM
aiua-10838	69	19	,	,	PUNCT
aiua-10838	69	20	hr	hr	NOUN
aiua-10838	69	21	0.75	0.75	NUM
aiua-10838	69	22	(	(	PUNCT
aiua-10838	69	23	95	95	NUM
aiua-10838	69	24	%	%	NOUN
aiua-10838	69	25	ci	ci	NOUN
aiua-10838	69	26	0.48–1.17	0.48–1.17	PROPN
aiua-10838	69	27	)	)	PUNCT
aiua-10838	69	28	cn+st	cn+st	NOUN
aiua-10838	69	29	vs	vs	ADP
aiua-10838	69	30	st+cn	st+cn	ADP
aiua-10838	69	31	36	36	NUM
aiua-10838	69	32	vs	vs	ADP
aiua-10838	69	33	48	48	NUM
aiua-10838	69	34	,	,	PUNCT
aiua-10838	69	35	hr	hr	NOUN
aiua-10838	69	36	0.66	0.66	NUM
aiua-10838	69	37	(	(	PUNCT
aiua-10838	69	38	95	95	NUM
aiua-10838	69	39	%	%	NOUN
aiua-10838	69	40	ci	ci	NOUN
aiua-10838	69	41	0.42–1.04	0.42–1.04	NUM
aiua-10838	69	42	)	)	PUNCT
aiua-10838	69	43	mejean	mejean	NOUN
aiua-10838	69	44	(	(	PUNCT
aiua-10838	69	45	2018	2018	NUM
aiua-10838	69	46	)	)	PUNCT
aiua-10838	69	47	(	(	PUNCT
aiua-10838	69	48	41	41	NUM
aiua-10838	69	49	)	)	PUNCT
aiua-10838	69	50	,	,	PUNCT
aiua-10838	69	51	prospective	prospective	ADJ
aiua-10838	69	52	randomized	randomized	ADJ
aiua-10838	69	53	trial	trial	NOUN
aiua-10838	69	54	,	,	PUNCT
aiua-10838	69	55	n	n	CCONJ
aiua-10838	69	56	(	(	PUNCT
aiua-10838	69	57	total	total	NOUN
aiua-10838	69	58	)	)	PUNCT
aiua-10838	69	59	=	=	SYM
aiua-10838	69	60	450	450	NUM
aiua-10838	69	61	sunitinib	sunitinib	NOUN
aiua-10838	69	62	cn	cn	VERB
aiua-10838	69	63	before	before	ADP
aiua-10838	69	64	or	or	CCONJ
aiua-10838	69	65	after	after	ADP
aiua-10838	69	66	st	st	PROPN
aiua-10838	69	67	13.9	13.9	NUM
aiua-10838	69	68	vs	vs	ADP
aiua-10838	69	69	18.4	18.4	NUM
aiua-10838	69	70	,	,	PUNCT
aiua-10838	69	71	hr	hr	NOUN
aiua-10838	69	72	0.89	0.89	NUM
aiua-10838	69	73	17	17	NUM
aiua-10838	69	74	%	%	NOUN
aiua-10838	69	75	of	of	ADP
aiua-10838	69	76	patients	patient	NOUN
aiua-10838	69	77	in	in	ADP
aiua-10838	69	78	the	the	DET
aiua-10838	69	79	sunitinib	sunitinib	NOUN
aiua-10838	69	80	-	-	PUNCT
aiua-10838	69	81	only	only	ADV
aiua-10838	69	82	france	france	PROPN
aiua-10838	69	83	,	,	PUNCT
aiua-10838	69	84	norway	norway	PROPN
aiua-10838	69	85	,	,	PUNCT
aiua-10838	69	86	england	england	PROPN
aiua-10838	69	87	,	,	PUNCT
aiua-10838	69	88	scotland	scotland	PROPN
aiua-10838	69	89	,	,	PUNCT
aiua-10838	69	90	n	n	CCONJ
aiua-10838	69	91	(	(	PUNCT
aiua-10838	69	92	cn	cn	PROPN
aiua-10838	69	93	)	)	PUNCT
aiua-10838	69	94	=	=	SYM
aiua-10838	69	95	226	226	NUM
aiua-10838	69	96	(	(	PUNCT
aiua-10838	69	97	95	95	NUM
aiua-10838	69	98	%	%	NOUN
aiua-10838	69	99	ci	ci	NOUN
aiua-10838	69	100	0.71–1.1	0.71–1.1	NOUN
aiua-10838	69	101	)	)	PUNCT
aiua-10838	69	102	arm	arm	NOUN
aiua-10838	69	103	received	receive	VERB
aiua-10838	69	104	subsequent	subsequent	ADJ
aiua-10838	69	105	cn	cn	PROPN
aiua-10838	69	106	sweden	sweden	PROPN
aiua-10838	69	107	2009	2009	NUM
aiua-10838	69	108	-	-	SYM
aiua-10838	69	109	2017	2017	NUM
aiua-10838	69	110	n	n	NOUN
aiua-10838	69	111	(	(	PUNCT
aiua-10838	69	112	no	no	DET
aiua-10838	69	113	cn	cn	NOUN
aiua-10838	69	114	)	)	PUNCT
aiua-10838	69	115	=	=	NOUN
aiua-10838	69	116	224	224	NUM
aiua-10838	69	117	bakouny	bakouny	NOUN
aiua-10838	69	118	(	(	PUNCT
aiua-10838	69	119	2020	2020	NUM
aiua-10838	69	120	)	)	PUNCT
aiua-10838	69	121	(	(	PUNCT
aiua-10838	69	122	42	42	NUM
aiua-10838	69	123	)	)	PUNCT
aiua-10838	69	124	retrospective	retrospective	ADJ
aiua-10838	69	125	cohort	cohort	NOUN
aiua-10838	69	126	,	,	PUNCT
aiua-10838	69	127	n	n	CCONJ
aiua-10838	69	128	(	(	PUNCT
aiua-10838	69	129	total	total	NOUN
aiua-10838	69	130	)	)	PUNCT
aiua-10838	69	131	=	=	SYM
aiua-10838	69	132	4054	4054	NUM
aiua-10838	69	133	nr	nr	INTJ
aiua-10838	69	134	cn	cn	PROPN
aiua-10838	69	135	before	before	ADP
aiua-10838	69	136	or	or	CCONJ
aiua-10838	69	137	after	after	ADP
aiua-10838	69	138	st	st	PROPN
aiua-10838	69	139	cn+	cn+	PROPN
aiua-10838	69	140	ici	ici	PROPN
aiua-10838	69	141	vs	vs	ADP
aiua-10838	69	142	ici	ici	PROPN
aiua-10838	69	143	one	one	NUM
aiua-10838	69	144	of	of	ADP
aiua-10838	69	145	few	few	ADJ
aiua-10838	69	146	studies	study	NOUN
aiua-10838	69	147	including	include	VERB
aiua-10838	69	148	patients	patient	NOUN
aiua-10838	69	149	treated	treat	VERB
aiua-10838	69	150	international	international	ADJ
aiua-10838	69	151	(	(	PUNCT
aiua-10838	69	152	imdc	imdc	PROPN
aiua-10838	69	153	)	)	PUNCT
aiua-10838	69	154	2009	2009	NUM
aiua-10838	69	155	-	-	SYM
aiua-10838	69	156	2019	2019	NUM
aiua-10838	69	157	n	n	NOUN
aiua-10838	69	158	(	(	PUNCT
aiua-10838	69	159	tt	tt	PROPN
aiua-10838	69	160	only	only	ADV
aiua-10838	69	161	)	)	PUNCT
aiua-10838	69	162	=	=	NOUN
aiua-10838	69	163	1386	1386	NUM
aiua-10838	69	164	53.6	53.6	NUM
aiua-10838	69	165	vs	vs	ADP
aiua-10838	69	166	21.4	21.4	NUM
aiua-10838	69	167	,	,	PUNCT
aiua-10838	69	168	hr	hr	NOUN
aiua-10838	69	169	=	=	NOUN
aiua-10838	69	170	0.44	0.44	NUM
aiua-10838	69	171	with	with	ADP
aiua-10838	69	172	ici	ici	PROPN
aiua-10838	69	173	n	n	PROPN
aiua-10838	69	174	(	(	PUNCT
aiua-10838	69	175	cn+tt	cn+tt	NOUN
aiua-10838	69	176	)	)	PUNCT
aiua-10838	69	177	=	=	SYM
aiua-10838	69	178	2470	2470	NUM
aiua-10838	69	179	(	(	PUNCT
aiua-10838	69	180	95	95	NUM
aiua-10838	69	181	%	%	NOUN
aiua-10838	69	182	ci	ci	NOUN
aiua-10838	69	183	0.30	0.30	NUM
aiua-10838	69	184	-	-	PUNCT
aiua-10838	69	185	0.64	0.64	NUM
aiua-10838	69	186	)	)	PUNCT
aiua-10838	69	187	n	n	CCONJ
aiua-10838	69	188	(	(	PUNCT
aiua-10838	69	189	cn+ici	cn+ici	NOUN
aiua-10838	69	190	)	)	PUNCT
aiua-10838	69	191	=	=	SYM
aiua-10838	69	192	143	143	NUM
aiua-10838	69	193	cn+	cn+	NOUN
aiua-10838	69	194	tt	tt	PROPN
aiua-10838	69	195	vs	vs	ADP
aiua-10838	69	196	tt	tt	PROPN
aiua-10838	69	197	26.5	26.5	NUM
aiua-10838	69	198	vs	vs	ADP
aiua-10838	69	199	10.3	10.3	NUM
aiua-10838	69	200	,	,	PUNCT
aiua-10838	69	201	hr	hr	NOUN
aiua-10838	69	202	=	=	SYM
aiua-10838	69	203	0.48	0.48	NUM
aiua-10838	69	204	n	n	NOUN
aiua-10838	69	205	(	(	PUNCT
aiua-10838	69	206	ici	ici	PROPN
aiua-10838	69	207	only	only	ADV
aiua-10838	69	208	)	)	PUNCT
aiua-10838	70	1	=	=	SYM
aiua-10838	70	2	282	282	NUM
aiua-10838	70	3	(	(	PUNCT
aiua-10838	70	4	95	95	NUM
aiua-10838	70	5	%	%	NOUN
aiua-10838	70	6	ci	ci	NOUN
aiua-10838	70	7	0.45	0.45	NUM
aiua-10838	70	8	-	-	SYM
aiua-10838	70	9	0.52	0.52	NUM
aiua-10838	70	10	)	)	PUNCT
aiua-10838	70	11	uprety	uprety	NOUN
aiua-10838	70	12	(	(	PUNCT
aiua-10838	70	13	2018	2018	NUM
aiua-10838	70	14	)	)	PUNCT
aiua-10838	70	15	(	(	PUNCT
aiua-10838	70	16	65	65	NUM
aiua-10838	70	17	)	)	PUNCT
aiua-10838	70	18	,	,	PUNCT
aiua-10838	70	19	retrospective	retrospective	ADJ
aiua-10838	70	20	cohort	cohort	NOUN
aiua-10838	70	21	,	,	PUNCT
aiua-10838	70	22	n	n	CCONJ
aiua-10838	70	23	(	(	PUNCT
aiua-10838	70	24	total	total	ADJ
aiua-10838	70	25	)	)	PUNCT
aiua-10838	70	26	=	=	SYM
aiua-10838	70	27	3376	3376	NUM
aiua-10838	70	28	nr	nr	PROPN
aiua-10838	70	29	nr	nr	PROPN
aiua-10838	70	30	18	18	NUM
aiua-10838	70	31	vs	vs	ADP
aiua-10838	70	32	4	4	NUM
aiua-10838	70	33	usa	usa	PROPN
aiua-10838	70	34	(	(	PUNCT
aiua-10838	70	35	seer	seer	NOUN
aiua-10838	70	36	)	)	PUNCT
aiua-10838	70	37	2006	2006	NUM
aiua-10838	70	38	-	-	SYM
aiua-10838	70	39	2012	2012	NUM
aiua-10838	70	40	n	n	CCONJ
aiua-10838	70	41	(	(	PUNCT
aiua-10838	70	42	cn	cn	PROPN
aiua-10838	70	43	)	)	PUNCT
aiua-10838	70	44	=	=	SYM
aiua-10838	70	45	1110	1110	NUM
aiua-10838	70	46	n	n	CCONJ
aiua-10838	70	47	(	(	PUNCT
aiua-10838	70	48	no	no	DET
aiua-10838	70	49	cn	cn	NOUN
aiua-10838	70	50	)	)	PUNCT
aiua-10838	70	51	=	=	SYM
aiua-10838	70	52	2266	2266	NUM
aiua-10838	70	53	cn	cn	X
aiua-10838	70	54	=	=	NOUN
aiua-10838	70	55	cytoreductive	cytoreductive	ADJ
aiua-10838	70	56	nephrectomy	nephrectomy	NOUN
aiua-10838	70	57	;	;	PUNCT
aiua-10838	71	1	dcn	dcn	PROPN
aiua-10838	71	2	=	=	PROPN
aiua-10838	71	3	deferred	defer	VERB
aiua-10838	71	4	cn	cn	X
aiua-10838	71	5	;	;	PUNCT
aiua-10838	71	6	os	os	NOUN
aiua-10838	71	7	=	=	VERB
aiua-10838	71	8	overall	overall	ADJ
aiua-10838	71	9	survival	survival	NOUN
aiua-10838	71	10	;	;	PUNCT
aiua-10838	71	11	hr	hr	NOUN
aiua-10838	71	12	=	=	PUNCT
aiua-10838	71	13	hazard	hazard	NOUN
aiua-10838	71	14	ratio	ratio	NOUN
aiua-10838	71	15	;	;	PUNCT
aiua-10838	71	16	st	st	PROPN
aiua-10838	71	17	=	=	SYM
aiua-10838	71	18	systemic	systemic	ADJ
aiua-10838	71	19	therapy	therapy	NOUN
aiua-10838	71	20	;	;	PUNCT
aiua-10838	71	21	nr	nr	PROPN
aiua-10838	71	22	=	=	PUNCT
aiua-10838	71	23	not	not	PART
aiua-10838	71	24	reported	report	VERB
aiua-10838	71	25	;	;	PUNCT
aiua-10838	71	26	ci	ci	NOUN
aiua-10838	71	27	=	=	NOUN
aiua-10838	71	28	confidence	confidence	NOUN
aiua-10838	71	29	interval	interval	NOUN
aiua-10838	71	30	;	;	PUNCT
aiua-10838	71	31	seer	seer	NOUN
aiua-10838	71	32	=	=	NOUN
aiua-10838	71	33	surveillance	surveillance	NOUN
aiua-10838	71	34	,	,	PUNCT
aiua-10838	71	35	epidemiology	epidemiology	NOUN
aiua-10838	71	36	,	,	PUNCT
aiua-10838	71	37	and	and	CCONJ
aiua-10838	71	38	end	end	VERB
aiua-10838	71	39	results	result	NOUN
aiua-10838	71	40	;	;	PUNCT
aiua-10838	71	41	ncdb	ncdb	NOUN
aiua-10838	71	42	=	=	PROPN
aiua-10838	71	43	national	national	ADJ
aiua-10838	71	44	cancer	cancer	NOUN
aiua-10838	71	45	database	database	NOUN
aiua-10838	71	46	;	;	PUNCT
aiua-10838	71	47	imdc	imdc	NOUN
aiua-10838	71	48	=	=	SYM
aiua-10838	71	49	international	international	ADJ
aiua-10838	71	50	metastatic	metastatic	ADJ
aiua-10838	71	51	renal	renal	ADJ
aiua-10838	71	52	cell	cell	NOUN
aiua-10838	71	53	carcinoma	carcinoma	NOUN
aiua-10838	71	54	database	database	NOUN
aiua-10838	71	55	consortium	consortium	NOUN
aiua-10838	71	56	.	.	PUNCT
aiua-10838	72	1	481archivio	481archivio	PROPN
aiua-10838	72	2	italiano	italiano	NOUN
aiua-10838	72	3	di	di	NOUN
aiua-10838	72	4	urologia	urologia	PROPN
aiua-10838	72	5	e	e	PROPN
aiua-10838	72	6	andrologia	andrologia	PROPN
aiua-10838	72	7	2022	2022	NUM
aiua-10838	72	8	;	;	PUNCT
aiua-10838	72	9	94	94	NUM
aiua-10838	72	10	,	,	PUNCT
aiua-10838	72	11	4	4	NUM
aiua-10838	72	12	nephrectomy	nephrectomy	NOUN
aiua-10838	72	13	for	for	ADP
aiua-10838	72	14	metastatic	metastatic	ADJ
aiua-10838	72	15	renal	renal	ADJ
aiua-10838	72	16	cell	cell	NOUN
aiua-10838	72	17	carcinoma	carcinoma	NOUN
aiua-10838	72	18	table	table	NOUN
aiua-10838	72	19	3	3	NUM
aiua-10838	72	20	.	.	PUNCT
aiua-10838	73	1	studies	study	NOUN
aiua-10838	73	2	evaluating	evaluate	VERB
aiua-10838	73	3	the	the	DET
aiua-10838	73	4	sequencing	sequencing	NOUN
aiua-10838	73	5	of	of	ADP
aiua-10838	73	6	cn	cn	PROPN
aiua-10838	73	7	and	and	CCONJ
aiua-10838	73	8	st	st	PROPN
aiua-10838	73	9	.	.	PROPN
aiua-10838	73	10	study	study	NOUN
aiua-10838	73	11	number	number	NOUN
aiua-10838	73	12	of	of	ADP
aiua-10838	73	13	patients	patient	NOUN
aiua-10838	73	14	comparison	comparison	NOUN
aiua-10838	73	15	findings	finding	VERB
aiua-10838	73	16	wood	wood	NOUN
aiua-10838	73	17	(	(	PUNCT
aiua-10838	73	18	2009	2009	NUM
aiua-10838	73	19	)	)	PUNCT
aiua-10838	73	20	(	(	PUNCT
aiua-10838	73	21	43	43	NUM
aiua-10838	73	22	)	)	PUNCT
aiua-10838	73	23	,	,	PUNCT
aiua-10838	73	24	retrospective	retrospective	ADJ
aiua-10838	73	25	cohort	cohort	NOUN
aiua-10838	73	26	,	,	PUNCT
aiua-10838	73	27	n	n	CCONJ
aiua-10838	73	28	(	(	PUNCT
aiua-10838	73	29	total	total	NOUN
aiua-10838	73	30	)	)	PUNCT
aiua-10838	73	31	=	=	SYM
aiua-10838	74	1	102	102	NUM
aiua-10838	74	2	cn	cn	NOUN
aiua-10838	74	3	followed	follow	VERB
aiua-10838	74	4	by	by	ADP
aiua-10838	74	5	tt	tt	PROPN
aiua-10838	74	6	versus	versus	ADP
aiua-10838	74	7	tt	tt	PROPN
aiua-10838	74	8	followed	follow	VERB
aiua-10838	74	9	by	by	ADP
aiua-10838	74	10	cn	cn	PROPN
aiua-10838	74	11	unadjusted	unadjuste	VERB
aiua-10838	74	12	km	km	NOUN
aiua-10838	74	13	analysis	analysis	NOUN
aiua-10838	74	14	revealed	reveal	VERB
aiua-10838	74	15	similar	similar	ADJ
aiua-10838	74	16	median	median	PROPN
aiua-10838	74	17	css	css	PROPN
aiua-10838	74	18	.	.	PROPN
aiua-10838	75	1	usa	usa	PROPN
aiua-10838	75	2	(	(	PUNCT
aiua-10838	75	3	single	single	ADJ
aiua-10838	75	4	center	center	NOUN
aiua-10838	75	5	)	)	PUNCT
aiua-10838	75	6	2005	2005	NUM
aiua-10838	75	7	-	-	SYM
aiua-10838	75	8	2007	2007	NUM
aiua-10838	75	9	n	n	CCONJ
aiua-10838	75	10	(	(	PUNCT
aiua-10838	75	11	cn+tt	cn+tt	NOUN
aiua-10838	75	12	)	)	PUNCT
aiua-10838	75	13	=	=	PUNCT
aiua-10838	75	14	58	58	NUM
aiua-10838	75	15	31	31	NUM
aiua-10838	75	16	vs	vs	ADP
aiua-10838	75	17	27.7	27.7	NUM
aiua-10838	75	18	mo	mo	NOUN
aiua-10838	75	19	,	,	PUNCT
aiua-10838	75	20	p	p	NOUN
aiua-10838	75	21	=	=	NOUN
aiua-10838	75	22	0.697	0.697	NUM
aiua-10838	75	23	n	n	PROPN
aiua-10838	75	24	(	(	PUNCT
aiua-10838	75	25	tt+cn	tt+cn	NUM
aiua-10838	75	26	)	)	PUNCT
aiua-10838	75	27	=	=	SYM
aiua-10838	75	28	44	44	NUM
aiua-10838	75	29	stroup	stroup	NOUN
aiua-10838	75	30	(	(	PUNCT
aiua-10838	75	31	2013	2013	NUM
aiua-10838	75	32	)	)	PUNCT
aiua-10838	75	33	(	(	PUNCT
aiua-10838	75	34	44	44	NUM
aiua-10838	75	35	)	)	PUNCT
aiua-10838	75	36	,	,	PUNCT
aiua-10838	75	37	retrospective	retrospective	ADJ
aiua-10838	75	38	cohort	cohort	NOUN
aiua-10838	75	39	,	,	PUNCT
aiua-10838	75	40	n	n	CCONJ
aiua-10838	75	41	(	(	PUNCT
aiua-10838	75	42	total	total	NOUN
aiua-10838	75	43	)	)	PUNCT
aiua-10838	75	44	=	=	SYM
aiua-10838	75	45	35	35	NUM
aiua-10838	75	46	cn	cn	NOUN
aiua-10838	75	47	followed	follow	VERB
aiua-10838	75	48	by	by	ADP
aiua-10838	75	49	sunitinib	sunitinib	NOUN
aiua-10838	75	50	versus	versus	ADP
aiua-10838	75	51	sunitinib	sunitinib	NOUN
aiua-10838	75	52	followed	follow	VERB
aiua-10838	75	53	by	by	ADP
aiua-10838	75	54	cn	cn	PROPN
aiua-10838	75	55	unadjusted	unadjuste	VERB
aiua-10838	75	56	km	km	NOUN
aiua-10838	75	57	analysis	analysis	NOUN
aiua-10838	75	58	revealed	reveal	VERB
aiua-10838	75	59	no	no	DET
aiua-10838	75	60	difference	difference	NOUN
aiua-10838	75	61	in	in	ADP
aiua-10838	75	62	os	os	PROPN
aiua-10838	75	63	usa	usa	PROPN
aiua-10838	75	64	(	(	PUNCT
aiua-10838	75	65	multi	multi	ADJ
aiua-10838	75	66	center	center	NOUN
aiua-10838	75	67	)	)	PUNCT
aiua-10838	75	68	2005	2005	NUM
aiua-10838	75	69	-	-	SYM
aiua-10838	75	70	2009	2009	NUM
aiua-10838	75	71	n	n	PROPN
aiua-10838	75	72	(	(	PUNCT
aiua-10838	75	73	cn+sunitinib	cn+sunitinib	PROPN
aiua-10838	75	74	)	)	PUNCT
aiua-10838	75	75	=	=	PUNCT
aiua-10838	76	1	17	17	NUM
aiua-10838	76	2	p	p	NOUN
aiua-10838	76	3	=	=	PUNCT
aiua-10838	76	4	0.579	0.579	NUM
aiua-10838	76	5	n	n	SYM
aiua-10838	76	6	(	(	PUNCT
aiua-10838	76	7	sunitinib+	sunitinib+	X
aiua-10838	76	8	cn	cn	PROPN
aiua-10838	76	9	)	)	PUNCT
aiua-10838	76	10	=	=	SYM
aiua-10838	76	11	18	18	NUM
aiua-10838	76	12	hanna	hanna	NOUN
aiua-10838	76	13	(	(	PUNCT
aiua-10838	76	14	2016	2016	NUM
aiua-10838	76	15	)	)	PUNCT
aiua-10838	76	16	(	(	PUNCT
aiua-10838	76	17	23	23	NUM
aiua-10838	76	18	)	)	PUNCT
aiua-10838	76	19	,	,	PUNCT
aiua-10838	76	20	retrospective	retrospective	ADJ
aiua-10838	76	21	cohort	cohort	NOUN
aiua-10838	76	22	,	,	PUNCT
aiua-10838	76	23	n	n	CCONJ
aiua-10838	76	24	(	(	PUNCT
aiua-10838	76	25	total	total	NOUN
aiua-10838	76	26	)	)	PUNCT
aiua-10838	76	27	=	=	SYM
aiua-10838	76	28	4223	4223	NUM
aiua-10838	76	29	cn	cn	PROPN
aiua-10838	76	30	followed	follow	VERB
aiua-10838	76	31	by	by	ADP
aiua-10838	76	32	tt	tt	PROPN
aiua-10838	76	33	versus	versus	ADP
aiua-10838	76	34	tt	tt	PROPN
aiua-10838	76	35	followed	follow	VERB
aiua-10838	76	36	by	by	ADP
aiua-10838	76	37	cn	cn	PROPN
aiua-10838	76	38	unadjusted	unadjuste	VERB
aiua-10838	76	39	km	km	NOUN
aiua-10838	76	40	analysis	analysis	NOUN
aiua-10838	76	41	revealed	reveal	VERB
aiua-10838	76	42	,	,	PUNCT
aiua-10838	76	43	1-	1-	X
aiua-10838	76	44	,	,	PUNCT
aiua-10838	76	45	2-	2-	NOUN
aiua-10838	76	46	,	,	PUNCT
aiua-10838	76	47	and	and	CCONJ
aiua-10838	76	48	3	3	NUM
aiua-10838	76	49	-	-	PUNCT
aiua-10838	76	50	year	year	NOUN
aiua-10838	76	51	os	os	NOUN
aiua-10838	76	52	rates	rate	NOUN
aiua-10838	76	53	were	be	AUX
aiua-10838	76	54	:	:	PUNCT
aiua-10838	76	55	61.2	61.2	NUM
aiua-10838	76	56	%	%	NOUN
aiua-10838	76	57	,	,	PUNCT
aiua-10838	76	58	usa	usa	PROPN
aiua-10838	76	59	(	(	PUNCT
aiua-10838	76	60	ncdb	ncdb	PROPN
aiua-10838	76	61	)	)	PUNCT
aiua-10838	76	62	2006	2006	NUM
aiua-10838	76	63	-	-	SYM
aiua-10838	76	64	2013	2013	NUM
aiua-10838	76	65	n	n	CCONJ
aiua-10838	76	66	(	(	PUNCT
aiua-10838	76	67	cn+tt	cn+tt	NOUN
aiua-10838	76	68	)	)	PUNCT
aiua-10838	76	69	=	=	NOUN
aiua-10838	76	70	3733	3733	NUM
aiua-10838	76	71	37.8	37.8	NUM
aiua-10838	76	72	%	%	NOUN
aiua-10838	76	73	,	,	PUNCT
aiua-10838	76	74	26.6	26.6	NUM
aiua-10838	76	75	%	%	NOUN
aiua-10838	76	76	for	for	ADP
aiua-10838	76	77	cn+tt	cn+tt	NOUN
aiua-10838	76	78	patients	patient	NOUN
aiua-10838	76	79	versus	versus	ADP
aiua-10838	76	80	73.3	73.3	NUM
aiua-10838	76	81	%	%	NOUN
aiua-10838	76	82	,	,	PUNCT
aiua-10838	76	83	48.1	48.1	NUM
aiua-10838	76	84	%	%	NOUN
aiua-10838	76	85	,	,	PUNCT
aiua-10838	76	86	35.3	35.3	NUM
aiua-10838	76	87	%	%	NOUN
aiua-10838	76	88	n	n	CCONJ
aiua-10838	76	89	(	(	PUNCT
aiua-10838	76	90	tt+cn	tt+cn	PROPN
aiua-10838	76	91	)	)	PUNCT
aiua-10838	76	92	=	=	SYM
aiua-10838	77	1	490	490	NUM
aiua-10838	77	2	for	for	ADP
aiua-10838	77	3	tt+cn	tt+cn	PROPN
aiua-10838	77	4	patients	patient	NOUN
aiua-10838	77	5	log	log	NOUN
aiua-10838	77	6	-	-	PUNCT
aiua-10838	77	7	rank	rank	NOUN
aiua-10838	77	8	p	p	X
aiua-10838	77	9	<	<	X
aiua-10838	77	10	0.001	0.001	NUM
aiua-10838	77	11	macleod	macleod	NOUN
aiua-10838	77	12	(	(	PUNCT
aiua-10838	77	13	2017	2017	NUM
aiua-10838	77	14	)	)	PUNCT
aiua-10838	77	15	(	(	PUNCT
aiua-10838	77	16	45	45	NUM
aiua-10838	77	17	)	)	PUNCT
aiua-10838	77	18	,	,	PUNCT
aiua-10838	77	19	retrospective	retrospective	ADJ
aiua-10838	77	20	cohort	cohort	NOUN
aiua-10838	77	21	,	,	PUNCT
aiua-10838	77	22	n	n	CCONJ
aiua-10838	77	23	(	(	PUNCT
aiua-10838	77	24	total	total	ADJ
aiua-10838	77	25	)	)	PUNCT
aiua-10838	77	26	=	=	SYM
aiua-10838	78	1	537	537	NUM
aiua-10838	78	2	cn	cn	NOUN
aiua-10838	78	3	followed	follow	VERB
aiua-10838	78	4	by	by	ADP
aiua-10838	78	5	tt	tt	PROPN
aiua-10838	78	6	versus	versus	ADP
aiua-10838	78	7	tt	tt	PROPN
aiua-10838	78	8	followed	follow	VERB
aiua-10838	78	9	by	by	ADP
aiua-10838	78	10	cn	cn	PROPN
aiua-10838	78	11	median	median	PROPN
aiua-10838	78	12	os	os	NOUN
aiua-10838	78	13	of	of	ADP
aiua-10838	78	14	cn+tt	cn+tt	NOUN
aiua-10838	78	15	vs	vs	ADP
aiua-10838	78	16	tt+cn	tt+cn	PROPN
aiua-10838	78	17	:	:	PUNCT
aiua-10838	78	18	17.4	17.4	NUM
aiua-10838	78	19	vs	vs	ADP
aiua-10838	78	20	9.2	9.2	NUM
aiua-10838	78	21	months	month	NOUN
aiua-10838	78	22	usa	usa	PROPN
aiua-10838	78	23	(	(	PUNCT
aiua-10838	78	24	seer	seer	PROPN
aiua-10838	78	25	)	)	PUNCT
aiua-10838	78	26	2006	2006	NUM
aiua-10838	78	27	-	-	SYM
aiua-10838	78	28	2011	2011	NUM
aiua-10838	78	29	n	n	PROPN
aiua-10838	78	30	(	(	PUNCT
aiua-10838	78	31	cn+tt	cn+tt	NOUN
aiua-10838	78	32	)	)	PUNCT
aiua-10838	78	33	=	=	SYM
aiua-10838	78	34	190	190	NUM
aiua-10838	78	35	hr	hr	NOUN
aiua-10838	78	36	0.50	0.50	NUM
aiua-10838	78	37	(	(	PUNCT
aiua-10838	78	38	95	95	NUM
aiua-10838	78	39	%	%	NOUN
aiua-10838	78	40	ci	ci	NOUN
aiua-10838	78	41	0.38	0.38	NUM
aiua-10838	78	42	-	-	SYM
aiua-10838	78	43	0.65	0.65	NUM
aiua-10838	78	44	)	)	PUNCT
aiua-10838	78	45	in	in	ADP
aiua-10838	78	46	propensity	propensity	NOUN
aiua-10838	78	47	score	score	NOUN
aiua-10838	78	48	matching	matching	NOUN
aiua-10838	78	49	:	:	PUNCT
aiua-10838	78	50	5.8	5.8	NUM
aiua-10838	78	51	n	n	CCONJ
aiua-10838	78	52	(	(	PUNCT
aiua-10838	78	53	tt+cn	tt+cn	PROPN
aiua-10838	78	54	)	)	PUNCT
aiua-10838	78	55	=	=	SYM
aiua-10838	78	56	347	347	NUM
aiua-10838	78	57	months	month	NOUN
aiua-10838	78	58	advantage	advantage	NOUN
aiua-10838	78	59	for	for	ADP
aiua-10838	78	60	immediate	immediate	ADJ
aiua-10838	78	61	cn	cn	PROPN
aiua-10838	78	62	bex	bex	PROPN
aiua-10838	78	63	(	(	PUNCT
aiua-10838	78	64	2018	2018	NUM
aiua-10838	78	65	)	)	PUNCT
aiua-10838	78	66	(	(	PUNCT
aiua-10838	78	67	7	7	NUM
aiua-10838	78	68	)	)	PUNCT
aiua-10838	78	69	,	,	PUNCT
aiua-10838	78	70	prospective	prospective	ADJ
aiua-10838	78	71	rct	rct	PROPN
aiua-10838	78	72	,	,	PUNCT
aiua-10838	78	73	n	n	PROPN
aiua-10838	78	74	(	(	PUNCT
aiua-10838	78	75	total	total	NOUN
aiua-10838	78	76	)	)	PUNCT
aiua-10838	78	77	=	=	SYM
aiua-10838	79	1	99	99	NUM
aiua-10838	79	2	cn	cn	NOUN
aiua-10838	79	3	followed	follow	VERB
aiua-10838	79	4	by	by	ADP
aiua-10838	79	5	sunitinib	sunitinib	NOUN
aiua-10838	79	6	versus	versus	ADP
aiua-10838	79	7	sunitinib	sunitinib	NOUN
aiua-10838	79	8	followed	follow	VERB
aiua-10838	79	9	by	by	ADP
aiua-10838	79	10	cn	cn	PROPN
aiua-10838	79	11	in	in	ADP
aiua-10838	79	12	the	the	DET
aiua-10838	79	13	itt	itt	ADJ
aiua-10838	79	14	population	population	NOUN
aiua-10838	79	15	,	,	PUNCT
aiua-10838	79	16	no	no	DET
aiua-10838	79	17	difference	difference	NOUN
aiua-10838	79	18	in	in	ADP
aiua-10838	79	19	pfr	pfr	NOUN
aiua-10838	79	20	at	at	ADP
aiua-10838	79	21	28	28	NUM
aiua-10838	79	22	weeks	week	NOUN
aiua-10838	79	23	the	the	DET
aiua-10838	79	24	netherlands	netherlands	PROPN
aiua-10838	79	25	,	,	PUNCT
aiua-10838	79	26	canada	canada	PROPN
aiua-10838	79	27	,	,	PUNCT
aiua-10838	79	28	uk	uk	PROPN
aiua-10838	79	29	,	,	PUNCT
aiua-10838	79	30	belgium	belgium	NOUN
aiua-10838	79	31	2010	2010	NUM
aiua-10838	79	32	-	-	SYM
aiua-10838	79	33	2016	2016	NUM
aiua-10838	79	34	n	n	PROPN
aiua-10838	79	35	(	(	PUNCT
aiua-10838	79	36	cn+sunitinib	cn+sunitinib	PROPN
aiua-10838	79	37	)	)	PUNCT
aiua-10838	79	38	=	=	SYM
aiua-10838	79	39	50	50	NUM
aiua-10838	79	40	(	(	PUNCT
aiua-10838	79	41	cn+sunit	cn+sunit	NOUN
aiua-10838	79	42	.	.	PUNCT
aiua-10838	80	1	42	42	NUM
aiua-10838	80	2	%	%	NOUN
aiua-10838	80	3	vs	vs	ADP
aiua-10838	80	4	sunit.+cn	sunit.+cn	NUM
aiua-10838	80	5	43	43	NUM
aiua-10838	80	6	%	%	NOUN
aiua-10838	80	7	p	p	NOUN
aiua-10838	80	8	=	=	NOUN
aiua-10838	80	9	0.61	0.61	NUM
aiua-10838	80	10	)	)	PUNCT
aiua-10838	80	11	n	n	CCONJ
aiua-10838	80	12	(	(	PUNCT
aiua-10838	80	13	sunitinib+	sunitinib+	X
aiua-10838	80	14	cn	cn	PROPN
aiua-10838	80	15	)	)	PUNCT
aiua-10838	80	16	=	=	SYM
aiua-10838	80	17	49	49	NUM
aiua-10838	80	18	median	median	NOUN
aiua-10838	80	19	os	os	NOUN
aiua-10838	80	20	of	of	ADP
aiua-10838	80	21	cn+sunit	cn+sunit	NOUN
aiua-10838	80	22	.	.	PUNCT
aiua-10838	81	1	vs	vs	ADP
aiua-10838	81	2	sunit.+cn	sunit.+cn	NUM
aiua-10838	81	3	:	:	SYM
aiua-10838	81	4	15	15	NUM
aiua-10838	81	5	vs	vs	ADP
aiua-10838	81	6	32.4	32.4	NUM
aiua-10838	81	7	months	month	NOUN
aiua-10838	81	8	hr	hr	NOUN
aiua-10838	81	9	0.57	0.57	NUM
aiua-10838	81	10	(	(	PUNCT
aiua-10838	81	11	95	95	NUM
aiua-10838	81	12	%	%	NOUN
aiua-10838	81	13	ci	ci	NOUN
aiua-10838	81	14	0.34	0.34	NUM
aiua-10838	81	15	-	-	PUNCT
aiua-10838	81	16	0.95	0.95	NUM
aiua-10838	81	17	)	)	PUNCT
aiua-10838	81	18	p	p	NOUN
aiua-10838	81	19	=	=	NOUN
aiua-10838	81	20	0.032	0.032	NUM
aiua-10838	81	21	in	in	ADP
aiua-10838	81	22	the	the	DET
aiua-10838	81	23	ppp	ppp	NOUN
aiua-10838	81	24	the	the	DET
aiua-10838	81	25	os	os	NOUN
aiua-10838	81	26	was	be	AUX
aiua-10838	81	27	greater	great	ADJ
aiua-10838	81	28	in	in	ADP
aiua-10838	81	29	deferred	defer	VERB
aiua-10838	81	30	cn	cn	PROPN
aiua-10838	81	31	but	but	CCONJ
aiua-10838	81	32	not	not	PART
aiua-10838	81	33	statistically	statistically	ADV
aiua-10838	81	34	significant	significant	ADJ
aiua-10838	81	35	p	p	NOUN
aiua-10838	81	36	=	=	NOUN
aiua-10838	81	37	0.23	0.23	NUM
aiua-10838	81	38	bhindi	bhindi	NOUN
aiua-10838	81	39	(	(	PUNCT
aiua-10838	81	40	2018	2018	NUM
aiua-10838	81	41	)	)	PUNCT
aiua-10838	81	42	(	(	PUNCT
aiua-10838	81	43	46	46	NUM
aiua-10838	81	44	)	)	PUNCT
aiua-10838	81	45	,	,	PUNCT
aiua-10838	81	46	retrospective	retrospective	ADJ
aiua-10838	81	47	cohort	cohort	NOUN
aiua-10838	81	48	,	,	PUNCT
aiua-10838	81	49	n	n	CCONJ
aiua-10838	81	50	(	(	PUNCT
aiua-10838	81	51	total	total	NOUN
aiua-10838	81	52	)	)	PUNCT
aiua-10838	81	53	=	=	SYM
aiua-10838	81	54	15068	15068	NUM
aiua-10838	81	55	cn	cn	PROPN
aiua-10838	81	56	followed	follow	VERB
aiua-10838	81	57	by	by	ADP
aiua-10838	81	58	tt	tt	PROPN
aiua-10838	81	59	versus	versus	ADP
aiua-10838	81	60	tt	tt	PROPN
aiua-10838	81	61	followed	follow	VERB
aiua-10838	81	62	by	by	ADP
aiua-10838	81	63	cn	cn	PROPN
aiua-10838	81	64	in	in	ADP
aiua-10838	81	65	iptw	iptw	NOUN
aiua-10838	81	66	analysis	analysis	NOUN
aiua-10838	81	67	,	,	PUNCT
aiua-10838	81	68	median	median	ADJ
aiua-10838	81	69	os	os	NOUN
aiua-10838	81	70	of	of	ADP
aiua-10838	81	71	cn+tt	cn+tt	NOUN
aiua-10838	81	72	vs	vs	ADP
aiua-10838	81	73	tt+cn	tt+cn	PROPN
aiua-10838	81	74	:	:	PUNCT
aiua-10838	81	75	16.5	16.5	NUM
aiua-10838	81	76	vs	vs	ADP
aiua-10838	81	77	9.2	9.2	NUM
aiua-10838	81	78	months	month	NOUN
aiua-10838	81	79	usa	usa	PROPN
aiua-10838	81	80	(	(	PUNCT
aiua-10838	81	81	ncdb	ncdb	PROPN
aiua-10838	81	82	)	)	PUNCT
aiua-10838	81	83	2006	2006	NUM
aiua-10838	81	84	-	-	SYM
aiua-10838	81	85	2013	2013	NUM
aiua-10838	81	86	n	n	CCONJ
aiua-10838	81	87	(	(	PUNCT
aiua-10838	81	88	cn+tt	cn+tt	NOUN
aiua-10838	81	89	)	)	PUNCT
aiua-10838	81	90	=	=	SYM
aiua-10838	81	91	6731	6731	NUM
aiua-10838	81	92	hr	hr	NOUN
aiua-10838	81	93	0.61	0.61	NUM
aiua-10838	81	94	(	(	PUNCT
aiua-10838	81	95	95	95	NUM
aiua-10838	81	96	%	%	NOUN
aiua-10838	81	97	ci	ci	NOUN
aiua-10838	81	98	0.59	0.59	NUM
aiua-10838	81	99	-	-	SYM
aiua-10838	81	100	0.64	0.64	NUM
aiua-10838	81	101	)	)	PUNCT
aiua-10838	82	1	p	p	X
aiua-10838	82	2	<	<	X
aiua-10838	82	3	0.001	0.001	NUM
aiua-10838	82	4	n	n	NOUN
aiua-10838	82	5	(	(	PUNCT
aiua-10838	82	6	tt+cn	tt+cn	PROPN
aiua-10838	82	7	)	)	PUNCT
aiua-10838	82	8	=	=	SYM
aiua-10838	82	9	8337	8337	NUM
aiua-10838	82	10	bhindi	bhindi	NOUN
aiua-10838	82	11	(	(	PUNCT
aiua-10838	82	12	2020	2020	NUM
aiua-10838	82	13	)	)	PUNCT
aiua-10838	82	14	(	(	PUNCT
aiua-10838	82	15	38	38	NUM
aiua-10838	82	16	)	)	PUNCT
aiua-10838	82	17	,	,	PUNCT
aiua-10838	82	18	retrospective	retrospective	ADJ
aiua-10838	82	19	cohort	cohort	NOUN
aiua-10838	82	20	,	,	PUNCT
aiua-10838	82	21	n	n	CCONJ
aiua-10838	82	22	(	(	PUNCT
aiua-10838	82	23	total	total	NOUN
aiua-10838	82	24	)	)	PUNCT
aiua-10838	83	1	=	=	SYM
aiua-10838	83	2	1541	1541	NUM
aiua-10838	83	3	cn	cn	NOUN
aiua-10838	83	4	followed	follow	VERB
aiua-10838	83	5	by	by	ADP
aiua-10838	83	6	sunitinib	sunitinib	NOUN
aiua-10838	83	7	versus	versus	ADP
aiua-10838	83	8	sunitinib	sunitinib	NOUN
aiua-10838	83	9	followed	follow	VERB
aiua-10838	83	10	by	by	ADP
aiua-10838	83	11	cn	cn	PROPN
aiua-10838	83	12	median	median	PROPN
aiua-10838	83	13	os	os	NOUN
aiua-10838	83	14	of	of	ADP
aiua-10838	83	15	cn+sunitinib	cn+sunitinib	NOUN
aiua-10838	83	16	vs	vs	ADP
aiua-10838	83	17	sunitinib+deferred	sunitinib+deferred	ADJ
aiua-10838	83	18	cn	cn	PROPN
aiua-10838	83	19	:	:	PUNCT
aiua-10838	83	20	19	19	NUM
aiua-10838	83	21	vs	vs	ADP
aiua-10838	83	22	46	46	NUM
aiua-10838	83	23	months	month	NOUN
aiua-10838	83	24	usa	usa	PROPN
aiua-10838	83	25	(	(	PUNCT
aiua-10838	83	26	imdc	imdc	PROPN
aiua-10838	83	27	)	)	PUNCT
aiua-10838	83	28	2006	2006	NUM
aiua-10838	83	29	-	-	SYM
aiua-10838	83	30	2018	2018	NUM
aiua-10838	83	31	n	n	PROPN
aiua-10838	83	32	(	(	PUNCT
aiua-10838	83	33	cn+sunitinib	cn+sunitinib	PROPN
aiua-10838	83	34	)	)	PUNCT
aiua-10838	83	35	=	=	SYM
aiua-10838	83	36	805	805	NUM
aiua-10838	83	37	hr	hr	NOUN
aiua-10838	83	38	0.52	0.52	NUM
aiua-10838	83	39	(	(	PUNCT
aiua-10838	83	40	95	95	NUM
aiua-10838	83	41	%	%	NOUN
aiua-10838	83	42	ci	ci	NOUN
aiua-10838	83	43	0.39–0.70	0.39–0.70	NUM
aiua-10838	83	44	)	)	PUNCT
aiua-10838	84	1	p	p	X
aiua-10838	84	2	<	<	X
aiua-10838	84	3	0.001	0.001	NUM
aiua-10838	84	4	n	n	NOUN
aiua-10838	84	5	(	(	PUNCT
aiua-10838	84	6	no	no	DET
aiua-10838	84	7	cn	cn	NOUN
aiua-10838	84	8	)	)	PUNCT
aiua-10838	84	9	=	=	SYM
aiua-10838	85	1	651	651	NUM
aiua-10838	85	2	n	n	NOUN
aiua-10838	85	3	(	(	PUNCT
aiua-10838	85	4	sunitinib+dcn	sunitinib+dcn	NOUN
aiua-10838	85	5	)	)	PUNCT
aiua-10838	85	6	=	=	SYM
aiua-10838	85	7	85	85	NUM
aiua-10838	85	8	kapoor	kapoor	NOUN
aiua-10838	85	9	(	(	PUNCT
aiua-10838	85	10	2019	2019	NUM
aiua-10838	85	11	)	)	PUNCT
aiua-10838	85	12	(	(	PUNCT
aiua-10838	85	13	47	47	NUM
aiua-10838	85	14	)	)	PUNCT
aiua-10838	85	15	,	,	PUNCT
aiua-10838	85	16	retrospective	retrospective	ADJ
aiua-10838	85	17	cohort	cohort	NOUN
aiua-10838	85	18	,	,	PUNCT
aiua-10838	85	19	n	n	CCONJ
aiua-10838	85	20	(	(	PUNCT
aiua-10838	85	21	total	total	NOUN
aiua-10838	85	22	)	)	PUNCT
aiua-10838	85	23	=	=	SYM
aiua-10838	85	24	54	54	NUM
aiua-10838	85	25	cn	cn	NOUN
aiua-10838	85	26	followed	follow	VERB
aiua-10838	85	27	by	by	ADP
aiua-10838	85	28	tt	tt	PROPN
aiua-10838	85	29	versus	versus	ADP
aiua-10838	85	30	tt	tt	PROPN
aiua-10838	85	31	followed	follow	VERB
aiua-10838	85	32	by	by	ADP
aiua-10838	85	33	cn	cn	PROPN
aiua-10838	85	34	median	median	PROPN
aiua-10838	85	35	os	os	NOUN
aiua-10838	85	36	of	of	ADP
aiua-10838	85	37	cn+tt	cn+tt	NOUN
aiua-10838	85	38	vs	vs	ADP
aiua-10838	85	39	tt+cn	tt+cn	PROPN
aiua-10838	85	40	:	:	PUNCT
aiua-10838	85	41	30.7	30.7	NUM
aiua-10838	85	42	vs	vs	ADP
aiua-10838	85	43	36.9	36.9	NUM
aiua-10838	85	44	months	month	NOUN
aiua-10838	85	45	canada	canada	PROPN
aiua-10838	85	46	(	(	PUNCT
aiua-10838	85	47	single	single	ADJ
aiua-10838	85	48	center	center	NOUN
aiua-10838	85	49	)	)	PUNCT
aiua-10838	85	50	2009	2009	NUM
aiua-10838	85	51	-	-	SYM
aiua-10838	85	52	2016	2016	NUM
aiua-10838	85	53	n	n	PROPN
aiua-10838	85	54	(	(	PUNCT
aiua-10838	85	55	cn+tt	cn+tt	NOUN
aiua-10838	85	56	)	)	PUNCT
aiua-10838	85	57	=	=	SYM
aiua-10838	85	58	32	32	NUM
aiua-10838	85	59	when	when	SCONJ
aiua-10838	85	60	stratified	stratify	VERB
aiua-10838	85	61	by	by	ADP
aiua-10838	85	62	number	number	NOUN
aiua-10838	85	63	of	of	ADP
aiua-10838	85	64	metastatic	metastatic	ADJ
aiua-10838	85	65	sites	site	NOUN
aiua-10838	85	66	(	(	PUNCT
aiua-10838	85	67	<	<	X
aiua-10838	85	68	3	3	NUM
aiua-10838	85	69	vs	vs	ADP
aiua-10838	85	70	≥	≥	NOUN
aiua-10838	85	71	3	3	NUM
aiua-10838	85	72	sites	site	NOUN
aiua-10838	85	73	)	)	PUNCT
aiua-10838	85	74	n	n	CCONJ
aiua-10838	85	75	(	(	PUNCT
aiua-10838	85	76	tt+cn	tt+cn	PROPN
aiua-10838	85	77	)	)	PUNCT
aiua-10838	85	78	=	=	SYM
aiua-10838	85	79	22	22	NUM
aiua-10838	85	80	median	median	NOUN
aiua-10838	85	81	os	os	NOUN
aiua-10838	85	82	was	be	AUX
aiua-10838	85	83	significantly	significantly	ADV
aiua-10838	85	84	longer	long	ADJ
aiua-10838	85	85	in	in	ADP
aiua-10838	85	86	the	the	DET
aiua-10838	85	87	upfront	upfront	NOUN
aiua-10838	85	88	tt	tt	PROPN
aiua-10838	85	89	group	group	PROPN
aiua-10838	85	90	with	with	ADP
aiua-10838	85	91	≥	≥	PROPN
aiua-10838	85	92	3	3	NUM
aiua-10838	85	93	metastasis	metastasis	NOUN
aiua-10838	85	94	sites	site	NOUN
aiua-10838	85	95	:	:	PUNCT
aiua-10838	85	96	33	33	NUM
aiua-10838	85	97	vs.	vs.	ADP
aiua-10838	85	98	12.1	12.1	NUM
aiua-10838	85	99	months	month	NOUN
aiua-10838	85	100	hr	hr	NOUN
aiua-10838	85	101	4.65	4.65	NUM
aiua-10838	85	102	(	(	PUNCT
aiua-10838	85	103	95	95	NUM
aiua-10838	85	104	%	%	NOUN
aiua-10838	85	105	ci	ci	NOUN
aiua-10838	85	106	1.18–18.39	1.18–18.39	NUM
aiua-10838	85	107	)	)	PUNCT
aiua-10838	85	108	p	p	NOUN
aiua-10838	86	1	=	=	NOUN
aiua-10838	86	2	0.03	0.03	NUM
aiua-10838	86	3	in	in	ADP
aiua-10838	86	4	intermediate	intermediate	ADJ
aiua-10838	86	5	-	-	PUNCT
aiua-10838	86	6	risk	risk	NOUN
aiua-10838	86	7	patients	patient	NOUN
aiua-10838	86	8	,	,	PUNCT
aiua-10838	86	9	upfront	upfront	ADJ
aiua-10838	86	10	tt	tt	PROPN
aiua-10838	86	11	group	group	PROPN
aiua-10838	86	12	had	have	AUX
aiua-10838	86	13	longer	long	ADV
aiua-10838	86	14	os	os	VERB
aiua-10838	86	15	:	:	PUNCT
aiua-10838	86	16	70.5	70.5	NUM
aiua-10838	86	17	vs.	vs.	ADP
aiua-10838	86	18	30.7	30.7	NUM
aiua-10838	86	19	months	month	NOUN
aiua-10838	86	20	hr	hr	NOUN
aiua-10838	86	21	3.25	3.25	NUM
aiua-10838	86	22	(	(	PUNCT
aiua-10838	86	23	95	95	NUM
aiua-10838	86	24	%	%	NOUN
aiua-10838	86	25	ci	ci	NOUN
aiua-10838	86	26	1.16–9.08	1.16–9.08	NUM
aiua-10838	86	27	)	)	PUNCT
aiua-10838	86	28	p	p	NOUN
aiua-10838	86	29	=	=	PUNCT
aiua-10838	86	30	0.03	0.03	NUM
aiua-10838	86	31	de	de	X
aiua-10838	86	32	bruijn	bruijn	PROPN
aiua-10838	86	33	(	(	PUNCT
aiua-10838	86	34	2020	2020	NUM
aiua-10838	86	35	)	)	PUNCT
aiua-10838	86	36	(	(	PUNCT
aiua-10838	86	37	48	48	NUM
aiua-10838	86	38	)	)	PUNCT
aiua-10838	86	39	,	,	PUNCT
aiua-10838	86	40	retrospective	retrospective	ADJ
aiua-10838	86	41	analysis	analysis	NOUN
aiua-10838	86	42	,	,	PUNCT
aiua-10838	86	43	n	n	CCONJ
aiua-10838	86	44	(	(	PUNCT
aiua-10838	86	45	total	total	NOUN
aiua-10838	86	46	)	)	PUNCT
aiua-10838	86	47	=	=	SYM
aiua-10838	87	1	338	338	NUM
aiua-10838	87	2	cn	cn	NOUN
aiua-10838	87	3	followed	follow	VERB
aiua-10838	87	4	by	by	ADP
aiua-10838	87	5	tt	tt	PROPN
aiua-10838	87	6	versus	versus	ADP
aiua-10838	87	7	tt	tt	PROPN
aiua-10838	87	8	followed	follow	VERB
aiua-10838	87	9	by	by	ADP
aiua-10838	87	10	cn	cn	PROPN
aiua-10838	87	11	in	in	ADP
aiua-10838	87	12	unselected	unselected	ADJ
aiua-10838	87	13	for	for	ADP
aiua-10838	87	14	risk	risk	NOUN
aiua-10838	87	15	group	group	NOUN
aiua-10838	87	16	pooled	pool	VERB
aiua-10838	87	17	data	datum	NOUN
aiua-10838	87	18	from	from	ADP
aiua-10838	87	19	prospective	prospective	ADJ
aiua-10838	87	20	trials	trial	NOUN
aiua-10838	87	21	2006	2006	NUM
aiua-10838	87	22	-	-	SYM
aiua-10838	87	23	2016	2016	NUM
aiua-10838	87	24	n	n	PROPN
aiua-10838	87	25	(	(	PUNCT
aiua-10838	87	26	cn+tt	cn+tt	NOUN
aiua-10838	87	27	)	)	PUNCT
aiua-10838	87	28	=	=	SYM
aiua-10838	87	29	149	149	NUM
aiua-10838	87	30	median	median	NOUN
aiua-10838	87	31	os	os	NOUN
aiua-10838	87	32	of	of	ADP
aiua-10838	87	33	cn+tt	cn+tt	NOUN
aiua-10838	87	34	vs	vs	ADP
aiua-10838	87	35	tt+cn	tt+cn	PROPN
aiua-10838	87	36	:	:	PUNCT
aiua-10838	87	37	18.4	18.4	NUM
aiua-10838	87	38	vs	vs	ADP
aiua-10838	87	39	24.3	24.3	NUM
aiua-10838	87	40	months	month	NOUN
aiua-10838	87	41	n	n	CCONJ
aiua-10838	87	42	(	(	PUNCT
aiua-10838	87	43	tt+cn	tt+cn	PROPN
aiua-10838	87	44	)	)	PUNCT
aiua-10838	87	45	=	=	SYM
aiua-10838	87	46	189	189	NUM
aiua-10838	87	47	hr	hr	NOUN
aiua-10838	87	48	0.78	0.78	NUM
aiua-10838	87	49	(	(	PUNCT
aiua-10838	87	50	95	95	NUM
aiua-10838	87	51	%	%	NOUN
aiua-10838	87	52	ci	ci	NOUN
aiua-10838	87	53	0.59–1.04	0.59–1.04	PROPN
aiua-10838	87	54	)	)	PUNCT
aiua-10838	87	55	p	p	NOUN
aiua-10838	88	1	=	=	PUNCT
aiua-10838	88	2	0.09	0.09	NUM
aiua-10838	88	3	in	in	ADP
aiua-10838	88	4	intermediate	intermediate	ADJ
aiua-10838	88	5	-	-	PUNCT
aiua-10838	88	6	risk	risk	NOUN
aiua-10838	88	7	group	group	NOUN
aiua-10838	88	8	median	median	NOUN
aiua-10838	88	9	os	os	NOUN
aiua-10838	88	10	of	of	ADP
aiua-10838	88	11	cn+tt	cn+tt	NOUN
aiua-10838	88	12	vs	vs	ADP
aiua-10838	88	13	tt+cn	tt+cn	PROPN
aiua-10838	88	14	:	:	PUNCT
aiua-10838	88	15	22.8	22.8	NUM
aiua-10838	88	16	vs	vs	ADP
aiua-10838	88	17	33	33	NUM
aiua-10838	88	18	months	month	NOUN
aiua-10838	88	19	hr	hr	NOUN
aiua-10838	88	20	0.72	0.72	NUM
aiua-10838	88	21	(	(	PUNCT
aiua-10838	88	22	95	95	NUM
aiua-10838	88	23	%	%	NOUN
aiua-10838	88	24	ci	ci	NOUN
aiua-10838	88	25	0.52–0.99	0.52–0.99	NOUN
aiua-10838	88	26	)	)	PUNCT
aiua-10838	89	1	p	p	X
aiua-10838	89	2	=	=	PUNCT
aiua-10838	89	3	0.047	0.047	NUM
aiua-10838	89	4	dragomir	dragomir	NOUN
aiua-10838	89	5	(	(	PUNCT
aiua-10838	89	6	2021	2021	NUM
aiua-10838	89	7	)	)	PUNCT
aiua-10838	89	8	(	(	PUNCT
aiua-10838	89	9	40	40	NUM
aiua-10838	89	10	)	)	PUNCT
aiua-10838	89	11	,	,	PUNCT
aiua-10838	89	12	retrospective	retrospective	ADJ
aiua-10838	89	13	cohort	cohort	NOUN
aiua-10838	89	14	,	,	PUNCT
aiua-10838	89	15	n	n	CCONJ
aiua-10838	89	16	(	(	PUNCT
aiua-10838	89	17	total	total	NOUN
aiua-10838	89	18	)	)	PUNCT
aiua-10838	89	19	=	=	SYM
aiua-10838	90	1	788	788	NUM
aiua-10838	90	2	cn	cn	NOUN
aiua-10838	90	3	followed	follow	VERB
aiua-10838	90	4	by	by	ADP
aiua-10838	90	5	st	st	PROPN
aiua-10838	90	6	versus	versus	ADP
aiua-10838	90	7	st	st	PROPN
aiua-10838	90	8	followed	follow	VERB
aiua-10838	90	9	by	by	ADP
aiua-10838	90	10	cn	cn	PROPN
aiua-10838	90	11	median	median	PROPN
aiua-10838	90	12	os	os	NOUN
aiua-10838	90	13	of	of	ADP
aiua-10838	90	14	cn+st	cn+st	PROPN
aiua-10838	90	15	vs	vs	ADP
aiua-10838	90	16	st+cn	st+cn	NOUN
aiua-10838	90	17	:	:	PUNCT
aiua-10838	90	18	36	36	NUM
aiua-10838	90	19	vs	vs	ADP
aiua-10838	90	20	48	48	NUM
aiua-10838	90	21	months	month	NOUN
aiua-10838	90	22	canada	canada	PROPN
aiua-10838	90	23	(	(	PUNCT
aiua-10838	90	24	multicenter	multicenter	NOUN
aiua-10838	90	25	)	)	PUNCT
aiua-10838	90	26	2011	2011	NUM
aiua-10838	90	27	-	-	SYM
aiua-10838	90	28	2020	2020	NUM
aiua-10838	90	29	n	n	CCONJ
aiua-10838	90	30	(	(	PUNCT
aiua-10838	90	31	cn	cn	PROPN
aiua-10838	90	32	)	)	PUNCT
aiua-10838	90	33	=	=	SYM
aiua-10838	90	34	80	80	NUM
aiua-10838	90	35	st	st	NOUN
aiua-10838	90	36	includes	include	VERB
aiua-10838	90	37	tt	tt	PROPN
aiua-10838	90	38	or	or	CCONJ
aiua-10838	90	39	immune	immune	ADJ
aiua-10838	90	40	check	check	NOUN
aiua-10838	90	41	point	point	NOUN
aiua-10838	90	42	inhibitors	inhibitor	NOUN
aiua-10838	90	43	hr	hr	NOUN
aiua-10838	90	44	0.66	0.66	NUM
aiua-10838	90	45	(	(	PUNCT
aiua-10838	90	46	95	95	NUM
aiua-10838	90	47	%	%	NOUN
aiua-10838	90	48	ci	ci	NOUN
aiua-10838	90	49	0.42–1.04	0.42–1.04	NUM
aiua-10838	90	50	)	)	PUNCT
aiua-10838	90	51	n	n	CCONJ
aiua-10838	90	52	(	(	PUNCT
aiua-10838	90	53	cn+st	cn+st	NOUN
aiua-10838	90	54	)	)	PUNCT
aiua-10838	90	55	=	=	SYM
aiua-10838	91	1	383	383	NUM
aiua-10838	91	2	n	n	NOUN
aiua-10838	91	3	(	(	PUNCT
aiua-10838	91	4	st+cn	st+cn	NOUN
aiua-10838	91	5	)	)	PUNCT
aiua-10838	91	6	=	=	SYM
aiua-10838	92	1	73	73	NUM
aiua-10838	92	2	n	n	SYM
aiua-10838	92	3	(	(	PUNCT
aiua-10838	92	4	st	st	PROPN
aiua-10838	92	5	only	only	ADV
aiua-10838	92	6	)	)	PUNCT
aiua-10838	92	7	=	=	SYM
aiua-10838	93	1	282	282	NUM
aiua-10838	93	2	cn	cn	NOUN
aiua-10838	93	3	=	=	NOUN
aiua-10838	93	4	cytoreductive	cytoreductive	ADJ
aiua-10838	93	5	nephrectomy	nephrectomy	NOUN
aiua-10838	93	6	;	;	PUNCT
aiua-10838	93	7	os	os	NOUN
aiua-10838	93	8	=	=	VERB
aiua-10838	93	9	overall	overall	ADJ
aiua-10838	93	10	survival	survival	NOUN
aiua-10838	93	11	;	;	PUNCT
aiua-10838	93	12	css	css	PROPN
aiua-10838	93	13	=	=	SYM
aiua-10838	93	14	cancer	cancer	NOUN
aiua-10838	93	15	specific	specific	ADJ
aiua-10838	93	16	survival	survival	NOUN
aiua-10838	93	17	,	,	PUNCT
aiua-10838	93	18	;	;	PUNCT
aiua-10838	93	19	hr	hr	NOUN
aiua-10838	93	20	=	=	PUNCT
aiua-10838	93	21	hazard	hazard	NOUN
aiua-10838	93	22	ratio	ratio	NOUN
aiua-10838	93	23	;	;	PUNCT
aiua-10838	93	24	st	st	PROPN
aiua-10838	93	25	=	=	SYM
aiua-10838	93	26	systemic	systemic	ADJ
aiua-10838	93	27	therapy	therapy	NOUN
aiua-10838	93	28	;	;	PUNCT
aiua-10838	93	29	tt	tt	PROPN
aiua-10838	93	30	=	=	SYM
aiua-10838	93	31	ttargeted	ttargete	VERB
aiua-10838	93	32	therapy	therapy	NOUN
aiua-10838	93	33	;	;	PUNCT
aiua-10838	93	34	ci	ci	NOUN
aiua-10838	93	35	=	=	NOUN
aiua-10838	93	36	confidence	confidence	NOUN
aiua-10838	93	37	interval	interval	NOUN
aiua-10838	93	38	;	;	PUNCT
aiua-10838	93	39	km	km	PROPN
aiua-10838	93	40	=	=	SYM
aiua-10838	93	41	kaplan	kaplan	PROPN
aiua-10838	93	42	meier	meier	PROPN
aiua-10838	93	43	;	;	PUNCT
aiua-10838	93	44	itt	itt	PROPN
aiua-10838	93	45	=	=	PUNCT
aiua-10838	93	46	intention	intention	NOUN
aiua-10838	93	47	to	to	PART
aiua-10838	93	48	treat	treat	VERB
aiua-10838	93	49	;	;	PUNCT
aiua-10838	93	50	ppp	ppp	NOUN
aiua-10838	93	51	=	=	PUNCT
aiua-10838	93	52	per	per	ADP
aiua-10838	93	53	protocol	protocol	NOUN
aiua-10838	93	54	population	population	NOUN
aiua-10838	93	55	;	;	PUNCT
aiua-10838	93	56	seer	seer	NOUN
aiua-10838	93	57	=	=	NOUN
aiua-10838	93	58	surveillance	surveillance	NOUN
aiua-10838	93	59	,	,	PUNCT
aiua-10838	93	60	epidemiology	epidemiology	NOUN
aiua-10838	93	61	,	,	PUNCT
aiua-10838	93	62	and	and	CCONJ
aiua-10838	93	63	end	end	VERB
aiua-10838	93	64	results	result	NOUN
aiua-10838	93	65	;	;	PUNCT
aiua-10838	93	66	ncdb	ncdb	NOUN
aiua-10838	93	67	=	=	PROPN
aiua-10838	93	68	national	national	ADJ
aiua-10838	93	69	cancer	cancer	NOUN
aiua-10838	93	70	database	database	NOUN
aiua-10838	93	71	;	;	PUNCT
aiua-10838	93	72	imdc	imdc	NOUN
aiua-10838	93	73	=	=	SYM
aiua-10838	93	74	international	international	ADJ
aiua-10838	93	75	metastatic	metastatic	ADJ
aiua-10838	93	76	renal	renal	ADJ
aiua-10838	93	77	cell	cell	NOUN
aiua-10838	93	78	carcinoma	carcinoma	NOUN
aiua-10838	93	79	database	database	NOUN
aiua-10838	93	80	consortium	consortium	NOUN
aiua-10838	93	81	.	.	PUNCT
aiua-10838	94	1	showed	show	VERB
aiua-10838	94	2	no	no	DET
aiua-10838	94	3	benefit	benefit	NOUN
aiua-10838	94	4	(	(	PUNCT
aiua-10838	94	5	33	33	NUM
aiua-10838	94	6	,	,	PUNCT
aiua-10838	94	7	34	34	NUM
aiua-10838	94	8	)	)	PUNCT
aiua-10838	94	9	.	.	PUNCT
aiua-10838	95	1	choueiri	choueiri	NOUN
aiua-10838	95	2	et	et	PROPN
aiua-10838	95	3	al	al	PROPN
aiua-10838	95	4	.	.	PUNCT
aiua-10838	96	1	(	(	PUNCT
aiua-10838	96	2	33	33	NUM
aiua-10838	96	3	)	)	PUNCT
aiua-10838	96	4	stratified	stratify	VERB
aiua-10838	96	5	patients	patient	NOUN
aiua-10838	96	6	according	accord	VERB
aiua-10838	96	7	to	to	ADP
aiua-10838	96	8	the	the	DET
aiua-10838	96	9	imdc	imdc	NOUN
aiua-10838	96	10	prognostic	prognostic	ADJ
aiua-10838	96	11	factors	factor	NOUN
aiua-10838	96	12	and	and	CCONJ
aiua-10838	96	13	demonstrated	demonstrate	VERB
aiua-10838	96	14	that	that	SCONJ
aiua-10838	96	15	poor	poor	ADJ
aiua-10838	96	16	-	-	PUNCT
aiua-10838	96	17	risk	risk	NOUN
aiua-10838	96	18	patients	patient	NOUN
aiua-10838	96	19	had	have	VERB
aiua-10838	96	20	no	no	DET
aiua-10838	96	21	significant	significant	ADJ
aiua-10838	96	22	benefit	benefit	NOUN
aiua-10838	96	23	in	in	ADP
aiua-10838	96	24	os	os	PROPN
aiua-10838	96	25	(	(	PUNCT
aiua-10838	96	26	hr	hr	NOUN
aiua-10838	96	27	0.67	0.67	NUM
aiua-10838	96	28	95	95	NUM
aiua-10838	96	29	%	%	NOUN
aiua-10838	96	30	ci	ci	NOUN
aiua-10838	96	31	0.44	0.44	NUM
aiua-10838	96	32	-	-	SYM
aiua-10838	96	33	1.01	1.01	NUM
aiua-10838	96	34	,	,	PUNCT
aiua-10838	96	35	p	p	NOUN
aiua-10838	96	36	=	=	NOUN
aiua-10838	96	37	0.06	0.06	NUM
aiua-10838	96	38	)	)	PUNCT
aiua-10838	96	39	.	.	PUNCT
aiua-10838	97	1	also	also	ADV
aiua-10838	97	2	,	,	PUNCT
aiua-10838	97	3	heng	heng	PROPN
aiua-10838	97	4	et	et	PROPN
aiua-10838	97	5	al	al	PROPN
aiua-10838	97	6	.	.	PROPN
aiua-10838	98	1	(	(	PUNCT
aiua-10838	98	2	34	34	NUM
aiua-10838	98	3	)	)	PUNCT
aiua-10838	98	4	,	,	PUNCT
aiua-10838	98	5	in	in	ADP
aiua-10838	98	6	a	a	DET
aiua-10838	98	7	similar	similar	ADJ
aiua-10838	98	8	subgroup	subgroup	NOUN
aiua-10838	98	9	analysis	analysis	NOUN
aiua-10838	98	10	showed	show	VERB
aiua-10838	98	11	absence	absence	NOUN
aiua-10838	98	12	of	of	ADP
aiua-10838	98	13	os	os	NOUN
aiua-10838	98	14	benefit	benefit	NOUN
aiua-10838	98	15	for	for	ADP
aiua-10838	98	16	poor	poor	ADJ
aiua-10838	98	17	risk	risk	NOUN
aiua-10838	98	18	patients	patient	NOUN
aiua-10838	98	19	(	(	PUNCT
aiua-10838	98	20	os	os	ADV
aiua-10838	98	21	6	6	NUM
aiua-10838	98	22	vs	vs	ADP
aiua-10838	98	23	5.4	5.4	NUM
aiua-10838	98	24	months	month	NOUN
aiua-10838	98	25	,	,	PUNCT
aiua-10838	98	26	p	p	X
aiua-10838	98	27	>	>	X
aiua-10838	98	28	0.1	0.1	NUM
aiua-10838	98	29	)	)	PUNCT
aiua-10838	98	30	.	.	PUNCT
aiua-10838	99	1	the	the	DET
aiua-10838	99	2	carmena	carmena	PROPN
aiua-10838	99	3	trial	trial	NOUN
aiua-10838	99	4	(	(	PUNCT
aiua-10838	99	5	41	41	NUM
aiua-10838	99	6	)	)	PUNCT
aiua-10838	99	7	,	,	PUNCT
aiua-10838	99	8	the	the	DET
aiua-10838	99	9	only	only	ADJ
aiua-10838	99	10	prospective	prospective	ADJ
aiua-10838	99	11	trial	trial	NOUN
aiua-10838	99	12	in	in	ADP
aiua-10838	99	13	this	this	DET
aiua-10838	99	14	review	review	NOUN
aiua-10838	99	15	,	,	PUNCT
aiua-10838	99	16	compared	compare	VERB
aiua-10838	99	17	sunitinib	sunitinib	NOUN
aiua-10838	99	18	plus	plus	CCONJ
aiua-10838	99	19	cn	cn	PROPN
aiua-10838	99	20	versus	versus	ADP
aiua-10838	99	21	sunitinib	sunitinib	NOUN
aiua-10838	99	22	alone	alone	ADV
aiua-10838	99	23	in	in	ADP
aiua-10838	99	24	mrcc	mrcc	NOUN
aiua-10838	99	25	patients	patient	NOUN
aiua-10838	99	26	and	and	CCONJ
aiua-10838	99	27	showed	show	VERB
aiua-10838	99	28	for	for	ADP
aiua-10838	99	29	the	the	DET
aiua-10838	99	30	first	first	ADJ
aiua-10838	99	31	time	time	NOUN
aiua-10838	99	32	the	the	DET
aiua-10838	99	33	non	non	NOUN
aiua-10838	99	34	-	-	NOUN
aiua-10838	99	35	inferiority	inferiority	NOUN
aiua-10838	99	36	of	of	ADP
aiua-10838	99	37	systemic	systemic	ADJ
aiua-10838	99	38	therapy	therapy	NOUN
aiua-10838	99	39	compared	compare	VERB
aiua-10838	99	40	to	to	ADP
aiua-10838	99	41	upfront	upfront	PROPN
aiua-10838	99	42	cn	cn	PROPN
aiua-10838	99	43	plus	plus	CCONJ
aiua-10838	99	44	sunitinib	sunitinib	NOUN
aiua-10838	99	45	,	,	PUNCT
aiua-10838	99	46	with	with	ADP
aiua-10838	99	47	os	os	NOUN
aiua-10838	99	48	18.4	18.4	NUM
aiua-10838	99	49	months	month	NOUN
aiua-10838	99	50	vs	vs	ADP
aiua-10838	99	51	13.9	13.9	NUM
aiua-10838	99	52	months	month	NOUN
aiua-10838	99	53	(	(	PUNCT
aiua-10838	99	54	hr	hr	NOUN
aiua-10838	99	55	0.89	0.89	NUM
aiua-10838	99	56	95	95	NUM
aiua-10838	99	57	%	%	NOUN
aiua-10838	99	58	ci	ci	NOUN
aiua-10838	99	59	0.71	0.71	NUM
aiua-10838	99	60	-	-	SYM
aiua-10838	99	61	1.1	1.1	NUM
aiua-10838	99	62	)	)	PUNCT
aiua-10838	99	63	.	.	PUNCT
aiua-10838	100	1	results	result	NOUN
aiua-10838	100	2	were	be	AUX
aiua-10838	100	3	similar	similar	ADJ
aiua-10838	100	4	in	in	ADP
aiua-10838	100	5	the	the	DET
aiua-10838	100	6	intermediate	intermediate	ADJ
aiua-10838	100	7	risk	risk	NOUN
aiua-10838	100	8	(	(	PUNCT
aiua-10838	100	9	hr	hr	NOUN
aiua-10838	100	10	0.92	0.92	NUM
aiua-10838	100	11	95	95	NUM
aiua-10838	100	12	%	%	NOUN
aiua-10838	100	13	ci	ci	NOUN
aiua-10838	100	14	0.68	0.68	NUM
aiua-10838	100	15	-	-	PUNCT
aiua-10838	100	16	1.24	1.24	NUM
aiua-10838	100	17	)	)	PUNCT
aiua-10838	100	18	and	and	CCONJ
aiua-10838	100	19	poorrisk	poorrisk	NOUN
aiua-10838	100	20	(	(	PUNCT
aiua-10838	100	21	hr	hr	NOUN
aiua-10838	100	22	0.86	0.86	NUM
aiua-10838	100	23	95	95	NUM
aiua-10838	100	24	%	%	NOUN
aiua-10838	100	25	ci	ci	NOUN
aiua-10838	100	26	0.62	0.62	NUM
aiua-10838	100	27	-	-	SYM
aiua-10838	100	28	1.17	1.17	NUM
aiua-10838	100	29	)	)	PUNCT
aiua-10838	100	30	patients	patient	NOUN
aiua-10838	100	31	.	.	PUNCT
aiua-10838	101	1	however	however	ADV
aiua-10838	101	2	,	,	PUNCT
aiua-10838	101	3	the	the	DET
aiua-10838	101	4	study	study	NOUN
aiua-10838	101	5	has	have	VERB
aiua-10838	101	6	some	some	DET
aiua-10838	101	7	serious	serious	ADJ
aiua-10838	101	8	limitations	limitation	NOUN
aiua-10838	101	9	.	.	PUNCT
aiua-10838	102	1	in	in	ADP
aiua-10838	102	2	the	the	DET
aiua-10838	102	3	sunitinib	sunitinib	NOUN
aiua-10838	102	4	alone	alone	ADV
aiua-10838	102	5	arm	arm	NOUN
aiua-10838	102	6	,	,	PUNCT
aiua-10838	102	7	17	17	NUM
aiua-10838	102	8	%	%	NOUN
aiua-10838	102	9	of	of	ADP
aiua-10838	102	10	the	the	DET
aiua-10838	102	11	patients	patient	NOUN
aiua-10838	102	12	underwent	undergo	VERB
aiua-10838	102	13	subsequent	subsequent	ADJ
aiua-10838	102	14	cn	cn	PROPN
aiua-10838	102	15	and	and	CCONJ
aiua-10838	102	16	7	7	NUM
aiua-10838	102	17	%	%	NOUN
aiua-10838	102	18	of	of	ADP
aiua-10838	102	19	patients	patient	NOUN
aiua-10838	102	20	in	in	ADP
aiua-10838	102	21	the	the	DET
aiua-10838	102	22	cn	cn	PROPN
aiua-10838	102	23	plus	plus	CCONJ
aiua-10838	102	24	sunitinib	sunitinib	NOUN
aiua-10838	102	25	arm	arm	NOUN
aiua-10838	102	26	did	do	AUX
aiua-10838	102	27	not	not	PART
aiua-10838	102	28	receive	receive	VERB
aiua-10838	102	29	surgery	surgery	NOUN
aiua-10838	102	30	.	.	PUNCT
aiua-10838	103	1	the	the	DET
aiua-10838	103	2	study	study	NOUN
aiua-10838	103	3	also	also	ADV
aiua-10838	103	4	included	include	VERB
aiua-10838	103	5	only	only	ADV
aiua-10838	103	6	poor	poor	ADJ
aiua-10838	103	7	-	-	PUNCT
aiua-10838	103	8	risk	risk	NOUN
aiua-10838	103	9	memorial	memorial	ADJ
aiua-10838	103	10	sloan	sloan	NOUN
aiua-10838	103	11	kettering	kettering	PROPN
aiua-10838	103	12	cancer	cancer	PROPN
aiua-10838	103	13	center	center	PROPN
aiua-10838	103	14	(	(	PUNCT
aiua-10838	103	15	mskcc	mskcc	PROPN
aiua-10838	103	16	)	)	PUNCT
aiua-10838	103	17	and	and	CCONJ
aiua-10838	103	18	intermediate	intermediate	ADJ
aiua-10838	103	19	-	-	PUNCT
aiua-10838	103	20	risk	risk	NOUN
aiua-10838	103	21	mskcc	mskcc	NOUN
aiua-10838	103	22	patients	patient	NOUN
aiua-10838	103	23	that	that	PRON
aiua-10838	103	24	have	have	AUX
aiua-10838	103	25	been	be	AUX
aiua-10838	103	26	shown	show	VERB
aiua-10838	103	27	before	before	ADP
aiua-10838	103	28	not	not	PART
aiua-10838	103	29	to	to	PART
aiua-10838	103	30	benefit	benefit	VERB
aiua-10838	103	31	from	from	ADP
aiua-10838	103	32	cn	cn	PROPN
aiua-10838	103	33	(	(	PUNCT
aiua-10838	103	34	33	33	NUM
aiua-10838	103	35	,	,	PUNCT
aiua-10838	103	36	34	34	NUM
aiua-10838	103	37	)	)	PUNCT
aiua-10838	103	38	.	.	PUNCT
aiua-10838	104	1	sequencing	sequence	VERB
aiua-10838	104	2	of	of	ADP
aiua-10838	104	3	cytoreductive	cytoreductive	ADJ
aiua-10838	104	4	nephrectomy	nephrectomy	ADJ
aiua-10838	104	5	and	and	CCONJ
aiua-10838	104	6	systemic	systemic	ADJ
aiua-10838	104	7	therapies	therapy	NOUN
aiua-10838	104	8	ten	ten	NUM
aiua-10838	104	9	studies	study	NOUN
aiua-10838	104	10	were	be	AUX
aiua-10838	104	11	included	include	VERB
aiua-10838	104	12	in	in	ADP
aiua-10838	104	13	the	the	DET
aiua-10838	104	14	analysis	analysis	NOUN
aiua-10838	104	15	of	of	ADP
aiua-10838	104	16	the	the	DET
aiua-10838	104	17	sequencing	sequencing	NOUN
aiua-10838	104	18	of	of	ADP
aiua-10838	104	19	cn	cn	PROPN
aiua-10838	104	20	and	and	CCONJ
aiua-10838	104	21	st	st	PROPN
aiua-10838	104	22	(	(	PUNCT
aiua-10838	104	23	table	table	NOUN
aiua-10838	104	24	3	3	NUM
aiua-10838	104	25	)	)	PUNCT
aiua-10838	104	26	.	.	PUNCT
aiua-10838	105	1	nine	nine	NUM
aiua-10838	105	2	studies	study	NOUN
aiua-10838	105	3	were	be	AUX
aiua-10838	105	4	retrospective	retrospective	ADJ
aiua-10838	105	5	cohorts	cohort	NOUN
aiua-10838	105	6	(	(	PUNCT
aiua-10838	105	7	23	23	NUM
aiua-10838	105	8	,	,	PUNCT
aiua-10838	105	9	38	38	NUM
aiua-10838	105	10	,	,	PUNCT
aiua-10838	105	11	40	40	NUM
aiua-10838	105	12	,	,	PUNCT
aiua-10838	105	13	43	43	NUM
aiua-10838	105	14	-	-	SYM
aiua-10838	105	15	48	48	NUM
aiua-10838	105	16	)	)	PUNCT
aiua-10838	105	17	,	,	PUNCT
aiua-10838	105	18	and	and	CCONJ
aiua-10838	105	19	one	one	NUM
aiua-10838	105	20	was	be	AUX
aiua-10838	105	21	a	a	DET
aiua-10838	105	22	prospecarchivio	prospecarchivio	NOUN
aiua-10838	105	23	italiano	italiano	NOUN
aiua-10838	105	24	di	di	X
aiua-10838	105	25	urologia	urologia	PROPN
aiua-10838	105	26	e	e	PROPN
aiua-10838	105	27	andrologia	andrologia	PROPN
aiua-10838	105	28	2022	2022	NUM
aiua-10838	105	29	;	;	PUNCT
aiua-10838	105	30	94	94	NUM
aiua-10838	105	31	,	,	PUNCT
aiua-10838	105	32	4	4	NUM
aiua-10838	105	33	s.	s.	PROPN
aiua-10838	105	34	katsimperis	katsimperis	PROPN
aiua-10838	105	35	,	,	PUNCT
aiua-10838	105	36	l.	l.	PROPN
aiua-10838	105	37	tzelves	tzelves	PROPN
aiua-10838	105	38	,	,	PUNCT
aiua-10838	105	39	t.	t.	PROPN
aiua-10838	105	40	bellos	bellos	PROPN
aiua-10838	105	41	,	,	PUNCT
aiua-10838	105	42	k.	k.	PROPN
aiua-10838	105	43	pikramenos	pikramenos	PROPN
aiua-10838	105	44	,	,	PUNCT
aiua-10838	105	45	i.	i.	PROPN
aiua-10838	105	46	manolitsis	manolitsis	PROPN
aiua-10838	105	47	,	,	PUNCT
aiua-10838	105	48	i.	i.	PROPN
aiua-10838	105	49	tsikopoulos	tsikopoulos	PROPN
aiua-10838	105	50	,	,	PUNCT
aiua-10838	105	51	i.	i.	NOUN
aiua-10838	105	52	mitsogiannis	mitsogiannis	PROPN
aiua-10838	105	53	482	482	NUM
aiua-10838	105	54	tive	tive	PROPN
aiua-10838	105	55	randomized	randomize	VERB
aiua-10838	105	56	controlled	control	VERB
aiua-10838	105	57	trial	trial	NOUN
aiua-10838	105	58	(	(	PUNCT
aiua-10838	105	59	rct	rct	PROPN
aiua-10838	105	60	)	)	PUNCT
aiua-10838	105	61	(	(	PUNCT
aiua-10838	105	62	7	7	NUM
aiua-10838	105	63	)	)	PUNCT
aiua-10838	105	64	.	.	PUNCT
aiua-10838	106	1	out	out	ADP
aiua-10838	106	2	of	of	ADP
aiua-10838	106	3	retrospective	retrospective	ADJ
aiua-10838	106	4	studies	study	NOUN
aiua-10838	106	5	,	,	PUNCT
aiua-10838	106	6	two	two	NUM
aiua-10838	106	7	were	be	AUX
aiua-10838	106	8	population	population	NOUN
aiua-10838	106	9	based	base	VERB
aiua-10838	106	10	(	(	PUNCT
aiua-10838	106	11	45	45	NUM
aiua-10838	106	12	,	,	PUNCT
aiua-10838	106	13	38	38	NUM
aiua-10838	106	14	)	)	PUNCT
aiua-10838	106	15	,	,	PUNCT
aiua-10838	106	16	three	three	NUM
aiua-10838	106	17	studies	study	NOUN
aiua-10838	106	18	used	use	VERB
aiua-10838	106	19	a	a	DET
aiua-10838	106	20	national	national	ADJ
aiua-10838	106	21	hospital	hospital	NOUN
aiua-10838	106	22	-	-	PUNCT
aiua-10838	106	23	based	base	VERB
aiua-10838	106	24	database	database	NOUN
aiua-10838	106	25	(	(	PUNCT
aiua-10838	106	26	46	46	NUM
aiua-10838	106	27	,	,	PUNCT
aiua-10838	106	28	23	23	NUM
aiua-10838	106	29	,	,	PUNCT
aiua-10838	106	30	40	40	NUM
aiua-10838	106	31	)	)	PUNCT
aiua-10838	106	32	,	,	PUNCT
aiua-10838	106	33	two	two	NUM
aiua-10838	106	34	were	be	AUX
aiua-10838	106	35	from	from	ADP
aiua-10838	106	36	a	a	DET
aiua-10838	106	37	single	single	ADJ
aiua-10838	106	38	institution	institution	NOUN
aiua-10838	106	39	(	(	PUNCT
aiua-10838	106	40	43	43	NUM
aiua-10838	106	41	,	,	PUNCT
aiua-10838	106	42	47	47	NUM
aiua-10838	106	43	)	)	PUNCT
aiua-10838	106	44	,	,	PUNCT
aiua-10838	106	45	one	one	NUM
aiua-10838	106	46	study	study	NOUN
aiua-10838	106	47	was	be	AUX
aiua-10838	106	48	multicenter	multicenter	NOUN
aiua-10838	106	49	(	(	PUNCT
aiua-10838	106	50	44	44	NUM
aiua-10838	106	51	)	)	PUNCT
aiua-10838	106	52	and	and	CCONJ
aiua-10838	106	53	one	one	NUM
aiua-10838	106	54	study	study	NOUN
aiua-10838	106	55	pooled	pool	VERB
aiua-10838	106	56	data	datum	NOUN
aiua-10838	106	57	from	from	ADP
aiua-10838	106	58	4	4	NUM
aiua-10838	106	59	prospective	prospective	ADJ
aiua-10838	106	60	trials	trial	NOUN
aiua-10838	106	61	(	(	PUNCT
aiua-10838	106	62	48	48	NUM
aiua-10838	106	63	)	)	PUNCT
aiua-10838	106	64	.	.	PUNCT
aiua-10838	107	1	in	in	ADP
aiua-10838	107	2	two	two	NUM
aiua-10838	107	3	studies	study	NOUN
aiua-10838	107	4	(	(	PUNCT
aiua-10838	107	5	45	45	NUM
aiua-10838	107	6	,	,	PUNCT
aiua-10838	107	7	46	46	NUM
aiua-10838	107	8	)	)	PUNCT
aiua-10838	107	9	,	,	PUNCT
aiua-10838	107	10	cn	cn	PROPN
aiua-10838	107	11	prior	prior	ADV
aiua-10838	107	12	to	to	ADP
aiua-10838	107	13	st	st	PROPN
aiua-10838	107	14	found	find	VERB
aiua-10838	107	15	to	to	PART
aiua-10838	107	16	have	have	VERB
aiua-10838	107	17	an	an	DET
aiua-10838	107	18	advantage	advantage	NOUN
aiua-10838	107	19	in	in	ADP
aiua-10838	107	20	os	os	PROPN
aiua-10838	107	21	.	.	PUNCT
aiua-10838	108	1	macleod	macleod	PROPN
aiua-10838	108	2	et	et	PROPN
aiua-10838	108	3	al	al	PROPN
aiua-10838	108	4	.	.	PROPN
aiua-10838	109	1	(	(	PUNCT
aiua-10838	109	2	45	45	NUM
aiua-10838	109	3	)	)	PUNCT
aiua-10838	109	4	showed	show	VERB
aiua-10838	109	5	that	that	SCONJ
aiua-10838	109	6	median	median	ADJ
aiua-10838	109	7	os	os	NOUN
aiua-10838	109	8	of	of	ADP
aiua-10838	109	9	immediate	immediate	ADJ
aiua-10838	109	10	cn	cn	PROPN
aiua-10838	109	11	was	be	AUX
aiua-10838	109	12	17.4	17.4	NUM
aiua-10838	109	13	months	month	NOUN
aiua-10838	109	14	vs	vs	ADP
aiua-10838	109	15	9.2	9.2	NUM
aiua-10838	109	16	in	in	ADP
aiua-10838	109	17	the	the	DET
aiua-10838	109	18	deferred	defer	VERB
aiua-10838	109	19	cn	cn	PROPN
aiua-10838	109	20	group	group	NOUN
aiua-10838	109	21	,	,	PUNCT
aiua-10838	109	22	with	with	ADP
aiua-10838	109	23	hr	hr	NOUN
aiua-10838	109	24	0.50	0.50	NUM
aiua-10838	109	25	(	(	PUNCT
aiua-10838	109	26	95	95	NUM
aiua-10838	109	27	%	%	NOUN
aiua-10838	109	28	ci	ci	NOUN
aiua-10838	109	29	0.38	0.38	NUM
aiua-10838	109	30	-	-	SYM
aiua-10838	109	31	0.65	0.65	NUM
aiua-10838	109	32	)	)	PUNCT
aiua-10838	109	33	.	.	PUNCT
aiua-10838	110	1	an	an	DET
aiua-10838	110	2	advantage	advantage	NOUN
aiua-10838	110	3	of	of	ADP
aiua-10838	110	4	5.8	5.8	NUM
aiua-10838	110	5	months	month	NOUN
aiua-10838	110	6	for	for	ADP
aiua-10838	110	7	the	the	DET
aiua-10838	110	8	immediate	immediate	ADJ
aiua-10838	110	9	cn	cn	PROPN
aiua-10838	110	10	group	group	PROPN
aiua-10838	110	11	was	be	AUX
aiua-10838	110	12	also	also	ADV
aiua-10838	110	13	found	find	VERB
aiua-10838	110	14	in	in	ADP
aiua-10838	110	15	propensity	propensity	NOUN
aiua-10838	110	16	score	score	NOUN
aiua-10838	110	17	matching	matching	NOUN
aiua-10838	110	18	.	.	PUNCT
aiua-10838	111	1	there	there	PRON
aiua-10838	111	2	was	be	VERB
aiua-10838	111	3	no	no	DET
aiua-10838	111	4	survival	survival	NOUN
aiua-10838	111	5	benefit	benefit	NOUN
aiua-10838	111	6	regarding	regard	VERB
aiua-10838	111	7	the	the	DET
aiua-10838	111	8	sequencing	sequencing	NOUN
aiua-10838	111	9	of	of	ADP
aiua-10838	111	10	cn	cn	PROPN
aiua-10838	111	11	and	and	CCONJ
aiua-10838	111	12	st	st	PROPN
aiua-10838	111	13	in	in	ADP
aiua-10838	111	14	three	three	NUM
aiua-10838	111	15	studies	study	NOUN
aiua-10838	111	16	(	(	PUNCT
aiua-10838	111	17	40	40	NUM
aiua-10838	111	18	,	,	PUNCT
aiua-10838	111	19	43	43	NUM
aiua-10838	111	20	,	,	PUNCT
aiua-10838	111	21	44	44	NUM
aiua-10838	111	22	)	)	PUNCT
aiua-10838	111	23	.	.	PUNCT
aiua-10838	112	1	unadjusted	unadjuste	VERB
aiua-10838	112	2	kaplan	kaplan	PROPN
aiua-10838	112	3	meier	meier	PROPN
aiua-10838	112	4	(	(	PUNCT
aiua-10838	112	5	km	km	PROPN
aiua-10838	112	6	)	)	PUNCT
aiua-10838	112	7	analyses	analysis	NOUN
aiua-10838	112	8	from	from	ADP
aiua-10838	112	9	both	both	DET
aiua-10838	112	10	wood	wood	NOUN
aiua-10838	112	11	et	et	PROPN
aiua-10838	112	12	al	al	PROPN
aiua-10838	112	13	.	.	PROPN
aiua-10838	112	14	and	and	CCONJ
aiua-10838	112	15	stroup	stroup	PROPN
aiua-10838	112	16	et	et	PROPN
aiua-10838	112	17	al	al	PROPN
aiua-10838	112	18	.	.	PROPN
aiua-10838	112	19	did	do	AUX
aiua-10838	112	20	not	not	PART
aiua-10838	112	21	reveal	reveal	VERB
aiua-10838	112	22	a	a	DET
aiua-10838	112	23	benefit	benefit	NOUN
aiua-10838	112	24	in	in	ADP
aiua-10838	112	25	survival	survival	NOUN
aiua-10838	112	26	in	in	ADP
aiua-10838	112	27	neither	neither	CCONJ
aiua-10838	112	28	the	the	DET
aiua-10838	112	29	upfront	upfront	NOUN
aiua-10838	112	30	nor	nor	CCONJ
aiua-10838	112	31	the	the	DET
aiua-10838	112	32	differed	differ	VERB
aiua-10838	112	33	cn	cn	PROPN
aiua-10838	112	34	group	group	PROPN
aiua-10838	112	35	(	(	PUNCT
aiua-10838	112	36	p	p	X
aiua-10838	112	37	=	=	NOUN
aiua-10838	112	38	0.697	0.697	NUM
aiua-10838	112	39	and	and	CCONJ
aiua-10838	112	40	p	p	X
aiua-10838	112	41	=	=	PROPN
aiua-10838	112	42	0.579	0.579	NUM
aiua-10838	112	43	respectively	respectively	ADV
aiua-10838	112	44	)	)	PUNCT
aiua-10838	112	45	.	.	PUNCT
aiua-10838	113	1	in	in	ADP
aiua-10838	113	2	the	the	DET
aiua-10838	113	3	only	only	ADJ
aiua-10838	113	4	prospective	prospective	ADJ
aiua-10838	113	5	rct	rct	PROPN
aiua-10838	113	6	from	from	ADP
aiua-10838	113	7	bex	bex	PROPN
aiua-10838	113	8	et	et	PROPN
aiua-10838	113	9	al	al	PROPN
aiua-10838	113	10	.	.	PROPN
aiua-10838	114	1	(	(	PUNCT
aiua-10838	114	2	7	7	X
aiua-10838	114	3	)	)	PUNCT
aiua-10838	114	4	median	median	NOUN
aiua-10838	114	5	os	os	NOUN
aiua-10838	114	6	in	in	ADP
aiua-10838	114	7	the	the	DET
aiua-10838	114	8	deferred	defer	VERB
aiua-10838	114	9	cn	cn	PROPN
aiua-10838	114	10	group	group	NOUN
aiua-10838	114	11	was	be	AUX
aiua-10838	114	12	greater	great	ADJ
aiua-10838	114	13	than	than	ADP
aiua-10838	114	14	in	in	ADP
aiua-10838	114	15	the	the	DET
aiua-10838	114	16	immediate	immediate	ADJ
aiua-10838	114	17	one	one	NOUN
aiua-10838	114	18	in	in	ADP
aiua-10838	114	19	the	the	DET
aiua-10838	114	20	intention	intention	NOUN
aiua-10838	114	21	to	to	PART
aiua-10838	114	22	treat	treat	VERB
aiua-10838	114	23	population	population	NOUN
aiua-10838	114	24	(	(	PUNCT
aiua-10838	114	25	32.4	32.4	NUM
aiua-10838	114	26	vs	vs	ADP
aiua-10838	114	27	15	15	NUM
aiua-10838	114	28	months	month	NOUN
aiua-10838	114	29	,	,	PUNCT
aiua-10838	114	30	hr	hr	NOUN
aiua-10838	114	31	0.57	0.57	NUM
aiua-10838	114	32	;	;	PUNCT
aiua-10838	114	33	95	95	NUM
aiua-10838	114	34	%	%	NOUN
aiua-10838	114	35	ci	ci	NOUN
aiua-10838	114	36	0.34	0.34	NUM
aiua-10838	114	37	-	-	SYM
aiua-10838	114	38	0.95	0.95	NUM
aiua-10838	114	39	,	,	PUNCT
aiua-10838	114	40	p	p	X
aiua-10838	114	41	=	=	NOUN
aiua-10838	114	42	0.032	0.032	NUM
aiua-10838	114	43	)	)	PUNCT
aiua-10838	114	44	but	but	CCONJ
aiua-10838	114	45	not	not	PART
aiua-10838	114	46	in	in	ADP
aiua-10838	114	47	the	the	DET
aiua-10838	114	48	per	per	ADP
aiua-10838	114	49	protocol	protocol	NOUN
aiua-10838	114	50	population	population	NOUN
aiua-10838	114	51	(	(	PUNCT
aiua-10838	114	52	hr	hr	NOUN
aiua-10838	114	53	0.71	0.71	NUM
aiua-10838	114	54	;	;	PUNCT
aiua-10838	114	55	95	95	NUM
aiua-10838	114	56	%	%	NOUN
aiua-10838	114	57	ci	ci	NOUN
aiua-10838	114	58	0.401.24	0.401.24	NUM
aiua-10838	114	59	,	,	PUNCT
aiua-10838	114	60	p	p	NOUN
aiua-10838	114	61	=	=	NOUN
aiua-10838	114	62	0.23	0.23	NUM
aiua-10838	114	63	)	)	PUNCT
aiua-10838	114	64	.	.	PUNCT
aiua-10838	115	1	similar	similar	ADJ
aiua-10838	115	2	results	result	NOUN
aiua-10838	115	3	with	with	ADP
aiua-10838	115	4	advantage	advantage	NOUN
aiua-10838	115	5	of	of	ADP
aiua-10838	115	6	deferred	deferred	ADJ
aiua-10838	115	7	cn	cn	PROPN
aiua-10838	115	8	were	be	AUX
aiua-10838	115	9	reported	report	VERB
aiua-10838	115	10	in	in	ADP
aiua-10838	115	11	four	four	NUM
aiua-10838	115	12	more	more	ADJ
aiua-10838	115	13	studies	study	NOUN
aiua-10838	115	14	(	(	PUNCT
aiua-10838	115	15	23	23	NUM
aiua-10838	115	16	,	,	PUNCT
aiua-10838	115	17	38	38	NUM
aiua-10838	115	18	,	,	PUNCT
aiua-10838	115	19	47	47	NUM
aiua-10838	115	20	,	,	PUNCT
aiua-10838	115	21	48	48	NUM
aiua-10838	115	22	)	)	PUNCT
aiua-10838	115	23	.	.	PUNCT
aiua-10838	116	1	interestingly	interestingly	ADV
aiua-10838	116	2	,	,	PUNCT
aiua-10838	116	3	bhindi	bhindi	PROPN
aiua-10838	116	4	et	et	PROPN
aiua-10838	116	5	al	al	PROPN
aiua-10838	116	6	.	.	PROPN
aiua-10838	117	1	(	(	PUNCT
aiua-10838	117	2	38	38	NUM
aiua-10838	117	3	,	,	PUNCT
aiua-10838	117	4	46	46	NUM
aiua-10838	117	5	)	)	PUNCT
aiua-10838	117	6	,	,	PUNCT
aiua-10838	117	7	in	in	ADP
aiua-10838	117	8	two	two	NUM
aiua-10838	117	9	studies	study	NOUN
aiua-10838	117	10	reported	report	VERB
aiua-10838	117	11	contradictory	contradictory	ADJ
aiua-10838	117	12	results	result	NOUN
aiua-10838	117	13	for	for	ADP
aiua-10838	117	14	the	the	DET
aiua-10838	117	15	role	role	NOUN
aiua-10838	117	16	of	of	ADP
aiua-10838	117	17	deferred	deferred	ADJ
aiua-10838	117	18	cn	cn	PROPN
aiua-10838	117	19	.	.	PUNCT
aiua-10838	118	1	when	when	SCONJ
aiua-10838	118	2	initial	initial	ADJ
aiua-10838	118	3	treatment	treatment	NOUN
aiua-10838	118	4	with	with	ADP
aiua-10838	118	5	cn	cn	PROPN
aiua-10838	118	6	,	,	PUNCT
aiua-10838	118	7	with	with	ADP
aiua-10838	118	8	or	or	CCONJ
aiua-10838	118	9	without	without	ADP
aiua-10838	118	10	subsequent	subsequent	ADJ
aiua-10838	118	11	targeted	target	VERB
aiua-10838	118	12	therapy	therapy	NOUN
aiua-10838	118	13	(	(	PUNCT
aiua-10838	118	14	tt	tt	PROPN
aiua-10838	118	15	)	)	PUNCT
aiua-10838	118	16	was	be	AUX
aiua-10838	118	17	compared	compare	VERB
aiua-10838	118	18	to	to	ADP
aiua-10838	118	19	initial	initial	ADJ
aiua-10838	118	20	treatment	treatment	NOUN
aiua-10838	118	21	with	with	ADP
aiua-10838	118	22	tt	tt	PROPN
aiua-10838	118	23	,	,	PUNCT
aiua-10838	118	24	with	with	ADP
aiua-10838	118	25	or	or	CCONJ
aiua-10838	118	26	without	without	ADP
aiua-10838	118	27	subsequent	subsequent	ADJ
aiua-10838	118	28	cn	cn	PROPN
aiua-10838	118	29	in	in	ADP
aiua-10838	118	30	a	a	DET
aiua-10838	118	31	sample	sample	NOUN
aiua-10838	118	32	population	population	NOUN
aiua-10838	118	33	pooled	pool	VERB
aiua-10838	118	34	from	from	ADP
aiua-10838	118	35	national	national	ADJ
aiua-10838	118	36	cancer	cancer	NOUN
aiua-10838	118	37	data	datum	NOUN
aiua-10838	118	38	base	base	NOUN
aiua-10838	118	39	(	(	PUNCT
aiua-10838	118	40	ncdb	ncdb	NOUN
aiua-10838	118	41	)	)	PUNCT
aiua-10838	118	42	(	(	PUNCT
aiua-10838	118	43	46	46	NUM
aiua-10838	118	44	)	)	PUNCT
aiua-10838	118	45	,	,	PUNCT
aiua-10838	118	46	authors	author	NOUN
aiua-10838	118	47	found	find	VERB
aiua-10838	118	48	an	an	DET
aiua-10838	118	49	os	os	NOUN
aiua-10838	118	50	benefit	benefit	NOUN
aiua-10838	118	51	for	for	ADP
aiua-10838	118	52	the	the	DET
aiua-10838	118	53	first	first	ADJ
aiua-10838	118	54	group	group	NOUN
aiua-10838	118	55	(	(	PUNCT
aiua-10838	118	56	hr	hr	NOUN
aiua-10838	118	57	0.61	0.61	NUM
aiua-10838	118	58	;	;	PUNCT
aiua-10838	118	59	95	95	NUM
aiua-10838	118	60	%	%	NOUN
aiua-10838	118	61	ci	ci	NOUN
aiua-10838	118	62	0.59	0.59	NUM
aiua-10838	118	63	-	-	SYM
aiua-10838	118	64	0.64	0.64	NUM
aiua-10838	118	65	,	,	PUNCT
aiua-10838	118	66	p	p	X
aiua-10838	118	67	<	<	X
aiua-10838	118	68	0.001	0.001	NUM
aiua-10838	118	69	)	)	PUNCT
aiua-10838	118	70	.	.	PUNCT
aiua-10838	119	1	however	however	ADV
aiua-10838	119	2	,	,	PUNCT
aiua-10838	119	3	in	in	ADP
aiua-10838	119	4	a	a	DET
aiua-10838	119	5	more	more	ADV
aiua-10838	119	6	recent	recent	ADJ
aiua-10838	119	7	study	study	NOUN
aiua-10838	119	8	(	(	PUNCT
aiua-10838	119	9	38	38	NUM
aiua-10838	119	10	)	)	PUNCT
aiua-10838	119	11	,	,	PUNCT
aiua-10838	119	12	a	a	DET
aiua-10838	119	13	retrospective	retrospective	ADJ
aiua-10838	119	14	cohort	cohort	NOUN
aiua-10838	119	15	with	with	ADP
aiua-10838	119	16	data	datum	NOUN
aiua-10838	119	17	from	from	ADP
aiua-10838	119	18	international	international	ADJ
aiua-10838	119	19	mrcc	mrcc	NOUN
aiua-10838	119	20	database	database	NOUN
aiua-10838	119	21	consortium	consortium	PROPN
aiua-10838	119	22	(	(	PUNCT
aiua-10838	119	23	imdc	imdc	PROPN
aiua-10838	119	24	)	)	PUNCT
aiua-10838	119	25	,	,	PUNCT
aiua-10838	119	26	comparison	comparison	NOUN
aiua-10838	119	27	of	of	ADP
aiua-10838	119	28	cn	cn	PROPN
aiua-10838	119	29	followed	follow	VERB
aiua-10838	119	30	by	by	ADP
aiua-10838	119	31	sunitinib	sunitinib	NOUN
aiua-10838	119	32	versus	versus	ADP
aiua-10838	119	33	sunitinib	sunitinib	NOUN
aiua-10838	119	34	followed	follow	VERB
aiua-10838	119	35	by	by	ADP
aiua-10838	119	36	cn	cn	PROPN
aiua-10838	119	37	,	,	PUNCT
aiua-10838	119	38	favored	favor	VERB
aiua-10838	119	39	the	the	DET
aiua-10838	119	40	latter	latter	ADJ
aiua-10838	119	41	(	(	PUNCT
aiua-10838	119	42	hr	hr	NOUN
aiua-10838	119	43	0.52	0.52	NUM
aiua-10838	119	44	;	;	PUNCT
aiua-10838	119	45	95	95	NUM
aiua-10838	119	46	%	%	NOUN
aiua-10838	119	47	ci	ci	NOUN
aiua-10838	119	48	0.39	0.39	NUM
aiua-10838	119	49	-	-	SYM
aiua-10838	119	50	0.70	0.70	NUM
aiua-10838	119	51	,	,	PUNCT
aiua-10838	119	52	p	p	X
aiua-10838	119	53	<	<	X
aiua-10838	119	54	0.001	0.001	NUM
aiua-10838	119	55	)	)	PUNCT
aiua-10838	119	56	.	.	PUNCT
aiua-10838	120	1	another	another	DET
aiua-10838	120	2	study	study	NOUN
aiua-10838	120	3	of	of	ADP
aiua-10838	120	4	notable	notable	ADJ
aiua-10838	120	5	mention	mention	NOUN
aiua-10838	120	6	comes	come	VERB
aiua-10838	120	7	from	from	ADP
aiua-10838	120	8	dragomir	dragomir	VERB
aiua-10838	120	9	et	et	PROPN
aiua-10838	120	10	al	al	PROPN
aiua-10838	120	11	.	.	PROPN
aiua-10838	121	1	(	(	PUNCT
aiua-10838	121	2	40	40	NUM
aiua-10838	121	3	)	)	PUNCT
aiua-10838	121	4	,	,	PUNCT
aiua-10838	121	5	as	as	SCONJ
aiua-10838	121	6	it	it	PRON
aiua-10838	121	7	is	be	AUX
aiua-10838	121	8	the	the	DET
aiua-10838	121	9	only	only	ADJ
aiua-10838	121	10	one	one	NUM
aiua-10838	121	11	that	that	PRON
aiua-10838	121	12	included	include	VERB
aiua-10838	121	13	in	in	ADP
aiua-10838	121	14	the	the	DET
aiua-10838	121	15	st	st	PROPN
aiua-10838	121	16	arm	arm	NOUN
aiua-10838	121	17	patients	patient	NOUN
aiua-10838	121	18	who	who	PRON
aiua-10838	121	19	were	be	AUX
aiua-10838	121	20	also	also	ADV
aiua-10838	121	21	treated	treat	VERB
aiua-10838	121	22	with	with	ADP
aiua-10838	121	23	ici	ici	PROPN
aiua-10838	121	24	.	.	PUNCT
aiua-10838	122	1	this	this	DET
aiua-10838	122	2	study	study	NOUN
aiua-10838	122	3	also	also	ADV
aiua-10838	122	4	favors	favor	VERB
aiua-10838	122	5	deferred	defer	VERB
aiua-10838	122	6	than	than	ADP
aiua-10838	122	7	initial	initial	ADJ
aiua-10838	122	8	cn	cn	PROPN
aiua-10838	122	9	(	(	PUNCT
aiua-10838	122	10	hr	hr	NOUN
aiua-10838	122	11	0.66	0.66	NUM
aiua-10838	122	12	;	;	PUNCT
aiua-10838	122	13	95	95	NUM
aiua-10838	122	14	%	%	NOUN
aiua-10838	122	15	ci	ci	NOUN
aiua-10838	122	16	0.42	0.42	NUM
aiua-10838	122	17	-	-	PUNCT
aiua-10838	122	18	1.04	1.04	NUM
aiua-10838	122	19	)	)	PUNCT
aiua-10838	122	20	.	.	PUNCT
aiua-10838	123	1	prognostic	prognostic	ADJ
aiua-10838	123	2	factors	factor	NOUN
aiua-10838	123	3	for	for	ADP
aiua-10838	123	4	os	os	NOUN
aiua-10838	123	5	with	with	ADP
aiua-10838	123	6	cn	cn	PROPN
aiua-10838	123	7	twenty	twenty	NUM
aiua-10838	123	8	-	-	PUNCT
aiua-10838	123	9	four	four	NUM
aiua-10838	123	10	studies	study	NOUN
aiua-10838	123	11	were	be	AUX
aiua-10838	123	12	included	include	VERB
aiua-10838	123	13	in	in	ADP
aiua-10838	123	14	the	the	DET
aiua-10838	123	15	analysis	analysis	NOUN
aiua-10838	123	16	of	of	ADP
aiua-10838	123	17	possible	possible	ADJ
aiua-10838	123	18	prognostic	prognostic	ADJ
aiua-10838	123	19	factors	factor	NOUN
aiua-10838	123	20	for	for	ADP
aiua-10838	123	21	os	os	NOUN
aiua-10838	123	22	with	with	ADP
aiua-10838	123	23	cn	cn	PROPN
aiua-10838	123	24	.	.	PUNCT
aiua-10838	124	1	in	in	ADP
aiua-10838	124	2	figure	figure	NOUN
aiua-10838	124	3	2	2	NUM
aiua-10838	124	4	independent	independent	ADJ
aiua-10838	124	5	prognostic	prognostic	ADJ
aiua-10838	124	6	factors	factor	NOUN
aiua-10838	124	7	are	be	AUX
aiua-10838	124	8	demonstrated	demonstrate	VERB
aiua-10838	124	9	with	with	ADP
aiua-10838	124	10	green	green	ADJ
aiua-10838	124	11	color	color	NOUN
aiua-10838	124	12	,	,	PUNCT
aiua-10838	124	13	those	those	PRON
aiua-10838	124	14	found	find	VERB
aiua-10838	124	15	not	not	PART
aiua-10838	124	16	to	to	PART
aiua-10838	124	17	be	be	AUX
aiua-10838	124	18	independent	independent	ADJ
aiua-10838	124	19	prognostic	prognostic	ADJ
aiua-10838	124	20	factors	factor	NOUN
aiua-10838	124	21	are	be	AUX
aiua-10838	124	22	demonstrated	demonstrate	VERB
aiua-10838	124	23	with	with	ADP
aiua-10838	124	24	red	red	ADJ
aiua-10838	124	25	,	,	PUNCT
aiua-10838	124	26	while	while	SCONJ
aiua-10838	124	27	those	those	PRON
aiua-10838	124	28	not	not	PART
aiua-10838	124	29	assessed	assess	VERB
aiua-10838	124	30	are	be	AUX
aiua-10838	124	31	the	the	DET
aiua-10838	124	32	ones	one	NOUN
aiua-10838	124	33	in	in	ADP
aiua-10838	124	34	the	the	DET
aiua-10838	124	35	white	white	ADJ
aiua-10838	124	36	cells	cell	NOUN
aiua-10838	124	37	.	.	PUNCT
aiua-10838	125	1	most	most	ADJ
aiua-10838	125	2	common	common	ADJ
aiua-10838	125	3	prognostic	prognostic	ADJ
aiua-10838	125	4	factors	factor	NOUN
aiua-10838	125	5	found	find	VERB
aiua-10838	125	6	in	in	ADP
aiua-10838	125	7	the	the	DET
aiua-10838	125	8	analysis	analysis	NOUN
aiua-10838	125	9	were	be	AUX
aiua-10838	125	10	age	age	NOUN
aiua-10838	125	11	(	(	PUNCT
aiua-10838	125	12	in	in	ADP
aiua-10838	125	13	8	8	NUM
aiua-10838	125	14	studies	study	NOUN
aiua-10838	125	15	)	)	PUNCT
aiua-10838	125	16	(	(	PUNCT
aiua-10838	125	17	15	15	NUM
aiua-10838	125	18	,	,	PUNCT
aiua-10838	125	19	18	18	NUM
aiua-10838	125	20	,	,	PUNCT
aiua-10838	125	21	23	23	NUM
aiua-10838	125	22	,	,	PUNCT
aiua-10838	125	23	27	27	NUM
aiua-10838	125	24	,	,	PUNCT
aiua-10838	125	25	30	30	NUM
aiua-10838	125	26	,	,	PUNCT
aiua-10838	125	27	39	39	NUM
aiua-10838	125	28	,	,	PUNCT
aiua-10838	125	29	52	52	NUM
aiua-10838	125	30	,	,	PUNCT
aiua-10838	125	31	53	53	NUM
aiua-10838	125	32	,	,	PUNCT
aiua-10838	125	33	57	57	NUM
aiua-10838	125	34	)	)	PUNCT
aiua-10838	125	35	,	,	PUNCT
aiua-10838	125	36	tumor	tumor	NOUN
aiua-10838	125	37	histology	histology	NOUN
aiua-10838	125	38	(	(	PUNCT
aiua-10838	125	39	in	in	ADP
aiua-10838	125	40	7	7	NUM
aiua-10838	125	41	studies	study	NOUN
aiua-10838	125	42	)	)	PUNCT
aiua-10838	125	43	(	(	PUNCT
aiua-10838	125	44	15	15	NUM
aiua-10838	125	45	,	,	PUNCT
aiua-10838	125	46	18	18	NUM
aiua-10838	125	47	,	,	PUNCT
aiua-10838	125	48	26	26	NUM
aiua-10838	125	49	,	,	PUNCT
aiua-10838	125	50	27	27	NUM
aiua-10838	125	51	,	,	PUNCT
aiua-10838	125	52	32	32	NUM
aiua-10838	125	53	,	,	PUNCT
aiua-10838	125	54	51	51	NUM
aiua-10838	125	55	-	-	SYM
aiua-10838	125	56	53	53	NUM
aiua-10838	125	57	)	)	PUNCT
aiua-10838	125	58	,	,	PUNCT
aiua-10838	125	59	number	number	NOUN
aiua-10838	125	60	of	of	ADP
aiua-10838	125	61	metastasis	metastasis	NOUN
aiua-10838	125	62	(	(	PUNCT
aiua-10838	125	63	in	in	ADP
aiua-10838	125	64	6	6	NUM
aiua-10838	125	65	studies	study	NOUN
aiua-10838	125	66	)	)	PUNCT
aiua-10838	125	67	(	(	PUNCT
aiua-10838	125	68	18	18	NUM
aiua-10838	125	69	,	,	PUNCT
aiua-10838	125	70	30	30	NUM
aiua-10838	125	71	,	,	PUNCT
aiua-10838	125	72	45	45	NUM
aiua-10838	125	73	,	,	PUNCT
aiua-10838	125	74	51	51	NUM
aiua-10838	125	75	,	,	PUNCT
aiua-10838	125	76	55	55	NUM
aiua-10838	125	77	,	,	PUNCT
aiua-10838	125	78	60	60	NUM
aiua-10838	125	79	)	)	PUNCT
aiua-10838	125	80	,	,	PUNCT
aiua-10838	125	81	and	and	CCONJ
aiua-10838	125	82	t	t	PROPN
aiua-10838	125	83	stage	stage	NOUN
aiua-10838	125	84	(	(	PUNCT
aiua-10838	125	85	in	in	ADP
aiua-10838	125	86	6	6	NUM
aiua-10838	125	87	studies	study	NOUN
aiua-10838	125	88	)	)	PUNCT
aiua-10838	125	89	(	(	PUNCT
aiua-10838	125	90	18	18	NUM
aiua-10838	125	91	,	,	PUNCT
aiua-10838	125	92	31	31	NUM
aiua-10838	125	93	,	,	PUNCT
aiua-10838	125	94	51	51	NUM
aiua-10838	125	95	-	-	SYM
aiua-10838	125	96	53	53	NUM
aiua-10838	125	97	,	,	PUNCT
aiua-10838	125	98	57	57	NUM
aiua-10838	125	99	,	,	PUNCT
aiua-10838	125	100	58	58	NUM
aiua-10838	125	101	)	)	PUNCT
aiua-10838	125	102	.	.	PUNCT
aiua-10838	126	1	other	other	ADJ
aiua-10838	126	2	factors	factor	NOUN
aiua-10838	126	3	were	be	AUX
aiua-10838	126	4	,	,	PUNCT
aiua-10838	126	5	sarcomatoid	sarcomatoid	NOUN
aiua-10838	126	6	histology	histology	NOUN
aiua-10838	126	7	,	,	PUNCT
aiua-10838	126	8	imdc	imdc	NOUN
aiua-10838	126	9	or	or	CCONJ
aiua-10838	126	10	mskcc	mskcc	NOUN
aiua-10838	126	11	classification	classification	NOUN
aiua-10838	126	12	,	,	PUNCT
aiua-10838	126	13	systemic	systemic	ADJ
aiua-10838	126	14	symptoms	symptom	NOUN
aiua-10838	126	15	,	,	PUNCT
aiua-10838	126	16	lymphadenopathy	lymphadenopathy	ADJ
aiua-10838	126	17	,	,	PUNCT
aiua-10838	126	18	hemoglobin	hemoglobin	NOUN
aiua-10838	126	19	and	and	CCONJ
aiua-10838	126	20	albumin	albumin	ADJ
aiua-10838	126	21	level	level	NOUN
aiua-10838	126	22	,	,	PUNCT
aiua-10838	126	23	levels	level	NOUN
aiua-10838	126	24	of	of	ADP
aiua-10838	126	25	serum	serum	NOUN
aiua-10838	126	26	calcium	calcium	NOUN
aiua-10838	126	27	or	or	CCONJ
aiua-10838	126	28	creatinine	creatinine	NOUN
aiua-10838	126	29	or	or	CCONJ
aiua-10838	126	30	platelets	platelet	NOUN
aiua-10838	126	31	,	,	PUNCT
aiua-10838	126	32	c	c	NOUN
aiua-10838	126	33	-	-	PUNCT
aiua-10838	126	34	reactive	reactive	ADJ
aiua-10838	126	35	protein	protein	NOUN
aiua-10838	126	36	(	(	PUNCT
aiua-10838	126	37	crp	crp	NOUN
aiua-10838	126	38	)	)	PUNCT
aiua-10838	126	39	level	level	NOUN
aiua-10838	126	40	,	,	PUNCT
aiua-10838	126	41	absolute	absolute	ADJ
aiua-10838	126	42	neutrophil	neutrophil	ADJ
aiua-10838	126	43	count	count	NOUN
aiua-10838	126	44	and	and	CCONJ
aiua-10838	126	45	neutrophillymphocyte	neutrophillymphocyte	ADJ
aiua-10838	126	46	ratio	ratio	NOUN
aiua-10838	126	47	,	,	PUNCT
aiua-10838	126	48	bone	bone	NOUN
aiua-10838	126	49	metastasis	metastasis	NOUN
aiua-10838	126	50	,	,	PUNCT
aiua-10838	126	51	lymph	lymph	NOUN
aiua-10838	126	52	node	node	NOUN
aiua-10838	126	53	metastasis	metastasis	NOUN
aiua-10838	126	54	,	,	PUNCT
aiua-10838	126	55	visceral	visceral	ADJ
aiua-10838	126	56	metastasis	metastasis	NOUN
aiua-10838	126	57	or	or	CCONJ
aiua-10838	126	58	liver	liver	NOUN
aiua-10838	126	59	metastasis	metastasis	NOUN
aiua-10838	126	60	,	,	PUNCT
aiua-10838	126	61	tumor	tumor	NOUN
aiua-10838	126	62	grade	grade	NOUN
aiua-10838	126	63	,	,	PUNCT
aiua-10838	126	64	sex	sex	NOUN
aiua-10838	126	65	,	,	PUNCT
aiua-10838	126	66	body	body	NOUN
aiua-10838	126	67	mass	mass	NOUN
aiua-10838	126	68	index	index	NOUN
aiua-10838	126	69	(	(	PUNCT
aiua-10838	126	70	bmi	bmi	PROPN
aiua-10838	126	71	)	)	PUNCT
aiua-10838	126	72	,	,	PUNCT
aiua-10838	126	73	marital	marital	ADJ
aiua-10838	126	74	status	status	NOUN
aiua-10838	126	75	,	,	PUNCT
aiua-10838	126	76	race	race	NOUN
aiua-10838	126	77	,	,	PUNCT
aiua-10838	126	78	level	level	NOUN
aiua-10838	126	79	of	of	ADP
aiua-10838	126	80	thrombus	thrombus	NOUN
aiua-10838	126	81	,	,	PUNCT
aiua-10838	126	82	if	if	SCONJ
aiua-10838	126	83	existing	exist	VERB
aiua-10838	126	84	,	,	PUNCT
aiua-10838	126	85	and	and	CCONJ
aiua-10838	126	86	other	other	ADJ
aiua-10838	126	87	comorbidities	comorbiditie	NOUN
aiua-10838	126	88	.	.	PUNCT
aiua-10838	127	1	from	from	ADP
aiua-10838	127	2	the	the	DET
aiua-10838	127	3	factors	factor	NOUN
aiua-10838	127	4	mentioned	mention	VERB
aiua-10838	127	5	above	above	ADV
aiua-10838	127	6	,	,	PUNCT
aiua-10838	127	7	those	those	PRON
aiua-10838	127	8	associated	associate	VERB
aiua-10838	127	9	with	with	ADP
aiua-10838	127	10	poor	poor	ADJ
aiua-10838	127	11	overall	overall	ADJ
aiua-10838	127	12	survival	survival	NOUN
aiua-10838	127	13	after	after	SCONJ
aiua-10838	127	14	cn	cn	PROPN
aiua-10838	127	15	are	be	AUX
aiua-10838	127	16	high	high	ADJ
aiua-10838	127	17	t	t	NOUN
aiua-10838	127	18	stage	stage	NOUN
aiua-10838	127	19	and	and	CCONJ
aiua-10838	127	20	number	number	NOUN
aiua-10838	127	21	of	of	ADP
aiua-10838	127	22	metastasis	metastasis	NOUN
aiua-10838	127	23	,	,	PUNCT
aiua-10838	127	24	sarcomatoid	sarcomatoid	ADJ
aiua-10838	127	25	histology	histology	NOUN
aiua-10838	127	26	,	,	PUNCT
aiua-10838	127	27	bone	bone	NOUN
aiua-10838	127	28	metastasis	metastasis	NOUN
aiua-10838	127	29	,	,	PUNCT
aiua-10838	127	30	lymph	lymph	NOUN
aiua-10838	127	31	node	node	NOUN
aiua-10838	127	32	metastasis	metastasis	NOUN
aiua-10838	127	33	,	,	PUNCT
aiua-10838	127	34	visceral	visceral	ADJ
aiua-10838	127	35	metastasis	metastasis	NOUN
aiua-10838	127	36	or	or	CCONJ
aiua-10838	127	37	liver	liver	NOUN
aiua-10838	127	38	metastasis	metastasis	NOUN
aiua-10838	127	39	,	,	PUNCT
aiua-10838	127	40	thrombus	thrombus	ADJ
aiua-10838	127	41	level	level	NOUN
aiua-10838	127	42	above	above	ADP
aiua-10838	127	43	the	the	DET
aiua-10838	127	44	diaphragm	diaphragm	NOUN
aiua-10838	127	45	,	,	PUNCT
aiua-10838	127	46	existing	exist	VERB
aiua-10838	127	47	comorbidities	comorbiditie	NOUN
aiua-10838	127	48	,	,	PUNCT
aiua-10838	127	49	presence	presence	NOUN
aiua-10838	127	50	of	of	ADP
aiua-10838	127	51	systemic	systemic	ADJ
aiua-10838	127	52	symptoms	symptom	NOUN
aiua-10838	127	53	,	,	PUNCT
aiua-10838	127	54	poor	poor	ADJ
aiua-10838	127	55	imdc	imdc	NOUN
aiua-10838	127	56	or	or	CCONJ
aiua-10838	127	57	mskcc	mskcc	NOUN
aiua-10838	127	58	classification	classification	NOUN
aiua-10838	127	59	,	,	PUNCT
aiua-10838	127	60	unmarried	unmarried	ADJ
aiua-10838	127	61	status	status	NOUN
aiua-10838	127	62	,	,	PUNCT
aiua-10838	127	63	poor	poor	ADJ
aiua-10838	127	64	figure	figure	NOUN
aiua-10838	127	65	2	2	NUM
aiua-10838	127	66	.	.	PUNCT
aiua-10838	127	67	prognostic	prognostic	ADJ
aiua-10838	127	68	factors	factor	NOUN
aiua-10838	127	69	.	.	PUNCT
aiua-10838	128	1	483archivio	483archivio	PROPN
aiua-10838	128	2	italiano	italiano	NOUN
aiua-10838	128	3	di	di	X
aiua-10838	128	4	urologia	urologia	PROPN
aiua-10838	128	5	e	e	PROPN
aiua-10838	128	6	andrologia	andrologia	PROPN
aiua-10838	128	7	2022	2022	NUM
aiua-10838	128	8	;	;	PUNCT
aiua-10838	128	9	94	94	NUM
aiua-10838	128	10	,	,	PUNCT
aiua-10838	128	11	4	4	NUM
aiua-10838	128	12	nephrectomy	nephrectomy	NOUN
aiua-10838	128	13	for	for	ADP
aiua-10838	128	14	metastatic	metastatic	ADJ
aiua-10838	128	15	renal	renal	ADJ
aiua-10838	128	16	cell	cell	NOUN
aiua-10838	128	17	carcinoma	carcinoma	NOUN
aiua-10838	128	18	performance	performance	NOUN
aiua-10838	128	19	status	status	NOUN
aiua-10838	128	20	,	,	PUNCT
aiua-10838	128	21	hemoglobin	hemoglobin	NOUN
aiua-10838	128	22	level	level	NOUN
aiua-10838	128	23	less	less	ADJ
aiua-10838	128	24	than	than	ADP
aiua-10838	128	25	the	the	DET
aiua-10838	128	26	lower	low	ADJ
aiua-10838	128	27	limit	limit	NOUN
aiua-10838	128	28	of	of	ADP
aiua-10838	128	29	normal	normal	ADJ
aiua-10838	128	30	,	,	PUNCT
aiua-10838	128	31	ldh	ldh	ADJ
aiua-10838	128	32	level	level	NOUN
aiua-10838	128	33	above	above	ADP
aiua-10838	128	34	the	the	DET
aiua-10838	128	35	upper	upper	ADJ
aiua-10838	128	36	limit	limit	NOUN
aiua-10838	128	37	of	of	ADP
aiua-10838	128	38	normal	normal	ADJ
aiua-10838	128	39	and	and	CCONJ
aiua-10838	128	40	a	a	DET
aiua-10838	128	41	neutrophile	neutrophile	ADJ
aiua-10838	128	42	/	/	PUNCT
aiua-10838	128	43	lymphocyte	lymphocyte	NOUN
aiua-10838	128	44	ratio	ratio	NOUN
aiua-10838	128	45	≥	≥	NOUN
aiua-10838	128	46	4	4	NUM
aiua-10838	128	47	.	.	PUNCT
aiua-10838	128	48	female	female	ADJ
aiua-10838	128	49	gender	gender	NOUN
aiua-10838	128	50	,	,	PUNCT
aiua-10838	128	51	thrombocytosis	thrombocytosis	NOUN
aiua-10838	128	52	,	,	PUNCT
aiua-10838	128	53	crp	crp	NOUN
aiua-10838	128	54	level	level	NOUN
aiua-10838	128	55	≥	≥	PROPN
aiua-10838	128	56	1	1	NUM
aiua-10838	128	57	ng	ng	PROPN
aiua-10838	128	58	/	/	SYM
aiua-10838	128	59	ml	ml	PROPN
aiua-10838	128	60	,	,	PUNCT
aiua-10838	128	61	good	good	ADJ
aiua-10838	128	62	performance	performance	NOUN
aiua-10838	128	63	status	status	NOUN
aiua-10838	128	64	,	,	PUNCT
aiua-10838	128	65	and	and	CCONJ
aiua-10838	128	66	good	good	ADJ
aiua-10838	128	67	/	/	SYM
aiua-10838	128	68	intermediate	intermediate	ADJ
aiua-10838	128	69	imdc	imdc	NOUN
aiua-10838	128	70	or	or	CCONJ
aiua-10838	128	71	mskcc	mskcc	NOUN
aiua-10838	128	72	classification	classification	NOUN
aiua-10838	128	73	were	be	AUX
aiua-10838	128	74	considered	consider	VERB
aiua-10838	128	75	having	have	VERB
aiua-10838	128	76	an	an	DET
aiua-10838	128	77	os	os	NOUN
aiua-10838	128	78	benefit	benefit	NOUN
aiua-10838	128	79	.	.	PUNCT
aiua-10838	129	1	discussion	discussion	NOUN
aiua-10838	129	2	treatment	treatment	NOUN
aiua-10838	129	3	of	of	ADP
aiua-10838	129	4	synchronous	synchronous	ADJ
aiua-10838	129	5	mrcc	mrcc	NOUN
aiua-10838	129	6	has	have	AUX
aiua-10838	129	7	faced	face	VERB
aiua-10838	129	8	many	many	ADJ
aiua-10838	129	9	changes	change	NOUN
aiua-10838	129	10	in	in	ADP
aiua-10838	129	11	recent	recent	ADJ
aiua-10838	129	12	years	year	NOUN
aiua-10838	129	13	,	,	PUNCT
aiua-10838	129	14	due	due	ADP
aiua-10838	129	15	to	to	ADP
aiua-10838	129	16	the	the	DET
aiua-10838	129	17	ongoing	ongoing	ADJ
aiua-10838	129	18	development	development	NOUN
aiua-10838	129	19	of	of	ADP
aiua-10838	129	20	new	new	ADJ
aiua-10838	129	21	drugs	drug	NOUN
aiua-10838	129	22	,	,	PUNCT
aiua-10838	129	23	making	make	VERB
aiua-10838	129	24	the	the	DET
aiua-10838	129	25	therapeutic	therapeutic	ADJ
aiua-10838	129	26	choice	choice	NOUN
aiua-10838	129	27	a	a	DET
aiua-10838	129	28	complex	complex	ADJ
aiua-10838	129	29	task	task	NOUN
aiua-10838	129	30	.	.	PUNCT
aiua-10838	130	1	the	the	DET
aiua-10838	130	2	two	two	NUM
aiua-10838	130	3	well	well	ADV
aiua-10838	130	4	-	-	PUNCT
aiua-10838	130	5	known	know	VERB
aiua-10838	130	6	rcts	rct	NOUN
aiua-10838	130	7	that	that	PRON
aiua-10838	130	8	were	be	AUX
aiua-10838	130	9	published	publish	VERB
aiua-10838	130	10	regarding	regard	VERB
aiua-10838	130	11	the	the	DET
aiua-10838	130	12	role	role	NOUN
aiua-10838	130	13	of	of	ADP
aiua-10838	130	14	cn	cn	PROPN
aiua-10838	130	15	in	in	ADP
aiua-10838	130	16	mrcc	mrcc	NOUN
aiua-10838	130	17	patients	patient	NOUN
aiua-10838	130	18	,	,	PUNCT
aiua-10838	130	19	carmena	carmena	NOUN
aiua-10838	130	20	and	and	CCONJ
aiua-10838	130	21	surtime	surtime	NOUN
aiua-10838	130	22	,	,	PUNCT
aiua-10838	130	23	changed	change	VERB
aiua-10838	130	24	what	what	PRON
aiua-10838	130	25	we	we	PRON
aiua-10838	130	26	thought	think	VERB
aiua-10838	130	27	to	to	PART
aiua-10838	130	28	be	be	AUX
aiua-10838	130	29	the	the	DET
aiua-10838	130	30	standard	standard	NOUN
aiua-10838	130	31	of	of	ADP
aiua-10838	130	32	care	care	NOUN
aiua-10838	130	33	.	.	PUNCT
aiua-10838	131	1	the	the	DET
aiua-10838	131	2	role	role	NOUN
aiua-10838	131	3	of	of	ADP
aiua-10838	131	4	cn	cn	PROPN
aiua-10838	131	5	was	be	AUX
aiua-10838	131	6	deeply	deeply	ADV
aiua-10838	131	7	questioned	question	VERB
aiua-10838	131	8	,	,	PUNCT
aiua-10838	131	9	and	and	CCONJ
aiua-10838	131	10	systemic	systemic	ADJ
aiua-10838	131	11	therapies	therapy	NOUN
aiua-10838	131	12	were	be	AUX
aiua-10838	131	13	found	find	VERB
aiua-10838	131	14	to	to	PART
aiua-10838	131	15	be	be	AUX
aiua-10838	131	16	more	more	ADV
aiua-10838	131	17	effective	effective	ADJ
aiua-10838	131	18	.	.	PUNCT
aiua-10838	132	1	results	result	NOUN
aiua-10838	132	2	from	from	ADP
aiua-10838	132	3	surtime	surtime	NOUN
aiua-10838	132	4	and	and	CCONJ
aiua-10838	132	5	carmena	carmena	PROPN
aiua-10838	132	6	(	(	PUNCT
aiua-10838	132	7	6	6	NUM
aiua-10838	132	8	,	,	PUNCT
aiua-10838	132	9	7	7	NUM
aiua-10838	132	10	)	)	PUNCT
aiua-10838	132	11	demonstrated	demonstrate	VERB
aiua-10838	132	12	an	an	DET
aiua-10838	132	13	absence	absence	NOUN
aiua-10838	132	14	of	of	ADP
aiua-10838	132	15	benefit	benefit	NOUN
aiua-10838	132	16	in	in	ADP
aiua-10838	132	17	immediate	immediate	ADJ
aiua-10838	132	18	cn	cn	PROPN
aiua-10838	132	19	,	,	PUNCT
aiua-10838	132	20	while	while	SCONJ
aiua-10838	132	21	deferred	defer	VERB
aiua-10838	132	22	cn	cn	PROPN
aiua-10838	132	23	showed	show	VERB
aiua-10838	132	24	an	an	DET
aiua-10838	132	25	os	os	ADJ
aiua-10838	132	26	benefit	benefit	NOUN
aiua-10838	132	27	in	in	ADP
aiua-10838	132	28	intermediate	intermediate	ADJ
aiua-10838	132	29	risk	risk	NOUN
aiua-10838	132	30	patients	patient	NOUN
aiua-10838	132	31	.	.	PUNCT
aiua-10838	133	1	however	however	ADV
aiua-10838	133	2	,	,	PUNCT
aiua-10838	133	3	their	their	PRON
aiua-10838	133	4	results	result	NOUN
aiua-10838	133	5	should	should	AUX
aiua-10838	133	6	be	be	AUX
aiua-10838	133	7	interpreted	interpret	VERB
aiua-10838	133	8	with	with	ADP
aiua-10838	133	9	caution	caution	NOUN
aiua-10838	133	10	as	as	ADP
aiua-10838	133	11	both	both	DET
aiua-10838	133	12	carmena	carmena	NOUN
aiua-10838	133	13	and	and	CCONJ
aiua-10838	133	14	surtime	surtime	NOUN
aiua-10838	133	15	,	,	PUNCT
aiua-10838	133	16	are	be	AUX
aiua-10838	133	17	found	find	VERB
aiua-10838	133	18	to	to	PART
aiua-10838	133	19	have	have	VERB
aiua-10838	133	20	certain	certain	ADJ
aiua-10838	133	21	pitfalls	pitfall	NOUN
aiua-10838	133	22	.	.	PUNCT
aiua-10838	134	1	for	for	ADP
aiua-10838	134	2	instance	instance	NOUN
aiua-10838	134	3	,	,	PUNCT
aiua-10838	134	4	in	in	ADP
aiua-10838	134	5	carmena	carmena	NOUN
aiua-10838	134	6	there	there	PRON
aiua-10838	134	7	was	be	VERB
aiua-10838	134	8	a	a	DET
aiua-10838	134	9	significant	significant	ADJ
aiua-10838	134	10	crossover	crossover	NOUN
aiua-10838	134	11	with	with	ADP
aiua-10838	134	12	17	17	NUM
aiua-10838	134	13	%	%	NOUN
aiua-10838	134	14	of	of	ADP
aiua-10838	134	15	patients	patient	NOUN
aiua-10838	134	16	in	in	ADP
aiua-10838	134	17	the	the	DET
aiua-10838	134	18	sunitinib	sunitinib	NOUN
aiua-10838	134	19	alone	alone	ADV
aiua-10838	134	20	arm	arm	VERB
aiua-10838	134	21	undergoing	undergo	VERB
aiua-10838	134	22	subsequent	subsequent	ADJ
aiua-10838	134	23	cn	cn	PROPN
aiua-10838	134	24	,	,	PUNCT
aiua-10838	134	25	and	and	CCONJ
aiua-10838	134	26	7	7	NUM
aiua-10838	134	27	%	%	NOUN
aiua-10838	134	28	of	of	ADP
aiua-10838	134	29	patients	patient	NOUN
aiua-10838	134	30	in	in	ADP
aiua-10838	134	31	the	the	DET
aiua-10838	134	32	cn	cn	PROPN
aiua-10838	134	33	plus	plus	CCONJ
aiua-10838	134	34	sunitinib	sunitinib	NOUN
aiua-10838	134	35	arm	arm	VERB
aiua-10838	134	36	not	not	PART
aiua-10838	134	37	receiving	receive	VERB
aiua-10838	134	38	surgery	surgery	NOUN
aiua-10838	134	39	.	.	PUNCT
aiua-10838	135	1	surtime	surtime	NOUN
aiua-10838	135	2	on	on	ADP
aiua-10838	135	3	the	the	DET
aiua-10838	135	4	other	other	ADJ
aiua-10838	135	5	hand	hand	NOUN
aiua-10838	135	6	,	,	PUNCT
aiua-10838	135	7	suffered	suffer	VERB
aiua-10838	135	8	from	from	ADP
aiua-10838	135	9	poor	poor	ADJ
aiua-10838	135	10	accrual	accrual	ADJ
aiua-10838	135	11	,	,	PUNCT
aiua-10838	135	12	changing	change	VERB
aiua-10838	135	13	the	the	DET
aiua-10838	135	14	primary	primary	ADJ
aiua-10838	135	15	endpoint	endpoint	NOUN
aiua-10838	135	16	from	from	ADP
aiua-10838	135	17	progression	progression	NOUN
aiua-10838	135	18	free	free	ADJ
aiua-10838	135	19	survival	survival	NOUN
aiua-10838	135	20	(	(	PUNCT
aiua-10838	135	21	pfs	pfs	PROPN
aiua-10838	135	22	)	)	PUNCT
aiua-10838	135	23	to	to	PART
aiua-10838	135	24	progression	progression	VERB
aiua-10838	135	25	free	free	ADJ
aiua-10838	135	26	rate	rate	NOUN
aiua-10838	135	27	(	(	PUNCT
aiua-10838	135	28	pfr	pfr	NOUN
aiua-10838	135	29	)	)	PUNCT
aiua-10838	135	30	.	.	PUNCT
aiua-10838	136	1	a	a	DET
aiua-10838	136	2	discordance	discordance	NOUN
aiua-10838	136	3	was	be	AUX
aiua-10838	136	4	also	also	ADV
aiua-10838	136	5	found	find	VERB
aiua-10838	136	6	,	,	PUNCT
aiua-10838	136	7	between	between	ADP
aiua-10838	136	8	the	the	DET
aiua-10838	136	9	intention	intention	NOUN
aiua-10838	136	10	to	to	PART
aiua-10838	136	11	treat	treat	VERB
aiua-10838	136	12	and	and	CCONJ
aiua-10838	136	13	per	per	ADP
aiua-10838	136	14	protocol	protocol	NOUN
aiua-10838	136	15	population	population	NOUN
aiua-10838	136	16	,	,	PUNCT
aiua-10838	136	17	os	os	NOUN
aiua-10838	136	18	outcome	outcome	NOUN
aiua-10838	136	19	.	.	PUNCT
aiua-10838	137	1	for	for	ADP
aiua-10838	137	2	that	that	DET
aiua-10838	137	3	reason	reason	NOUN
aiua-10838	137	4	,	,	PUNCT
aiua-10838	137	5	the	the	DET
aiua-10838	137	6	selection	selection	NOUN
aiua-10838	137	7	of	of	ADP
aiua-10838	137	8	patients	patient	NOUN
aiua-10838	137	9	who	who	PRON
aiua-10838	137	10	might	might	AUX
aiua-10838	137	11	benefit	benefit	VERB
aiua-10838	137	12	from	from	ADP
aiua-10838	137	13	cn	cn	PROPN
aiua-10838	137	14	is	be	AUX
aiua-10838	137	15	of	of	ADP
aiua-10838	137	16	great	great	ADJ
aiua-10838	137	17	importance	importance	NOUN
aiua-10838	137	18	.	.	PUNCT
aiua-10838	138	1	in	in	ADP
aiua-10838	138	2	our	our	PRON
aiua-10838	138	3	review	review	NOUN
aiua-10838	138	4	,	,	PUNCT
aiua-10838	138	5	most	most	ADJ
aiua-10838	138	6	of	of	ADP
aiua-10838	138	7	the	the	DET
aiua-10838	138	8	studies	study	NOUN
aiua-10838	138	9	evaluating	evaluate	VERB
aiua-10838	138	10	the	the	DET
aiua-10838	138	11	effect	effect	NOUN
aiua-10838	138	12	of	of	ADP
aiua-10838	138	13	cn	cn	PROPN
aiua-10838	138	14	in	in	ADP
aiua-10838	138	15	os	os	NOUN
aiua-10838	138	16	showed	show	VERB
aiua-10838	138	17	a	a	DET
aiua-10838	138	18	benefit	benefit	NOUN
aiua-10838	138	19	of	of	ADP
aiua-10838	138	20	cn	cn	PROPN
aiua-10838	138	21	(	(	PUNCT
aiua-10838	138	22	1425	1425	NUM
aiua-10838	138	23	,	,	PUNCT
aiua-10838	138	24	27	27	NUM
aiua-10838	138	25	-	-	SYM
aiua-10838	138	26	42	42	NUM
aiua-10838	138	27	)	)	PUNCT
aiua-10838	138	28	.	.	PUNCT
aiua-10838	139	1	although	although	SCONJ
aiua-10838	139	2	most	most	ADJ
aiua-10838	139	3	of	of	ADP
aiua-10838	139	4	these	these	DET
aiua-10838	139	5	studies	study	NOUN
aiua-10838	139	6	are	be	AUX
aiua-10838	139	7	retrospective	retrospective	ADJ
aiua-10838	139	8	and	and	CCONJ
aiua-10838	139	9	observational	observational	ADJ
aiua-10838	139	10	,	,	PUNCT
aiua-10838	139	11	their	their	PRON
aiua-10838	139	12	results	result	NOUN
aiua-10838	139	13	can	can	AUX
aiua-10838	139	14	not	not	PART
aiua-10838	139	15	be	be	AUX
aiua-10838	139	16	overlooked	overlook	VERB
aiua-10838	139	17	.	.	PUNCT
aiua-10838	140	1	in	in	ADP
aiua-10838	140	2	three	three	NUM
aiua-10838	140	3	studies	study	NOUN
aiua-10838	140	4	that	that	PRON
aiua-10838	140	5	used	use	VERB
aiua-10838	140	6	icis	icis	NOUN
aiua-10838	140	7	(	(	PUNCT
aiua-10838	140	8	2	2	NUM
aiua-10838	140	9	,	,	PUNCT
aiua-10838	140	10	40	40	NUM
aiua-10838	140	11	,	,	PUNCT
aiua-10838	140	12	42	42	NUM
aiua-10838	140	13	)	)	PUNCT
aiua-10838	140	14	,	,	PUNCT
aiua-10838	140	15	cn	cn	PROPN
aiua-10838	140	16	demonstrated	demonstrate	VERB
aiua-10838	140	17	an	an	DET
aiua-10838	140	18	os	os	NOUN
aiua-10838	140	19	benefit	benefit	NOUN
aiua-10838	140	20	.	.	PUNCT
aiua-10838	141	1	given	give	VERB
aiua-10838	141	2	the	the	DET
aiua-10838	141	3	absence	absence	NOUN
aiua-10838	141	4	of	of	ADP
aiua-10838	141	5	prospective	prospective	ADJ
aiua-10838	141	6	studies	study	NOUN
aiua-10838	141	7	with	with	ADP
aiua-10838	141	8	patients	patient	NOUN
aiua-10838	141	9	treated	treat	VERB
aiua-10838	141	10	with	with	ADP
aiua-10838	141	11	icis	icis	PROPN
aiua-10838	141	12	,	,	PUNCT
aiua-10838	141	13	these	these	DET
aiua-10838	141	14	results	result	NOUN
aiua-10838	141	15	underline	underline	VERB
aiua-10838	141	16	the	the	DET
aiua-10838	141	17	importance	importance	NOUN
aiua-10838	141	18	of	of	ADP
aiua-10838	141	19	cn	cn	PROPN
aiua-10838	141	20	in	in	ADP
aiua-10838	141	21	the	the	DET
aiua-10838	141	22	mrcc	mrcc	NOUN
aiua-10838	141	23	treatment	treatment	NOUN
aiua-10838	141	24	.	.	PUNCT
aiua-10838	142	1	prognostic	prognostic	ADJ
aiua-10838	142	2	factors	factor	NOUN
aiua-10838	142	3	have	have	AUX
aiua-10838	142	4	been	be	AUX
aiua-10838	142	5	described	describe	VERB
aiua-10838	142	6	,	,	PUNCT
aiua-10838	142	7	with	with	ADP
aiua-10838	142	8	age	age	NOUN
aiua-10838	142	9	,	,	PUNCT
aiua-10838	142	10	tumor	tumor	NOUN
aiua-10838	142	11	histology	histology	NOUN
aiua-10838	142	12	,	,	PUNCT
aiua-10838	142	13	number	number	NOUN
aiua-10838	142	14	of	of	ADP
aiua-10838	142	15	metastasis	metastasis	NOUN
aiua-10838	142	16	and	and	CCONJ
aiua-10838	142	17	t	t	NOUN
aiua-10838	142	18	stage	stage	NOUN
aiua-10838	142	19	being	be	AUX
aiua-10838	142	20	the	the	DET
aiua-10838	142	21	most	most	ADV
aiua-10838	142	22	common	common	ADJ
aiua-10838	142	23	.	.	PUNCT
aiua-10838	143	1	there	there	PRON
aiua-10838	143	2	are	be	VERB
aiua-10838	143	3	also	also	ADV
aiua-10838	143	4	two	two	NUM
aiua-10838	143	5	prognostic	prognostic	ADJ
aiua-10838	143	6	models	model	NOUN
aiua-10838	143	7	allowing	allow	VERB
aiua-10838	143	8	patient	patient	ADJ
aiua-10838	143	9	risk	risk	NOUN
aiua-10838	143	10	stratification	stratification	NOUN
aiua-10838	143	11	:	:	PUNCT
aiua-10838	143	12	mskcc	mskcc	NOUN
aiua-10838	143	13	and	and	CCONJ
aiua-10838	143	14	imdc	imdc	NOUN
aiua-10838	143	15	risk	risk	NOUN
aiua-10838	143	16	scores	score	NOUN
aiua-10838	143	17	(	(	PUNCT
aiua-10838	143	18	34	34	NUM
aiua-10838	143	19	,	,	PUNCT
aiua-10838	143	20	63	63	NUM
aiua-10838	143	21	)	)	PUNCT
aiua-10838	143	22	.	.	PUNCT
aiua-10838	144	1	these	these	DET
aiua-10838	144	2	models	model	NOUN
aiua-10838	144	3	stratify	stratify	VERB
aiua-10838	144	4	patients	patient	NOUN
aiua-10838	144	5	in	in	ADP
aiua-10838	144	6	favor	favor	NOUN
aiua-10838	144	7	,	,	PUNCT
aiua-10838	144	8	intermediate	intermediate	ADJ
aiua-10838	144	9	and	and	CCONJ
aiua-10838	144	10	poor	poor	ADJ
aiua-10838	144	11	risk	risk	NOUN
aiua-10838	144	12	categories	category	NOUN
aiua-10838	144	13	,	,	PUNCT
aiua-10838	144	14	using	use	VERB
aiua-10838	144	15	performance	performance	NOUN
aiua-10838	144	16	status	status	NOUN
aiua-10838	144	17	(	(	PUNCT
aiua-10838	144	18	ps	ps	NOUN
aiua-10838	144	19	)	)	PUNCT
aiua-10838	144	20	,	,	PUNCT
aiua-10838	144	21	time	time	NOUN
aiua-10838	144	22	from	from	ADP
aiua-10838	144	23	diagnosis	diagnosis	NOUN
aiua-10838	144	24	to	to	ADP
aiua-10838	144	25	treatment	treatment	NOUN
aiua-10838	144	26	,	,	PUNCT
aiua-10838	144	27	hemoglobin	hemoglobin	NOUN
aiua-10838	144	28	concentration	concentration	NOUN
aiua-10838	144	29	,	,	PUNCT
aiua-10838	144	30	calcium	calcium	NOUN
aiua-10838	144	31	level	level	NOUN
aiua-10838	144	32	and	and	CCONJ
aiua-10838	144	33	lactate	lactate	NOUN
aiua-10838	144	34	dehydrogenase	dehydrogenase	NOUN
aiua-10838	144	35	level	level	NOUN
aiua-10838	144	36	as	as	ADP
aiua-10838	144	37	criteria	criterion	NOUN
aiua-10838	144	38	.	.	PUNCT
aiua-10838	145	1	according	accord	VERB
aiua-10838	145	2	to	to	ADP
aiua-10838	145	3	current	current	ADJ
aiua-10838	145	4	evidence	evidence	NOUN
aiua-10838	145	5	,	,	PUNCT
aiua-10838	145	6	poor	poor	ADJ
aiua-10838	145	7	mskcc	mskcc	NOUN
aiua-10838	145	8	/	/	SYM
aiua-10838	145	9	imdc	imdc	NOUN
aiua-10838	145	10	risk	risk	NOUN
aiua-10838	145	11	patients	patient	NOUN
aiua-10838	145	12	do	do	AUX
aiua-10838	145	13	not	not	PART
aiua-10838	145	14	seem	seem	VERB
aiua-10838	145	15	to	to	PART
aiua-10838	145	16	benefit	benefit	VERB
aiua-10838	145	17	from	from	ADP
aiua-10838	145	18	upfront	upfront	ADJ
aiua-10838	145	19	cn	cn	PROPN
aiua-10838	145	20	(	(	PUNCT
aiua-10838	145	21	33	33	NUM
aiua-10838	145	22	,	,	PUNCT
aiua-10838	145	23	34	34	NUM
aiua-10838	145	24	)	)	PUNCT
aiua-10838	145	25	while	while	SCONJ
aiua-10838	145	26	other	other	ADJ
aiua-10838	145	27	patients	patient	NOUN
aiua-10838	145	28	such	such	ADJ
aiua-10838	145	29	as	as	ADP
aiua-10838	145	30	those	those	PRON
aiua-10838	145	31	with	with	ADP
aiua-10838	145	32	good	good	ADJ
aiua-10838	145	33	risk	risk	NOUN
aiua-10838	145	34	prognosis	prognosis	NOUN
aiua-10838	145	35	and	and	CCONJ
aiua-10838	145	36	good	good	ADJ
aiua-10838	145	37	ps	ps	NOUN
aiua-10838	145	38	seem	seem	VERB
aiua-10838	145	39	to	to	PART
aiua-10838	145	40	benefit	benefit	VERB
aiua-10838	145	41	the	the	DET
aiua-10838	145	42	most	most	ADJ
aiua-10838	145	43	from	from	ADP
aiua-10838	145	44	cn	cn	PROPN
aiua-10838	145	45	.	.	PUNCT
aiua-10838	146	1	it	it	PRON
aiua-10838	146	2	should	should	AUX
aiua-10838	146	3	be	be	AUX
aiua-10838	146	4	noted	note	VERB
aiua-10838	146	5	however	however	ADV
aiua-10838	146	6	,	,	PUNCT
aiua-10838	146	7	that	that	SCONJ
aiua-10838	146	8	mskcc	mskcc	NOUN
aiua-10838	146	9	/	/	SYM
aiua-10838	146	10	imdc	imdc	PROPN
aiua-10838	146	11	prognostic	prognostic	ADJ
aiua-10838	146	12	scores	score	NOUN
aiua-10838	146	13	were	be	AUX
aiua-10838	146	14	originally	originally	ADV
aiua-10838	146	15	designed	design	VERB
aiua-10838	146	16	to	to	PART
aiua-10838	146	17	predict	predict	VERB
aiua-10838	146	18	os	os	NOUN
aiua-10838	146	19	in	in	ADP
aiua-10838	146	20	patients	patient	NOUN
aiua-10838	146	21	with	with	ADP
aiua-10838	146	22	mrcc	mrcc	NOUN
aiua-10838	146	23	,	,	PUNCT
aiua-10838	146	24	and	and	CCONJ
aiua-10838	146	25	not	not	PART
aiua-10838	146	26	the	the	DET
aiua-10838	146	27	os	os	NOUN
aiua-10838	146	28	benefit	benefit	NOUN
aiua-10838	146	29	associated	associate	VERB
aiua-10838	146	30	with	with	ADP
aiua-10838	146	31	cn	cn	PROPN
aiua-10838	146	32	(	(	PUNCT
aiua-10838	146	33	65	65	NUM
aiua-10838	146	34	)	)	PUNCT
aiua-10838	146	35	.	.	PUNCT
aiua-10838	147	1	that	that	PRON
aiua-10838	147	2	shows	show	VERB
aiua-10838	147	3	the	the	DET
aiua-10838	147	4	need	need	NOUN
aiua-10838	147	5	for	for	ADP
aiua-10838	147	6	new	new	ADJ
aiua-10838	147	7	validated	validated	ADJ
aiua-10838	147	8	prognostic	prognostic	ADJ
aiua-10838	147	9	models	model	NOUN
aiua-10838	147	10	.	.	PUNCT
aiua-10838	148	1	among	among	ADP
aiua-10838	148	2	patients	patient	NOUN
aiua-10838	148	3	that	that	PRON
aiua-10838	148	4	were	be	AUX
aiua-10838	148	5	found	find	VERB
aiua-10838	148	6	to	to	PART
aiua-10838	148	7	benefit	benefit	VERB
aiua-10838	148	8	from	from	ADP
aiua-10838	148	9	cn	cn	PROPN
aiua-10838	148	10	,	,	PUNCT
aiua-10838	148	11	the	the	DET
aiua-10838	148	12	optimal	optimal	ADJ
aiua-10838	148	13	sequence	sequence	NOUN
aiua-10838	148	14	between	between	ADP
aiua-10838	148	15	cn	cn	PROPN
aiua-10838	148	16	and	and	CCONJ
aiua-10838	148	17	tt	tt	PROPN
aiua-10838	148	18	is	be	AUX
aiua-10838	148	19	not	not	PART
aiua-10838	148	20	yet	yet	ADV
aiua-10838	148	21	well	well	ADV
aiua-10838	148	22	established	establish	VERB
aiua-10838	148	23	,	,	PUNCT
aiua-10838	148	24	as	as	SCONJ
aiua-10838	148	25	was	be	AUX
aiua-10838	148	26	also	also	ADV
aiua-10838	148	27	documented	document	VERB
aiua-10838	148	28	in	in	ADP
aiua-10838	148	29	our	our	PRON
aiua-10838	148	30	review	review	NOUN
aiua-10838	148	31	.	.	PUNCT
aiua-10838	149	1	deferred	defer	VERB
aiua-10838	149	2	cn	cn	PROPN
aiua-10838	149	3	demonstrated	demonstrate	VERB
aiua-10838	149	4	better	well	ADJ
aiua-10838	149	5	results	result	NOUN
aiua-10838	149	6	,	,	PUNCT
aiua-10838	149	7	in	in	ADP
aiua-10838	149	8	more	more	ADJ
aiua-10838	149	9	studies	study	NOUN
aiua-10838	149	10	than	than	ADP
aiua-10838	149	11	upfront	upfront	ADJ
aiua-10838	149	12	cn	cn	X
aiua-10838	149	13	(	(	PUNCT
aiua-10838	149	14	7	7	NUM
aiua-10838	149	15	,	,	PUNCT
aiua-10838	149	16	23	23	NUM
aiua-10838	149	17	,	,	PUNCT
aiua-10838	149	18	38	38	NUM
aiua-10838	149	19	,	,	PUNCT
aiua-10838	149	20	47	47	NUM
aiua-10838	149	21	,	,	PUNCT
aiua-10838	149	22	48	48	NUM
aiua-10838	149	23	)	)	PUNCT
aiua-10838	149	24	but	but	CCONJ
aiua-10838	149	25	a	a	DET
aiua-10838	149	26	certain	certain	ADJ
aiua-10838	149	27	advantage	advantage	NOUN
aiua-10838	149	28	was	be	AUX
aiua-10838	149	29	not	not	PART
aiua-10838	149	30	clear	clear	ADJ
aiua-10838	149	31	.	.	PUNCT
aiua-10838	150	1	despite	despite	SCONJ
aiua-10838	150	2	the	the	DET
aiua-10838	150	3	new	new	ADJ
aiua-10838	150	4	insights	insight	NOUN
aiua-10838	150	5	into	into	ADP
aiua-10838	150	6	the	the	DET
aiua-10838	150	7	treatment	treatment	NOUN
aiua-10838	150	8	of	of	ADP
aiua-10838	150	9	mrcc	mrcc	NOUN
aiua-10838	150	10	patients	patient	NOUN
aiua-10838	150	11	that	that	PRON
aiua-10838	150	12	carmena	carmena	VERB
aiua-10838	150	13	and	and	CCONJ
aiua-10838	150	14	surtime	surtime	NOUN
aiua-10838	150	15	provided	provide	VERB
aiua-10838	150	16	,	,	PUNCT
aiua-10838	150	17	tkis	tkis	PROPN
aiua-10838	150	18	are	be	AUX
aiua-10838	150	19	not	not	PART
aiua-10838	150	20	anymore	anymore	ADV
aiua-10838	150	21	considered	consider	VERB
aiua-10838	150	22	the	the	DET
aiua-10838	150	23	standard	standard	NOUN
aiua-10838	150	24	of	of	ADP
aiua-10838	150	25	care	care	NOUN
aiua-10838	150	26	as	as	ADP
aiua-10838	150	27	icis	icis	PROPN
aiua-10838	150	28	have	have	AUX
aiua-10838	150	29	been	be	AUX
aiua-10838	150	30	established	establish	VERB
aiua-10838	150	31	as	as	ADP
aiua-10838	150	32	first	first	ADJ
aiua-10838	150	33	-	-	PUNCT
aiua-10838	150	34	line	line	NOUN
aiua-10838	150	35	therapy	therapy	NOUN
aiua-10838	150	36	in	in	ADP
aiua-10838	150	37	mrcc	mrcc	NOUN
aiua-10838	150	38	patients	patient	NOUN
aiua-10838	150	39	.	.	PUNCT
aiua-10838	151	1	three	three	NUM
aiua-10838	151	2	randomized	randomized	ADJ
aiua-10838	151	3	trials	trial	NOUN
aiua-10838	151	4	:	:	PUNCT
aiua-10838	151	5	the	the	DET
aiua-10838	151	6	checkmate-214	checkmate-214	NOUN
aiua-10838	151	7	(	(	PUNCT
aiua-10838	151	8	nivolumab	nivolumab	NOUN
aiua-10838	151	9	plus	plus	CCONJ
aiua-10838	151	10	ipilimumab	ipilimumab	VERB
aiua-10838	151	11	vs	vs	ADP
aiua-10838	151	12	sunitinib	sunitinib	NOUN
aiua-10838	151	13	)	)	PUNCT
aiua-10838	151	14	,	,	PUNCT
aiua-10838	151	15	keynote426	keynote426	PROPN
aiua-10838	151	16	(	(	PUNCT
aiua-10838	151	17	pembrolizumab	pembrolizumab	NOUN
aiua-10838	151	18	plus	plus	CCONJ
aiua-10838	151	19	axitinib	axitinib	NOUN
aiua-10838	151	20	vs	vs	ADP
aiua-10838	151	21	sunitinib	sunitinib	NOUN
aiua-10838	151	22	)	)	PUNCT
aiua-10838	151	23	,	,	PUNCT
aiua-10838	151	24	and	and	CCONJ
aiua-10838	151	25	javelin	javelin	PROPN
aiua-10838	151	26	renal	renal	PROPN
aiua-10838	151	27	101	101	NUM
aiua-10838	151	28	(	(	PUNCT
aiua-10838	151	29	avelumab	avelumab	X
aiua-10838	151	30	plus	plus	CCONJ
aiua-10838	151	31	axitinib	axitinib	NOUN
aiua-10838	151	32	vs	vs	ADP
aiua-10838	151	33	sunitinib	sunitinib	NOUN
aiua-10838	151	34	)	)	PUNCT
aiua-10838	151	35	demonstrated	demonstrate	VERB
aiua-10838	151	36	the	the	DET
aiua-10838	151	37	superiority	superiority	NOUN
aiua-10838	151	38	of	of	ADP
aiua-10838	151	39	icis	icis	NOUN
aiua-10838	151	40	in	in	ADP
aiua-10838	151	41	the	the	DET
aiua-10838	151	42	treatment	treatment	NOUN
aiua-10838	151	43	of	of	ADP
aiua-10838	151	44	mrcc	mrcc	NOUN
aiua-10838	151	45	whereas	whereas	SCONJ
aiua-10838	151	46	sunitinib	sunitinib	NOUN
aiua-10838	151	47	and	and	CCONJ
aiua-10838	151	48	other	other	ADJ
aiua-10838	151	49	vegfr	vegfr	ADJ
aiua-10838	151	50	-	-	PUNCT
aiua-10838	151	51	tki	tki	NOUN
aiua-10838	151	52	monotherapies	monotherapie	NOUN
aiua-10838	151	53	are	be	AUX
aiua-10838	151	54	reserved	reserve	VERB
aiua-10838	151	55	for	for	ADP
aiua-10838	151	56	those	those	PRON
aiua-10838	151	57	who	who	PRON
aiua-10838	151	58	can	can	AUX
aiua-10838	151	59	not	not	PART
aiua-10838	151	60	tolerate	tolerate	VERB
aiua-10838	151	61	ici	ici	NOUN
aiua-10838	151	62	combination	combination	NOUN
aiua-10838	151	63	or	or	CCONJ
aiua-10838	151	64	have	have	VERB
aiua-10838	151	65	no	no	DET
aiua-10838	151	66	access	access	NOUN
aiua-10838	151	67	to	to	ADP
aiua-10838	151	68	these	these	DET
aiua-10838	151	69	drugs(9	drugs(9	NOUN
aiua-10838	151	70	-	-	PUNCT
aiua-10838	151	71	11	11	NUM
aiua-10838	151	72	)	)	PUNCT
aiua-10838	151	73	.	.	PUNCT
aiua-10838	152	1	what	what	PRON
aiua-10838	152	2	we	we	PRON
aiua-10838	152	3	already	already	ADV
aiua-10838	152	4	know	know	VERB
aiua-10838	152	5	from	from	ADP
aiua-10838	152	6	carmena	carmena	NOUN
aiua-10838	152	7	and	and	CCONJ
aiua-10838	152	8	surtime	surtime	NOUN
aiua-10838	152	9	has	have	VERB
aiua-10838	152	10	to	to	PART
aiua-10838	152	11	be	be	AUX
aiua-10838	152	12	re	re	VERB
aiua-10838	152	13	-	-	VERB
aiua-10838	152	14	evaluated	evaluated	ADJ
aiua-10838	152	15	.	.	PUNCT
aiua-10838	153	1	singla	singla	INTJ
aiua-10838	153	2	et	et	PROPN
aiua-10838	153	3	al	al	PROPN
aiua-10838	153	4	.	.	PROPN
aiua-10838	154	1	(	(	PUNCT
aiua-10838	154	2	24	24	NUM
aiua-10838	154	3	)	)	PUNCT
aiua-10838	154	4	in	in	ADP
aiua-10838	154	5	the	the	DET
aiua-10838	154	6	first	first	ADJ
aiua-10838	154	7	retrospective	retrospective	ADJ
aiua-10838	154	8	analysis	analysis	NOUN
aiua-10838	154	9	of	of	ADP
aiua-10838	154	10	the	the	DET
aiua-10838	154	11	role	role	NOUN
aiua-10838	154	12	of	of	ADP
aiua-10838	154	13	cn	cn	PROPN
aiua-10838	154	14	in	in	ADP
aiua-10838	154	15	the	the	DET
aiua-10838	154	16	immunotherapy	immunotherapy	NOUN
aiua-10838	154	17	era	era	NOUN
aiua-10838	154	18	,	,	PUNCT
aiua-10838	154	19	demonstrated	demonstrate	VERB
aiua-10838	154	20	an	an	DET
aiua-10838	154	21	os	os	NOUN
aiua-10838	154	22	benefit	benefit	NOUN
aiua-10838	154	23	for	for	ADP
aiua-10838	154	24	those	those	DET
aiua-10838	154	25	patients	patient	NOUN
aiua-10838	154	26	treated	treat	VERB
aiua-10838	154	27	with	with	ADP
aiua-10838	154	28	ici	ici	PROPN
aiua-10838	154	29	plus	plus	CCONJ
aiua-10838	154	30	cn	cn	PROPN
aiua-10838	154	31	compared	compare	VERB
aiua-10838	154	32	to	to	ADP
aiua-10838	154	33	ici	ici	PROPN
aiua-10838	154	34	alone	alone	ADV
aiua-10838	154	35	(	(	PUNCT
aiua-10838	154	36	hr	hr	NOUN
aiua-10838	154	37	0.23	0.23	NUM
aiua-10838	154	38	;	;	PUNCT
aiua-10838	154	39	95	95	NUM
aiua-10838	154	40	%	%	NOUN
aiua-10838	154	41	ci	ci	NOUN
aiua-10838	154	42	0.15	0.15	NUM
aiua-10838	154	43	-	-	SYM
aiua-10838	154	44	0.37	0.37	NUM
aiua-10838	154	45	)	)	PUNCT
aiua-10838	154	46	.	.	PUNCT
aiua-10838	155	1	in	in	ADP
aiua-10838	155	2	this	this	DET
aiua-10838	155	3	regard	regard	NOUN
aiua-10838	155	4	,	,	PUNCT
aiua-10838	155	5	further	further	ADJ
aiua-10838	155	6	data	datum	NOUN
aiua-10838	155	7	from	from	ADP
aiua-10838	155	8	high	high	ADJ
aiua-10838	155	9	level	level	NOUN
aiua-10838	155	10	of	of	ADP
aiua-10838	155	11	evidence	evidence	NOUN
aiua-10838	155	12	studies	study	NOUN
aiua-10838	155	13	are	be	AUX
aiua-10838	155	14	required	require	VERB
aiua-10838	155	15	in	in	ADP
aiua-10838	155	16	order	order	NOUN
aiua-10838	155	17	to	to	PART
aiua-10838	155	18	define	define	VERB
aiua-10838	155	19	the	the	DET
aiua-10838	155	20	role	role	NOUN
aiua-10838	155	21	of	of	ADP
aiua-10838	155	22	cn	cn	PROPN
aiua-10838	155	23	in	in	ADP
aiua-10838	155	24	the	the	DET
aiua-10838	155	25	modern	modern	ADJ
aiua-10838	155	26	immune	immune	ADJ
aiua-10838	155	27	oncology	oncology	NOUN
aiua-10838	155	28	(	(	PUNCT
aiua-10838	155	29	io	io	NOUN
aiua-10838	155	30	)	)	PUNCT
aiua-10838	155	31	era	era	NOUN
aiua-10838	155	32	.	.	PUNCT
aiua-10838	156	1	currently	currently	ADV
aiua-10838	156	2	there	there	PRON
aiua-10838	156	3	are	be	VERB
aiua-10838	156	4	two	two	NUM
aiua-10838	156	5	rcts	rct	NOUN
aiua-10838	156	6	underway	underway	ADJ
aiua-10838	156	7	,	,	PUNCT
aiua-10838	156	8	to	to	PART
aiua-10838	156	9	guide	guide	VERB
aiua-10838	156	10	us	we	PRON
aiua-10838	156	11	to	to	ADP
aiua-10838	156	12	that	that	PRON
aiua-10838	156	13	.	.	PUNCT
aiua-10838	157	1	the	the	DET
aiua-10838	157	2	probe	probe	NOUN
aiua-10838	157	3	trial	trial	NOUN
aiua-10838	157	4	(	(	PUNCT
aiua-10838	157	5	nct04510597	nct04510597	ADV
aiua-10838	157	6	)	)	PUNCT
aiua-10838	157	7	will	will	AUX
aiua-10838	157	8	evaluate	evaluate	VERB
aiua-10838	157	9	the	the	DET
aiua-10838	157	10	combination	combination	NOUN
aiua-10838	157	11	of	of	ADP
aiua-10838	157	12	cn	cn	PROPN
aiua-10838	157	13	followed	follow	VERB
aiua-10838	157	14	by	by	ADP
aiua-10838	157	15	io	io	NOUN
aiua-10838	157	16	or	or	CCONJ
aiua-10838	157	17	tki+	tki+	PROPN
aiua-10838	157	18	io	io	X
aiua-10838	157	19	compared	compare	VERB
aiua-10838	157	20	to	to	ADP
aiua-10838	157	21	no	no	DET
aiua-10838	157	22	cn	cn	PROPN
aiua-10838	157	23	.	.	PUNCT
aiua-10838	158	1	the	the	DET
aiua-10838	158	2	nordic	nordic	ADJ
aiua-10838	158	3	-	-	PUNCT
aiua-10838	158	4	sun	sun	NOUN
aiua-10838	158	5	trial	trial	NOUN
aiua-10838	158	6	(	(	PUNCT
aiua-10838	158	7	nct03977571	nct03977571	ADJ
aiua-10838	158	8	)	)	PUNCT
aiua-10838	158	9	will	will	AUX
aiua-10838	158	10	evaluate	evaluate	VERB
aiua-10838	158	11	the	the	DET
aiua-10838	158	12	role	role	NOUN
aiua-10838	158	13	of	of	ADP
aiua-10838	158	14	deferred	defer	VERB
aiua-10838	158	15	cn	cn	PROPN
aiua-10838	158	16	in	in	ADP
aiua-10838	158	17	patients	patient	NOUN
aiua-10838	158	18	receiving	receive	VERB
aiua-10838	158	19	combination	combination	NOUN
aiua-10838	158	20	io	io	NOUN
aiua-10838	158	21	.	.	PUNCT
aiua-10838	159	1	we	we	PRON
aiua-10838	159	2	acknowledge	acknowledge	VERB
aiua-10838	159	3	that	that	SCONJ
aiua-10838	159	4	the	the	DET
aiua-10838	159	5	present	present	ADJ
aiua-10838	159	6	study	study	NOUN
aiua-10838	159	7	had	have	VERB
aiua-10838	159	8	several	several	ADJ
aiua-10838	159	9	limitations	limitation	NOUN
aiua-10838	159	10	.	.	PUNCT
aiua-10838	160	1	the	the	DET
aiua-10838	160	2	major	major	ADJ
aiua-10838	160	3	limitations	limitation	NOUN
aiua-10838	160	4	were	be	AUX
aiua-10838	160	5	the	the	DET
aiua-10838	160	6	retrospective	retrospective	ADJ
aiua-10838	160	7	nature	nature	NOUN
aiua-10838	160	8	of	of	ADP
aiua-10838	160	9	the	the	DET
aiua-10838	160	10	studies	study	NOUN
aiua-10838	160	11	included	include	VERB
aiua-10838	160	12	and	and	CCONJ
aiua-10838	160	13	the	the	DET
aiua-10838	160	14	small	small	ADJ
aiua-10838	160	15	number	number	NOUN
aiua-10838	160	16	of	of	ADP
aiua-10838	160	17	studies	study	NOUN
aiua-10838	160	18	having	have	VERB
aiua-10838	160	19	icis	icis	NOUN
aiua-10838	160	20	as	as	SCONJ
aiua-10838	160	21	the	the	DET
aiua-10838	160	22	main	main	ADJ
aiua-10838	160	23	agent	agent	NOUN
aiua-10838	160	24	used	use	VERB
aiua-10838	160	25	.	.	PUNCT
aiua-10838	161	1	the	the	DET
aiua-10838	161	2	retrospective	retrospective	ADJ
aiua-10838	161	3	nature	nature	NOUN
aiua-10838	161	4	could	could	AUX
aiua-10838	161	5	have	have	AUX
aiua-10838	161	6	resulted	result	VERB
aiua-10838	161	7	in	in	ADP
aiua-10838	161	8	selection	selection	NOUN
aiua-10838	161	9	bias	bias	NOUN
aiua-10838	161	10	in	in	ADP
aiua-10838	161	11	performance	performance	NOUN
aiua-10838	161	12	of	of	ADP
aiua-10838	161	13	cn	cn	PROPN
aiua-10838	161	14	.	.	PUNCT
aiua-10838	162	1	moreover	moreover	ADV
aiua-10838	162	2	,	,	PUNCT
aiua-10838	162	3	many	many	ADJ
aiua-10838	162	4	studies	study	NOUN
aiua-10838	162	5	come	come	VERB
aiua-10838	162	6	from	from	ADP
aiua-10838	162	7	an	an	DET
aiua-10838	162	8	era	era	NOUN
aiua-10838	162	9	when	when	SCONJ
aiua-10838	162	10	systemic	systemic	ADJ
aiua-10838	162	11	therapies	therapy	NOUN
aiua-10838	162	12	were	be	AUX
aiua-10838	162	13	not	not	PART
aiua-10838	162	14	well	well	ADV
aiua-10838	162	15	established	establish	VERB
aiua-10838	162	16	.	.	PUNCT
aiua-10838	163	1	conclusions	conclusion	NOUN
aiua-10838	163	2	the	the	DET
aiua-10838	163	3	role	role	NOUN
aiua-10838	163	4	of	of	ADP
aiua-10838	163	5	cn	cn	PROPN
aiua-10838	163	6	on	on	ADP
aiua-10838	163	7	mrcc	mrcc	NOUN
aiua-10838	163	8	treatment	treatment	NOUN
aiua-10838	163	9	remains	remain	VERB
aiua-10838	163	10	a	a	DET
aiua-10838	163	11	controversial	controversial	ADJ
aiua-10838	163	12	issue	issue	NOUN
aiua-10838	163	13	.	.	PUNCT
aiua-10838	164	1	data	datum	NOUN
aiua-10838	164	2	from	from	ADP
aiua-10838	164	3	most	most	ADJ
aiua-10838	164	4	recent	recent	ADJ
aiua-10838	164	5	studies	study	NOUN
aiua-10838	164	6	have	have	AUX
aiua-10838	164	7	questioned	question	VERB
aiua-10838	164	8	the	the	DET
aiua-10838	164	9	benefit	benefit	NOUN
aiua-10838	164	10	from	from	ADP
aiua-10838	164	11	cn	cn	PROPN
aiua-10838	164	12	,	,	PUNCT
aiua-10838	164	13	shifting	shift	VERB
aiua-10838	164	14	the	the	DET
aiua-10838	164	15	first	first	ADJ
aiua-10838	164	16	line	line	NOUN
aiua-10838	164	17	treatment	treatment	NOUN
aiua-10838	164	18	from	from	ADP
aiua-10838	164	19	surgical	surgical	ADJ
aiua-10838	164	20	to	to	ADP
aiua-10838	164	21	medical	medical	ADJ
aiua-10838	164	22	.	.	PUNCT
aiua-10838	165	1	cn	cn	PROPN
aiua-10838	165	2	can	can	AUX
aiua-10838	165	3	still	still	ADV
aiua-10838	165	4	play	play	VERB
aiua-10838	165	5	an	an	DET
aiua-10838	165	6	important	important	ADJ
aiua-10838	165	7	role	role	NOUN
aiua-10838	165	8	in	in	ADP
aiua-10838	165	9	wisely	wisely	ADV
aiua-10838	165	10	selected	select	VERB
aiua-10838	165	11	patients	patient	NOUN
aiua-10838	165	12	,	,	PUNCT
aiua-10838	165	13	although	although	SCONJ
aiua-10838	165	14	the	the	DET
aiua-10838	165	15	role	role	NOUN
aiua-10838	165	16	of	of	ADP
aiua-10838	165	17	cn	cn	PROPN
aiua-10838	165	18	in	in	ADP
aiua-10838	165	19	the	the	DET
aiua-10838	165	20	new	new	ADJ
aiua-10838	165	21	immunotherapy	immunotherapy	NOUN
aiua-10838	165	22	era	era	NOUN
aiua-10838	165	23	still	still	ADV
aiua-10838	165	24	needs	need	VERB
aiua-10838	165	25	to	to	PART
aiua-10838	165	26	be	be	AUX
aiua-10838	165	27	defined	define	VERB
aiua-10838	165	28	.	.	PUNCT
aiua-10838	166	1	references	reference	NOUN
aiua-10838	166	2	1	1	NUM
aiua-10838	166	3	.	.	PUNCT
aiua-10838	166	4	flanigan	flanigan	PROPN
aiua-10838	166	5	rc	rc	PROPN
aiua-10838	166	6	,	,	PUNCT
aiua-10838	166	7	salmon	salmon	PROPN
aiua-10838	166	8	se	se	PROPN
aiua-10838	166	9	,	,	PUNCT
aiua-10838	166	10	blumenstein	blumenstein	PROPN
aiua-10838	166	11	ba	ba	PROPN
aiua-10838	166	12	,	,	PUNCT
aiua-10838	166	13	et	et	PROPN
aiua-10838	166	14	al	al	PROPN
aiua-10838	166	15	.	.	PROPN
aiua-10838	166	16	nephrectomy	nephrectomy	PROPN
aiua-10838	166	17	followed	follow	VERB
aiua-10838	166	18	by	by	ADP
aiua-10838	166	19	interferon	interferon	NOUN
aiua-10838	166	20	alfa-2b	alfa-2b	CCONJ
aiua-10838	166	21	compared	compare	VERB
aiua-10838	166	22	with	with	ADP
aiua-10838	166	23	interferon	interferon	NOUN
aiua-10838	166	24	alfa-2b	alfa-2b	CCONJ
aiua-10838	166	25	alone	alone	ADJ
aiua-10838	166	26	for	for	ADP
aiua-10838	166	27	metastatic	metastatic	ADJ
aiua-10838	166	28	renal	renal	ADJ
aiua-10838	166	29	-	-	PUNCT
aiua-10838	166	30	cell	cell	NOUN
aiua-10838	166	31	cancer	cancer	NOUN
aiua-10838	166	32	.	.	PUNCT
aiua-10838	167	1	n	n	PROPN
aiua-10838	167	2	engl	engl	PROPN
aiua-10838	167	3	j	j	PROPN
aiua-10838	167	4	med	med	PROPN
aiua-10838	167	5	.	.	PUNCT
aiua-10838	167	6	2001	2001	NUM
aiua-10838	167	7	;	;	PUNCT
aiua-10838	167	8	345:1655	345:1655	NUM
aiua-10838	167	9	-	-	SYM
aiua-10838	167	10	9	9	NUM
aiua-10838	167	11	.	.	NOUN
aiua-10838	167	12	2	2	NUM
aiua-10838	167	13	.	.	X
aiua-10838	167	14	mickisch	mickisch	PROPN
aiua-10838	167	15	gh	gh	PROPN
aiua-10838	167	16	,	,	PUNCT
aiua-10838	167	17	garin	garin	PROPN
aiua-10838	167	18	a	a	PROPN
aiua-10838	167	19	,	,	PUNCT
aiua-10838	167	20	van	van	PROPN
aiua-10838	167	21	poppel	poppel	PROPN
aiua-10838	167	22	h	h	PROPN
aiua-10838	167	23	,	,	PUNCT
aiua-10838	167	24	et	et	PROPN
aiua-10838	167	25	al	al	PROPN
aiua-10838	167	26	.	.	PROPN
aiua-10838	168	1	radical	radical	ADJ
aiua-10838	168	2	nephrectomy	nephrectomy	ADJ
aiua-10838	168	3	plus	plus	CCONJ
aiua-10838	168	4	interferon	interferon	ADJ
aiua-10838	168	5	-	-	PUNCT
aiua-10838	168	6	alfa	alfa	NOUN
aiua-10838	168	7	-	-	PUNCT
aiua-10838	168	8	based	base	VERB
aiua-10838	168	9	immunotherapy	immunotherapy	NOUN
aiua-10838	168	10	compared	compare	VERB
aiua-10838	168	11	with	with	ADP
aiua-10838	168	12	interferon	interferon	ADJ
aiua-10838	168	13	alfa	alfa	NOUN
aiua-10838	168	14	alone	alone	ADV
aiua-10838	168	15	in	in	ADP
aiua-10838	168	16	metastatic	metastatic	ADJ
aiua-10838	168	17	renal	renal	ADJ
aiua-10838	168	18	-	-	PUNCT
aiua-10838	168	19	cell	cell	NOUN
aiua-10838	168	20	carcinoma	carcinoma	NOUN
aiua-10838	168	21	:	:	PUNCT
aiua-10838	168	22	a	a	DET
aiua-10838	168	23	randomised	randomised	ADJ
aiua-10838	168	24	trial	trial	NOUN
aiua-10838	168	25	.	.	PUNCT
aiua-10838	169	1	lancet	lancet	PROPN
aiua-10838	169	2	.	.	PUNCT
aiua-10838	170	1	2001	2001	NUM
aiua-10838	170	2	;	;	PUNCT
aiua-10838	171	1	358:966	358:966	X
aiua-10838	171	2	-	-	SYM
aiua-10838	171	3	70	70	NUM
aiua-10838	171	4	.	.	PUNCT
aiua-10838	172	1	3	3	X
aiua-10838	172	2	.	.	X
aiua-10838	172	3	flanigan	flanigan	PROPN
aiua-10838	172	4	rc	rc	PROPN
aiua-10838	172	5	,	,	PUNCT
aiua-10838	172	6	mickisch	mickisch	PROPN
aiua-10838	172	7	g	g	PROPN
aiua-10838	172	8	,	,	PUNCT
aiua-10838	172	9	sylvester	sylvester	ADJ
aiua-10838	172	10	r	r	NOUN
aiua-10838	172	11	,	,	PUNCT
aiua-10838	172	12	et	et	PROPN
aiua-10838	172	13	al	al	PROPN
aiua-10838	172	14	.	.	PUNCT
aiua-10838	173	1	cytoreductive	cytoreductive	PROPN
aiua-10838	173	2	nephrectomy	nephrectomy	ADV
aiua-10838	173	3	in	in	ADP
aiua-10838	173	4	patients	patient	NOUN
aiua-10838	173	5	with	with	ADP
aiua-10838	173	6	metastatic	metastatic	ADJ
aiua-10838	173	7	renal	renal	ADJ
aiua-10838	173	8	cancer	cancer	NOUN
aiua-10838	173	9	:	:	PUNCT
aiua-10838	173	10	a	a	DET
aiua-10838	173	11	combined	combine	VERB
aiua-10838	173	12	analysis.j	analysis.j	PROPN
aiua-10838	173	13	urol	urol	NOUN
aiua-10838	173	14	.	.	PUNCT
aiua-10838	174	1	2004	2004	NUM
aiua-10838	174	2	;	;	PUNCT
aiua-10838	174	3	171:1071	171:1071	NUM
aiua-10838	174	4	-	-	SYM
aiua-10838	174	5	6	6	NUM
aiua-10838	174	6	.	.	NOUN
aiua-10838	174	7	4	4	NUM
aiua-10838	174	8	.	.	X
aiua-10838	174	9	motzer	motzer	PROPN
aiua-10838	174	10	rj	rj	PROPN
aiua-10838	174	11	,	,	PUNCT
aiua-10838	174	12	hutson	hutson	PROPN
aiua-10838	174	13	te	te	PROPN
aiua-10838	174	14	,	,	PUNCT
aiua-10838	174	15	tomczak	tomczak	NOUN
aiua-10838	174	16	p	p	NOUN
aiua-10838	174	17	,	,	PUNCT
aiua-10838	174	18	et	et	PROPN
aiua-10838	174	19	al	al	PROPN
aiua-10838	174	20	.	.	PUNCT
aiua-10838	174	21	sunitinib	sunitinib	NOUN
aiua-10838	174	22	versus	versus	ADP
aiua-10838	174	23	interferon	interferon	ADJ
aiua-10838	174	24	alfa	alfa	NOUN
aiua-10838	174	25	in	in	ADP
aiua-10838	174	26	metastatic	metastatic	ADJ
aiua-10838	174	27	renal	renal	ADJ
aiua-10838	174	28	-	-	PUNCT
aiua-10838	174	29	cell	cell	NOUN
aiua-10838	174	30	carcinoma	carcinoma	NOUN
aiua-10838	174	31	.	.	PUNCT
aiua-10838	175	1	n	n	PRON
aiua-10838	175	2	engl	engl	PROPN
aiua-10838	175	3	j	j	PROPN
aiua-10838	175	4	med	med	PROPN
aiua-10838	175	5	.	.	PUNCT
aiua-10838	175	6	2007	2007	NUM
aiua-10838	175	7	;	;	PUNCT
aiua-10838	175	8	356:115	356:115	PROPN
aiua-10838	175	9	-	-	PUNCT
aiua-10838	175	10	24	24	NUM
aiua-10838	175	11	.	.	PUNCT
aiua-10838	176	1	5	5	X
aiua-10838	176	2	.	.	X
aiua-10838	177	1	coppin	coppin	PROPN
aiua-10838	177	2	c	c	PROPN
aiua-10838	177	3	,	,	PUNCT
aiua-10838	177	4	le	le	X
aiua-10838	177	5	l	l	NOUN
aiua-10838	177	6	,	,	PUNCT
aiua-10838	177	7	porzsolt	porzsolt	NOUN
aiua-10838	177	8	f	f	PROPN
aiua-10838	177	9	,	,	PUNCT
aiua-10838	177	10	wilt	wilt	ADJ
aiua-10838	177	11	t.	t.	NOUN
aiua-10838	177	12	targeted	target	VERB
aiua-10838	177	13	therapy	therapy	NOUN
aiua-10838	177	14	for	for	ADP
aiua-10838	177	15	archivio	archivio	NOUN
aiua-10838	177	16	italiano	italiano	X
aiua-10838	177	17	di	di	X
aiua-10838	177	18	urologia	urologia	PROPN
aiua-10838	177	19	e	e	PROPN
aiua-10838	177	20	andrologia	andrologia	PROPN
aiua-10838	177	21	2022	2022	NUM
aiua-10838	177	22	;	;	PUNCT
aiua-10838	177	23	94	94	NUM
aiua-10838	177	24	,	,	PUNCT
aiua-10838	177	25	4	4	NUM
aiua-10838	177	26	s.	s.	PROPN
aiua-10838	177	27	katsimperis	katsimperis	PROPN
aiua-10838	177	28	,	,	PUNCT
aiua-10838	177	29	l.	l.	PROPN
aiua-10838	177	30	tzelves	tzelves	PROPN
aiua-10838	177	31	,	,	PUNCT
aiua-10838	177	32	t.	t.	PROPN
aiua-10838	177	33	bellos	bellos	PROPN
aiua-10838	177	34	,	,	PUNCT
aiua-10838	177	35	k.	k.	PROPN
aiua-10838	177	36	pikramenos	pikramenos	PROPN
aiua-10838	177	37	,	,	PUNCT
aiua-10838	177	38	i.	i.	PROPN
aiua-10838	177	39	manolitsis	manolitsis	PROPN
aiua-10838	177	40	,	,	PUNCT
aiua-10838	177	41	i.	i.	PROPN
aiua-10838	177	42	tsikopoulos	tsikopoulos	PROPN
aiua-10838	177	43	,	,	PUNCT
aiua-10838	177	44	i.	i.	PROPN
aiua-10838	177	45	mitsogiannis	mitsogiannis	PROPN
aiua-10838	177	46	484	484	NUM
aiua-10838	177	47	advanced	advanced	ADJ
aiua-10838	177	48	renal	renal	ADJ
aiua-10838	177	49	cell	cell	NOUN
aiua-10838	177	50	carcinoma	carcinoma	NOUN
aiua-10838	177	51	.	.	PUNCT
aiua-10838	178	1	cochrane	cochrane	NOUN
aiua-10838	178	2	database	database	PROPN
aiua-10838	178	3	syst	syst	PROPN
aiua-10838	178	4	rev	rev	PROPN
aiua-10838	178	5	.	.	PROPN
aiua-10838	178	6	2008	2008	NUM
aiua-10838	178	7	:	:	PUNCT
aiua-10838	179	1	cd006017	cd006017	X
aiua-10838	179	2	.	.	PUNCT
aiua-10838	180	1	6	6	NUM
aiua-10838	180	2	.	.	X
aiua-10838	180	3	méjean	méjean	PROPN
aiua-10838	180	4	a	a	PRON
aiua-10838	180	5	,	,	PUNCT
aiua-10838	180	6	ravaud	ravaud	NOUN
aiua-10838	180	7	a	a	PRON
aiua-10838	180	8	,	,	PUNCT
aiua-10838	180	9	thezenas	thezenas	PROPN
aiua-10838	180	10	s	s	PROPN
aiua-10838	180	11	,	,	PUNCT
aiua-10838	180	12	et	et	PROPN
aiua-10838	180	13	al	al	PROPN
aiua-10838	180	14	.	.	PUNCT
aiua-10838	180	15	sunitinib	sunitinib	NOUN
aiua-10838	180	16	alone	alone	ADV
aiua-10838	180	17	or	or	CCONJ
aiua-10838	180	18	after	after	ADP
aiua-10838	180	19	nephrectomy	nephrectomy	NOUN
aiua-10838	180	20	in	in	ADP
aiua-10838	180	21	metastatic	metastatic	ADJ
aiua-10838	180	22	renal	renal	ADJ
aiua-10838	180	23	-	-	PUNCT
aiua-10838	180	24	cell	cell	NOUN
aiua-10838	180	25	carcinoma	carcinoma	NOUN
aiua-10838	180	26	.	.	PUNCT
aiua-10838	181	1	n	n	PRON
aiua-10838	181	2	engl	engl	PROPN
aiua-10838	181	3	j	j	PROPN
aiua-10838	181	4	med	med	PROPN
aiua-10838	181	5	.	.	PROPN
aiua-10838	181	6	2018	2018	NUM
aiua-10838	181	7	;	;	PUNCT
aiua-10838	181	8	379:417	379:417	NUM
aiua-10838	181	9	-	-	SYM
aiua-10838	181	10	427	427	NUM
aiua-10838	181	11	.	.	PUNCT
aiua-10838	182	1	7	7	X
aiua-10838	182	2	.	.	X
aiua-10838	182	3	bex	bex	PROPN
aiua-10838	182	4	a	a	PRON
aiua-10838	182	5	,	,	PUNCT
aiua-10838	182	6	mulders	mulder	NOUN
aiua-10838	182	7	p	p	NOUN
aiua-10838	182	8	,	,	PUNCT
aiua-10838	182	9	jewett	jewett	PROPN
aiua-10838	182	10	m	m	PROPN
aiua-10838	182	11	,	,	PUNCT
aiua-10838	182	12	et	et	PROPN
aiua-10838	182	13	al	al	PROPN
aiua-10838	182	14	.	.	PROPN
aiua-10838	182	15	comparison	comparison	NOUN
aiua-10838	182	16	of	of	ADP
aiua-10838	182	17	immediate	immediate	ADJ
aiua-10838	182	18	vs	vs	ADP
aiua-10838	182	19	deferred	defer	VERB
aiua-10838	182	20	cytoreductive	cytoreductive	ADJ
aiua-10838	182	21	nephrectomy	nephrectomy	NOUN
aiua-10838	182	22	in	in	ADP
aiua-10838	182	23	patients	patient	NOUN
aiua-10838	182	24	with	with	ADP
aiua-10838	182	25	synchronous	synchronous	ADJ
aiua-10838	182	26	metastatic	metastatic	ADJ
aiua-10838	182	27	renal	renal	ADJ
aiua-10838	182	28	cell	cell	NOUN
aiua-10838	182	29	carcinoma	carcinoma	NOUN
aiua-10838	182	30	receiving	receive	VERB
aiua-10838	182	31	sunitinib	sunitinib	NOUN
aiua-10838	182	32	.	.	PUNCT
aiua-10838	183	1	the	the	DET
aiua-10838	183	2	surtime	surtime	NOUN
aiua-10838	183	3	randomized	randomize	VERB
aiua-10838	183	4	clinical	clinical	ADJ
aiua-10838	183	5	trial	trial	NOUN
aiua-10838	183	6	.	.	PUNCT
aiua-10838	184	1	jama	jama	PROPN
aiua-10838	184	2	oncol	oncol	ADJ
aiua-10838	184	3	.	.	PUNCT
aiua-10838	184	4	2019	2019	NUM
aiua-10838	184	5	;	;	PUNCT
aiua-10838	184	6	5:164	5:164	NUM
aiua-10838	184	7	-	-	SYM
aiua-10838	184	8	170	170	NUM
aiua-10838	184	9	.	.	NOUN
aiua-10838	184	10	8	8	NUM
aiua-10838	184	11	.	.	PUNCT
aiua-10838	184	12	motzer	motzer	PROPN
aiua-10838	184	13	rj	rj	PROPN
aiua-10838	184	14	,	,	PUNCT
aiua-10838	184	15	tannir	tannir	PROPN
aiua-10838	184	16	nm	nm	PROPN
aiua-10838	184	17	,	,	PUNCT
aiua-10838	184	18	mcdermott	mcdermott	PROPN
aiua-10838	184	19	df	df	PROPN
aiua-10838	184	20	,	,	PUNCT
aiua-10838	184	21	et	et	PROPN
aiua-10838	184	22	al	al	PROPN
aiua-10838	184	23	.	.	PROPN
aiua-10838	184	24	nivolumab	nivolumab	PROPN
aiua-10838	184	25	plus	plus	CCONJ
aiua-10838	184	26	ipilimumab	ipilimumab	X
aiua-10838	184	27	versus	versus	ADP
aiua-10838	184	28	sunitinib	sunitinib	NOUN
aiua-10838	184	29	in	in	ADP
aiua-10838	184	30	advanced	advanced	ADJ
aiua-10838	184	31	renal	renal	ADJ
aiua-10838	184	32	-	-	PUNCT
aiua-10838	184	33	cell	cell	NOUN
aiua-10838	184	34	carcinoma	carcinoma	NOUN
aiua-10838	184	35	.	.	PUNCT
aiua-10838	185	1	n	n	PRON
aiua-10838	185	2	engl	engl	PROPN
aiua-10838	185	3	j	j	PROPN
aiua-10838	185	4	med	med	PROPN
aiua-10838	185	5	.	.	PROPN
aiua-10838	185	6	2018	2018	NUM
aiua-10838	185	7	;	;	PUNCT
aiua-10838	185	8	378:1277	378:1277	NUM
aiua-10838	185	9	-	-	SYM
aiua-10838	185	10	1290	1290	NUM
aiua-10838	185	11	.	.	PUNCT
aiua-10838	186	1	9	9	X
aiua-10838	186	2	.	.	PUNCT
aiua-10838	186	3	rini	rini	PROPN
aiua-10838	186	4	bi	bi	PROPN
aiua-10838	186	5	,	,	PUNCT
aiua-10838	186	6	plimack	plimack	NOUN
aiua-10838	186	7	er	er	INTJ
aiua-10838	186	8	,	,	PUNCT
aiua-10838	186	9	stus	stus	PROPN
aiua-10838	186	10	v	v	PROPN
aiua-10838	186	11	,	,	PUNCT
aiua-10838	186	12	et	et	PROPN
aiua-10838	186	13	al	al	PROPN
aiua-10838	186	14	.	.	PROPN
aiua-10838	186	15	pembrolizumab	pembrolizumab	NOUN
aiua-10838	186	16	plus	plus	CCONJ
aiua-10838	186	17	axitinib	axitinib	NOUN
aiua-10838	186	18	versus	versus	ADP
aiua-10838	186	19	sunitinib	sunitinib	NOUN
aiua-10838	186	20	for	for	ADP
aiua-10838	186	21	advanced	advanced	ADJ
aiua-10838	186	22	renal	renal	ADJ
aiua-10838	186	23	-	-	PUNCT
aiua-10838	186	24	cell	cell	NOUN
aiua-10838	186	25	carcinoma	carcinoma	NOUN
aiua-10838	186	26	.	.	PUNCT
aiua-10838	187	1	n	n	PRON
aiua-10838	187	2	engl	engl	PROPN
aiua-10838	187	3	j	j	PROPN
aiua-10838	187	4	med	med	PROPN
aiua-10838	187	5	.	.	PROPN
aiua-10838	188	1	2019	2019	NUM
aiua-10838	188	2	;	;	PUNCT
aiua-10838	188	3	380:1116	380:1116	NUM
aiua-10838	188	4	-	-	SYM
aiua-10838	188	5	1127	1127	NUM
aiua-10838	188	6	.	.	PUNCT
aiua-10838	189	1	10	10	NUM
aiua-10838	189	2	.	.	PUNCT
aiua-10838	189	3	motzer	motzer	PROPN
aiua-10838	189	4	rj	rj	PROPN
aiua-10838	189	5	,	,	PUNCT
aiua-10838	189	6	penkov	penkov	PROPN
aiua-10838	189	7	k	k	PROPN
aiua-10838	189	8	,	,	PUNCT
aiua-10838	189	9	haanen	haanen	PROPN
aiua-10838	189	10	j	j	PROPN
aiua-10838	189	11	,	,	PUNCT
aiua-10838	189	12	et	et	PROPN
aiua-10838	189	13	al	al	PROPN
aiua-10838	189	14	.	.	PROPN
aiua-10838	189	15	avelumab	avelumab	PROPN
aiua-10838	189	16	plus	plus	CCONJ
aiua-10838	189	17	axitinib	axitinib	NOUN
aiua-10838	189	18	versus	versus	ADP
aiua-10838	189	19	sunitinib	sunitinib	NOUN
aiua-10838	189	20	for	for	ADP
aiua-10838	189	21	advanced	advanced	ADJ
aiua-10838	189	22	renal	renal	ADJ
aiua-10838	189	23	-	-	PUNCT
aiua-10838	189	24	cell	cell	NOUN
aiua-10838	189	25	carcinoma	carcinoma	NOUN
aiua-10838	189	26	.	.	PUNCT
aiua-10838	190	1	n	n	CCONJ
aiua-10838	190	2	engl	engl	PROPN
aiua-10838	190	3	j	j	PROPN
aiua-10838	190	4	med.2019	med.2019	NUM
aiua-10838	190	5	;	;	PUNCT
aiua-10838	190	6	380:1103	380:1103	NUM
aiua-10838	190	7	-	-	SYM
aiua-10838	190	8	1115	1115	NUM
aiua-10838	190	9	.	.	PUNCT
aiua-10838	191	1	11	11	NUM
aiua-10838	191	2	.	.	PUNCT
aiua-10838	192	1	moher	moher	PROPN
aiua-10838	192	2	d	d	PROPN
aiua-10838	192	3	,	,	PUNCT
aiua-10838	192	4	liberati	liberati	PROPN
aiua-10838	192	5	a	a	PRON
aiua-10838	192	6	,	,	PUNCT
aiua-10838	192	7	tetzlaff	tetzlaff	PROPN
aiua-10838	192	8	j	j	PROPN
aiua-10838	192	9	,	,	PUNCT
aiua-10838	192	10	altman	altman	PROPN
aiua-10838	192	11	dg	dg	PROPN
aiua-10838	192	12	;	;	PUNCT
aiua-10838	192	13	prisma	prisma	PROPN
aiua-10838	192	14	group	group	NOUN
aiua-10838	192	15	.	.	PUNCT
aiua-10838	193	1	preferred	preferred	ADJ
aiua-10838	193	2	reporting	reporting	NOUN
aiua-10838	193	3	items	item	NOUN
aiua-10838	193	4	for	for	ADP
aiua-10838	193	5	systematic	systematic	ADJ
aiua-10838	193	6	reviews	review	NOUN
aiua-10838	193	7	and	and	CCONJ
aiua-10838	193	8	meta	meta	NOUN
aiua-10838	193	9	-	-	PUNCT
aiua-10838	193	10	analyses	analysis	NOUN
aiua-10838	193	11	:	:	PUNCT
aiua-10838	193	12	the	the	DET
aiua-10838	193	13	prisma	prisma	PROPN
aiua-10838	193	14	statement	statement	NOUN
aiua-10838	193	15	.	.	PUNCT
aiua-10838	194	1	j	j	PROPN
aiua-10838	194	2	clin	clin	PROPN
aiua-10838	194	3	epidemiol	epidemiol	PROPN
aiua-10838	194	4	.	.	PUNCT
aiua-10838	194	5	2009	2009	NUM
aiua-10838	194	6	;	;	PUNCT
aiua-10838	194	7	62:1006	62:1006	NOUN
aiua-10838	194	8	-	-	NOUN
aiua-10838	194	9	1012	1012	NUM
aiua-10838	194	10	.	.	PUNCT
aiua-10838	195	1	12	12	NUM
aiua-10838	195	2	.	.	PUNCT
aiua-10838	196	1	higgins	higgins	PROPN
aiua-10838	196	2	jp	jp	PROPN
aiua-10838	196	3	,	,	PUNCT
aiua-10838	196	4	altman	altman	PROPN
aiua-10838	196	5	dg	dg	PROPN
aiua-10838	196	6	,	,	PUNCT
aiua-10838	196	7	gotzsche	gotzsche	NOUN
aiua-10838	196	8	pc	pc	PROPN
aiua-10838	196	9	,	,	PUNCT
aiua-10838	196	10	et	et	PROPN
aiua-10838	196	11	al	al	PROPN
aiua-10838	196	12	.	.	PUNCT
aiua-10838	197	1	the	the	DET
aiua-10838	197	2	cochrane	cochrane	PROPN
aiua-10838	197	3	collaboration	collaboration	NOUN
aiua-10838	197	4	's	's	PART
aiua-10838	197	5	tool	tool	NOUN
aiua-10838	197	6	for	for	ADP
aiua-10838	197	7	assessing	assess	VERB
aiua-10838	197	8	risk	risk	NOUN
aiua-10838	197	9	of	of	ADP
aiua-10838	197	10	bias	bias	NOUN
aiua-10838	197	11	in	in	ADP
aiua-10838	197	12	randomised	randomised	ADJ
aiua-10838	197	13	trials	trial	NOUN
aiua-10838	197	14	.	.	PUNCT
aiua-10838	198	1	bmj	bmj	PROPN
aiua-10838	198	2	.	.	PUNCT
aiua-10838	199	1	2011	2011	NUM
aiua-10838	199	2	;	;	PUNCT
aiua-10838	199	3	343	343	NUM
aiua-10838	199	4	:	:	PUNCT
aiua-10838	199	5	d5928	d5928	VERB
aiua-10838	199	6	13	13	NUM
aiua-10838	199	7	.	.	PUNCT
aiua-10838	200	1	sterne	sterne	PROPN
aiua-10838	200	2	ja	ja	PROPN
aiua-10838	200	3	,	,	PUNCT
aiua-10838	200	4	hernan	hernan	PROPN
aiua-10838	200	5	ma	ma	PROPN
aiua-10838	200	6	,	,	PUNCT
aiua-10838	200	7	reeves	reeves	PROPN
aiua-10838	200	8	bc	bc	PROPN
aiua-10838	200	9	,	,	PUNCT
aiua-10838	200	10	et	et	PROPN
aiua-10838	200	11	al	al	PROPN
aiua-10838	200	12	.	.	PUNCT
aiua-10838	201	1	robins	robins	PROPN
aiua-10838	201	2	-	-	PUNCT
aiua-10838	201	3	i	i	PRON
aiua-10838	201	4	:	:	PUNCT
aiua-10838	201	5	a	a	DET
aiua-10838	201	6	tool	tool	NOUN
aiua-10838	201	7	for	for	ADP
aiua-10838	201	8	assessing	assess	VERB
aiua-10838	201	9	risk	risk	NOUN
aiua-10838	201	10	of	of	ADP
aiua-10838	201	11	bias	bias	NOUN
aiua-10838	201	12	in	in	ADP
aiua-10838	201	13	non	non	ADJ
aiua-10838	201	14	-	-	ADJ
aiua-10838	201	15	randomised	randomised	ADJ
aiua-10838	201	16	studies	study	NOUN
aiua-10838	201	17	of	of	ADP
aiua-10838	201	18	interventions	intervention	NOUN
aiua-10838	201	19	.	.	PUNCT
aiua-10838	202	1	bmj	bmj	PROPN
aiua-10838	202	2	2016	2016	NUM
aiua-10838	202	3	;	;	PUNCT
aiua-10838	202	4	355	355	NUM
aiua-10838	202	5	:	:	PUNCT
aiua-10838	202	6	i4919	i4919	PROPN
aiua-10838	202	7	.	.	PROPN
aiua-10838	202	8	14	14	NUM
aiua-10838	202	9	.	.	PUNCT
aiua-10838	203	1	conti	conti	PROPN
aiua-10838	203	2	sl	sl	PROPN
aiua-10838	203	3	,	,	PUNCT
aiua-10838	203	4	thomas	thomas	PROPN
aiua-10838	203	5	ic	ic	PROPN
aiua-10838	203	6	,	,	PUNCT
aiua-10838	203	7	hagedorn	hagedorn	PROPN
aiua-10838	203	8	jc	jc	PROPN
aiua-10838	203	9	,	,	PUNCT
aiua-10838	203	10	et	et	PROPN
aiua-10838	203	11	al	al	PROPN
aiua-10838	203	12	.	.	PUNCT
aiua-10838	203	13	utilization	utilization	NOUN
aiua-10838	203	14	of	of	ADP
aiua-10838	203	15	cytoreductive	cytoreductive	ADJ
aiua-10838	203	16	nephrectomy	nephrectomy	ADJ
aiua-10838	203	17	and	and	CCONJ
aiua-10838	203	18	patient	patient	ADJ
aiua-10838	203	19	survival	survival	NOUN
aiua-10838	203	20	in	in	ADP
aiua-10838	203	21	the	the	DET
aiua-10838	203	22	targeted	target	VERB
aiua-10838	203	23	therapy	therapy	NOUN
aiua-10838	203	24	era	era	NOUN
aiua-10838	203	25	.	.	PUNCT
aiua-10838	204	1	int	int	NOUN
aiua-10838	204	2	j	j	PROPN
aiua-10838	204	3	cancer	cancer	NOUN
aiua-10838	204	4	.	.	PUNCT
aiua-10838	205	1	2014	2014	NUM
aiua-10838	205	2	;	;	PUNCT
aiua-10838	205	3	134:2245	134:2245	NUM
aiua-10838	205	4	-	-	SYM
aiua-10838	205	5	52	52	NUM
aiua-10838	205	6	.	.	NOUN
aiua-10838	206	1	15	15	NUM
aiua-10838	206	2	.	.	PUNCT
aiua-10838	207	1	aizer	aizer	NOUN
aiua-10838	207	2	aa	aa	NOUN
aiua-10838	207	3	,	,	PUNCT
aiua-10838	207	4	urun	urun	PROPN
aiua-10838	207	5	y	y	PROPN
aiua-10838	207	6	,	,	PUNCT
aiua-10838	207	7	mckay	mckay	PROPN
aiua-10838	207	8	rr	rr	PROPN
aiua-10838	207	9	,	,	PUNCT
aiua-10838	207	10	et	et	PROPN
aiua-10838	207	11	al	al	PROPN
aiua-10838	207	12	.	.	PUNCT
aiua-10838	208	1	cytoreductive	cytoreductive	PROPN
aiua-10838	208	2	nephrectomy	nephrectomy	ADV
aiua-10838	208	3	in	in	ADP
aiua-10838	208	4	patients	patient	NOUN
aiua-10838	208	5	with	with	ADP
aiua-10838	208	6	metastatic	metastatic	ADJ
aiua-10838	208	7	non	non	ADJ
aiua-10838	208	8	-	-	ADJ
aiua-10838	208	9	clear	clear	ADJ
aiua-10838	208	10	-	-	PUNCT
aiua-10838	208	11	cell	cell	NOUN
aiua-10838	208	12	renal	renal	ADJ
aiua-10838	208	13	cell	cell	NOUN
aiua-10838	208	14	carcinoma	carcinoma	NOUN
aiua-10838	208	15	(	(	PUNCT
aiua-10838	208	16	rcc	rcc	PROPN
aiua-10838	208	17	)	)	PUNCT
aiua-10838	208	18	.	.	PUNCT
aiua-10838	209	1	bju	bju	PROPN
aiua-10838	209	2	int	int	PROPN
aiua-10838	209	3	.	.	PUNCT
aiua-10838	210	1	2014	2014	NUM
aiua-10838	210	2	;	;	PUNCT
aiua-10838	210	3	113	113	NUM
aiua-10838	210	4	:	:	PUNCT
aiua-10838	210	5	e67	e67	NOUN
aiua-10838	210	6	-	-	PUNCT
aiua-10838	210	7	74	74	NUM
aiua-10838	210	8	.	.	PUNCT
aiua-10838	211	1	16	16	NUM
aiua-10838	211	2	.	.	PUNCT
aiua-10838	212	1	abern	abern	PROPN
aiua-10838	212	2	mr	mr	PROPN
aiua-10838	212	3	,	,	PUNCT
aiua-10838	212	4	scosyrev	scosyrev	X
aiua-10838	212	5	e	e	NOUN
aiua-10838	212	6	,	,	PUNCT
aiua-10838	212	7	tsivian	tsivian	PROPN
aiua-10838	212	8	m	m	PROPN
aiua-10838	212	9	,	,	PUNCT
aiua-10838	212	10	et	et	PROPN
aiua-10838	212	11	al	al	PROPN
aiua-10838	212	12	.	.	PROPN
aiua-10838	212	13	survival	survival	NOUN
aiua-10838	212	14	of	of	ADP
aiua-10838	212	15	patients	patient	NOUN
aiua-10838	212	16	undergoing	undergo	VERB
aiua-10838	212	17	cytoreductive	cytoreductive	ADJ
aiua-10838	212	18	surgery	surgery	NOUN
aiua-10838	212	19	for	for	ADP
aiua-10838	212	20	metastatic	metastatic	ADJ
aiua-10838	212	21	renal	renal	ADJ
aiua-10838	212	22	cell	cell	NOUN
aiua-10838	212	23	carcinoma	carcinoma	NOUN
aiua-10838	212	24	in	in	ADP
aiua-10838	212	25	the	the	DET
aiua-10838	212	26	targeted	target	VERB
aiua-10838	212	27	-	-	PUNCT
aiua-10838	212	28	therapy	therapy	NOUN
aiua-10838	212	29	era	era	NOUN
aiua-10838	212	30	.	.	PUNCT
aiua-10838	213	1	anticancer	anticancer	NOUN
aiua-10838	213	2	res	re	NOUN
aiua-10838	213	3	.	.	PUNCT
aiua-10838	213	4	2014	2014	NUM
aiua-10838	213	5	;	;	PUNCT
aiua-10838	213	6	34:2405	34:2405	NUM
aiua-10838	213	7	-	-	SYM
aiua-10838	213	8	11	11	NUM
aiua-10838	213	9	.	.	PUNCT
aiua-10838	214	1	17	17	NUM
aiua-10838	214	2	.	.	X
aiua-10838	214	3	vaishampayan	vaishampayan	PROPN
aiua-10838	214	4	u	u	PROPN
aiua-10838	214	5	,	,	PUNCT
aiua-10838	214	6	george	george	PROPN
aiua-10838	214	7	j	j	PROPN
aiua-10838	214	8	,	,	PUNCT
aiua-10838	214	9	vigneau	vigneau	PROPN
aiua-10838	214	10	f.	f.	PROPN
aiua-10838	214	11	predictors	predictor	NOUN
aiua-10838	214	12	of	of	ADP
aiua-10838	214	13	cytoreductive	cytoreductive	ADJ
aiua-10838	214	14	nephrectomy	nephrectomy	NOUN
aiua-10838	214	15	for	for	ADP
aiua-10838	214	16	metastatic	metastatic	ADJ
aiua-10838	214	17	kidney	kidney	NOUN
aiua-10838	214	18	cancer	cancer	NOUN
aiua-10838	214	19	in	in	ADP
aiua-10838	214	20	seer	seer	PROPN
aiua-10838	214	21	and	and	CCONJ
aiua-10838	214	22	metropolitan	metropolitan	PROPN
aiua-10838	214	23	detroit	detroit	PROPN
aiua-10838	214	24	databases	database	NOUN
aiua-10838	214	25	.	.	PUNCT
aiua-10838	215	1	j	j	PROPN
aiua-10838	215	2	kidney	kidney	PROPN
aiua-10838	215	3	cancer	cancer	PROPN
aiua-10838	215	4	vhl	vhl	PROPN
aiua-10838	215	5	.	.	PUNCT
aiua-10838	216	1	2019	2019	NUM
aiua-10838	216	2	;	;	PUNCT
aiua-10838	216	3	6:13	6:13	NUM
aiua-10838	216	4	-	-	SYM
aiua-10838	216	5	25	25	NUM
aiua-10838	216	6	.	.	PUNCT
aiua-10838	216	7	18	18	NUM
aiua-10838	216	8	.	.	PUNCT
aiua-10838	217	1	zhao	zhao	PROPN
aiua-10838	217	2	z	z	PROPN
aiua-10838	217	3	,	,	PUNCT
aiua-10838	217	4	wu	wu	PROPN
aiua-10838	217	5	w	w	PROPN
aiua-10838	217	6	,	,	PUNCT
aiua-10838	217	7	duan	duan	PROPN
aiua-10838	217	8	x	x	PROPN
aiua-10838	217	9	,	,	PUNCT
aiua-10838	217	10	et	et	PROPN
aiua-10838	217	11	al	al	PROPN
aiua-10838	217	12	.	.	PUNCT
aiua-10838	218	1	the	the	DET
aiua-10838	218	2	value	value	NOUN
aiua-10838	218	3	of	of	ADP
aiua-10838	218	4	cytoreductive	cytoreductive	ADJ
aiua-10838	218	5	nephrectomy	nephrectomy	NOUN
aiua-10838	218	6	on	on	ADP
aiua-10838	218	7	the	the	DET
aiua-10838	218	8	survival	survival	NOUN
aiua-10838	218	9	of	of	ADP
aiua-10838	218	10	metastatic	metastatic	ADJ
aiua-10838	218	11	renal	renal	ADJ
aiua-10838	218	12	carcinoma	carcinoma	NOUN
aiua-10838	218	13	patients	patient	NOUN
aiua-10838	218	14	based	base	VERB
aiua-10838	218	15	on	on	ADP
aiua-10838	218	16	the	the	DET
aiua-10838	218	17	number	number	NOUN
aiua-10838	218	18	of	of	ADP
aiua-10838	218	19	site	site	NOUN
aiua-10838	218	20	-	-	PUNCT
aiua-10838	218	21	specific	specific	ADJ
aiua-10838	218	22	metastases	metastasis	NOUN
aiua-10838	218	23	.	.	PUNCT
aiua-10838	219	1	plos	plos	PROPN
aiua-10838	219	2	one	one	NUM
aiua-10838	219	3	.	.	PUNCT
aiua-10838	219	4	2019	2019	NUM
aiua-10838	219	5	;	;	PUNCT
aiua-10838	219	6	14	14	NUM
aiua-10838	219	7	:	:	PUNCT
aiua-10838	219	8	e0215861	e0215861	PROPN
aiua-10838	219	9	.	.	PUNCT
aiua-10838	220	1	19	19	NUM
aiua-10838	220	2	.	.	PUNCT
aiua-10838	220	3	marchioni	marchioni	PROPN
aiua-10838	220	4	m	m	PROPN
aiua-10838	220	5	,	,	PUNCT
aiua-10838	220	6	bandini	bandini	PROPN
aiua-10838	220	7	m	m	PROPN
aiua-10838	220	8	,	,	PUNCT
aiua-10838	220	9	preisser	preisser	NOUN
aiua-10838	220	10	f	f	PROPN
aiua-10838	220	11	,	,	PUNCT
aiua-10838	220	12	et	et	PROPN
aiua-10838	220	13	al	al	PROPN
aiua-10838	220	14	.	.	PROPN
aiua-10838	220	15	survival	survival	PROPN
aiua-10838	220	16	after	after	ADP
aiua-10838	220	17	cytoreductive	cytoreductive	NUM
aiua-10838	220	18	nephrectomy	nephrectomy	ADV
aiua-10838	220	19	in	in	ADP
aiua-10838	220	20	metastatic	metastatic	ADJ
aiua-10838	220	21	non	non	ADJ
aiua-10838	220	22	-	-	ADJ
aiua-10838	220	23	clear	clear	ADJ
aiua-10838	220	24	cell	cell	NOUN
aiua-10838	220	25	renal	renal	ADJ
aiua-10838	220	26	cell	cell	NOUN
aiua-10838	220	27	carcinoma	carcinoma	NOUN
aiua-10838	220	28	patients	patient	NOUN
aiua-10838	220	29	:	:	PUNCT
aiua-10838	220	30	a	a	DET
aiua-10838	220	31	population	population	NOUN
aiua-10838	220	32	-	-	PUNCT
aiua-10838	220	33	based	base	VERB
aiua-10838	220	34	study	study	NOUN
aiua-10838	220	35	.	.	PUNCT
aiua-10838	221	1	eur	eur	PROPN
aiua-10838	221	2	urol	urol	PROPN
aiua-10838	221	3	focus	focus	NOUN
aiua-10838	221	4	.	.	PUNCT
aiua-10838	222	1	2019	2019	NUM
aiua-10838	222	2	;	;	PUNCT
aiua-10838	222	3	5:488	5:488	NUM
aiua-10838	222	4	-	-	SYM
aiua-10838	222	5	496	496	NUM
aiua-10838	222	6	.	.	PUNCT
aiua-10838	223	1	20	20	NUM
aiua-10838	223	2	.	.	PUNCT
aiua-10838	224	1	palumbo	palumbo	PROPN
aiua-10838	224	2	c	c	PROPN
aiua-10838	224	3	,	,	PUNCT
aiua-10838	224	4	mistretta	mistretta	PROPN
aiua-10838	224	5	fa	fa	PROPN
aiua-10838	224	6	,	,	PUNCT
aiua-10838	224	7	knipper	knipper	PROPN
aiua-10838	224	8	s	s	PROPN
aiua-10838	224	9	,	,	PUNCT
aiua-10838	224	10	et	et	PROPN
aiua-10838	224	11	al	al	PROPN
aiua-10838	224	12	.	.	PUNCT
aiua-10838	225	1	contemporary	contemporary	ADJ
aiua-10838	225	2	cytoreductive	cytoreductive	PROPN
aiua-10838	225	3	nephrectomy	nephrectomy	NOUN
aiua-10838	225	4	provides	provide	VERB
aiua-10838	225	5	survival	survival	NOUN
aiua-10838	225	6	benefit	benefit	NOUN
aiua-10838	225	7	in	in	ADP
aiua-10838	225	8	clear	clear	ADJ
aiua-10838	225	9	-	-	PUNCT
aiua-10838	225	10	cell	cell	NOUN
aiua-10838	225	11	metastatic	metastatic	ADJ
aiua-10838	225	12	renal	renal	ADJ
aiua-10838	225	13	cell	cell	NOUN
aiua-10838	225	14	carcinoma	carcinoma	NOUN
aiua-10838	225	15	.	.	PUNCT
aiua-10838	226	1	clin	clin	PROPN
aiua-10838	226	2	genitourin	genitourin	NOUN
aiua-10838	226	3	cancer	cancer	NOUN
aiua-10838	226	4	.	.	PUNCT
aiua-10838	227	1	2020	2020	NUM
aiua-10838	227	2	;	;	PUNCT
aiua-10838	227	3	18	18	NUM
aiua-10838	227	4	:	:	PUNCT
aiua-10838	227	5	e730	e730	NUM
aiua-10838	227	6	-	-	SYM
aiua-10838	227	7	e738	e738	PROPN
aiua-10838	227	8	.	.	NOUN
aiua-10838	227	9	21	21	NUM
aiua-10838	227	10	.	.	PUNCT
aiua-10838	228	1	luzzago	luzzago	PROPN
aiua-10838	228	2	s	s	PROPN
aiua-10838	228	3	,	,	PUNCT
aiua-10838	228	4	palumbo	palumbo	PROPN
aiua-10838	228	5	c	c	X
aiua-10838	228	6	,	,	PUNCT
aiua-10838	228	7	rosiello	rosiello	VERB
aiua-10838	228	8	g	g	PROPN
aiua-10838	228	9	,	,	PUNCT
aiua-10838	228	10	et	et	PROPN
aiua-10838	228	11	al	al	PROPN
aiua-10838	228	12	.	.	PROPN
aiua-10838	228	13	association	association	PROPN
aiua-10838	228	14	between	between	ADP
aiua-10838	228	15	systemic	systemic	ADJ
aiua-10838	228	16	therapy	therapy	NOUN
aiua-10838	228	17	and/or	and/or	CCONJ
aiua-10838	228	18	cytoreductive	cytoreductive	VERB
aiua-10838	228	19	nephrectomy	nephrectomy	NOUN
aiua-10838	228	20	and	and	CCONJ
aiua-10838	228	21	survival	survival	NOUN
aiua-10838	228	22	in	in	ADP
aiua-10838	228	23	contemporary	contemporary	PROPN
aiua-10838	228	24	metastatic	metastatic	ADJ
aiua-10838	228	25	non	non	ADJ
aiua-10838	228	26	-	-	ADJ
aiua-10838	228	27	clear	clear	ADJ
aiua-10838	228	28	cell	cell	NOUN
aiua-10838	228	29	renal	renal	ADJ
aiua-10838	228	30	cell	cell	NOUN
aiua-10838	228	31	carcinoma	carcinoma	NOUN
aiua-10838	228	32	patients	patient	NOUN
aiua-10838	228	33	.	.	PUNCT
aiua-10838	229	1	eur	eur	PROPN
aiua-10838	229	2	urol	urol	ADJ
aiua-10838	229	3	focus	focus	NOUN
aiua-10838	229	4	.	.	PUNCT
aiua-10838	230	1	2021	2021	NUM
aiua-10838	230	2	;	;	PUNCT
aiua-10838	230	3	7:598	7:598	NUM
aiua-10838	230	4	-	-	SYM
aiua-10838	230	5	607	607	NUM
aiua-10838	230	6	.	.	PUNCT
aiua-10838	231	1	22	22	NUM
aiua-10838	231	2	.	.	PUNCT
aiua-10838	232	1	alnimer	alnimer	PROPN
aiua-10838	232	2	y	y	PROPN
aiua-10838	232	3	,	,	PUNCT
aiua-10838	232	4	qasrawi	qasrawi	PROPN
aiua-10838	232	5	a	a	X
aiua-10838	232	6	,	,	PUNCT
aiua-10838	232	7	yan	yan	PROPN
aiua-10838	233	1	d	d	NOUN
aiua-10838	233	2	,	,	PUNCT
aiua-10838	233	3	wang	wang	PROPN
aiua-10838	233	4	p.	p.	PROPN
aiua-10838	233	5	prognostic	prognostic	PROPN
aiua-10838	233	6	impact	impact	NOUN
aiua-10838	233	7	of	of	ADP
aiua-10838	233	8	cytoreductive	cytoreductive	ADJ
aiua-10838	233	9	nephrectomy	nephrectomy	NOUN
aiua-10838	233	10	in	in	ADP
aiua-10838	233	11	patients	patient	NOUN
aiua-10838	233	12	with	with	ADP
aiua-10838	233	13	metastatic	metastatic	ADJ
aiua-10838	233	14	renal	renal	ADJ
aiua-10838	233	15	cell	cell	NOUN
aiua-10838	233	16	carcinoma	carcinoma	NOUN
aiua-10838	233	17	:	:	PUNCT
aiua-10838	233	18	data	datum	NOUN
aiua-10838	233	19	from	from	ADP
aiua-10838	233	20	a	a	DET
aiua-10838	233	21	large	large	ADJ
aiua-10838	233	22	population	population	NOUN
aiua-10838	233	23	-	-	PUNCT
aiua-10838	233	24	based	base	VERB
aiua-10838	233	25	database	database	NOUN
aiua-10838	233	26	.	.	PUNCT
aiua-10838	234	1	urol	urol	PROPN
aiua-10838	234	2	j.	j.	PROPN
aiua-10838	234	3	2021	2021	NUM
aiua-10838	234	4	;	;	PUNCT
aiua-10838	234	5	19:111	19:111	NUM
aiua-10838	234	6	-	-	SYM
aiua-10838	234	7	119	119	NUM
aiua-10838	234	8	23	23	NUM
aiua-10838	234	9	.	.	PUNCT
aiua-10838	235	1	hanna	hanna	PROPN
aiua-10838	235	2	n	n	CCONJ
aiua-10838	235	3	,	,	PUNCT
aiua-10838	235	4	sun	sun	PROPN
aiua-10838	235	5	m	m	PROPN
aiua-10838	235	6	,	,	PUNCT
aiua-10838	235	7	meyer	meyer	PROPN
aiua-10838	235	8	cp	cp	PROPN
aiua-10838	235	9	,	,	PUNCT
aiua-10838	235	10	et	et	PROPN
aiua-10838	235	11	al	al	PROPN
aiua-10838	235	12	.	.	PUNCT
aiua-10838	235	13	survival	survival	NOUN
aiua-10838	235	14	analyses	analysis	NOUN
aiua-10838	235	15	of	of	ADP
aiua-10838	235	16	patients	patient	NOUN
aiua-10838	235	17	with	with	ADP
aiua-10838	235	18	metastatic	metastatic	ADJ
aiua-10838	235	19	renal	renal	ADJ
aiua-10838	235	20	cancer	cancer	NOUN
aiua-10838	235	21	treated	treat	VERB
aiua-10838	235	22	with	with	ADP
aiua-10838	235	23	targeted	target	VERB
aiua-10838	235	24	therapy	therapy	NOUN
aiua-10838	235	25	with	with	ADP
aiua-10838	235	26	or	or	CCONJ
aiua-10838	235	27	without	without	ADP
aiua-10838	235	28	cytoreductive	cytoreductive	ADJ
aiua-10838	235	29	nephrectomy	nephrectomy	NOUN
aiua-10838	235	30	:	:	PUNCT
aiua-10838	235	31	a	a	DET
aiua-10838	235	32	national	national	ADJ
aiua-10838	235	33	cancer	cancer	NOUN
aiua-10838	235	34	data	data	PROPN
aiua-10838	235	35	base	base	PROPN
aiua-10838	235	36	study	study	NOUN
aiua-10838	235	37	.	.	PUNCT
aiua-10838	236	1	j	j	PROPN
aiua-10838	236	2	clin	clin	PROPN
aiua-10838	236	3	oncol	oncol	PROPN
aiua-10838	236	4	.	.	PUNCT
aiua-10838	237	1	2016	2016	NUM
aiua-10838	237	2	;	;	PUNCT
aiua-10838	238	1	34:3267	34:3267	NUM
aiua-10838	238	2	-	-	SYM
aiua-10838	238	3	75	75	NUM
aiua-10838	238	4	.	.	PUNCT
aiua-10838	238	5	24	24	NUM
aiua-10838	238	6	singla	singla	PROPN
aiua-10838	238	7	n	n	CCONJ
aiua-10838	238	8	,	,	PUNCT
aiua-10838	238	9	hutchinson	hutchinson	PROPN
aiua-10838	238	10	rc	rc	PROPN
aiua-10838	238	11	,	,	PUNCT
aiua-10838	238	12	ghandour	ghandour	PROPN
aiua-10838	238	13	ra	ra	PROPN
aiua-10838	238	14	,	,	PUNCT
aiua-10838	238	15	et	et	PROPN
aiua-10838	238	16	al	al	PROPN
aiua-10838	238	17	.	.	PROPN
aiua-10838	238	18	improved	improved	ADJ
aiua-10838	238	19	survival	survival	NOUN
aiua-10838	238	20	after	after	ADP
aiua-10838	238	21	cytoreductive	cytoreductive	NOUN
aiua-10838	238	22	nephrectomy	nephrectomy	NOUN
aiua-10838	238	23	for	for	ADP
aiua-10838	238	24	metastatic	metastatic	ADJ
aiua-10838	238	25	renal	renal	ADJ
aiua-10838	238	26	cell	cell	NOUN
aiua-10838	238	27	carcinoma	carcinoma	NOUN
aiua-10838	238	28	in	in	ADP
aiua-10838	238	29	the	the	DET
aiua-10838	238	30	contemporary	contemporary	ADJ
aiua-10838	238	31	immunotherapy	immunotherapy	NOUN
aiua-10838	238	32	era	era	NOUN
aiua-10838	238	33	:	:	PUNCT
aiua-10838	238	34	an	an	DET
aiua-10838	238	35	analysis	analysis	NOUN
aiua-10838	238	36	of	of	ADP
aiua-10838	238	37	the	the	DET
aiua-10838	238	38	national	national	ADJ
aiua-10838	238	39	cancer	cancer	NOUN
aiua-10838	238	40	database	database	NOUN
aiua-10838	238	41	.	.	PUNCT
aiua-10838	239	1	urol	urol	PROPN
aiua-10838	239	2	oncol	oncol	PROPN
aiua-10838	239	3	.	.	PUNCT
aiua-10838	240	1	2020	2020	NUM
aiua-10838	240	2	;	;	PUNCT
aiua-10838	240	3	38:604.e9	38:604.e9	NUM
aiua-10838	240	4	-	-	SYM
aiua-10838	240	5	604.e17.25	604.e17.25	PROPN
aiua-10838	240	6	.	.	PROPN
aiua-10838	240	7	26	26	NUM
aiua-10838	240	8	.	.	PUNCT
aiua-10838	241	1	janisch	janisch	PROPN
aiua-10838	241	2	f	f	PROPN
aiua-10838	241	3	,	,	PUNCT
aiua-10838	241	4	hillemacher	hillemacher	PROPN
aiua-10838	241	5	t	t	PROPN
aiua-10838	241	6	,	,	PUNCT
aiua-10838	241	7	fuehner	fuehner	PROPN
aiua-10838	241	8	c	c	NOUN
aiua-10838	241	9	,	,	PUNCT
aiua-10838	241	10	et	et	PROPN
aiua-10838	241	11	al	al	PROPN
aiua-10838	241	12	.	.	PUNCT
aiua-10838	242	1	the	the	DET
aiua-10838	242	2	impact	impact	NOUN
aiua-10838	242	3	of	of	ADP
aiua-10838	242	4	cytoreductive	cytoreductive	ADJ
aiua-10838	242	5	nephrectomy	nephrectomy	NOUN
aiua-10838	242	6	on	on	ADP
aiua-10838	242	7	survival	survival	NOUN
aiua-10838	242	8	outcomes	outcome	NOUN
aiua-10838	242	9	in	in	ADP
aiua-10838	242	10	patients	patient	NOUN
aiua-10838	242	11	treated	treat	VERB
aiua-10838	242	12	with	with	ADP
aiua-10838	242	13	tyrosine	tyrosine	PROPN
aiua-10838	242	14	kinase	kinase	PROPN
aiua-10838	242	15	inhibitors	inhibitor	NOUN
aiua-10838	242	16	for	for	ADP
aiua-10838	242	17	metastatic	metastatic	ADJ
aiua-10838	242	18	renal	renal	ADJ
aiua-10838	242	19	cell	cell	NOUN
aiua-10838	242	20	carcinoma	carcinoma	NOUN
aiua-10838	242	21	in	in	ADP
aiua-10838	242	22	a	a	DET
aiua-10838	242	23	real	real	ADJ
aiua-10838	242	24	-	-	PUNCT
aiua-10838	242	25	world	world	NOUN
aiua-10838	242	26	cohort	cohort	NOUN
aiua-10838	242	27	.	.	PUNCT
aiua-10838	243	1	urol	urol	PROPN
aiua-10838	243	2	oncol	oncol	PROPN
aiua-10838	243	3	.	.	PUNCT
aiua-10838	244	1	2020	2020	NUM
aiua-10838	244	2	;	;	PUNCT
aiua-10838	245	1	38:739.e9	38:739.e9	NUM
aiua-10838	245	2	-	-	PUNCT
aiua-10838	245	3	739.e15	739.e15	PROPN
aiua-10838	245	4	.	.	PROPN
aiua-10838	245	5	27	27	NUM
aiua-10838	245	6	.	.	PUNCT
aiua-10838	246	1	you	you	PRON
aiua-10838	246	2	d	d	PROPN
aiua-10838	246	3	,	,	PUNCT
aiua-10838	246	4	jeong	jeong	PROPN
aiua-10838	246	5	ig	ig	PROPN
aiua-10838	246	6	,	,	PUNCT
aiua-10838	246	7	ahn	ahn	PROPN
aiua-10838	246	8	jh	jh	PROPN
aiua-10838	246	9	,	,	PUNCT
aiua-10838	246	10	et	et	PROPN
aiua-10838	246	11	al	al	PROPN
aiua-10838	246	12	.	.	PUNCT
aiua-10838	247	1	the	the	DET
aiua-10838	247	2	value	value	NOUN
aiua-10838	247	3	of	of	ADP
aiua-10838	247	4	cytoreductive	cytoreductive	ADJ
aiua-10838	247	5	nephrectomy	nephrectomy	NOUN
aiua-10838	247	6	for	for	ADP
aiua-10838	247	7	metastatic	metastatic	ADJ
aiua-10838	247	8	renal	renal	ADJ
aiua-10838	247	9	cell	cell	NOUN
aiua-10838	247	10	carcinoma	carcinoma	NOUN
aiua-10838	247	11	in	in	ADP
aiua-10838	247	12	the	the	DET
aiua-10838	247	13	era	era	NOUN
aiua-10838	247	14	of	of	ADP
aiua-10838	247	15	targeted	target	VERB
aiua-10838	247	16	therapy	therapy	NOUN
aiua-10838	247	17	.	.	PUNCT
aiua-10838	248	1	j	j	PROPN
aiua-10838	248	2	urol	urol	PROPN
aiua-10838	248	3	.	.	PUNCT
aiua-10838	249	1	2011	2011	NUM
aiua-10838	249	2	;	;	PUNCT
aiua-10838	249	3	185:54	185:54	NUM
aiua-10838	249	4	-	-	SYM
aiua-10838	249	5	9	9	NUM
aiua-10838	249	6	.	.	NOUN
aiua-10838	249	7	28	28	NUM
aiua-10838	249	8	.	.	PUNCT
aiua-10838	250	1	graham	graham	PROPN
aiua-10838	250	2	j	j	PROPN
aiua-10838	250	3	,	,	PUNCT
aiua-10838	250	4	wells	wells	PROPN
aiua-10838	250	5	jc	jc	PROPN
aiua-10838	250	6	,	,	PUNCT
aiua-10838	250	7	donskov	donskov	PROPN
aiua-10838	250	8	f	f	X
aiua-10838	250	9	,	,	PUNCT
aiua-10838	250	10	et	et	PROPN
aiua-10838	250	11	al	al	PROPN
aiua-10838	250	12	.	.	PUNCT
aiua-10838	251	1	cytoreductive	cytoreductive	PROPN
aiua-10838	251	2	nephrectomy	nephrectomy	ADV
aiua-10838	251	3	in	in	ADP
aiua-10838	251	4	metastatic	metastatic	ADJ
aiua-10838	251	5	papillary	papillary	ADJ
aiua-10838	251	6	renal	renal	ADJ
aiua-10838	251	7	cell	cell	NOUN
aiua-10838	251	8	carcinoma	carcinoma	NOUN
aiua-10838	251	9	:	:	PUNCT
aiua-10838	251	10	results	result	NOUN
aiua-10838	251	11	from	from	ADP
aiua-10838	251	12	the	the	DET
aiua-10838	251	13	international	international	ADJ
aiua-10838	251	14	metastatic	metastatic	ADJ
aiua-10838	251	15	renal	renal	ADJ
aiua-10838	251	16	cell	cell	NOUN
aiua-10838	251	17	carcinoma	carcinoma	NOUN
aiua-10838	251	18	database	database	NOUN
aiua-10838	251	19	consortium	consortium	NOUN
aiua-10838	251	20	.	.	PUNCT
aiua-10838	252	1	eur	eur	PROPN
aiua-10838	252	2	urol	urol	PROPN
aiua-10838	252	3	oncol	oncol	PROPN
aiua-10838	252	4	.	.	PUNCT
aiua-10838	253	1	2019	2019	NUM
aiua-10838	253	2	;	;	PUNCT
aiua-10838	253	3	2:643	2:643	NUM
aiua-10838	253	4	-	-	SYM
aiua-10838	253	5	648	648	NUM
aiua-10838	253	6	.	.	PUNCT
aiua-10838	254	1	29	29	NUM
aiua-10838	254	2	.	.	PUNCT
aiua-10838	254	3	klatte	klatte	PROPN
aiua-10838	254	4	t	t	PROPN
aiua-10838	254	5	,	,	PUNCT
aiua-10838	254	6	fife	fife	PROPN
aiua-10838	254	7	k	k	PROPN
aiua-10838	254	8	,	,	PUNCT
aiua-10838	254	9	welsh	welsh	NOUN
aiua-10838	254	10	sj	sj	PROPN
aiua-10838	254	11	,	,	PUNCT
aiua-10838	254	12	et	et	PROPN
aiua-10838	254	13	al	al	PROPN
aiua-10838	254	14	.	.	PROPN
aiua-10838	255	1	prognostic	prognostic	ADJ
aiua-10838	255	2	effect	effect	NOUN
aiua-10838	255	3	of	of	ADP
aiua-10838	255	4	cytoreductive	cytoreductive	ADJ
aiua-10838	255	5	nephrectomy	nephrectomy	NOUN
aiua-10838	255	6	in	in	ADP
aiua-10838	255	7	synchronous	synchronous	ADJ
aiua-10838	255	8	metastatic	metastatic	ADJ
aiua-10838	255	9	renal	renal	ADJ
aiua-10838	255	10	cell	cell	NOUN
aiua-10838	255	11	carcinoma	carcinoma	NOUN
aiua-10838	255	12	:	:	PUNCT
aiua-10838	255	13	a	a	DET
aiua-10838	255	14	comparative	comparative	ADJ
aiua-10838	255	15	study	study	NOUN
aiua-10838	255	16	using	use	VERB
aiua-10838	255	17	inverse	inverse	NOUN
aiua-10838	255	18	probability	probability	NOUN
aiua-10838	255	19	of	of	ADP
aiua-10838	255	20	treatment	treatment	NOUN
aiua-10838	255	21	weighting	weighting	NOUN
aiua-10838	255	22	.	.	PUNCT
aiua-10838	256	1	world	world	PROPN
aiua-10838	256	2	j	j	PROPN
aiua-10838	256	3	urol	urol	PROPN
aiua-10838	256	4	.	.	PROPN
aiua-10838	256	5	2018	2018	NUM
aiua-10838	256	6	;	;	PUNCT
aiua-10838	256	7	36:417	36:417	NUM
aiua-10838	256	8	-	-	SYM
aiua-10838	256	9	425	425	NUM
aiua-10838	256	10	.	.	NOUN
aiua-10838	256	11	30	30	NUM
aiua-10838	256	12	.	.	PUNCT
aiua-10838	257	1	you	you	PRON
aiua-10838	257	2	d	d	PROPN
aiua-10838	257	3	,	,	PUNCT
aiua-10838	257	4	jeong	jeong	PROPN
aiua-10838	257	5	ig	ig	PROPN
aiua-10838	257	6	,	,	PUNCT
aiua-10838	257	7	song	song	NOUN
aiua-10838	257	8	c	c	PROPN
aiua-10838	257	9	,	,	PUNCT
aiua-10838	257	10	et	et	PROPN
aiua-10838	257	11	al	al	PROPN
aiua-10838	257	12	.	.	PUNCT
aiua-10838	258	1	analysis	analysis	NOUN
aiua-10838	258	2	of	of	ADP
aiua-10838	258	3	pre	pre	ADJ
aiua-10838	258	4	-	-	ADJ
aiua-10838	258	5	operative	operative	ADJ
aiua-10838	258	6	variables	variable	NOUN
aiua-10838	258	7	for	for	ADP
aiua-10838	258	8	identifying	identify	VERB
aiua-10838	258	9	patients	patient	NOUN
aiua-10838	258	10	who	who	PRON
aiua-10838	258	11	might	might	AUX
aiua-10838	258	12	benefit	benefit	VERB
aiua-10838	258	13	from	from	ADP
aiua-10838	258	14	upfront	upfront	ADJ
aiua-10838	258	15	cytoreductive	cytoreductive	ADJ
aiua-10838	258	16	nephrectomy	nephrectomy	NOUN
aiua-10838	258	17	for	for	ADP
aiua-10838	258	18	metastatic	metastatic	ADJ
aiua-10838	258	19	renal	renal	ADJ
aiua-10838	258	20	cell	cell	NOUN
aiua-10838	258	21	carcinoma	carcinoma	NOUN
aiua-10838	258	22	in	in	ADP
aiua-10838	258	23	the	the	DET
aiua-10838	258	24	targeted	target	VERB
aiua-10838	258	25	therapy	therapy	NOUN
aiua-10838	258	26	era	era	NOUN
aiua-10838	258	27	.	.	PUNCT
aiua-10838	259	1	jpn	jpn	PROPN
aiua-10838	259	2	j	j	PROPN
aiua-10838	259	3	clin	clin	PROPN
aiua-10838	259	4	oncol	oncol	PROPN
aiua-10838	259	5	.	.	PUNCT
aiua-10838	260	1	2015	2015	NUM
aiua-10838	260	2	;	;	PUNCT
aiua-10838	260	3	45:96	45:96	NUM
aiua-10838	260	4	-	-	SYM
aiua-10838	260	5	102	102	NUM
aiua-10838	260	6	.	.	PUNCT
aiua-10838	261	1	31	31	NUM
aiua-10838	261	2	.	.	PUNCT
aiua-10838	262	1	tatsugami	tatsugami	PROPN
aiua-10838	262	2	k	k	NOUN
aiua-10838	262	3	,	,	PUNCT
aiua-10838	262	4	shinohara	shinohara	PROPN
aiua-10838	262	5	n	n	SYM
aiua-10838	262	6	,	,	PUNCT
aiua-10838	262	7	kondo	kondo	PROPN
aiua-10838	262	8	t	t	PROPN
aiua-10838	262	9	,	,	PUNCT
aiua-10838	262	10	et	et	PROPN
aiua-10838	262	11	al	al	PROPN
aiua-10838	262	12	.	.	PROPN
aiua-10838	263	1	role	role	NOUN
aiua-10838	263	2	of	of	ADP
aiua-10838	263	3	cytoreductive	cytoreductive	ADJ
aiua-10838	263	4	nephrectomy	nephrectomy	NOUN
aiua-10838	263	5	for	for	ADP
aiua-10838	263	6	japanese	japanese	ADJ
aiua-10838	263	7	patients	patient	NOUN
aiua-10838	263	8	with	with	ADP
aiua-10838	263	9	primary	primary	ADJ
aiua-10838	263	10	renal	renal	ADJ
aiua-10838	263	11	cell	cell	NOUN
aiua-10838	263	12	carcinoma	carcinoma	NOUN
aiua-10838	263	13	in	in	ADP
aiua-10838	263	14	the	the	DET
aiua-10838	263	15	cytokine	cytokine	NOUN
aiua-10838	263	16	and	and	CCONJ
aiua-10838	263	17	targeted	target	VERB
aiua-10838	263	18	therapy	therapy	NOUN
aiua-10838	263	19	era	era	NOUN
aiua-10838	263	20	.	.	PUNCT
aiua-10838	264	1	int	int	PROPN
aiua-10838	264	2	j	j	PROPN
aiua-10838	264	3	urol	urol	PROPN
aiua-10838	264	4	.	.	PUNCT
aiua-10838	265	1	2015	2015	NUM
aiua-10838	265	2	;	;	PUNCT
aiua-10838	265	3	22:736	22:736	NUM
aiua-10838	265	4	-	-	SYM
aiua-10838	265	5	40	40	NUM
aiua-10838	265	6	.	.	PUNCT
aiua-10838	266	1	32	32	NUM
aiua-10838	266	2	.	.	PUNCT
aiua-10838	267	1	day	day	NOUN
aiua-10838	267	2	d	d	PROPN
aiua-10838	267	3	,	,	PUNCT
aiua-10838	267	4	kanjanapan	kanjanapan	PROPN
aiua-10838	267	5	y	y	PROPN
aiua-10838	267	6	,	,	PUNCT
aiua-10838	267	7	kwan	kwan	PROPN
aiua-10838	267	8	e	e	PROPN
aiua-10838	267	9	,	,	PUNCT
aiua-10838	267	10	et	et	PROPN
aiua-10838	267	11	al	al	PROPN
aiua-10838	267	12	.	.	PROPN
aiua-10838	267	13	benefit	benefit	PROPN
aiua-10838	267	14	from	from	ADP
aiua-10838	267	15	cytoreductive	cytoreductive	ADJ
aiua-10838	267	16	nephrectomy	nephrectomy	NOUN
aiua-10838	267	17	and	and	CCONJ
aiua-10838	267	18	the	the	DET
aiua-10838	267	19	prognostic	prognostic	ADJ
aiua-10838	267	20	role	role	NOUN
aiua-10838	267	21	of	of	ADP
aiua-10838	267	22	neutrophil	neutrophil	ADJ
aiua-10838	267	23	-	-	PUNCT
aiua-10838	267	24	to	to	ADP
aiua-10838	267	25	-	-	PUNCT
aiua-10838	267	26	lymphocyte	lymphocyte	ADJ
aiua-10838	267	27	ratio	ratio	NOUN
aiua-10838	267	28	in	in	ADP
aiua-10838	267	29	patients	patient	NOUN
aiua-10838	267	30	with	with	ADP
aiua-10838	267	31	metastatic	metastatic	ADJ
aiua-10838	267	32	renal	renal	ADJ
aiua-10838	267	33	cell	cell	NOUN
aiua-10838	267	34	carcinoma	carcinoma	NOUN
aiua-10838	267	35	.	.	PUNCT
aiua-10838	268	1	intern	intern	PROPN
aiua-10838	268	2	med	med	PROPN
aiua-10838	268	3	j.	j.	PROPN
aiua-10838	268	4	2016	2016	NUM
aiua-10838	268	5	;	;	PUNCT
aiua-10838	268	6	46:1291	46:1291	PROPN
aiua-10838	268	7	-	-	SYM
aiua-10838	268	8	1297	1297	NUM
aiua-10838	268	9	.	.	PUNCT
aiua-10838	269	1	33	33	NUM
aiua-10838	269	2	.	.	PUNCT
aiua-10838	269	3	choueiri	choueiri	PROPN
aiua-10838	269	4	tk	tk	PROPN
aiua-10838	269	5	,	,	PUNCT
aiua-10838	269	6	xie	xie	PROPN
aiua-10838	269	7	w	w	PROPN
aiua-10838	269	8	,	,	PUNCT
aiua-10838	269	9	kollmannsberger	kollmannsberger	NOUN
aiua-10838	269	10	c	c	NOUN
aiua-10838	269	11	,	,	PUNCT
aiua-10838	269	12	et	et	PROPN
aiua-10838	269	13	al	al	PROPN
aiua-10838	269	14	.	.	PUNCT
aiua-10838	270	1	the	the	DET
aiua-10838	270	2	impact	impact	NOUN
aiua-10838	270	3	of	of	ADP
aiua-10838	270	4	cytoreductive	cytoreductive	ADJ
aiua-10838	270	5	nephrectomy	nephrectomy	NOUN
aiua-10838	270	6	on	on	ADP
aiua-10838	270	7	survival	survival	NOUN
aiua-10838	270	8	of	of	ADP
aiua-10838	270	9	patients	patient	NOUN
aiua-10838	270	10	with	with	ADP
aiua-10838	270	11	metastatic	metastatic	ADJ
aiua-10838	270	12	renal	renal	ADJ
aiua-10838	270	13	cell	cell	NOUN
aiua-10838	270	14	carcinoma	carcinoma	NOUN
aiua-10838	270	15	receiving	receive	VERB
aiua-10838	270	16	vascular	vascular	ADJ
aiua-10838	270	17	endothelial	endothelial	ADJ
aiua-10838	270	18	growth	growth	NOUN
aiua-10838	270	19	factor	factor	NOUN
aiua-10838	270	20	targeted	target	VERB
aiua-10838	270	21	therapy	therapy	NOUN
aiua-10838	270	22	.	.	PUNCT
aiua-10838	271	1	j	j	PROPN
aiua-10838	271	2	urol	urol	PROPN
aiua-10838	271	3	.	.	PUNCT
aiua-10838	272	1	2011	2011	NUM
aiua-10838	272	2	;	;	PUNCT
aiua-10838	272	3	185:60	185:60	NUM
aiua-10838	272	4	-	-	SYM
aiua-10838	272	5	6	6	NUM
aiua-10838	272	6	.	.	PUNCT
aiua-10838	273	1	34	34	NUM
aiua-10838	273	2	.	.	PUNCT
aiua-10838	274	1	heng	heng	PROPN
aiua-10838	274	2	dy	dy	PROPN
aiua-10838	274	3	,	,	PUNCT
aiua-10838	274	4	wells	wells	PROPN
aiua-10838	274	5	jc	jc	PROPN
aiua-10838	274	6	,	,	PUNCT
aiua-10838	274	7	rini	rini	PROPN
aiua-10838	274	8	bi	bi	PROPN
aiua-10838	274	9	,	,	PUNCT
aiua-10838	274	10	et	et	PROPN
aiua-10838	274	11	al	al	PROPN
aiua-10838	274	12	.	.	PUNCT
aiua-10838	275	1	cytoreductive	cytoreductive	PROPN
aiua-10838	275	2	nephrectomy	nephrectomy	ADV
aiua-10838	275	3	in	in	ADP
aiua-10838	275	4	patients	patient	NOUN
aiua-10838	275	5	with	with	ADP
aiua-10838	275	6	synchronous	synchronous	ADJ
aiua-10838	275	7	metastases	metastasis	NOUN
aiua-10838	275	8	from	from	ADP
aiua-10838	275	9	renal	renal	ADJ
aiua-10838	275	10	cell	cell	NOUN
aiua-10838	275	11	carcinoma	carcinoma	NOUN
aiua-10838	275	12	:	:	PUNCT
aiua-10838	275	13	results	result	NOUN
aiua-10838	275	14	from	from	ADP
aiua-10838	275	15	the	the	DET
aiua-10838	275	16	international	international	ADJ
aiua-10838	275	17	metastatic	metastatic	ADJ
aiua-10838	275	18	renal	renal	ADJ
aiua-10838	275	19	cell	cell	NOUN
aiua-10838	275	20	carcinoma	carcinoma	NOUN
aiua-10838	275	21	database	database	NOUN
aiua-10838	275	22	consortium	consortium	NOUN
aiua-10838	275	23	.	.	PUNCT
aiua-10838	276	1	eur	eur	PROPN
aiua-10838	276	2	urol	urol	PROPN
aiua-10838	276	3	.	.	PUNCT
aiua-10838	276	4	2014	2014	NUM
aiua-10838	276	5	;	;	PUNCT
aiua-10838	276	6	66:704	66:704	NUM
aiua-10838	276	7	-	-	SYM
aiua-10838	276	8	10	10	NUM
aiua-10838	276	9	.	.	PUNCT
aiua-10838	276	10	35	35	NUM
aiua-10838	276	11	.	.	X
aiua-10838	277	1	de	de	AUX
aiua-10838	277	2	groot	groot	PROPN
aiua-10838	277	3	s	s	PROPN
aiua-10838	277	4	,	,	PUNCT
aiua-10838	277	5	redekop	redekop	PROPN
aiua-10838	277	6	wk	wk	PROPN
aiua-10838	277	7	,	,	PUNCT
aiua-10838	277	8	sleijfer	sleijfer	VERB
aiua-10838	277	9	s	s	PROPN
aiua-10838	277	10	,	,	PUNCT
aiua-10838	277	11	et	et	PROPN
aiua-10838	277	12	al	al	PROPN
aiua-10838	277	13	.	.	PROPN
aiua-10838	277	14	survival	survival	PROPN
aiua-10838	277	15	in	in	ADP
aiua-10838	277	16	patients	patient	NOUN
aiua-10838	277	17	with	with	ADP
aiua-10838	277	18	primary	primary	ADJ
aiua-10838	277	19	metastatic	metastatic	ADJ
aiua-10838	277	20	renal	renal	ADJ
aiua-10838	277	21	cell	cell	NOUN
aiua-10838	277	22	carcinoma	carcinoma	NOUN
aiua-10838	277	23	treated	treat	VERB
aiua-10838	277	24	with	with	ADP
aiua-10838	277	25	sunitinib	sunitinib	NOUN
aiua-10838	277	26	with	with	ADP
aiua-10838	277	27	or	or	CCONJ
aiua-10838	277	28	without	without	ADP
aiua-10838	277	29	previous	previous	ADJ
aiua-10838	277	30	cytoreductive	cytoreductive	ADJ
aiua-10838	277	31	nephrectomy	nephrectomy	NOUN
aiua-10838	277	32	:	:	PUNCT
aiua-10838	277	33	results	result	NOUN
aiua-10838	277	34	from	from	ADP
aiua-10838	277	35	a	a	DET
aiua-10838	277	36	population	population	NOUN
aiua-10838	277	37	-	-	PUNCT
aiua-10838	277	38	based	base	VERB
aiua-10838	277	39	registry	registry	NOUN
aiua-10838	277	40	.	.	PUNCT
aiua-10838	278	1	urology	urology	NOUN
aiua-10838	278	2	.	.	PUNCT
aiua-10838	279	1	2016	2016	NUM
aiua-10838	279	2	;	;	PUNCT
aiua-10838	279	3	95:121	95:121	NUM
aiua-10838	279	4	-	-	SYM
aiua-10838	279	5	7	7	NUM
aiua-10838	279	6	.	.	NUM
aiua-10838	279	7	36	36	NUM
aiua-10838	279	8	.	.	PUNCT
aiua-10838	280	1	poprach	poprach	VERB
aiua-10838	280	2	a	a	PRON
aiua-10838	280	3	,	,	PUNCT
aiua-10838	280	4	holanek	holanek	NOUN
aiua-10838	280	5	m	m	PROPN
aiua-10838	280	6	,	,	PUNCT
aiua-10838	280	7	chloupkova	chloupkova	PROPN
aiua-10838	280	8	r	r	NOUN
aiua-10838	280	9	,	,	PUNCT
aiua-10838	280	10	et	et	PROPN
aiua-10838	280	11	al	al	PROPN
aiua-10838	280	12	.	.	PUNCT
aiua-10838	281	1	cytoreductive	cytoreductive	NUM
aiua-10838	281	2	nephrectomy	nephrectomy	ADJ
aiua-10838	281	3	and	and	CCONJ
aiua-10838	281	4	overall	overall	ADJ
aiua-10838	281	5	survival	survival	NOUN
aiua-10838	281	6	of	of	ADP
aiua-10838	281	7	patients	patient	NOUN
aiua-10838	281	8	with	with	ADP
aiua-10838	281	9	metastatic	metastatic	ADJ
aiua-10838	281	10	renal	renal	ADJ
aiua-10838	281	11	cell	cell	NOUN
aiua-10838	281	12	carcinoma	carcinoma	NOUN
aiua-10838	281	13	treated	treat	VERB
aiua-10838	281	14	with	with	ADP
aiua-10838	281	15	targeted	target	VERB
aiua-10838	281	16	therapy	therapy	NOUN
aiua-10838	281	17	-	-	PUNCT
aiua-10838	281	18	data	data	NOUN
aiua-10838	281	19	from	from	ADP
aiua-10838	281	20	the	the	DET
aiua-10838	281	21	national	national	PROPN
aiua-10838	281	22	renis	renis	PROPN
aiua-10838	281	23	registry	registry	NOUN
aiua-10838	281	24	.	.	PUNCT
aiua-10838	282	1	cancers	cancer	NOUN
aiua-10838	282	2	(	(	PUNCT
aiua-10838	282	3	basel	basel	PROPN
aiua-10838	282	4	)	)	PUNCT
aiua-10838	282	5	.	.	PUNCT
aiua-10838	283	1	2020	2020	NUM
aiua-10838	283	2	;	;	PUNCT
aiua-10838	283	3	12:2911	12:2911	X
aiua-10838	283	4	.	.	X
aiua-10838	284	1	37	37	NUM
aiua-10838	284	2	.	.	PUNCT
aiua-10838	285	1	song	song	PROPN
aiua-10838	285	2	y	y	PROPN
aiua-10838	285	3	,	,	PUNCT
aiua-10838	285	4	du	du	PROPN
aiua-10838	285	5	cx	cx	PROPN
aiua-10838	285	6	,	,	PUNCT
aiua-10838	285	7	zhang	zhang	PROPN
aiua-10838	285	8	w	w	PROPN
aiua-10838	285	9	,	,	PUNCT
aiua-10838	285	10	et	et	PROPN
aiua-10838	285	11	al	al	PROPN
aiua-10838	285	12	.	.	PROPN
aiua-10838	285	13	impact	impact	NOUN
aiua-10838	285	14	of	of	ADP
aiua-10838	285	15	cytoreductive	cytoreductive	ADJ
aiua-10838	285	16	nephrectomy	nephrectomy	NOUN
aiua-10838	285	17	on	on	ADP
aiua-10838	285	18	survival	survival	NOUN
aiua-10838	285	19	in	in	ADP
aiua-10838	285	20	patients	patient	NOUN
aiua-10838	285	21	with	with	ADP
aiua-10838	285	22	metastatic	metastatic	ADJ
aiua-10838	285	23	renal	renal	ADJ
aiua-10838	285	24	cell	cell	NOUN
aiua-10838	285	25	carcinoma	carcinoma	NOUN
aiua-10838	285	26	treated	treat	VERB
aiua-10838	285	27	by	by	ADP
aiua-10838	285	28	targeted	target	VERB
aiua-10838	285	29	therapy	therapy	NOUN
aiua-10838	285	30	.	.	PUNCT
aiua-10838	286	1	chin	chin	PROPN
aiua-10838	286	2	med	med	PROPN
aiua-10838	286	3	j	j	PROPN
aiua-10838	286	4	(	(	PUNCT
aiua-10838	286	5	engl	engl	PROPN
aiua-10838	286	6	)	)	PUNCT
aiua-10838	286	7	.	.	PUNCT
aiua-10838	287	1	2016	2016	NUM
aiua-10838	287	2	;	;	PUNCT
aiua-10838	287	3	129:530	129:530	NUM
aiua-10838	287	4	-	-	SYM
aiua-10838	287	5	5	5	NUM
aiua-10838	287	6	.	.	NOUN
aiua-10838	287	7	38	38	NUM
aiua-10838	287	8	.	.	PUNCT
aiua-10838	288	1	bhindi	bhindi	PROPN
aiua-10838	288	2	b	b	PROPN
aiua-10838	288	3	,	,	PUNCT
aiua-10838	288	4	graham	graham	PROPN
aiua-10838	288	5	j	j	PROPN
aiua-10838	288	6	,	,	PUNCT
aiua-10838	288	7	wells	wells	PROPN
aiua-10838	288	8	jc	jc	PROPN
aiua-10838	288	9	,	,	PUNCT
aiua-10838	288	10	et	et	PROPN
aiua-10838	288	11	al	al	PROPN
aiua-10838	288	12	.	.	PROPN
aiua-10838	288	13	deferred	defer	VERB
aiua-10838	288	14	cytoreductive	cytoreductive	ADJ
aiua-10838	288	15	nephrectomy	nephrectomy	NOUN
aiua-10838	288	16	in	in	ADP
aiua-10838	288	17	patients	patient	NOUN
aiua-10838	288	18	with	with	ADP
aiua-10838	288	19	newly	newly	ADV
aiua-10838	288	20	diagnosed	diagnose	VERB
aiua-10838	288	21	metastatic	metastatic	ADJ
aiua-10838	288	22	renal	renal	ADJ
aiua-10838	288	23	cell	cell	NOUN
aiua-10838	288	24	carcinoma	carcinoma	NOUN
aiua-10838	288	25	.	.	PUNCT
aiua-10838	289	1	eur	eur	PROPN
aiua-10838	289	2	urol	urol	PROPN
aiua-10838	289	3	.	.	PUNCT
aiua-10838	290	1	2020	2020	NUM
aiua-10838	290	2	;	;	PUNCT
aiua-10838	290	3	78:615	78:615	NUM
aiua-10838	290	4	-	-	SYM
aiua-10838	290	5	623	623	NUM
aiua-10838	290	6	.	.	PUNCT
aiua-10838	290	7	39	39	NUM
aiua-10838	290	8	.	.	PUNCT
aiua-10838	291	1	patel	patel	PROPN
aiua-10838	291	2	mi	mi	PROPN
aiua-10838	291	3	,	,	PUNCT
aiua-10838	291	4	beattie	beattie	PROPN
aiua-10838	291	5	k	k	PROPN
aiua-10838	291	6	,	,	PUNCT
aiua-10838	291	7	bang	bang	PROPN
aiua-10838	291	8	a	a	X
aiua-10838	291	9	,	,	PUNCT
aiua-10838	291	10	et	et	PROPN
aiua-10838	291	11	al	al	PROPN
aiua-10838	291	12	.	.	PUNCT
aiua-10838	292	1	cytoreductive	cytoreductive	PROPN
aiua-10838	292	2	nephrectomy	nephrectomy	ADV
aiua-10838	292	3	for	for	ADP
aiua-10838	292	4	metastatic	metastatic	ADJ
aiua-10838	292	5	renal	renal	ADJ
aiua-10838	292	6	cell	cell	NOUN
aiua-10838	292	7	carcinoma	carcinoma	NOUN
aiua-10838	292	8	:	:	PUNCT
aiua-10838	292	9	inequities	inequity	NOUN
aiua-10838	292	10	in	in	ADP
aiua-10838	292	11	access	access	NOUN
aiua-10838	292	12	exist	exist	VERB
aiua-10838	292	13	despite	despite	SCONJ
aiua-10838	292	14	improved	improved	ADJ
aiua-10838	292	15	survival	survival	NOUN
aiua-10838	292	16	.	.	PUNCT
aiua-10838	293	1	cancer	cancer	NOUN
aiua-10838	293	2	med	med	PROPN
aiua-10838	293	3	.	.	PROPN
aiua-10838	293	4	2017	2017	NUM
aiua-10838	293	5	;	;	PUNCT
aiua-10838	293	6	6:2188	6:2188	X
aiua-10838	293	7	-	-	SYM
aiua-10838	293	8	2193	2193	NUM
aiua-10838	293	9	485archivio	485archivio	PROPN
aiua-10838	293	10	italiano	italiano	NOUN
aiua-10838	293	11	di	di	X
aiua-10838	293	12	urologia	urologia	PROPN
aiua-10838	293	13	e	e	PROPN
aiua-10838	293	14	andrologia	andrologia	PROPN
aiua-10838	293	15	2022	2022	NUM
aiua-10838	293	16	;	;	PUNCT
aiua-10838	293	17	94	94	NUM
aiua-10838	293	18	,	,	PUNCT
aiua-10838	293	19	4	4	NUM
aiua-10838	293	20	nephrectomy	nephrectomy	NOUN
aiua-10838	293	21	for	for	ADP
aiua-10838	293	22	metastatic	metastatic	ADJ
aiua-10838	293	23	renal	renal	ADJ
aiua-10838	293	24	cell	cell	NOUN
aiua-10838	293	25	carcinoma	carcinoma	NOUN
aiua-10838	293	26	40	40	NUM
aiua-10838	293	27	.	.	PUNCT
aiua-10838	294	1	dragomir	dragomir	VERB
aiua-10838	294	2	a	a	PRON
aiua-10838	294	3	,	,	PUNCT
aiua-10838	294	4	nazha	nazha	PROPN
aiua-10838	294	5	s	s	PART
aiua-10838	294	6	,	,	PUNCT
aiua-10838	294	7	tanguay	tanguay	PROPN
aiua-10838	294	8	s	s	PROPN
aiua-10838	294	9	,	,	PUNCT
aiua-10838	294	10	et	et	PROPN
aiua-10838	294	11	al	al	PROPN
aiua-10838	294	12	.	.	PUNCT
aiua-10838	295	1	outcomes	outcome	NOUN
aiua-10838	295	2	of	of	ADP
aiua-10838	295	3	cytoreductive	cytoreductive	ADJ
aiua-10838	295	4	nephrectomy	nephrectomy	NOUN
aiua-10838	295	5	for	for	ADP
aiua-10838	295	6	patients	patient	NOUN
aiua-10838	295	7	with	with	ADP
aiua-10838	295	8	metastatic	metastatic	ADJ
aiua-10838	295	9	renal	renal	ADJ
aiua-10838	295	10	cell	cell	NOUN
aiua-10838	295	11	carcinoma	carcinoma	NOUN
aiua-10838	295	12	:	:	PUNCT
aiua-10838	295	13	real	real	ADJ
aiua-10838	295	14	world	world	NOUN
aiua-10838	295	15	data	datum	NOUN
aiua-10838	295	16	from	from	ADP
aiua-10838	295	17	canadian	canadian	ADJ
aiua-10838	295	18	centers	center	NOUN
aiua-10838	295	19	.	.	PUNCT
aiua-10838	296	1	eur	eur	PROPN
aiua-10838	296	2	urol	urol	ADJ
aiua-10838	296	3	focus	focus	NOUN
aiua-10838	296	4	.	.	PUNCT
aiua-10838	297	1	2021	2021	NUM
aiua-10838	297	2	:	:	PUNCT
aiua-10838	297	3	s2405	s2405	PROPN
aiua-10838	297	4	-	-	PUNCT
aiua-10838	297	5	4569(21)00276	4569(21)00276	NOUN
aiua-10838	297	6	-	-	PUNCT
aiua-10838	297	7	5	5	NUM
aiua-10838	297	8	.	.	NOUN
aiua-10838	297	9	41	41	NUM
aiua-10838	297	10	.	.	PUNCT
aiua-10838	298	1	méjean	méjean	PROPN
aiua-10838	298	2	a	a	PRON
aiua-10838	298	3	,	,	PUNCT
aiua-10838	298	4	ravaud	ravaud	NOUN
aiua-10838	298	5	a	a	PRON
aiua-10838	298	6	,	,	PUNCT
aiua-10838	298	7	thezenas	thezenas	PROPN
aiua-10838	298	8	s	s	PROPN
aiua-10838	298	9	,	,	PUNCT
aiua-10838	298	10	et	et	PROPN
aiua-10838	298	11	al	al	PROPN
aiua-10838	298	12	.	.	PUNCT
aiua-10838	298	13	sunitinib	sunitinib	NOUN
aiua-10838	298	14	alone	alone	ADV
aiua-10838	298	15	or	or	CCONJ
aiua-10838	298	16	after	after	ADP
aiua-10838	298	17	nephrectomy	nephrectomy	NOUN
aiua-10838	298	18	in	in	ADP
aiua-10838	298	19	metastatic	metastatic	ADJ
aiua-10838	298	20	renal	renal	ADJ
aiua-10838	298	21	-	-	PUNCT
aiua-10838	298	22	cell	cell	NOUN
aiua-10838	298	23	carcinoma	carcinoma	NOUN
aiua-10838	298	24	.	.	PUNCT
aiua-10838	299	1	n	n	PRON
aiua-10838	299	2	engl	engl	PROPN
aiua-10838	299	3	j	j	PROPN
aiua-10838	299	4	med	med	PROPN
aiua-10838	299	5	.	.	PROPN
aiua-10838	299	6	2018	2018	NUM
aiua-10838	299	7	;	;	PUNCT
aiua-10838	299	8	379:417	379:417	NUM
aiua-10838	299	9	-	-	SYM
aiua-10838	299	10	427	427	NUM
aiua-10838	299	11	.	.	PUNCT
aiua-10838	300	1	42	42	NUM
aiua-10838	300	2	.	.	PUNCT
aiua-10838	301	1	bakouny	bakouny	PROPN
aiua-10838	301	2	z	z	PROPN
aiua-10838	301	3	,	,	PUNCT
aiua-10838	301	4	xie	xie	PROPN
aiua-10838	301	5	w	w	PROPN
aiua-10838	301	6	,	,	PUNCT
aiua-10838	301	7	dudani	dudani	PROPN
aiua-10838	301	8	s	s	PART
aiua-10838	301	9	,	,	PUNCT
aiua-10838	301	10	et	et	PROPN
aiua-10838	301	11	al	al	PROPN
aiua-10838	301	12	.	.	PUNCT
aiua-10838	302	1	cytoreductive	cytoreductive	PROPN
aiua-10838	302	2	nephrectomy	nephrectomy	ADV
aiua-10838	302	3	(	(	PUNCT
aiua-10838	302	4	cn	cn	INTJ
aiua-10838	302	5	)	)	PUNCT
aiua-10838	302	6	for	for	ADP
aiua-10838	302	7	metastatic	metastatic	ADJ
aiua-10838	302	8	renal	renal	ADJ
aiua-10838	302	9	cell	cell	NOUN
aiua-10838	302	10	carcinoma	carcinoma	NOUN
aiua-10838	302	11	(	(	PUNCT
aiua-10838	302	12	mrcc	mrcc	NOUN
aiua-10838	302	13	)	)	PUNCT
aiua-10838	302	14	treated	treat	VERB
aiua-10838	302	15	with	with	ADP
aiua-10838	302	16	immune	immune	ADJ
aiua-10838	302	17	checkpoint	checkpoint	NOUN
aiua-10838	302	18	inhibitors	inhibitor	NOUN
aiua-10838	302	19	(	(	PUNCT
aiua-10838	302	20	ici	ici	NOUN
aiua-10838	302	21	)	)	PUNCT
aiua-10838	302	22	or	or	CCONJ
aiua-10838	302	23	targeted	target	VERB
aiua-10838	302	24	therapy	therapy	NOUN
aiua-10838	302	25	(	(	PUNCT
aiua-10838	302	26	tt	tt	PROPN
aiua-10838	302	27	):	):	PUNCT
aiua-10838	302	28	a	a	DET
aiua-10838	302	29	propensity	propensity	NOUN
aiua-10838	302	30	score	score	NOUN
aiua-10838	302	31	-	-	PUNCT
aiua-10838	302	32	based	base	VERB
aiua-10838	302	33	analysis	analysis	NOUN
aiua-10838	302	34	.	.	PUNCT
aiua-10838	303	1	journal	journal	NOUN
aiua-10838	303	2	of	of	ADP
aiua-10838	303	3	clinical	clinical	ADJ
aiua-10838	303	4	oncology	oncology	NOUN
aiua-10838	303	5	2020	2020	NUM
aiua-10838	303	6	;	;	PUNCT
aiua-10838	303	7	38(6_suppl	38(6_suppl	NUM
aiua-10838	303	8	):	):	PUNCT
aiua-10838	303	9	608	608	NUM
aiua-10838	303	10	-	-	SYM
aiua-10838	303	11	608	608	NUM
aiua-10838	303	12	.	.	PUNCT
aiua-10838	304	1	43	43	NUM
aiua-10838	304	2	.	.	PUNCT
aiua-10838	305	1	wood	wood	NOUN
aiua-10838	305	2	cg	cg	PROPN
aiua-10838	305	3	,	,	PUNCT
aiua-10838	305	4	margulis	marguli	NOUN
aiua-10838	305	5	v.	v.	ADP
aiua-10838	305	6	neoadjuvant	neoadjuvant	ADJ
aiua-10838	305	7	(	(	PUNCT
aiua-10838	305	8	presurgical	presurgical	ADJ
aiua-10838	305	9	)	)	PUNCT
aiua-10838	305	10	therapy	therapy	NOUN
aiua-10838	305	11	for	for	ADP
aiua-10838	305	12	renal	renal	ADJ
aiua-10838	305	13	cell	cell	NOUN
aiua-10838	305	14	carcinoma	carcinoma	NOUN
aiua-10838	305	15	:	:	PUNCT
aiua-10838	305	16	a	a	DET
aiua-10838	305	17	new	new	ADJ
aiua-10838	305	18	treatment	treatment	NOUN
aiua-10838	305	19	paradigm	paradigm	NOUN
aiua-10838	305	20	for	for	ADP
aiua-10838	305	21	locally	locally	ADV
aiua-10838	305	22	advanced	advanced	ADJ
aiua-10838	305	23	and	and	CCONJ
aiua-10838	305	24	metastatic	metastatic	ADJ
aiua-10838	305	25	disease	disease	NOUN
aiua-10838	305	26	.	.	PUNCT
aiua-10838	306	1	cancer	cancer	NOUN
aiua-10838	306	2	.	.	PUNCT
aiua-10838	307	1	2009	2009	NUM
aiua-10838	307	2	;	;	PUNCT
aiua-10838	307	3	115(10	115(10	NUM
aiua-10838	307	4	suppl):2355	suppl):2355	PROPN
aiua-10838	307	5	-	-	PUNCT
aiua-10838	307	6	60	60	NUM
aiua-10838	307	7	.	.	PUNCT
aiua-10838	308	1	44	44	NUM
aiua-10838	308	2	.	.	PUNCT
aiua-10838	309	1	stroup	stroup	PROPN
aiua-10838	309	2	sp	sp	PROPN
aiua-10838	309	3	,	,	PUNCT
aiua-10838	309	4	raheem	raheem	PROPN
aiua-10838	309	5	oa	oa	NOUN
aiua-10838	309	6	,	,	PUNCT
aiua-10838	309	7	palazzi	palazzi	PROPN
aiua-10838	309	8	kl	kl	PROPN
aiua-10838	309	9	,	,	PUNCT
aiua-10838	309	10	et	et	PROPN
aiua-10838	309	11	al	al	PROPN
aiua-10838	309	12	.	.	PROPN
aiua-10838	309	13	does	do	VERB
aiua-10838	309	14	timing	timing	NOUN
aiua-10838	309	15	of	of	ADP
aiua-10838	309	16	cytoreductive	cytoreductive	ADJ
aiua-10838	309	17	nephrectomy	nephrectomy	ADJ
aiua-10838	309	18	impact	impact	NOUN
aiua-10838	309	19	patient	patient	ADJ
aiua-10838	309	20	survival	survival	NOUN
aiua-10838	309	21	with	with	ADP
aiua-10838	309	22	metastatic	metastatic	ADJ
aiua-10838	309	23	renal	renal	ADJ
aiua-10838	309	24	cell	cell	NOUN
aiua-10838	309	25	carcinoma	carcinoma	NOUN
aiua-10838	309	26	in	in	ADP
aiua-10838	309	27	the	the	DET
aiua-10838	309	28	tyrosine	tyrosine	NOUN
aiua-10838	309	29	kinase	kinase	PROPN
aiua-10838	309	30	inhibitor	inhibitor	PROPN
aiua-10838	309	31	era	era	PROPN
aiua-10838	309	32	?	?	PUNCT
aiua-10838	310	1	a	a	DET
aiua-10838	310	2	multi	multi	ADJ
aiua-10838	310	3	-	-	ADJ
aiua-10838	310	4	institutional	institutional	ADJ
aiua-10838	310	5	study	study	NOUN
aiua-10838	310	6	.	.	PUNCT
aiua-10838	311	1	urology	urology	NOUN
aiua-10838	311	2	.	.	PUNCT
aiua-10838	312	1	2013	2013	NUM
aiua-10838	312	2	;	;	PUNCT
aiua-10838	312	3	81:805	81:805	NUM
aiua-10838	312	4	-	-	SYM
aiua-10838	312	5	11	11	NUM
aiua-10838	312	6	.	.	X
aiua-10838	313	1	45	45	NUM
aiua-10838	313	2	.	.	PUNCT
aiua-10838	314	1	macleod	macleod	PROPN
aiua-10838	314	2	lc	lc	PROPN
aiua-10838	314	3	,	,	PUNCT
aiua-10838	314	4	odisho	odisho	PROPN
aiua-10838	314	5	ay	ay	NOUN
aiua-10838	314	6	,	,	PUNCT
aiua-10838	314	7	tykodi	tykodi	PROPN
aiua-10838	314	8	ss	ss	PROPN
aiua-10838	314	9	,	,	PUNCT
aiua-10838	314	10	et	et	PROPN
aiua-10838	314	11	al	al	PROPN
aiua-10838	314	12	.	.	PROPN
aiua-10838	314	13	comparative	comparative	ADJ
aiua-10838	314	14	effectiveness	effectiveness	NOUN
aiua-10838	314	15	of	of	ADP
aiua-10838	314	16	initial	initial	ADJ
aiua-10838	314	17	surgery	surgery	NOUN
aiua-10838	314	18	vs	vs	ADP
aiua-10838	314	19	initial	initial	ADJ
aiua-10838	314	20	systemic	systemic	ADJ
aiua-10838	314	21	therapy	therapy	NOUN
aiua-10838	314	22	for	for	ADP
aiua-10838	314	23	metastatic	metastatic	ADJ
aiua-10838	314	24	kidney	kidney	NOUN
aiua-10838	314	25	cancer	cancer	NOUN
aiua-10838	314	26	in	in	ADP
aiua-10838	314	27	the	the	DET
aiua-10838	314	28	targeted	target	VERB
aiua-10838	314	29	therapy	therapy	NOUN
aiua-10838	314	30	era	era	NOUN
aiua-10838	314	31	:	:	PUNCT
aiua-10838	314	32	analysis	analysis	NOUN
aiua-10838	314	33	of	of	ADP
aiua-10838	314	34	a	a	DET
aiua-10838	314	35	population	population	NOUN
aiua-10838	314	36	-	-	PUNCT
aiua-10838	314	37	based	base	VERB
aiua-10838	314	38	cohort	cohort	NOUN
aiua-10838	314	39	.	.	PUNCT
aiua-10838	315	1	urology	urology	NOUN
aiua-10838	315	2	.	.	PUNCT
aiua-10838	316	1	2018	2018	NUM
aiua-10838	316	2	;	;	PUNCT
aiua-10838	316	3	113:146	113:146	NUM
aiua-10838	316	4	-	-	SYM
aiua-10838	316	5	152	152	NUM
aiua-10838	316	6	.	.	PUNCT
aiua-10838	317	1	46	46	NUM
aiua-10838	317	2	.	.	PUNCT
aiua-10838	318	1	bhindi	bhindi	PROPN
aiua-10838	318	2	b	b	PROPN
aiua-10838	318	3	,	,	PUNCT
aiua-10838	318	4	habermann	habermann	PROPN
aiua-10838	318	5	eb	eb	PROPN
aiua-10838	318	6	,	,	PUNCT
aiua-10838	318	7	mason	mason	PROPN
aiua-10838	318	8	rj	rj	PROPN
aiua-10838	318	9	,	,	PUNCT
aiua-10838	318	10	et	et	PROPN
aiua-10838	318	11	al	al	PROPN
aiua-10838	318	12	.	.	PROPN
aiua-10838	319	1	comparative	comparative	ADJ
aiua-10838	319	2	survival	survival	NOUN
aiua-10838	319	3	following	follow	VERB
aiua-10838	319	4	initial	initial	ADJ
aiua-10838	319	5	cytoreductive	cytoreductive	ADJ
aiua-10838	319	6	nephrectomy	nephrectomy	NOUN
aiua-10838	319	7	versus	versus	ADP
aiua-10838	319	8	initial	initial	ADJ
aiua-10838	319	9	targeted	target	VERB
aiua-10838	319	10	therapy	therapy	NOUN
aiua-10838	319	11	for	for	ADP
aiua-10838	319	12	metastatic	metastatic	ADJ
aiua-10838	319	13	renal	renal	ADJ
aiua-10838	319	14	cell	cell	NOUN
aiua-10838	319	15	carcinoma	carcinoma	NOUN
aiua-10838	319	16	.	.	PUNCT
aiua-10838	320	1	j	j	PROPN
aiua-10838	320	2	urol	urol	PROPN
aiua-10838	320	3	.	.	PROPN
aiua-10838	320	4	2018	2018	NUM
aiua-10838	320	5	;	;	PUNCT
aiua-10838	320	6	200:528	200:528	NUM
aiua-10838	320	7	-	-	SYM
aiua-10838	320	8	534	534	NUM
aiua-10838	320	9	.	.	PUNCT
aiua-10838	321	1	47	47	NUM
aiua-10838	321	2	.	.	PUNCT
aiua-10838	322	1	kapoor	kapoor	PROPN
aiua-10838	322	2	a	a	PROPN
aiua-10838	322	3	,	,	PUNCT
aiua-10838	322	4	wong	wong	PROPN
aiua-10838	322	5	ecl	ecl	PROPN
aiua-10838	322	6	,	,	PUNCT
aiua-10838	322	7	fang	fang	PROPN
aiua-10838	322	8	w	w	PROPN
aiua-10838	322	9	,	,	PUNCT
aiua-10838	322	10	wong	wong	PROPN
aiua-10838	322	11	nc	nc	PROPN
aiua-10838	322	12	.	.	PROPN
aiua-10838	322	13	upfront	upfront	PROPN
aiua-10838	322	14	cytoreductive	cytoreductive	ADJ
aiua-10838	322	15	nephrectomy	nephrectomy	NOUN
aiua-10838	322	16	vs.	vs.	ADP
aiua-10838	322	17	upfront	upfront	ADJ
aiua-10838	322	18	systemic	systemic	ADJ
aiua-10838	322	19	therapy	therapy	NOUN
aiua-10838	322	20	in	in	ADP
aiua-10838	322	21	metastatic	metastatic	ADJ
aiua-10838	322	22	kidney	kidney	NOUN
aiua-10838	322	23	cancer	cancer	NOUN
aiua-10838	322	24	.	.	PUNCT
aiua-10838	323	1	can	can	AUX
aiua-10838	323	2	urol	urol	VERB
aiua-10838	323	3	assoc	assoc	PROPN
aiua-10838	323	4	j.	j.	PROPN
aiua-10838	323	5	2019	2019	NUM
aiua-10838	323	6	;	;	PUNCT
aiua-10838	323	7	13	13	NUM
aiua-10838	323	8	:	:	PUNCT
aiua-10838	323	9	e377	e377	PROPN
aiua-10838	323	10	-	-	PUNCT
aiua-10838	323	11	e381	e381	PROPN
aiua-10838	323	12	.	.	PUNCT
aiua-10838	324	1	48	48	NUM
aiua-10838	324	2	.	.	PUNCT
aiua-10838	324	3	de	de	PROPN
aiua-10838	324	4	bruijn	bruijn	PROPN
aiua-10838	324	5	r	r	PROPN
aiua-10838	324	6	,	,	PUNCT
aiua-10838	324	7	wimalasingham	wimalasingham	VERB
aiua-10838	324	8	a	a	NOUN
aiua-10838	324	9	,	,	PUNCT
aiua-10838	324	10	szabados	szabado	NOUN
aiua-10838	324	11	b	b	X
aiua-10838	324	12	,	,	PUNCT
aiua-10838	324	13	et	et	PROPN
aiua-10838	324	14	al	al	PROPN
aiua-10838	324	15	.	.	PROPN
aiua-10838	324	16	deferred	defer	VERB
aiua-10838	324	17	cytoreductive	cytoreductive	ADJ
aiua-10838	324	18	nephrectomy	nephrectomy	NOUN
aiua-10838	324	19	following	follow	VERB
aiua-10838	324	20	presurgical	presurgical	ADJ
aiua-10838	324	21	vascular	vascular	ADJ
aiua-10838	324	22	endothelial	endothelial	NOUN
aiua-10838	324	23	growth	growth	NOUN
aiua-10838	324	24	factor	factor	NOUN
aiua-10838	324	25	receptor	receptor	NOUN
aiua-10838	324	26	-	-	PUNCT
aiua-10838	324	27	targeted	target	VERB
aiua-10838	324	28	therapy	therapy	NOUN
aiua-10838	324	29	in	in	ADP
aiua-10838	324	30	patients	patient	NOUN
aiua-10838	324	31	with	with	ADP
aiua-10838	324	32	primary	primary	ADJ
aiua-10838	324	33	metastatic	metastatic	ADJ
aiua-10838	324	34	clear	clear	ADJ
aiua-10838	324	35	cell	cell	NOUN
aiua-10838	324	36	renal	renal	ADJ
aiua-10838	324	37	cell	cell	NOUN
aiua-10838	324	38	carcinoma	carcinoma	NOUN
aiua-10838	324	39	:	:	PUNCT
aiua-10838	324	40	a	a	DET
aiua-10838	324	41	pooled	pool	VERB
aiua-10838	324	42	analysis	analysis	NOUN
aiua-10838	324	43	of	of	ADP
aiua-10838	324	44	prospective	prospective	ADJ
aiua-10838	324	45	trial	trial	NOUN
aiua-10838	324	46	data	datum	NOUN
aiua-10838	324	47	.	.	PUNCT
aiua-10838	325	1	eur	eur	PROPN
aiua-10838	325	2	urol	urol	PROPN
aiua-10838	325	3	oncol	oncol	PROPN
aiua-10838	325	4	.	.	PUNCT
aiua-10838	326	1	2020	2020	NUM
aiua-10838	326	2	;	;	PUNCT
aiua-10838	326	3	3:168	3:168	NUM
aiua-10838	326	4	-	-	SYM
aiua-10838	326	5	173	173	NUM
aiua-10838	326	6	.	.	PUNCT
aiua-10838	326	7	49	49	NUM
aiua-10838	326	8	.	.	PUNCT
aiua-10838	327	1	abel	abel	PROPN
aiua-10838	327	2	ej	ej	PROPN
aiua-10838	327	3	,	,	PUNCT
aiua-10838	327	4	spiess	spiess	PROPN
aiua-10838	327	5	pe	pe	PROPN
aiua-10838	327	6	,	,	PUNCT
aiua-10838	327	7	margulis	margulis	PROPN
aiua-10838	327	8	v	v	PROPN
aiua-10838	327	9	,	,	PUNCT
aiua-10838	327	10	et	et	PROPN
aiua-10838	327	11	al	al	PROPN
aiua-10838	327	12	.	.	PUNCT
aiua-10838	328	1	cytoreductive	cytoreductive	PROPN
aiua-10838	328	2	nephrectomy	nephrectomy	ADV
aiua-10838	328	3	for	for	ADP
aiua-10838	328	4	renal	renal	ADJ
aiua-10838	328	5	cell	cell	NOUN
aiua-10838	328	6	carcinoma	carcinoma	NOUN
aiua-10838	328	7	with	with	ADP
aiua-10838	328	8	venous	venous	ADJ
aiua-10838	328	9	tumor	tumor	NOUN
aiua-10838	328	10	thrombus	thrombus	NOUN
aiua-10838	328	11	.	.	PUNCT
aiua-10838	329	1	j	j	PROPN
aiua-10838	329	2	urol	urol	PROPN
aiua-10838	329	3	.	.	PROPN
aiua-10838	329	4	2017	2017	NUM
aiua-10838	329	5	;	;	PUNCT
aiua-10838	329	6	198:281	198:281	NUM
aiua-10838	329	7	-	-	SYM
aiua-10838	329	8	288	288	NUM
aiua-10838	329	9	.	.	PUNCT
aiua-10838	330	1	50	50	NUM
aiua-10838	330	2	.	.	X
aiua-10838	331	1	dashek	dashek	PROPN
aiua-10838	331	2	jj	jj	PROPN
aiua-10838	331	3	,	,	PUNCT
aiua-10838	331	4	zhang	zhang	PROPN
aiua-10838	331	5	y	y	PROPN
aiua-10838	331	6	,	,	PUNCT
aiua-10838	331	7	skelton	skelton	PROPN
aiua-10838	331	8	wp	wp	PROPN
aiua-10838	331	9	4th	4th	PROPN
aiua-10838	331	10	,	,	PUNCT
aiua-10838	331	11	et	et	PROPN
aiua-10838	331	12	al	al	PROPN
aiua-10838	331	13	.	.	PUNCT
aiua-10838	332	1	dissecting	dissect	VERB
aiua-10838	332	2	outcomes	outcome	NOUN
aiua-10838	332	3	:	:	PUNCT
aiua-10838	332	4	should	should	AUX
aiua-10838	332	5	cytoreductive	cytoreductive	VERB
aiua-10838	332	6	nephrectomy	nephrectomy	ADV
aiua-10838	332	7	be	be	AUX
aiua-10838	332	8	performed	perform	VERB
aiua-10838	332	9	for	for	ADP
aiua-10838	332	10	patients	patient	NOUN
aiua-10838	332	11	with	with	ADP
aiua-10838	332	12	metastatic	metastatic	ADJ
aiua-10838	332	13	renal	renal	ADJ
aiua-10838	332	14	cell	cell	NOUN
aiua-10838	332	15	carcinoma	carcinoma	NOUN
aiua-10838	332	16	with	with	ADP
aiua-10838	332	17	sarcomatoid	sarcomatoid	NOUN
aiua-10838	332	18	dedifferentiation	dedifferentiation	NOUN
aiua-10838	332	19	?	?	PUNCT
aiua-10838	333	1	front	front	ADJ
aiua-10838	333	2	oncol	oncol	ADJ
aiua-10838	333	3	.	.	PUNCT
aiua-10838	334	1	2021	2021	NUM
aiua-10838	334	2	;	;	PUNCT
aiua-10838	334	3	10:627025	10:627025	NUM
aiua-10838	334	4	.	.	NOUN
aiua-10838	335	1	51	51	NUM
aiua-10838	335	2	.	.	PUNCT
aiua-10838	335	3	corcoran	corcoran	NOUN
aiua-10838	335	4	at	at	ADP
aiua-10838	335	5	,	,	PUNCT
aiua-10838	335	6	kaffenberger	kaffenberger	NOUN
aiua-10838	335	7	sd	sd	PROPN
aiua-10838	335	8	,	,	PUNCT
aiua-10838	335	9	clark	clark	PROPN
aiua-10838	335	10	pe	pe	PROPN
aiua-10838	335	11	,	,	PUNCT
aiua-10838	336	1	et	et	PROPN
aiua-10838	336	2	al	al	PROPN
aiua-10838	336	3	.	.	PUNCT
aiua-10838	336	4	hypoalbuminaemia	hypoalbuminaemia	PROPN
aiua-10838	336	5	is	be	AUX
aiua-10838	336	6	associated	associate	VERB
aiua-10838	336	7	with	with	ADP
aiua-10838	336	8	mortality	mortality	NOUN
aiua-10838	336	9	in	in	ADP
aiua-10838	336	10	patients	patient	NOUN
aiua-10838	336	11	undergoing	undergo	VERB
aiua-10838	336	12	cytoreductive	cytoreductive	ADJ
aiua-10838	336	13	nephrectomy	nephrectomy	NOUN
aiua-10838	336	14	.	.	PUNCT
aiua-10838	337	1	bju	bju	NOUN
aiua-10838	337	2	int	int	PROPN
aiua-10838	337	3	.	.	PUNCT
aiua-10838	338	1	2015	2015	NUM
aiua-10838	338	2	;	;	PUNCT
aiua-10838	338	3	116:351	116:351	NOUN
aiua-10838	338	4	-	-	PUNCT
aiua-10838	338	5	7	7	NUM
aiua-10838	338	6	.	.	NOUN
aiua-10838	338	7	52	52	NUM
aiua-10838	338	8	.	.	PUNCT
aiua-10838	339	1	culp	culp	PROPN
aiua-10838	339	2	sh	sh	PROPN
aiua-10838	339	3	,	,	PUNCT
aiua-10838	339	4	tannir	tannir	PROPN
aiua-10838	339	5	nm	nm	PROPN
aiua-10838	339	6	,	,	PUNCT
aiua-10838	339	7	abel	abel	PROPN
aiua-10838	339	8	ej	ej	PROPN
aiua-10838	339	9	,	,	PUNCT
aiua-10838	339	10	et	et	PROPN
aiua-10838	339	11	al	al	PROPN
aiua-10838	339	12	.	.	PUNCT
aiua-10838	339	13	can	can	AUX
aiua-10838	339	14	we	we	PRON
aiua-10838	339	15	better	well	ADV
aiua-10838	339	16	select	select	VERB
aiua-10838	339	17	patients	patient	NOUN
aiua-10838	339	18	with	with	ADP
aiua-10838	339	19	metastatic	metastatic	ADJ
aiua-10838	339	20	renal	renal	ADJ
aiua-10838	339	21	cell	cell	NOUN
aiua-10838	339	22	carcinoma	carcinoma	NOUN
aiua-10838	339	23	for	for	ADP
aiua-10838	339	24	cytoreductive	cytoreductive	ADJ
aiua-10838	339	25	nephrectomy	nephrectomy	NOUN
aiua-10838	339	26	?	?	PUNCT
aiua-10838	340	1	cancer	cancer	NOUN
aiua-10838	340	2	.	.	PUNCT
aiua-10838	341	1	2010	2010	NUM
aiua-10838	341	2	;	;	PUNCT
aiua-10838	341	3	116:3378	116:3378	NUM
aiua-10838	341	4	-	-	SYM
aiua-10838	341	5	88	88	NUM
aiua-10838	341	6	.	.	PUNCT
aiua-10838	342	1	53	53	NUM
aiua-10838	342	2	.	.	PUNCT
aiua-10838	343	1	culp	culp	PROPN
aiua-10838	343	2	sh	sh	PROPN
aiua-10838	343	3	,	,	PUNCT
aiua-10838	343	4	karam	karam	PROPN
aiua-10838	343	5	ja	ja	PROPN
aiua-10838	343	6	,	,	PUNCT
aiua-10838	343	7	wood	wood	NOUN
aiua-10838	343	8	cg	cg	NOUN
aiua-10838	343	9	.	.	PUNCT
aiua-10838	344	1	population	population	NOUN
aiua-10838	344	2	-	-	PUNCT
aiua-10838	344	3	based	base	VERB
aiua-10838	344	4	analysis	analysis	NOUN
aiua-10838	344	5	of	of	ADP
aiua-10838	344	6	factors	factor	NOUN
aiua-10838	344	7	associated	associate	VERB
aiua-10838	344	8	with	with	ADP
aiua-10838	344	9	survival	survival	NOUN
aiua-10838	344	10	in	in	ADP
aiua-10838	344	11	patients	patient	NOUN
aiua-10838	344	12	undergoing	undergo	VERB
aiua-10838	344	13	cytoreductive	cytoreductive	ADJ
aiua-10838	344	14	nephrectomy	nephrectomy	NOUN
aiua-10838	344	15	in	in	ADP
aiua-10838	344	16	the	the	DET
aiua-10838	344	17	targeted	target	VERB
aiua-10838	344	18	therapy	therapy	NOUN
aiua-10838	344	19	era	era	NOUN
aiua-10838	344	20	.	.	PUNCT
aiua-10838	345	1	urol	urol	PROPN
aiua-10838	345	2	oncol	oncol	PROPN
aiua-10838	345	3	.	.	PUNCT
aiua-10838	346	1	2014	2014	NUM
aiua-10838	346	2	;	;	PUNCT
aiua-10838	346	3	32:561	32:561	NUM
aiua-10838	346	4	-	-	SYM
aiua-10838	346	5	8	8	NUM
aiua-10838	346	6	.	.	X
aiua-10838	347	1	54	54	NUM
aiua-10838	347	2	.	.	PUNCT
aiua-10838	348	1	kalogirou	kalogirou	PROPN
aiua-10838	348	2	c	c	PROPN
aiua-10838	348	3	,	,	PUNCT
aiua-10838	348	4	mulfinger	mulfinger	NOUN
aiua-10838	348	5	p	p	NOUN
aiua-10838	348	6	,	,	PUNCT
aiua-10838	348	7	sokolakis	sokolakis	PROPN
aiua-10838	348	8	i	i	PRON
aiua-10838	348	9	,	,	PUNCT
aiua-10838	348	10	et	et	PROPN
aiua-10838	348	11	al	al	PROPN
aiua-10838	348	12	.	.	PROPN
aiua-10838	348	13	preoperative	preoperative	ADJ
aiua-10838	348	14	creactive	creactive	ADJ
aiua-10838	348	15	protein	protein	NOUN
aiua-10838	348	16	values	value	NOUN
aiua-10838	348	17	as	as	ADP
aiua-10838	348	18	a	a	DET
aiua-10838	348	19	potential	potential	ADJ
aiua-10838	348	20	component	component	NOUN
aiua-10838	348	21	in	in	ADP
aiua-10838	348	22	outcome	outcome	NOUN
aiua-10838	348	23	prediction	prediction	NOUN
aiua-10838	348	24	models	model	NOUN
aiua-10838	348	25	of	of	ADP
aiua-10838	348	26	metastasized	metastasize	VERB
aiua-10838	348	27	renal	renal	ADJ
aiua-10838	348	28	cell	cell	NOUN
aiua-10838	348	29	carcinoma	carcinoma	NOUN
aiua-10838	348	30	patients	patient	NOUN
aiua-10838	348	31	receiving	receive	VERB
aiua-10838	348	32	cytoreductive	cytoreductive	ADJ
aiua-10838	348	33	nephrectomy	nephrectomy	NOUN
aiua-10838	348	34	.	.	PUNCT
aiua-10838	349	1	urol	urol	PROPN
aiua-10838	349	2	int	int	PROPN
aiua-10838	349	3	.	.	PUNCT
aiua-10838	350	1	2017	2017	NUM
aiua-10838	350	2	;	;	PUNCT
aiua-10838	350	3	99:297	99:297	NUM
aiua-10838	350	4	-	-	SYM
aiua-10838	350	5	307	307	NUM
aiua-10838	350	6	.	.	PUNCT
aiua-10838	351	1	55	55	NUM
aiua-10838	351	2	.	.	PUNCT
aiua-10838	352	1	kapoor	kapoor	PROPN
aiua-10838	352	2	a	a	PROPN
aiua-10838	352	3	,	,	PUNCT
aiua-10838	352	4	wong	wong	PROPN
aiua-10838	352	5	ecl	ecl	PROPN
aiua-10838	352	6	,	,	PUNCT
aiua-10838	352	7	fang	fang	PROPN
aiua-10838	352	8	w	w	PROPN
aiua-10838	352	9	,	,	PUNCT
aiua-10838	352	10	wong	wong	PROPN
aiua-10838	352	11	nc	nc	PROPN
aiua-10838	352	12	.	.	PROPN
aiua-10838	352	13	upfront	upfront	PROPN
aiua-10838	352	14	cytoreductive	cytoreductive	ADJ
aiua-10838	352	15	nephrectomy	nephrectomy	NOUN
aiua-10838	352	16	vs.	vs.	ADP
aiua-10838	352	17	upfront	upfront	ADJ
aiua-10838	352	18	systemic	systemic	ADJ
aiua-10838	352	19	therapy	therapy	NOUN
aiua-10838	352	20	in	in	ADP
aiua-10838	352	21	metastatic	metastatic	ADJ
aiua-10838	352	22	kidney	kidney	NOUN
aiua-10838	352	23	cancer	cancer	NOUN
aiua-10838	352	24	.	.	PUNCT
aiua-10838	353	1	can	can	AUX
aiua-10838	353	2	urol	urol	VERB
aiua-10838	353	3	assoc	assoc	PROPN
aiua-10838	353	4	j.	j.	PROPN
aiua-10838	353	5	2019	2019	NUM
aiua-10838	353	6	;	;	PUNCT
aiua-10838	353	7	13	13	NUM
aiua-10838	353	8	:	:	PUNCT
aiua-10838	353	9	e377	e377	PROPN
aiua-10838	353	10	-	-	PUNCT
aiua-10838	353	11	e381	e381	PROPN
aiua-10838	353	12	.	.	PUNCT
aiua-10838	354	1	56	56	NUM
aiua-10838	354	2	.	.	PUNCT
aiua-10838	354	3	klatte	klatte	PROPN
aiua-10838	354	4	t	t	PROPN
aiua-10838	354	5	,	,	PUNCT
aiua-10838	354	6	fife	fife	PROPN
aiua-10838	354	7	k	k	PROPN
aiua-10838	354	8	,	,	PUNCT
aiua-10838	354	9	welsh	welsh	NOUN
aiua-10838	354	10	sj	sj	PROPN
aiua-10838	354	11	,	,	PUNCT
aiua-10838	354	12	et	et	PROPN
aiua-10838	354	13	al	al	PROPN
aiua-10838	354	14	.	.	PROPN
aiua-10838	355	1	prognostic	prognostic	ADJ
aiua-10838	355	2	effect	effect	NOUN
aiua-10838	355	3	of	of	ADP
aiua-10838	355	4	cytoreductive	cytoreductive	ADJ
aiua-10838	355	5	nephrectomy	nephrectomy	NOUN
aiua-10838	355	6	in	in	ADP
aiua-10838	355	7	synchronous	synchronous	ADJ
aiua-10838	355	8	metastatic	metastatic	ADJ
aiua-10838	355	9	renal	renal	ADJ
aiua-10838	355	10	cell	cell	NOUN
aiua-10838	355	11	carcinoma	carcinoma	NOUN
aiua-10838	355	12	:	:	PUNCT
aiua-10838	355	13	a	a	DET
aiua-10838	355	14	comparative	comparative	ADJ
aiua-10838	355	15	study	study	NOUN
aiua-10838	355	16	using	use	VERB
aiua-10838	355	17	inverse	inverse	NOUN
aiua-10838	355	18	probability	probability	NOUN
aiua-10838	355	19	of	of	ADP
aiua-10838	355	20	treatment	treatment	NOUN
aiua-10838	355	21	weighting	weighting	NOUN
aiua-10838	355	22	.	.	PUNCT
aiua-10838	356	1	world	world	PROPN
aiua-10838	356	2	j	j	PROPN
aiua-10838	356	3	urol	urol	PROPN
aiua-10838	356	4	.	.	PROPN
aiua-10838	356	5	2018	2018	NUM
aiua-10838	356	6	;	;	PUNCT
aiua-10838	356	7	36:417	36:417	NUM
aiua-10838	356	8	-	-	SYM
aiua-10838	356	9	425	425	NUM
aiua-10838	356	10	.	.	PUNCT
aiua-10838	356	11	57	57	NUM
aiua-10838	356	12	.	.	PUNCT
aiua-10838	357	1	ljungberg	ljungberg	PROPN
aiua-10838	357	2	b	b	PROPN
aiua-10838	357	3	,	,	PUNCT
aiua-10838	357	4	sundqvist	sundqvist	NOUN
aiua-10838	357	5	p	p	NOUN
aiua-10838	357	6	,	,	PUNCT
aiua-10838	357	7	lindblad	lindblad	X
aiua-10838	357	8	p	p	X
aiua-10838	357	9	,	,	PUNCT
aiua-10838	357	10	et	et	PROPN
aiua-10838	357	11	al	al	PROPN
aiua-10838	357	12	.	.	PROPN
aiua-10838	357	13	survival	survival	PROPN
aiua-10838	357	14	advantage	advantage	NOUN
aiua-10838	357	15	of	of	ADP
aiua-10838	357	16	upfront	upfront	ADJ
aiua-10838	357	17	cytoreductive	cytoreductive	ADJ
aiua-10838	357	18	nephrectomy	nephrectomy	NOUN
aiua-10838	357	19	in	in	ADP
aiua-10838	357	20	patients	patient	NOUN
aiua-10838	357	21	with	with	ADP
aiua-10838	357	22	primary	primary	ADJ
aiua-10838	357	23	metastatic	metastatic	ADJ
aiua-10838	357	24	renal	renal	ADJ
aiua-10838	357	25	cell	cell	NOUN
aiua-10838	357	26	carcinoma	carcinoma	NOUN
aiua-10838	357	27	compared	compare	VERB
aiua-10838	357	28	with	with	ADP
aiua-10838	357	29	systemic	systemic	ADJ
aiua-10838	357	30	and	and	CCONJ
aiua-10838	357	31	palliative	palliative	ADJ
aiua-10838	357	32	treatments	treatment	NOUN
aiua-10838	357	33	in	in	ADP
aiua-10838	357	34	a	a	DET
aiua-10838	357	35	real	real	ADJ
aiua-10838	357	36	-	-	PUNCT
aiua-10838	357	37	world	world	NOUN
aiua-10838	357	38	setting	setting	NOUN
aiua-10838	357	39	.	.	PUNCT
aiua-10838	358	1	scand	scand	PROPN
aiua-10838	358	2	j	j	PROPN
aiua-10838	358	3	urol	urol	PROPN
aiua-10838	358	4	.	.	PUNCT
aiua-10838	359	1	2020	2020	NUM
aiua-10838	359	2	;	;	PUNCT
aiua-10838	360	1	54:487	54:487	NUM
aiua-10838	360	2	-	-	SYM
aiua-10838	360	3	492	492	NUM
aiua-10838	360	4	.	.	PUNCT
aiua-10838	361	1	58	58	NUM
aiua-10838	361	2	.	.	PUNCT
aiua-10838	362	1	mcintosh	mcintosh	PROPN
aiua-10838	362	2	ag	ag	PROPN
aiua-10838	362	3	,	,	PUNCT
aiua-10838	362	4	umbreit	umbreit	PROPN
aiua-10838	362	5	ec	ec	PROPN
aiua-10838	362	6	,	,	PUNCT
aiua-10838	362	7	holland	holland	PROPN
aiua-10838	362	8	lc	lc	PROPN
aiua-10838	362	9	,	,	PUNCT
aiua-10838	362	10	et	et	PROPN
aiua-10838	362	11	al	al	PROPN
aiua-10838	362	12	.	.	PUNCT
aiua-10838	362	13	optimizing	optimize	VERB
aiua-10838	362	14	patient	patient	ADJ
aiua-10838	362	15	selection	selection	NOUN
aiua-10838	362	16	for	for	ADP
aiua-10838	362	17	cytoreductive	cytoreductive	ADJ
aiua-10838	362	18	nephrectomy	nephrectomy	NOUN
aiua-10838	362	19	based	base	VERB
aiua-10838	362	20	on	on	ADP
aiua-10838	362	21	outcomes	outcome	NOUN
aiua-10838	362	22	in	in	ADP
aiua-10838	362	23	the	the	DET
aiua-10838	362	24	contemporary	contemporary	ADJ
aiua-10838	362	25	era	era	NOUN
aiua-10838	362	26	of	of	ADP
aiua-10838	362	27	systemic	systemic	ADJ
aiua-10838	362	28	therapy	therapy	NOUN
aiua-10838	362	29	.	.	PUNCT
aiua-10838	363	1	cancer	cancer	NOUN
aiua-10838	363	2	.	.	PUNCT
aiua-10838	364	1	2020	2020	NUM
aiua-10838	364	2	;	;	PUNCT
aiua-10838	365	1	126:39503960	126:39503960	NUM
aiua-10838	365	2	.	.	PUNCT
aiua-10838	366	1	59	59	NUM
aiua-10838	366	2	.	.	PUNCT
aiua-10838	367	1	rosiello	rosiello	PROPN
aiua-10838	367	2	g	g	PROPN
aiua-10838	367	3	,	,	PUNCT
aiua-10838	367	4	knipper	knipper	NOUN
aiua-10838	367	5	s	s	PROPN
aiua-10838	367	6	,	,	PUNCT
aiua-10838	367	7	palumbo	palumbo	PROPN
aiua-10838	367	8	c	c	X
aiua-10838	367	9	,	,	PUNCT
aiua-10838	367	10	et	et	PROPN
aiua-10838	367	11	al	al	PROPN
aiua-10838	367	12	.	.	PROPN
aiua-10838	367	13	unmarried	unmarried	ADJ
aiua-10838	367	14	status	status	NOUN
aiua-10838	367	15	is	be	AUX
aiua-10838	367	16	a	a	DET
aiua-10838	367	17	barrier	barrier	NOUN
aiua-10838	367	18	for	for	ADP
aiua-10838	367	19	access	access	NOUN
aiua-10838	367	20	to	to	ADP
aiua-10838	367	21	treatment	treatment	NOUN
aiua-10838	367	22	in	in	ADP
aiua-10838	367	23	patients	patient	NOUN
aiua-10838	367	24	with	with	ADP
aiua-10838	367	25	metastatic	metastatic	ADJ
aiua-10838	367	26	renal	renal	ADJ
aiua-10838	367	27	cell	cell	NOUN
aiua-10838	367	28	carcinoma	carcinoma	NOUN
aiua-10838	367	29	.	.	PUNCT
aiua-10838	368	1	int	int	NOUN
aiua-10838	368	2	urol	urol	ADJ
aiua-10838	368	3	nephrol	nephrol	NOUN
aiua-10838	368	4	.	.	PUNCT
aiua-10838	369	1	2019	2019	NUM
aiua-10838	369	2	;	;	PUNCT
aiua-10838	369	3	51:2181	51:2181	NUM
aiua-10838	369	4	-	-	SYM
aiua-10838	369	5	2188	2188	NUM
aiua-10838	369	6	.	.	PUNCT
aiua-10838	370	1	60	60	NUM
aiua-10838	370	2	sharma	sharma	PROPN
aiua-10838	370	3	p	p	X
aiua-10838	370	4	,	,	PUNCT
aiua-10838	370	5	zargar	zargar	NOUN
aiua-10838	370	6	-	-	PUNCT
aiua-10838	370	7	shoshtari	shoshtari	ADJ
aiua-10838	370	8	k	k	PROPN
aiua-10838	370	9	,	,	PUNCT
aiua-10838	370	10	caracciolo	caracciolo	PROPN
aiua-10838	370	11	jt	jt	PROPN
aiua-10838	370	12	,	,	PUNCT
aiua-10838	370	13	et	et	PROPN
aiua-10838	370	14	al	al	PROPN
aiua-10838	370	15	.	.	PUNCT
aiua-10838	370	16	sarcopenia	sarcopenia	PROPN
aiua-10838	370	17	as	as	ADP
aiua-10838	370	18	a	a	DET
aiua-10838	370	19	predictor	predictor	NOUN
aiua-10838	370	20	of	of	ADP
aiua-10838	370	21	overall	overall	ADJ
aiua-10838	370	22	survival	survival	NOUN
aiua-10838	370	23	after	after	ADP
aiua-10838	370	24	cytoreductive	cytoreductive	NOUN
aiua-10838	370	25	nephrectomy	nephrectomy	NOUN
aiua-10838	370	26	for	for	ADP
aiua-10838	370	27	metastatic	metastatic	ADJ
aiua-10838	370	28	renal	renal	ADJ
aiua-10838	370	29	cell	cell	NOUN
aiua-10838	370	30	carcinoma	carcinoma	NOUN
aiua-10838	370	31	.	.	PUNCT
aiua-10838	371	1	urol	urol	PROPN
aiua-10838	371	2	oncol	oncol	PROPN
aiua-10838	371	3	.	.	PUNCT
aiua-10838	372	1	2015	2015	NUM
aiua-10838	372	2	;	;	PUNCT
aiua-10838	372	3	33:339.e17	33:339.e17	NUM
aiua-10838	372	4	-	-	SYM
aiua-10838	372	5	23	23	NUM
aiua-10838	372	6	.	.	PUNCT
aiua-10838	373	1	61	61	NUM
aiua-10838	373	2	.	.	PUNCT
aiua-10838	374	1	sakai	sakai	PROPN
aiua-10838	374	2	i	i	PROPN
aiua-10838	374	3	,	,	PUNCT
aiua-10838	374	4	miyake	miyake	PROPN
aiua-10838	374	5	h	h	PROPN
aiua-10838	374	6	,	,	PUNCT
aiua-10838	374	7	hinata	hinata	PROPN
aiua-10838	374	8	n	n	CCONJ
aiua-10838	374	9	,	,	PUNCT
aiua-10838	374	10	fujisawa	fujisawa	PROPN
aiua-10838	374	11	m.	m.	NOUN
aiua-10838	374	12	improved	improve	VERB
aiua-10838	374	13	survival	survival	NOUN
aiua-10838	374	14	in	in	ADP
aiua-10838	374	15	patients	patient	NOUN
aiua-10838	374	16	with	with	ADP
aiua-10838	374	17	metastatic	metastatic	ADJ
aiua-10838	374	18	renal	renal	ADJ
aiua-10838	374	19	cell	cell	NOUN
aiua-10838	374	20	carcinoma	carcinoma	NOUN
aiua-10838	374	21	undergoing	undergo	VERB
aiua-10838	374	22	cytoreductive	cytoreductive	ADJ
aiua-10838	374	23	nephrectomy	nephrectomy	NOUN
aiua-10838	374	24	in	in	ADP
aiua-10838	374	25	the	the	DET
aiua-10838	374	26	era	era	NOUN
aiua-10838	374	27	of	of	ADP
aiua-10838	374	28	targeted	target	VERB
aiua-10838	374	29	therapy	therapy	NOUN
aiua-10838	374	30	.	.	PUNCT
aiua-10838	375	1	int	int	PROPN
aiua-10838	376	1	j	j	PROPN
aiua-10838	376	2	clin	clin	PROPN
aiua-10838	376	3	oncol	oncol	PROPN
aiua-10838	376	4	.	.	PUNCT
aiua-10838	377	1	2014	2014	NUM
aiua-10838	377	2	;	;	PUNCT
aiua-10838	377	3	19:674	19:674	NUM
aiua-10838	377	4	-	-	SYM
aiua-10838	377	5	8	8	NUM
aiua-10838	377	6	.	.	PUNCT
aiua-10838	378	1	62	62	NUM
aiua-10838	378	2	.	.	PUNCT
aiua-10838	379	1	teishima	teishima	PROPN
aiua-10838	379	2	j	j	PROPN
aiua-10838	379	3	,	,	PUNCT
aiua-10838	379	4	ohara	ohara	PROPN
aiua-10838	379	5	s	s	PROPN
aiua-10838	379	6	,	,	PUNCT
aiua-10838	379	7	shinmei	shinmei	PROPN
aiua-10838	379	8	s	s	PROPN
aiua-10838	379	9	,	,	PUNCT
aiua-10838	379	10	et	et	PROPN
aiua-10838	379	11	al	al	PROPN
aiua-10838	379	12	.	.	PUNCT
aiua-10838	380	1	normalization	normalization	NOUN
aiua-10838	380	2	of	of	ADP
aiua-10838	380	3	c	c	NOUN
aiua-10838	380	4	-	-	PUNCT
aiua-10838	380	5	reactive	reactive	ADJ
aiua-10838	380	6	protein	protein	NOUN
aiua-10838	380	7	levels	level	NOUN
aiua-10838	380	8	following	follow	VERB
aiua-10838	380	9	cytoreductive	cytoreductive	ADJ
aiua-10838	380	10	nephrectomy	nephrectomy	NOUN
aiua-10838	380	11	in	in	ADP
aiua-10838	380	12	patients	patient	NOUN
aiua-10838	380	13	with	with	ADP
aiua-10838	380	14	metastatic	metastatic	ADJ
aiua-10838	380	15	renal	renal	ADJ
aiua-10838	380	16	cell	cell	NOUN
aiua-10838	380	17	carcinoma	carcinoma	NOUN
aiua-10838	380	18	treated	treat	VERB
aiua-10838	380	19	with	with	ADP
aiua-10838	380	20	tyrosine	tyrosine	PROPN
aiua-10838	380	21	kinase	kinase	PROPN
aiua-10838	380	22	inhibitors	inhibitor	NOUN
aiua-10838	380	23	is	be	AUX
aiua-10838	380	24	associated	associate	VERB
aiua-10838	380	25	with	with	ADP
aiua-10838	380	26	improved	improve	VERB
aiua-10838	380	27	overall	overall	ADJ
aiua-10838	380	28	survival	survival	NOUN
aiua-10838	380	29	.	.	PUNCT
aiua-10838	381	1	urol	urol	PROPN
aiua-10838	381	2	oncol	oncol	PROPN
aiua-10838	381	3	.	.	PUNCT
aiua-10838	382	1	2018	2018	NUM
aiua-10838	382	2	;	;	PUNCT
aiua-10838	382	3	36:339.e9	36:339.e9	NUM
aiua-10838	382	4	-	-	SYM
aiua-10838	382	5	339.e15	339.e15	PROPN
aiua-10838	382	6	.	.	PROPN
aiua-10838	383	1	63	63	NUM
aiua-10838	383	2	.	.	PUNCT
aiua-10838	383	3	motzer	motzer	PROPN
aiua-10838	383	4	rj	rj	PROPN
aiua-10838	383	5	,	,	PUNCT
aiua-10838	383	6	bacik	bacik	PROPN
aiua-10838	383	7	j	j	PROPN
aiua-10838	383	8	,	,	PUNCT
aiua-10838	383	9	schwartz	schwartz	PROPN
aiua-10838	383	10	lh	lh	PROPN
aiua-10838	383	11	,	,	PUNCT
aiua-10838	383	12	et	et	PROPN
aiua-10838	383	13	al	al	PROPN
aiua-10838	383	14	.	.	PUNCT
aiua-10838	384	1	prognostic	prognostic	ADJ
aiua-10838	384	2	factors	factor	NOUN
aiua-10838	384	3	for	for	ADP
aiua-10838	384	4	survival	survival	NOUN
aiua-10838	384	5	in	in	ADP
aiua-10838	384	6	previously	previously	ADV
aiua-10838	384	7	treated	treat	VERB
aiua-10838	384	8	patients	patient	NOUN
aiua-10838	384	9	with	with	ADP
aiua-10838	384	10	metastatic	metastatic	ADJ
aiua-10838	384	11	renal	renal	ADJ
aiua-10838	384	12	cell	cell	NOUN
aiua-10838	384	13	carcinoma	carcinoma	NOUN
aiua-10838	384	14	.	.	PUNCT
aiua-10838	385	1	j	j	PROPN
aiua-10838	385	2	clin	clin	PROPN
aiua-10838	385	3	oncol	oncol	PROPN
aiua-10838	385	4	.	.	PUNCT
aiua-10838	386	1	2004	2004	NUM
aiua-10838	386	2	;	;	PUNCT
aiua-10838	386	3	22:454	22:454	NUM
aiua-10838	386	4	-	-	SYM
aiua-10838	386	5	63	63	NUM
aiua-10838	386	6	.	.	PUNCT
aiua-10838	387	1	64	64	NUM
aiua-10838	387	2	.	.	PUNCT
aiua-10838	388	1	westerman	westerman	PROPN
aiua-10838	388	2	me	i	PRON
aiua-10838	388	3	,	,	PUNCT
aiua-10838	388	4	shapiro	shapiro	PROPN
aiua-10838	388	5	dd	dd	PROPN
aiua-10838	388	6	,	,	PUNCT
aiua-10838	388	7	tannir	tannir	NOUN
aiua-10838	388	8	nm	nm	PROPN
aiua-10838	388	9	,	,	PUNCT
aiua-10838	388	10	et	et	PROPN
aiua-10838	388	11	al	al	PROPN
aiua-10838	388	12	.	.	PROPN
aiua-10838	388	13	survival	survival	PROPN
aiua-10838	388	14	following	follow	VERB
aiua-10838	388	15	cytoreductive	cytoreductive	ADJ
aiua-10838	388	16	nephrectomy	nephrectomy	NOUN
aiua-10838	388	17	:	:	PUNCT
aiua-10838	388	18	a	a	DET
aiua-10838	388	19	comparison	comparison	NOUN
aiua-10838	388	20	of	of	ADP
aiua-10838	388	21	existing	exist	VERB
aiua-10838	388	22	prognostic	prognostic	ADJ
aiua-10838	388	23	models	model	NOUN
aiua-10838	388	24	.	.	PUNCT
aiua-10838	389	1	bju	bju	NOUN
aiua-10838	389	2	int	int	PROPN
aiua-10838	389	3	.	.	PUNCT
aiua-10838	390	1	2020	2020	NUM
aiua-10838	390	2	;	;	PUNCT
aiua-10838	390	3	126:745	126:745	NOUN
aiua-10838	390	4	-	-	PUNCT
aiua-10838	390	5	753	753	NUM
aiua-10838	390	6	.	.	PUNCT
aiua-10838	391	1	65	65	NUM
aiua-10838	391	2	.	.	PUNCT
aiua-10838	391	3	uprety	uprety	PROPN
aiua-10838	392	1	d	d	PROPN
aiua-10838	392	2	,	,	PUNCT
aiua-10838	392	3	bista	bista	PROPN
aiua-10838	392	4	a	a	PROPN
aiua-10838	392	5	,	,	PUNCT
aiua-10838	392	6	smith	smith	PROPN
aiua-10838	392	7	al	al	PROPN
aiua-10838	392	8	,	,	PUNCT
aiua-10838	392	9	et	et	PROPN
aiua-10838	392	10	al	al	PROPN
aiua-10838	392	11	.	.	PUNCT
aiua-10838	393	1	cytoreductive	cytoreductive	PROPN
aiua-10838	393	2	nephrectomy	nephrectomy	ADV
aiua-10838	393	3	in	in	ADP
aiua-10838	393	4	elderly	elderly	ADJ
aiua-10838	393	5	patients	patient	NOUN
aiua-10838	393	6	with	with	ADP
aiua-10838	393	7	metastatic	metastatic	ADJ
aiua-10838	393	8	renal	renal	ADJ
aiua-10838	393	9	cell	cell	NOUN
aiua-10838	393	10	carcinoma	carcinoma	NOUN
aiua-10838	393	11	in	in	ADP
aiua-10838	393	12	the	the	DET
aiua-10838	393	13	targeted	target	VERB
aiua-10838	393	14	therapy	therapy	NOUN
aiua-10838	393	15	era	era	NOUN
aiua-10838	393	16	.	.	PUNCT
aiua-10838	394	1	anticancer	anticancer	NOUN
aiua-10838	394	2	res	re	NOUN
aiua-10838	394	3	.	.	PROPN
aiua-10838	394	4	2018	2018	NUM
aiua-10838	394	5	;	;	PUNCT
aiua-10838	394	6	38:3013	38:3013	NUM
aiua-10838	394	7	-	-	SYM
aiua-10838	394	8	3018	3018	NUM
aiua-10838	394	9	.	.	PUNCT
aiua-10838	395	1	correspondence	correspondence	NOUN
aiua-10838	395	2	stamatios	stamatio	NOUN
aiua-10838	395	3	katsimperis	katsimperis	PROPN
aiua-10838	395	4	,	,	PUNCT
aiua-10838	395	5	md	md	PROPN
aiua-10838	395	6	stamk1992@gmail.com	stamk1992@gmail.com	PROPN
aiua-10838	395	7	lazaros	lazaro	VERB
aiua-10838	395	8	tzelves	tzelve	NOUN
aiua-10838	395	9	,	,	PUNCT
aiua-10838	395	10	md	md	PROPN
aiua-10838	395	11	lazarostzelves@gmail.com	lazarostzelves@gmail.com	PROPN
aiua-10838	396	1	themistoklis	themistoklis	PROPN
aiua-10838	396	2	bellos	bellos	PROPN
aiua-10838	396	3	,	,	PUNCT
aiua-10838	396	4	md	md	PROPN
aiua-10838	396	5	bellos.themistoklis@yahoo.com	bellos.themistoklis@yahoo.com	X
aiua-10838	396	6	konstantinos	konstantinos	PROPN
aiua-10838	396	7	pikramenos	pikramenos	PROPN
aiua-10838	396	8	,	,	PUNCT
aiua-10838	396	9	md	md	PROPN
aiua-10838	396	10	k.pikramenos@gmail.com	k.pikramenos@gmail.com	PROPN
aiua-10838	396	11	ioannis	ioannis	PROPN
aiua-10838	396	12	manolitsis	manolitsis	PROPN
aiua-10838	396	13	,	,	PUNCT
aiua-10838	396	14	md	md	PROPN
aiua-10838	396	15	giannismanolit@gmail.com	giannismanolit@gmail.com	PROPN
aiua-10838	396	16	ioannis	ioannis	PROPN
aiua-10838	396	17	tsikopoulos	tsikopoulos	PROPN
aiua-10838	396	18	,	,	PUNCT
aiua-10838	396	19	md	md	PROPN
aiua-10838	396	20	ioannistsikopoulos@yahoo.com	ioannistsikopoulos@yahoo.com	PROPN
aiua-10838	396	21	iraklis	iraklis	PROPN
aiua-10838	396	22	mitsogiannis	mitsogiannis	PROPN
aiua-10838	396	23	,	,	PUNCT
aiua-10838	396	24	md	md	PROPN
aiua-10838	396	25	imitsog@med.uoa.gr	imitsog@med.uoa.gr	PROPN
aiua-10838	396	26	department	department	PROPN
aiua-10838	396	27	of	of	ADP
aiua-10838	396	28	urology	urology	NOUN
aiua-10838	396	29	,	,	PUNCT
aiua-10838	396	30	athens	athens	PROPN
aiua-10838	396	31	,	,	PUNCT
aiua-10838	396	32	greece	greece	PROPN